

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:55:00 ; Search time 11.2849 Seconds
(without alignments)
5501.769 Million cell updates/sec

Title: US-10-676-079-6
Perfect score: 23
Sequence: 1 ttcgaccgaagaagatcacac 23

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq 19Jun03.*
1: /SIDSI/gcgdata/geneq/geneq-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/geneq/geneq-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/geneq/geneq-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/geneq/geneq-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/geneq/geneq-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/geneq/geneq-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/geneq/geneq-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/geneq/geneq-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/geneq/geneq-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/geneq/geneq-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/geneq/geneq-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/geneq/geneq-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/geneq/geneq-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/geneq/geneq-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/geneq/geneq-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/geneq/geneq-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/geneq/geneq-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/geneq/geneq-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/geneq/geneq-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/geneq/geneq-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/geneq/geneq-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/geneq/geneq-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/geneq/geneq-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/geneq/geneq-emb1/NA2002.DAT.*
25: /SIDSI/gcgdata/geneq/geneq-emb1/NA2003.DAT.*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	23	100.0	23	20	AAK35646
2	23	100.0	23	21	AAA75049
3	23	100.0	23	21	AAA75063
4	23	100.0	23	21	AAZ33293
5	23	100.0	1584	24	ABL40753
6	23	100.0	1593	20	AAZ11236
7	23	100.0	1669	25	ABZ22816
8	23	100.0	1713	20	AAK37259

9	23	100.0	1721	20	AAK35648
10	23	100.0	1721	21	AAA75051
11	23	100.0	1721	21	AAZ39195
12	23	100.0	1721	21	AAZ33290
13	23	100.0	1721	21	AAA81112
14	23	100.0	1722	22	AAZ37188
15	23	100.0	1723	20	AAK37260
16	23	100.0	1724	22	AAH20940
17	23	100.0	1899	20	AAK35650
18	23	100.0	1899	21	AAZ75053
19	23	100.0	3726	20	AAK86671
20	23	100.0	44848	21	AAZ75080
21	23	95.7	474	22	AAZ75080
22	17.2	74.8	2884	16	AAO84613
23	17.2	74.8	159400	24	ABO88126
24	17.2	74.8	160271	22	AAZ85750
25	17.2	74.8	160271	22	AAZ85756
26	17.2	74.8	160271	22	AAZ85756
27	17.2	74.8	160271	22	AAZ85756
28	17.2	74.8	160271	22	AAZ85756
29	17.2	74.8	160271	22	AAZ85756
30	17.2	74.8	160271	22	AAZ85756
31	17.2	74.8	160271	22	AAZ85756
32	16.8	73.0	343	21	AAZ7423
33	16.8	73.0	367	24	ABN15848
34	16.8	73.0	577	22	ABA53814
35	16.8	73.0	577	22	ABA30999
36	16.8	73.0	577	22	AAK12323
37	16.8	73.0	577	22	AAK38044
38	16.8	73.0	577	22	AAK18816
39	16.8	73.0	577	22	AAZ3938
40	16.8	73.0	577	23	ABZ37665
41	16.8	73.0	577	24	ABZ12053
42	16.8	73.0	588	22	AAH08812
43	16.8	73.0	1731	22	AAH13668
44	16.8	73.0	2747	23	AAZ64307
45	16.8	73.0	2747	23	AAZ64928

ALIGNMENTS

RESULT 1
AAK35646
ID AAK35646 standard; DNA; 23 BP.

AAK35646;

09-JUL-1999 (first entry)

PCR primer used to amplify human hp3.cDNA.

Heparanase; hp; modulator; heparin-binding growth factor;

cellular response; cytokine; cell interaction; plasma lipoprotein;

cellular susceptibility; infection; disintegration;

neurodegenerative plaque; wound healing; angiogenesis; restenosis;

atherosclerosis; inflammation; neurodegenerative disease; neuritis;

plasma heparin; micrometastasis; autoimmune lesion; renal failure;

PCR primer; ss.

Synthetic.

WO9911798-A1.

11-MAR-1999.

31-AUG-1998; 98WO-US17954.

02-JUL-1998; 98US-0109386.

02-SEP-1997; 97US-0922170.

(FRIE/) FRIEDMAN M M.

(HADA-) HADASIT MEDICAL RES SERVICES & DEV.

CDNA encoding a hu
CDNA encoding a hu
Human heparanase e
Human heparanase n
Human heparanase
Human cDNA encodin
Seq ID No: 14 of W
Human heparanase i
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
Nucleotide sequenc
Primer specific fo
Rat AT2 receptor c
Human osteoblast d
Bipolar affective
Human chromosome 1
Human chromosome 1
Human chromosome 1
Human chromosome 1
160kb fragment of
Human chromosome 1
Nucleotide sequenc
Human secreted pro
Human ORFX polynuc
Human foetal liver
Probe #9465 for ge
Human brain expres
Human bone marrow
Probe #8749 for ge
Probe #12624 used
Human liver single
Human genome-deriv
Human cDNA clone (c
Human cDNA sequenc
DNA encoding novel
DNA encoding novel

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodayvsky I;
XX
XX MPI; 1999-302255/25.
DR
XX
XX New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
XX Example 1; Page 23; 63pp; English.
XX
XX The specification describes a polypeptide having heparanase (hp)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC PCR primers AAX35646-47 were used to amplify hp3 cDNA, in the course of
CC the invention.
XX
SQ Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;
Query Match 100.0%; Score 23; DB 20; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTCGATCCCAAGAGAAATCAAC 23
Db 1 TTCGATCCCAAGAGAAATCAAC 23
RESULT 2
AAAT75049
ID AAA75049 standard; DNA; 23 BP.
XX
XX AAA75049;
AC
XX
XX 15-JAN-2001 (first entry)
DT
XX
XX PCR primer HPU35 used to amplify human cDNA encoding heparanase.
DE
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease;
KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200052178-A1.
PN
XX
XX 08-SEP-2000.
PD
XX
XX 14-FEB-2000; 2000WO-US03542.
PF
XX
XX 01-MAR-1999; 99US-0258892.
PR
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodayvsky I, Feinstein E;
PI
XX
XX MPI; 2000-579289/54.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating

PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
XX
XX Disclosure; Page 44; 152pp; English.
XX
XX The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The
CC heparanase (hpa) polynucleotide is useful in gene therapy, particularly
CC in treating tumour, inflammation or autoimmunity. Particularly, the
CC polynucleotide is useful in modulating the bioavailability of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8),
CC cell interaction with plasma lipoproteins, cellular susceptibility to
CC certain viral and some bacterial and protozoa infections, or
CC disintegration of neurodegenerative plaques. The polynucleotide is
CC also useful in wound healing (e.g. thermal, chemical or radiation burns),
CC and in the treatment of angiogenesis, restenosis, atherosclerosis,
CC inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome
CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.
XX
SQ Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;
Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19; Mismatches 0; Indels 0; Gaps 0;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTCGATCCCAAGAGAAATCAAC 23
Db 1 TTCGATCCCAAGAGAAATCAAC 23
RESULT 3
AAAT75063
ID AAA75063 standard; DNA; 23 BP.
XX
XX AAA75063;
AC
XX
XX 15-JAN-2001 (first entry)
DT
XX
XX PCR primer Hpu-335 used to amplify human cDNA encoding heparanase.
DE
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease;
KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200052178-A1.
PN
XX
XX 08-SEP-2000.
PD
XX
XX 14-FEB-2000; 2000WO-US03542.
PF
XX
XX 01-MAR-1999; 99US-0258892.
PR
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodayvsky I, Feinstein E;
PI
XX
XX MPI; 2000-579289/54.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
XX
XX Disclosure; Page 45; 152pp; English.
XX
XX The present PCR primer was used to amplify a human cDNA sequence,
CC which encoded a protein with heparanase catalytic activity. The

heparanase (hpa) polynucleotide is useful in gene therapy, particularly in treating tumor, inflammation or autoimmunity. Particularly, the polynucleotide is useful in modulating the bioavailability of heparin-binding growth factors, cellular responses to heparin-binding growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins, cellular susceptibility to certain viral and some bacterial and protozoa infections, or disintegration of neurodegenerative plaques. The polynucleotide is also useful in wound healing (e.g. thermal, chemical or radiation burns), and in the treatment of angiogenesis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-Sträussler Syndrome or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa infections.

Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTGCATCCCAAGAGGATCAAC 23
1 TTGCATCCCAAGAGGATCAAC 23

RESULT 4
AA233293 standard; DNA; 23 BP.

AA233293;
21-FEB-2000 (first entry)

Human heparanase PCR primer Hpu-355 SEQ ID NO:6.

Human; heparanase; hpa; diagnosis; therapy; tumor; cytostatic; anti-diabetic; immunomodulatory; anti-inflammatory; nephrotropic; metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma; mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes; inflammation; haemorrhagic nephritis; nephrotic syndrome; autoimmune disease; anticancer; kidney disease; PCR primer; ss.

Synthetic.
Homo sapiens.

WO9957153-A1.
11-NOV-1999.

29-APR-1999; 99WO-US09255.
01-MAY-1998; 98US-0071739.

(INSI-) INSIGHT STRATEGY & MARKETING LTD.
(HADA-) HADASIT MEDICAL RES SERVICES & DEV.
(PRIE/) FRIEDMAN M M.

Pecker I, Vlodavsky I, Friedman Y, Perets T;
WPI; 2000-052944/04.

Heparanase-specific molecular probes useful for diagnosis and treatment, e.g. of tumors, and for targeted drug delivery -
Example; Page 30; 90pp; English.

The present invention describes heparanase-specific molecular probes, useful for methods of detecting heparanase in situ. The probes and anti-heparanase antibodies are used to detect or quantify the expression of heparanase, for diagnosis and monitoring of diseases (especially metastasis), for treatment of heparanase-associated diseases (e.g. tumor, adenocarcinoma, squamous cell carcinoma, teratocarcinoma, mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its

metastases) derived from liver, prostate, bladder, breast, ovary, cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic syndrome, sepsis and inflammatory or autoimmune disease), for targeted drug delivery (e.g. of anticancer agents) and as research reagents. The present sequence represents a PCR primer for human heparanase, which is used in an example from the present invention.

Sequence 23 BP; 9 A; 6 C; 4 G; 4 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 23;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1 TTGCATCCCAAGAGGATCAAC 23
1 TTGCATCCCAAGAGGATCAAC 23

RESULT 5
ABL40753 standard; cDNA; 1584 BP.

ABL40753;
03-JUL-2002 (first entry)

Chicken signal peptide/human heparanase chimeric cDNA.

Heparanase; catalytic; cytostatic; antiviral; antibacterial; enzyme; anti-protocozan; neuroprotective; heparin; chicken; human; chimeric; ss.

Synthetic.
Gallus gallus.
Homo sapiens.

Key Location/Qualifiers
CDS 1..1584
FT /*tag= a
FT /product= "chimeric chicken-human heparanase"
FT sig_peptide 1..57
FT /*tag= b
FT /note= "chicken heparanase signal peptide"
FT mat_peptide 58..1581
FT /*tag= c
FT /note= "human mature heparanase"

US2002034810-A1.
21-MAR-2002.

16-AUG-2001; 2001US-0930218.
20-SEP-2000; 2000US-0666390.

(INSI-) INSIGHT STRATEGY & MARKETING LTD.
(INSI-) INSIGHT STRATEGY & MARKETING LTD.

Goldshmidt O, Pecker I, Vlodavsky I, Michal I, Zcharia E;
WPI; 2002-338926/37.
P-PSDB; ABB07815.

Nucleic acid encoding avian and reptile heparanase polypeptide is useful to treat various heparin-related disorders and the signal peptide is useful in production of membrane-targeted or secreted recombinant proteins -
Disclosure; Page 24-25; 39pp; English.

The invention relates to an isolated avian and reptile nucleic acid, encoding a polypeptide with heparanase catalytic activity. The signal peptide of the nucleic acid can be used to express membrane-associated or secreted proteins in heterologous expression systems. The encoded

CC polypeptides can be used to prevent tumour angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC delintegration of neurodegenerative plaques. The present sequence
CC represents a chicken signal peptide/human heparanase chimeric CDNA
CC sequence.
XX
SQ Sequence 1584 BP; 424 A; 361 C; 373 G; 426 T; 0 other;
Query Match 100.0%; Score 23; DB 24; Length 1584;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTTCGATCCCAAGAGATCAAC 23
DB 262 TTTCGATCCCAAGAGATCAAC 284
RESULT 6
AAZ11236
ID AAZ11236 standard; CDNA; 1593 BP.
AC AAZ11236;
DT 15-NOV-1999 (first entry)
XX
DE Human pre-proheparanase coding sequence.
XX
KW Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
KW inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
KW heparin degradation; anticoagulant neutralisation; ashenia; CNS disease;
KW inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
KW therapy; ds.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1593
FT /*tag= a
FT /product= pre-proheparanase
XX
PN MO9943830-A2.
XX
PD 02-SEP-1999.
XX
PF 18-FEB-1999; 99WO-US01489.
XX
PR 26-MAR-1998; 98US-0079401.
PR 24-FEB-1998; 98US-0075706.
XX
PA (PHAA) PHARMACIA & UPJOHN CO.
XX
PI Fairbanks MB, Heinrikson RL, Mildner AM;
XX
DR WPI: 1999-540598/45.
DR P-PSDB: AAY34173.
PT New isolated platelet heparanase polypeptides, used to develop
PT products for, e.g. wound healing and blocking angiogenesis
XX
PS Claim 2; Fig 7; 57pp; English.
XX
CC This sequence encodes the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.
CC Inhibitors of heparanase activity can be used in the treatment of

CC arthritis, asthma, and other inflammatory diseases, vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC disorders, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSG)/heparin.
XX
SQ Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;
Query Match 100.0%; Score 23; DB 20; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TTTCGATCCCAAGAGATCAAC 23
DB 271 TTTCGATCCCAAGAGATCAAC 293
RESULT 7
ABZ22816
ID ABZ22816 standard; CDNA; 1669 BP.
AC ABZ22816;
DT 02-APR-2003 (first entry)
XX
DE Human heparanase encoding CDNA SEQ ID NO:17.
XX
KW Human; heparanase; phosphorothioate; antisense oligonucleotide;
KW cytosolic; gene therapy; tumour; enzyme; gene; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 1..1638
FT /*tag= a
FT /product= "heparanase"
XX
PN MO2003004705-A1.
XX
PD 16-JAN-2003.
XX
PF 01-JUL-2002; 2002WO-US20636.
XX
PR 05-JUL-2001; 2001US-0899440.
XX
PA (UNIV) UNIV COLUMBIA NEW YORK.
XX
PI Stein C;
XX
DR WPI: 2003-201558/19.
DR P-PSDB: ABP56822.
PT New oligonucleotide having a sequence complementary to a sequence of
PT ribonucleic acid encoding a heparanase, useful for preparing a
PT composition for treating tumor -
XX
PS Disclosure; Fig 3; 48pp; English.
XX
CC The present invention describes an oligonucleotide having a sequence
CC complementary to a sequence of ribonucleic acid encoding a heparanase.
CC The oligonucleotide hybridises with the ribonucleic acid under conditions
CC of high stringency and has a sequence comprising 10-40 bp. The
CC internucleoside linkages of the oligonucleotide comprise at least one
CC phosphorothioate linkage. Hybridisation of the oligonucleotide to the
CC ribonucleic acid inhibits expression of the heparanase, where inhibition
CC of heparanase means at least a 50% reduction in the quality of
CC heparanase. Also described: (1) a method of inhibiting expression of a

CC heparanase in a cell; (2) a composition comprising the above
CC oligonucleotide in an amount effective to inhibit the expression of
CC heparanase in the cell and a carrier; and (3) a method of treating a
CC tumour in a subject comprising administering to the subject an amount of
CC the above oligonucleotide effective to inhibit expression of a heparanase
CC in the subject. Heparanase antisense oligonucleotides have cytostatic
CC activity, can be used in gene therapy, and can be used for preparing a
CC composition for treating tumours. The present sequence encodes human
CC heparanase, which is given in the exemplification of the present
CC invention.

XX
SQ Sequence 1669 BP; 445 A; 396 C; 388 G; 440 T; 0 other;

Query Match 100.0%; Score 23; DB 25; Length 1669;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCGATCCCAAGAGATCAAC 23
Db 316 TTCGATCCCAAGAGATCAAC 338
|||||

RESULT 8
AAK37259
ID AAK37259 standard; DNA; 1713 BP.
XX
AC AAK37259;
XX
DT 21-JUL-1999 (first entry)
XX
DE Human heparanase enzyme encoding DNA.
XX
KM Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KM metacastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KM arteriosclerosis; atherosclerosis; inflammation; tissue development;
KM human; HSPG; ss.
XX
OS Homo sapiens.
XX
PN WO9921975-A1.
PD 06-MAY-1999.
XX
PF 28-OCT-1998; 98WO-AU00898.
XX
PR 09-DEC-1997; 97AU-0000812.
PR 28-OCT-1997; 97AU-0000062.
XX
PA (AUSU) UNIV AUSTRALIAN NAT.
PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
XX
DR WPI; 1999-312956/26.
DR P-PSDB; AAY17082.
XX
PT Polynucleotides encoding mammalian endoglucuronidases, especially
PT heparanases, useful to promote wound healing
XX
PS Claim 3; Page 69-73; 112pp; English.

CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG. The

CC present sequence represents a DNA encoding human heparanase.
XX
SQ Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

Query Match 100.0%; Score 23; DB 20; Length 1713;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTCGATCCCAAGAGATCAAC 23
Db 355 TTCGATCCCAAGAGATCAAC 377
|||||

RESULT 9
AAK35648
ID AAK35648 standard; cDNA; 1721 BP.
XX
AC AAK35648;
XX
DT 09-JUL-1999 (first entry)
XX
DE cDNA encoding a human heparanase protein.
XX
KM Heparanase; hpa; modulator; heparin-binding growth factor;
KM cellular response; cytokine; cell interaction; plasma lipoprotein;
KM cellular susceptibility; infection; disintegration;
KM neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KM atherosclerosis; inflammation; neurodegenerative disease; neuritis;
KM plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KM ss.
XX
OS Homo sapiens.
XX
PN WO9911798-A1.
PD 11-MAR-1999.
XX
PF 31-AUG-1998; 98WO-US17954.
XX
PR 02-JUL-1998; 98US-0109386.
PR 02-SEP-1997; 97US-0922170.
XX
PA (FRIE/) FRIEDMAN M M.
PA (HADA) HADASIT MEDICAL RES SERVICES & DEV.
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PI Feinstein E, Pecker I, Vlodavsky I;
XX
DR WPI; 1999-302255/25.
DR P-PSDB; AAY02345.
XX
PT New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
PS Claim 4; Fig 1; 63pp; English.

CC The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be used to neutralize
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.

XX
SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 100.0%; Score 23; DB 20; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.32; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGATCAAC 23
Db 372 TTCGATCCCAAGAGATCAAC 394

RESULT 10

AAAT5051
ID AAAT5051 standard; cDNA; 1721 BP.

AC AAAT5051;

DT 15-JAN-2001 (first entry)

DE cDNA encoding a human heparanase polypeptide.

Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
heparin-binding growth factor; cytokine; neurodegenerative plaque;
wound healing; infection; burn; angiogenesis; restenosis;
atherosclerosis; inflammation; neurodegenerative disease;
Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; ds.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 63..1693

FT /tag= a

FT /product= "heparanase"

FT /tag= b

FT /note= "these nucleotides are likely to be involved

in forming stem and loop structures"

XX MO200052178-A1.

XX 08-SEP-2000.

XX 14-FEB-2000; 2000MO-US03542.

XX 01-MAR-1999; 99US-0258892.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.

XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodavsky I, Feinstein E;

XX WPI; 2000-579289/54.

XX P-PSDB; AAB08849.

XX The present sequence encodes a human protein with heparanase catalytic

activity. The heparanase (hpa) polynucleotide is useful in gene therapy,

particularly in treating tumour, inflammation or autoimmunity.

CC Particularly, the polynucleotide is useful in modulating the

bioavailability of heparin-binding growth factors, cellular responses

to heparin-binding growth factors (e.g. bFGF) and cytokines

(e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,

cellular susceptibility to certain viral and some bacterial and protozoa

infections, or disintegration of neurodegenerative plaques. The

polynucleotide is also useful in wound healing (e.g. thermal, chemical

or radiation burns), and in the treatment of angiogenesis, restenosis,

atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-

Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,

bacterial or protozoa infections.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 100.0%; Score 23; DB 21; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.32; Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGATCAAC 23
Db 372 TTCGATCCCAAGAGATCAAC 394

RESULT 11

AAZ39195
ID AAZ39195 standard; cDNA; 1721 BP.

AC AAZ39195;

DT 02-MAR-2000 (first entry)

DE Human heparanase encoding cDNA.

Human; heparanase; hpa; genetic modification; expression; anticancer;
angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour;
anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
metastasis; wound healing; restenosis; atherosclerosis; inflammation;
neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
micrometastasis; autoimmune lesion; kidney failure; ss.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 63..1694

FT /tag= a

FT /product= "heparanase"

XX MO9957244-A1.

XX 11-NOV-1999.

XX 29-APR-1999; 99WO-US09256.

XX 01-MAY-1998; 98US-0071618.

XX 02-MAR-1999; 99US-0260038.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.

XX (FRIE/) FRIEDMAN M M.

XX Ben-Attzi H, Ayal-HersHKovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;

XX Shlom Y;

XX WPI; 2000-062144/05.

XX P-PSDB; AAY57590.

XX The present invention describes genetically modified cells (A) containing

a polynucleotide (I) that encodes a polypeptide with heparanase activity,

and express recombinant heparanase (II). Heparanase cleaves heparan

sulphate (HS) at specific intrachain sites, resulting in release of

heparin-binding growth factors, enzymes and proteins that are sequestered

by HS in basement membranes, extracellular matrix or cell surfaces. It

may also be implicated in tumour angiogenesis and metastases. (II) is

potentially useful in wound healing and for treating angiogenesis,

restenosis, atherosclerosis, inflammation, neurodegeneration, viral

infection and cystic fibrosis. It can also be used to neutralise heparin

(an alternative to protamine) and to screen for specific inhibitors

(potentially useful for treating cancer and metastases). Antibodies

raised against (II) are used for immunodetection and diagnosis of


```
RESULT 14
AAF93788
ID AAF93788 standard; cDNA; 1722 BP.
XX
AC AAF93788;
XX
DT 23-MAY-2001 (first entry)
XX
DE Human cDNA encoding a membrane or secretory protein clone PSEC0090.
XX
KW Human; secretory protein; membrane protein; vaccine; gene therapy;
KW rheumatoid arthritis; diabetes; ss.
XX
OS Homo sapiens.
XX
PN EP1067182-A2.
XX
PD 10-JAN-2001.
XX
PF 07-JUL-2000; 2000EP-0114090.
XX
PR 08-JUL-1999; 99JP-0194179.
PR 11-JAN-2000; 2000JP-0118775.
PR 02-MAY-2000; 2000JP-0183766.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Isegai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
DR WPI; 2001-093989/11.
DR P-PSDB; AAB88361.
XX
PT Nucleic acid encoding secretory proteins/membrane proteins, useful in
XX gene therapy or as candidate target molecules in drug development -
XX
PS Claim 1; SEQ ID 89; 609BP + CD ROM; English.
XX
CC This invention relates to nucleic acid sequences AAF93744 - AAF93916
CC which encode human secretory or membrane proteins represented by
CC AAB88317 - AAB88419. Included in the invention are primers
CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
CC cDNA sequences of the invention. The invention also includes methods for
CC the production of antibodies directed against the proteins, and cDNA
CC sequences, which can be used in vaccines. The polynucleotide sequences
CC can be used in gene therapy. The polynucleotide sequences and the
CC proteins they encode may be used in the prevention, treatment and
CC diagnosis of diseases associated with inappropriate secretory
CC protein/membrane protein expression. The nucleic acids and complementary
CC sequences may also be used as DNA probes in diagnostic assays
CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
CC presence of similar nucleic acid sequences in samples. They may also be
CC used to study the expression and function of secretory proteins/membrane
CC polypeptides and their role in metabolism. The polypeptides may be used
CC as antigens in the production of antibodies against them and in assays to
CC identify modulators (agonists and antagonists) of expression and
CC activity. The antibodies and antagonists may also be used as therapeutic
CC agents to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of the
CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
CC (ELISA). Examples of diseases which may be treated include rheumatoid
CC arthritis and diabetes.
XX
SQ Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
```

```
Query Match 100.0%; Score 23; DB 22; Length 1722;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TTCGATCCCAAGAGGATCAAC 23
DB 373 TTCGATCCCAAGAGGATCAAC 395
```

```
RESULT 15
AA37260
ID AA37260 standard; DNA; 1723 BP.
XX
AC AA37260;
XX
DT 21-JUL-1999 (first entry)
XX
DE Seq ID No: 14 of WO9921975.
XX
KW Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
KW arteriosclerosis; atherosclerosis; inflammation; tissue development;
KW human; HSPG; ss.
XX
OS Homo sapiens.
XX
PN WO9921975-A1.
XX
PD 06-MAY-1999.
XX
PF 28-OCT-1998; 98WO-AU00898.
XX
PR 09-DEC-1997; 97AU-0000812.
PR 28-OCT-1997; 97AU-0000062.
XX
PA (AUSU ) UNIV AUSTRALIAN NAT.
XX
PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
DR WPI; 1999-312956/26.
DR P-PSDB; AAY17083.
XX
PT Polynucleotides encoding mammalian endoglucuronidases, especially
XX heparanases, useful to promote wound healing
XX
PS Claim 11; Page 76-79; 112BP; English.
XX
CC The invention relates to nucleic acid sequences that encode heparanase
CC enzymes having endoglucuronidase activity. Recombinant heparanases are
CC capable of removing the HS side chain from heparan sulfate proteoglycan
CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
CC inhibit heparanase, this is useful for treatment of a physiological or
CC medical condition associated with elevated heparanase activity, such as
CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
CC rat heparanases can be used to enhance wound healing, especially
CC associated with tissue development and repair. The conditions mentioned
CC above can be diagnosed using specific antibodies, and also using primers
CC and probes specific for the heparanase polynucleotides. Other uses of the
CC heparanases include sequencing sulfated molecules such as HSPG.
XX
SQ Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;
```

```
Query Match 100.0%; Score 23; DB 20; Length 1723;
Best Local Similarity 100.0%; Pred. No. 0.32;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1 TTCGATCCCAAGAGGATCAAC 23
DB 361 TTCGATCCCAAGAGGATCAAC 383
```

```
Search completed: February 16, 2004, 09:18:13
Job time : 13.2849 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 109.813 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-6

Perfect score: 23

Sequence: 1 ttctgaccccaagaagaatcaac 23

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 288871 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

```
GenBml: *
1: gb_ba: *
2: gb_htg: *
3: gb_in: *
4: gb_om: *
5: gb_ov: *
6: gb_pat: *
7: gb_ph: *
8: gb_pl: *
9: gb_pr: *
10: gb_ro: *
11: gb_sts: *
12: gb_sy: *
13: gb_un: *
14: gb_vt: *
15: gb_vt: *
16: em_ba: *
17: em_fun: *
18: em_hum: *
19: em_in: *
20: em_mu: *
21: em_om: *
22: em_or: *
23: em_ov: *
24: em_pat: *
25: em_ph: *
26: em_pl: *
27: em_ro: *
28: em_sts: *
29: em_un: *
30: em_vt: *
31: em_hum: *
32: em_htg: *
33: em_htg_inv: *
34: em_htg_mus: *
35: em_htg_pln: *
36: em_htg_rtd: *
37: em_htg_mam: *
38: em_htg_vrt: *
39: em_sy: *
40: em_hgo_hum: *
41: em_hgo_mus: *
41: em_hgo_other: *
```

Pred. No. is the number of results predicted by chance to have a

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	23	100.0	23	6	AR080677
2	23	100.0	23	6	AR125607
3	23	100.0	23	6	AR287439
4	23	100.0	23	6	AR287439
5	23	100.0	23	6	BD074425
6	23	100.0	558	6	BD110974
7	23	100.0	1593	6	AR210040
8	23	100.0	1593	6	BD136761
9	23	100.0	1669	9	AR084467
10	23	100.0	1694	9	AR152376
11	23	100.0	1713	6	AR034643
12	23	100.0	1721	6	AR080679
13	23	100.0	1721	6	AR080680
14	23	100.0	1721	6	AR125603
15	23	100.0	1721	6	AR125604
16	23	100.0	1721	6	AR194189
17	23	100.0	1721	6	AR194190
18	23	100.0	1721	6	AR221285
19	23	100.0	1721	6	AR221286
20	23	100.0	1721	6	AR243203
21	23	100.0	1721	6	AR243204
22	23	100.0	1721	6	AR287435
23	23	100.0	1721	6	AR287436
24	23	100.0	1721	6	BD074427
25	23	100.0	1721	6	BD074428
26	23	100.0	1722	6	AX136167
27	23	100.0	1722	6	BD123536
28	23	100.0	1722	9	AK075400
29	23	100.0	1723	6	AR156692
30	23	100.0	1723	6	AX034645
31	23	100.0	1724	6	AX147946
32	23	100.0	1724	9	AF165154
33	23	100.0	1758	9	AF144325
34	23	100.0	1810	9	BC051321
35	23	100.0	1899	6	BD074430
36	23	100.0	1899	6	BD074431
37	23	100.0	3726	6	AR235866
38	23	100.0	3726	6	AX019348
39	23	100.0	3726	6	BD131218
40	23	100.0	3726	9	AF155510
41	23	100.0	149188	9	AC114781
42	22	95.7	474	6	AX136496
43	22	95.7	474	6	BD123736
44	18.8	81.7	191721	10	AC101883
45	18.8	81.7	248754	2	AC134101

ALIGNMENTS

```
RESULT 1
AR080677
LOCUS
DEFINITION Sequence 6 from patent US 5968822.
ACCESSION AR080677
VERSION AR080677.1 GI:10007407
KEYWORDS
SOURCE
ORGANISM
REFERENCE
Pecker, I., Vlodavsky, I. and Feinstein, E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 6 19-OCT-1999;
```

FEATURES Location/Qualifiers
SOURCE 1..23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGGATCCCAAGAGGATCAAC 23
Db 1 TTGGATCCCAAGAGGATCAAC 23

RESULT 2
LOCUS AR125607
DEFINITION Sequence 6 from patent US 6177545.
ACCESSION AR125607
VERSION AR125607.1 GI:14111669
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Peretz,T.
TITLE Heparanase specific molecular probes and their use in research and medical applications
JOURNAL Patent: US 6177545-A 6 23-JAN-2001;
FEATURES Location/Qualifiers
SOURCE 1..23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGGATCCCAAGAGGATCAAC 23
Db 1 TTGGATCCCAAGAGGATCAAC 23

RESULT 3
LOCUS AR287439
DEFINITION Sequence 6 from patent US 6531129.
ACCESSION AR287439
VERSION AR287439.1 GI:29725133
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 23)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Peretz,T.
TITLE Heparanase specific molecular probes and their use in research and medical applications
JOURNAL Patent: US 6531129-A 6 11-MAR-2003;
FEATURES Location/Qualifiers
SOURCE 1..23
/organism="unknown"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGGATCCCAAGAGGATCAAC 23
Db 1 TTGGATCCCAAGAGGATCAAC 23

RESULT 4
LOCUS BD074425
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell.
ACCESSION BD074425
VERSION BD074425.1 GI:22620028
KEYWORDS JP 2001514855-A/6.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 23)
AUTHORS Pecker,I., Vlodavsky,I. and Elena,F.
TITLE Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell
JOURNAL Patent: JP 2001514855-A 6 18-SEP-2001;
COMMENT INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
OS Nucleic acid
PN JP 2001514855-A/6
PD 18-SEP-2001
PR 31-AUG-1998 JP 2000508806
PC 02-SEP-1997 US 08/922170,02-JUL-1998 US 09/109386 P1
IRIS PECKER,ISRAEL VLODAVSKY,FEINSTEIN ELENA
PC C12N15/09,A61K38/00,A61P9/10,A61P17/00,A61P29/00,A61P35/00,PC A61P37/00,
PC A61P43/00,C12N5/10,C12N9/24,C12Q1/68,G01N33/15,G01N33/50// PC A61K39/395
PC A61K39/395,C12N15/00,A61K37/02,C12N5/00
CC Polynucleotide encoding polypeptide having heparanase activity
CC and
CC expression of the polypeptide in induced cell FH Key
CC Location/Qualifiers
FT source 1..23
FT /organism="Nucleic acid".
FEATURES Location/Qualifiers
SOURCE 1..23
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
BASE COUNT 9 a 6 c 4 g 4 t
ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 23;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 TTGGATCCCAAGAGGATCAAC 23
Db 1 TTGGATCCCAAGAGGATCAAC 23

RESULT 5
LOCUS BD110974
DEFINITION EST and encoded human protein.
ACCESSION BD110974
VERSION BD110974.1 GI:23205792
KEYWORDS JP 2002010789-A/3051.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 558)
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 3051 15-JAN-2002;
COMMENT GENSER CORP
OS Homo sapiens (human)
PN JP 2002010789-A/3051

PD 15-JAN-2002
 PF 07-AUG-2000 JP 2000280989
 PR 05-AUG-1999 US 60/147499
 PI JEAN BABUTIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
 GIORDANO
 PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
 C12N1/21,
 PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
 C12N15/00
 CC EST and encoded human protein
 FH Key Location/Qualifiers
 FT CDS 140..403.
 Location/Qualifiers
 1..558
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"

BASE COUNT 181 a 111 c 108 g 157 t 1 others

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 558;
 Best Local Similarity 100.0%; Pred. No. 2.3;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 173 TTCGATCCCAAGAGGATCAAC 151

Db

RESULT 6
 AR210040 1593 bp DNA linear PAT 20-JUN-2002
 LOCUS Sequence 1 from patent US 6387643.
 ACCESSION AR210040
 VERSION AR210040.1 GI:21512167
 KEYWORDS
 SOURCE
 ORGANISM Unknown.
 Unclassified.
 1 (bases 1 to 1593)
 Heinrichson, R. Leroy., Fairbanks, M. B. and Milder, A. M.
 Human platelet heparanase polypeptides, polynucleotide molecules
 that encode them, and methods for the identification of compounds
 that alter heparanase activity
 Patent: US 6387643-A 1 14-MAY-2002;
 Location/Qualifiers
 1..1593
 /organism="Unknown"
 /organism="Unknown"

BASE COUNT 426 a 370 c 369 g 428 t

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1593;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 271 TTCGATCCCAAGAGGATCAAC 293

Db

RESULT 7
 BD136761 1593 bp DNA linear PAT 18-SEP-2002
 LOCUS Human platelet heparanase polypeptide, polynucleotide molecule
 DEFINITION encoding the same and method of identifying compound changing
 heparanase activity.
 BD136761
 BD136761
 ACCESSION BD136761.1 GI:23231706
 VERSION
 KEYWORDS JP 2002504376-A/1.
 SOURCE unidentified
 ORGANISM unidentified.
 1 (bases 1 to 1593)

REFERENCE

AUTHORS Heinrichson, R. L., Fairbanks, M. B. and Milder, A. M.
 TITLE Human platelet heparanase polypeptide, polynucleotide molecule
 encoding the same and method of identifying compound changing
 Patent: JP 2002504376-A 1 12-FEB-2002;
 JOURNAL
 PHARMACIA & UPJOHN CO
 OS Unidentified
 PN JP 2002504376-A/1
 PD 12-FEB-2002
 PF 18-FEB-1999 JP 2000533569
 PR 24-FEB-1999 US 60/075706, 26-MAR-1998 US 60/079401 PI
 ROBERT L. HEINRICHSON, MICHAEL B. FAIRBANKS, ANA M. MILDNER PC
 C12N15/09, C07K16/40, C12N1/21, C12N5/10, C12N9/24, C12Q1/34, C12N15/00, C12N5/00
 CC Strandedness: Double;
 CC Topology: Linear;
 CC Human platelet heparanase polypeptide, polynucleotide molecule

CC encoding
 CC the same and method of identifying compound changing CC
 FH heparanase activity Location/Qualifiers
 FT source 1..1593
 FT /organism="Unidentified".
 Location/Qualifiers
 1..1593
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

BASE COUNT 426 a 370 c 369 g 428 t

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1593;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGGATCAAC 23
 271 TTCGATCCCAAGAGGATCAAC 293

Db

RESULT 8
 AF084467 1669 bp mRNA linear PRI 18-OCT-2000
 LOCUS Homo sapiens heparanase mRNA, complete cds.
 ACCESSION AF084467
 VERSION AF084467.1 GI:5870623
 KEYWORDS
 SOURCE
 ORGANISM Homo sapiens (human)
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
 1 (bases 1 to 1669)
 Dempsey, L. A., Plummer, T. B., Combes, S. L. and Platt, J. L.
 Heparanase expression in invasive trophoblasts and acute vascular
 damage
 Glycobiology 10 (5), 467-475 (2000)

JOURNAL
 MEDLINE
 PUBMED
 2 (bases 1 to 1669)
 Dempsey, L. A., Holzknecht, R. A. and Platt, J. L.
 Identification of the cDNA encoding human heparanase
 Unpublished
 3 (bases 1 to 1669)
 Dempsey, L. A., Holzknecht, R. A. and Platt, J. L.
 Direct Submission
 Submitted (14-AUG-1998) Surgery, Duke University, Research Dr., Rm.
 401 MSRB, Durham, NC 27710, USA

FEATURES
 source
 1..1669
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /cell_line="mekakaryocyte"

CDS

/cissue_type="Placenta"
1..1638
/note="endoglycosidase; expressed in placenta and platelets"
/codon_start=1
/product="heparanase"
/protein_id="AAD54516.1"
/db_xref="GI:5870624"
/translation="MLRSKPALPPPLMLLLGLPGLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITDANLATDPRFLILGSPKLTARGLSPAYLRFGTKTD
FLIPDKKSTFEERSYQSYQVODICRYGSPVVERKTLREMPYEQLLREHYOK
KFKSTYRSRSYDVYTPANCGLDILIGNALLTRADQNNSSNAQILLDYCSKGY
NISWELGNEPNSFLKKADI.FINSGQLGDFIQHLKLRKSTFKNAKLGPVGQPRK
TAKMLKSPFKAGGEVIDSWYWHYLYNGTAFATREDPLNDVLDIFISSVQKPYVES
TRPGKVMIGETSAVGGGAPLSDTPAAGFMWLDKLGISAMGIEVMRQVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKLRYVHLCTNDPRYKEG
DUTLYAINHNTKYLRLPYPSNKNQVKKYLLRPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRGSSSLGAPAFSYSPFVIRNAKVAACI"

BASE COUNT 445 a 396 c 388 g 440 t

ORIGIN

Query Match 100.0%; Score 23; DB 9; Length 1669;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCGATCCCAAGAGGATCAAC 23
|||||
316 TTCGATCCCAAGAGGATCAAC 338

Db

RESULT 9
AF152376 1694 bp mRNA linear PRI 28-JUL-1999
LOCUS Homo sapiens heparanase mRNA, complete cds.
DEFINITION AF152376
ACCESSION AF152376.1 GI:5616196
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Euteleostomi; Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1694)
AUTHORS Kuesle,P.H., Hulmes,J.D., Ludwig,D.L., Patel,S., Navarro,E.C.,
Seddon,A.P., Giorgio,N.A. and Bohlen,P.
TITLE Cloning and functional expression of a human heparanase gene
JOURNAL Biochem. Biophys. Res. Commun. 261 (1), 183-187 (1999)
MEDLINE 9935379
PUBMED 10405343
2 (bases 1 to 1694)
AUTHORS Kuesle,P.H., Hulmes,J.D., Ludwig,D., Patel,S., Navarro,E.C.,
Seddon,A.P., Giorgio,N.A. and Bohlen,P.
TITLE Direct Submission
JOURNAL Submitted (18-MAY-1999) Protein Chemistry, Imclone Systems Inc.,
180 Varick Street, New York, NY 10014, USA
FEATURES
source
1..1694
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cissue_type="Placenta"
15..1646
/codon_start=1
/product="heparanase"
/protein_id="AAD45669.1"
/db_xref="GI:5616197"
/translation="MLRSKPALPPPLMLLLGLPGLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITDANLATDPRFLILGSPKLTARGLSPAYLRFGTKTD
FLIPDKKSTFEERSYQSYQVODICRYGSPVVERKTLREMPYEQLLREHYOK
KFKSTYRSRSYDVYTPANCGLDILIGNALLTRADQNNSSNAQILLDYCSKGY
NISWELGNEPNSFLKKADI.FINSGQLGDFIQHLKLRKSTFKNAKLGPVGQPRK
TAKMLKSPFKAGGEVIDSWYWHYLYNGTAFATREDPLNDVLDIFISSVQKPYVES
TRPGKVMIGETSAVGGGAPLSDTPAAGFMWLDKLGISAMGIEVMRQVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKLRYVHLCTNDPRYKEG
DUTLYAINHNTKYLRLPYPSNKNQVKKYLLRPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRGSSSLGAPAFSYSPFVIRNAKVAACI"

BASE COUNT 465 a 398 c 391 g 440 t

ORIGIN

Query Match 100.0%; Score 23; DB 9; Length 1694;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCGATCCCAAGAGGATCAAC 23
|||||
324 TTCGATCCCAAGAGGATCAAC 346

Db

RESULT 10
AR156691 1713 bp DNA linear PAT 08-AUG-2001
LOCUS Sequence 12 from patent US 6242238.
DEFINITION AR156691
ACCESSION AR156691.1 GI:15125395
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1713)
AUTHORS Freeman,C.Geoffrey., Hulet,M.Darren., Parish,C.Richard. and
Hamdorf,B.James.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
JOURNAL Patent: US 6242238-A 12-05-JUN-2001;
FEATURES
source
1..1713
/organism="unknown"
BASE COUNT 460 a 404 c 406 g 443 t

ORIGIN

Query Match 100.0%; Score 23; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 2.1;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TTCGATCCCAAGAGGATCAAC 23
|||||
355 TTCGATCCCAAGAGGATCAAC 377

Db

RESULT 11
AX034643 1713 bp DNA linear PAT 22-SEP-2000
LOCUS Sequence 12 from Patent EP1032656.
DEFINITION AX034643
ACCESSION AX034643
VERSION AX034643.1 GI:10303224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Euteleostomi; Mammalia; Eutheria; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Hamdorf,B.J., Freeman,C.G., Hulet,M.D. and Parish,C.R.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
JOURNAL Patent: EP 1032656-A 12-06-SEP-2000;
JOURNAL UNIV AUSTRALIAN (AU)
FEATURES
source
1..1713
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
46..1677
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC10139.1"
/db_xref="GI:10303225"
/translation="MLRSKPALPPPLMLLLGLPGLSPGALPRPAQADVDVLD
FTQEPHLVSPFLSVITDANLATDPRFLILGSPKLTARGLSPAYLRFGTKTD
FLIPDKKSTFEERSYQSYQVODICRYGSPVVERKTLREMPYEQLLREHYOK
KFKSTYRSRSYDVYTPANCGLDILIGNALLTRADQNNSSNAQILLDYCSKGY
NISWELGNEPNSFLKKADI.FINSGQLGDFIQHLKLRKSTFKNAKLGPVGQPRK
TAKMLKSPFKAGGEVIDSWYWHYLYNGTAFATREDPLNDVLDIFISSVQKPYVES
TRPGKVMIGETSAVGGGAPLSDTPAAGFMWLDKLGISAMGIEVMRQVFGAGN
YHLVDENFDPLPDYMLSLFLKLVGKVLMAVVOGSKRKLRYVHLCTNDPRYKEG
DUTLYAINHNTKYLRLPYPSNKNQVKKYLLRPLGPHGLSKSVQNLGTLTKWDDQ
TLPLMEKPLRGSSSLGAPAFSYSPFVIRNAKVAACI"

TOEPLHVPSPFLSVTIDANLATDPRFLILGSPKLTALNGLSPAYLRFSGTKTDFL
 IFDPKKESTFEERSQOVNODICKGSIIPDVEBKRLRMPYOEOLLEBHQKE
 KNTSYSSSVVLTTPANCSGLDIFGINALPTPADLOMNSNMLLDVCSGGYNT
 SWEIGNEPNSLKKADIFINSQGBEDTQJHKLKSTFRNALTGFDVQCPRKTR
 KMLKSFLEKAGEVIDSVTHHYLNGRTATEDPLNDVLDIPLSSVQKQVVESTR
 PGKRVMLGETSSAVGGAPLSDTFAAFPMWLDKGLSARMGIEVMQVFFGAGNH
 LVDPNFPDLPDYMLSLFKKLVGTKLMAVSQSKRRLRLRYLCTMTDNRYEGL
 TLVAINHNTKYLRLPYPSNKQVDKYLRLPGPHGLSSVOLNGLTLMVDDQL
 PLMEKPLRPSSSLGPRFSSFYIRAKYAACTI"

mat_peptide

BASE COUNT 460 a 404 c 406 g 443 t
 ORIGIN /product="unnamed"

Query Match 100.0%; Score 23; DB 6; Length 1713;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCGATCCCAAGAGGATCAAC 23
 Db 355 TTCGATCCCAAGAGGATCAAC 377

RESULT 12
 LOCUS AR080679 1721 bp DNA linear PAT 31-AUG-2000
 DEFINITION Sequence 9 from patent US 5968822.
 ACCESSION AR080679
 VERSION AR080679.1 GI:10007409
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1721)
 AUTHORS Pecker,I., Violdavsky,I. and Feinstein,E.
 TITLE Polynucleotide encoding a polypeptide having heparanase activity
 JOURNAL Patent: US 5968822-A 9 19-OCT-1999;
 FEATURES Location/Qualifiers
 source 1..1721
 /organism="unknown"

BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN /organism="unknown"

Query Match 100.0%; Score 23; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCGATCCCAAGAGGATCAAC 23
 Db 372 TTCGATCCCAAGAGGATCAAC 394

RESULT 13
 LOCUS AR080680 1721 bp DNA linear PAT 31-AUG-2000
 DEFINITION Sequence 11 from patent US 5968822.
 ACCESSION AR080680
 VERSION AR080680.1 GI:10007410
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1721)
 AUTHORS Pecker,I., Violdavsky,I. and Feinstein,E.
 TITLE Polynucleotide encoding a polypeptide having heparanase activity
 JOURNAL Patent: US 5968822-A 11 19-OCT-1999;
 FEATURES Location/Qualifiers
 source 1..1721
 /organism="unknown"

BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN /organism="unknown"

Query Match 100.0%; Score 23; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCGATCCCAAGAGGATCAAC 23
 Db 372 TTCGATCCCAAGAGGATCAAC 394

RESULT 14
 LOCUS AR125603 1721 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 1 from patent US 6177545.
 ACCESSION AR125603
 VERSION AR125603.1 GI:14111665
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1721)
 AUTHORS Pecker,I., Violdavsky,I., Friedman,Y. and Perets,T.
 TITLE Heparanase specific molecular probes and their use in research and
 medical applications
 JOURNAL Patent: US 6177545-A 1 23-JAN-2001;
 FEATURES Location/Qualifiers
 source 1..1721
 /organism="unknown"

BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN /organism="unknown"

Query Match 100.0%; Score 23; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCGATCCCAAGAGGATCAAC 23
 Db 372 TTCGATCCCAAGAGGATCAAC 394

RESULT 15
 LOCUS AR125604 1721 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 3 from patent US 6177545.
 ACCESSION AR125604
 VERSION AR125604.1 GI:14111666
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 1721)
 AUTHORS Pecker,I., Violdavsky,I., Friedman,Y. and Perets,T.
 TITLE Heparanase specific molecular probes and their use in research and
 medical applications
 JOURNAL Patent: US 6177545-A 3 23-JAN-2001;
 FEATURES Location/Qualifiers
 source 1..1721
 /organism="unknown"

BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN /organism="unknown"

Query Match 100.0%; Score 23; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 2.1;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 TTCGATCCCAAGAGGATCAAC 23
 Db 372 TTCGATCCCAAGAGGATCAAC 394

Search completed: February 16, 2004, 11:43:02
 Job time : 109.813 secs

This Page Blank (usp10)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 : Search time 89.3432 Seconds
(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-6
Perfect score: 23
Sequence: 1 ttcgacccaagaagatcaac 23

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 22781392 segs, 1215238056 residues
Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estcov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_ges_hum:*
18: em_ges_inv:*
19: em_ges_pln:*
20: em_ges_vrt:*
21: em_ges_fun:*
22: em_ges_mam:*
23: em_ges_mus:*
24: em_ges_pro:*
25: em_ges_rnd:*
26: em_ges_phg:*
27: em_ges_vrt1:*
28: gb_ges1:*
29: gb_ges2:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	23	100.0	881	14	CB988510
2	23	100.0	924	13	B0691142
3	23	100.0	1185	9	AL552174
4	23	100.0	1201	9	AL545270

C	5	18.8	81.7	494	29	CC066085	CSU-K33r.
C	6	18.8	81.7	711	29	B2537295	OGAEJ93TC
C	7	18.8	81.7	711	29	B2539243	OGAM62TC
C	8	18.4	80.0	581	9	A1965004	fc85e07.y
C	9	18.4	80.0	592	14	CB091033	gy83f07.g
C	10	18.4	80.0	594	14	CB091179	h899d02.g
C	11	18.2	79.1	401	9	A1624038	ts25h10.x
C	12	18.2	79.1	483	13	B0821234	UB20CPG09
C	13	18.2	79.1	519	13	B0833017	T040G08 P
C	14	18.2	79.1	568	29	CC327702	OC08S65TH
C	15	18.2	79.1	603	28	BH549506	BOHSC40TF
C	16	18.2	79.1	623	13	B0835590	T075H04 P
C	17	18.2	79.1	669	13	B0837501	T102E06 P
C	18	18.2	79.1	696	13	B0892096	P059D01 P
C	19	18.2	79.1	717	13	B0813251	T019D07 P
C	20	18.2	79.1	812	28	BH439125	BOHRS23TF
C	21	18.2	79.1	853	29	BZ409786	OGACF81TC
C	22	18.2	79.1	890	29	BZ973851	PUG1W57TB
C	23	18.2	79.1	948	29	CC008795	PUDM49TD
C	24	18.2	79.1	948	29	CA621440	w1ln-DK00
C	25	17.8	77.4	393	9	AJ225474	AJ225474
C	26	17.8	77.4	400	29	FR0048882	Fugu rubr
C	27	17.8	77.4	497	28	AQ716252	HS_5452-B
C	28	17.8	77.4	1072	29	CNS054DM	AL320611 Tetradon
C	29	17.8	77.4	1078	10	BE615628	601278645
C	30	17.4	75.7	420	29	CC054600	SALK_0778
C	31	17.4	75.7	572	29	CC414518	PUG542TD
C	32	17.4	75.7	597	28	AQ563293	HS_5334_B
C	33	17.4	75.7	659	14	CB449302	703490 MA
C	34	17.4	75.7	701	29	AG105115	Pan tlog1
C	35	17.4	75.7	716	28	BH095882	RPCT-24-2
C	36	17.4	75.7	720	28	BH427866	BOCMK6OTR
C	37	17.4	75.7	787	28	BH525146	BOHSD21TF
C	38	17.4	75.7	800	29	BZ285719	CH230-255
C	39	17.4	75.7	1071	28	BZ165314	CH230-462
C	40	17.2	74.8	140	29	BZ539173	OGAFV20TC
C	41	17.2	74.8	175	29	BZ712362	OGDM29TC
C	42	17.2	74.8	178	29	BZ712351	OGDM29TC
C	43	17.2	74.8	186	29	BZ659850	OGANU61TC
C	44	17.2	74.8	197	9	AV358527	AV358527
C	45	17.2	74.8	239	13	BQ454119	sac76c06.

ALIGNMENTS

RESULT 1
CB988510
LOCUS
DEFINITION AGENCOURT 13905817 NIH MGC 147 Homo sapiens cDNA clone
IMAGE:30340461 5', mRNA sequence.
ACCESSION CB988510
VERSION CB988510.1 GI:30283030
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 881)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished
COMMENT Contact: Robert Strusberg, Ph.D.
Email: cga@bbs-remail.nih.gov
Tissue Procurement: Dr. Stefan Hansson
CDNA Library Preparation: Michael J. Brownstein (NHGRI) with help
and advice from Piero Carninci (RIKEN)
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Agencourt Bioscience Corporation
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
http://image.llnl.gov
Plate: NDA370 row: f column: 22

FEATURES

source

High quality sequence stop: 664.

Location/Qualifiers

1..881

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone_image="30340461"

/tissue_type="Human Placenta"

/lab_host="DH10B Tona"

/clone_lib="NIH MGC 147"

/note="Organ: placenta; Vector: pBluescript; Site: 1: att-xhoI, Site 2: BamH; Oligo-dt primed using primer 5'-TTTTTTTTTTTNN-3', size-selected for average insert size 2.3 kb and normalized to R0T 5. This is a primary library enriched for full-length clones and constructed using the Cap-trapper method (Carinci, in preparation). Library constructed by M. Brownstein (NIH/NHGRI, National Institutes of Health). Note: This is a NIH MGC library."

BASE COUNT 200 a 244 c 229 g 208 t

ORIGIN

Query Match 100.0%; Score 23; DB 14; Length 881;

Best Local Similarity 100.0%; Pred. No. 4.3; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGATCAAC 23

Db 431 TTCGATCCCAAGAGATCAAC 453

RESULT 2

LOCUS

BO691142 924 bp mRNA linear EST 15-JUL-2002

DEFINITION AGSCCORT 8343629 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6250265

5' mRNA sequence.

BO691142.1 GI:21816458

EST.

ORGANISM Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 924)

NIH-MGC http://mgs.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cga@db-remail.nih.gov

Tissue Procurement: ATCC

CDNA Library Preparation: Rubin Laboratory

CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LNL at:

http://image.llnl.gov

Plate: L1CM2393 row: a column: 18

High quality sequence stop: 710.

FEATURES

source

Location/Qualifiers

1..924

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone_image="6250265"

/tissue_type="ductal carcinoma, cell line"

/lab_host="DH10B (phage-resistant)"

/clone_lib="NIH_MGC_110"

/note="Organ: pancreas; Vector: pOTB7; Site: 1: XhoI;

Site 2: EcoRI; CDNA made by oligo-dt priming.

directionally cloned into EcoRI/XhoI sites using the

following 5' adaptor: GGCACAG(G). Library constructed by

ling Hong in the laboratory of Gerald M. Rubin (University

of California, Berkeley) using ZAP-CDNA synthesis kit

BASE COUNT

(Stratagene) and Superscript II RT (Life Technologies).
Note: this is a NIH_MGC library."

203 a 271 c 227 g 219 t 4 others

ORIGIN

Query Match 100.0%; Score 23; DB 13; Length 924;

Best Local Similarity 100.0%; Pred. No. 4.4; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGATCAAC 23

Db 444 TTCGATCCCAAGAGATCAAC 466

RESULT 3

LOCUS

AL552174 1185 bp mRNA linear EST 31-MAY-2003

DEFINITION AL552174 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

clone CSOD1059YN15 5-PRIME, mRNA sequence.

AL552174.2 GI:31273990

EST.

ORGANISM Homo sapiens (human)

Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 1185)

Li, W.B., Gruber, C., Jessee, J., and Polayes, D.

Full-length cDNA libraries and normalization

Unpublished

On Feb 15, 2001 this sequence version replaced gi:12890820.

Contact: Genoscope

Genoscope - Centre National de Sequencage

BP 191 91006 Evry cedex - France

Email: seqref@genoscope.cns.fr, Web: www.genoscope.cns.fr

Library was constructed by Life Technologies, a division of

Invitrogen. This sequence belongs to sequence cluster 2469.r For

more information about this cluster, see

http://www.genoscope.cns.fr/

cgf-bin/cluster.cgi?seq=CSOD1059CG08QP1&cluster=2469.r. Contact:

Feng Liang Email: fliang@lifetech.com URL: http://fulllength.invitrogen.com/Invitrogen Corporation 1600

Paradey Avenue Genoscope sequence ID: CSOD1059CG08QP1.

FEATURES

source

Location/Qualifiers

1..1185

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="CSOD1059YN15"

/tissue_type="PLACENTA COT 25-NORMALIZED"

/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"

/note="1st strand cDNA was primed with a NotI-oligo (GT)

primer. Five prime end enriched, double-strand cDNA was

digested with Not I and cloned into the Not I and EcoR V

sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT 280 a 293 c 293 g 280 t 39 others

ORIGIN

Query Match 100.0%; Score 23; DB 9; Length 1185;

Best Local Similarity 100.0%; Pred. No. 4.7; Mismatches 0; Indels 0; Gaps 0;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TTCGATCCCAAGAGATCAAC 23

Db 438 TTCGATCCCAAGAGATCAAC 460

RESULT 4

LOCUS

AL545270 1201 bp mRNA linear EST 31-MAY-2003

DEFINITION AL545270 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

clone CSOD1028YF04 5-PRIME, mRNA sequence.

ACCESSION AL545270

```

VERSION      AL545270.2  GI:31267106
KEYWORDS     EST.
SOURCE       Homo sapiens (human)
ORGANISM     Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE    1 (bases 1 to 1201)
AUTHORS      Li, W.B., Gruber, C., Jesssee, J., and Polayes, D.
TITLE        Full-length cDNA libraries and normalization
JOURNAL      Unpublished
COMMENT      On Feb 15, 2001 this sequence version replaced gi:12877751.
              Contact: Genoscope
              Genoscope - Centre National de Sequencage
              BP 191 91006 Evry cedex - France
              Email: segre@genoscope.cns.fr, Web : www.genoscope.cns.fr
              Library was constructed by Life Technologies, a division of
              Invitrogen. This sequence belongs to sequence cluster 2469.r For
              more information about this cluster, see
              http://www.genoscope.cns.fr/
              cgi-bin/cluster.cgi?seq=CSOD1028DC020P1&cluster=2469.r. Contact :
              Feng Liang Email : fliang@lifetech.com URL : Corporation 1600
              Faraday Avenue Genoscope sequence ID : CSOD1028DC020P1.
              Location/Qualifiers
                1..1201
                  /organism="Homo sapiens"
                  /mol_type="mRNA"
                  /db_xref="taxon:9606"
                  /clone="CSOD1028P04"
                  /cdate="PLACENTA COT 25-NORMALIZED"
                  /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
                  /note="1st strand cDNA was primed with a NotI-oligo (dT)
                  primer. Five prime end enriched, double-strand cDNA was
                  digested with Not I and cloned into the Not I and EcoR V
                  sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT   292 a      282 c      305 g      279 t
ORIGIN
Query Match 100.0%; Score 23; DB 9; Length 1201;
Best Local Similarity 100.0%; Pred. No. 4.7;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAAC 23
    |||||
Db 431 TTGCATCCCAAGAGGATCAAC 453

RESULT 5
CC066085/c 494 bp DNA linear GSS 16-APR-2003
LOCUS      CSU-K33r.41K4.T7 CSU-K33r Aedes aegypti genomic clone CSU-K33r.41K4
DEFINITION , genomic survey sequence.
ACCESSION  CC066085
VERSION    CC066085.1 GI:29904591
KEYWORDS   GSS.
SOURCE     Aedes aegypti (yellow fever mosquito)
ORGANISM   Aedes aegypti
            Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
            Neoptera; Endopterygota; Diptera; Nematocera; Culicoidae; Aedes.
            1 (bases 1 to 494)
            Loftus, B., Shetty, J., Severson, D., Brown, S. and Knudson, D.
            Unpublished
            Other_GSSs: CSU-K33r.41K4.SP6
            Contact: Brendan Loftus
            Department of Eukaryotic Genomics
            TIGR
            9712 Medical Center Drive, Rockville, MD 20850, USA
            Tel: 301-838-3543
            Fax: 301-838-0208
            Email: enta@tigr.org
            Library was provided by Susan Brown and Dennis Knudson at Colorado
            State University:

```

```

Seq primer: T7
Class: BAC ends.
Location/Qualifiers
  1..494
    /organism="Aedes aegypti"
    /mol_type="genomic DNA"
    /strain="Rockville"
    /db_xref="taxon:7159"
    /clone="CSU-K33r.41K4"
    /note="Vector: pBelBAC11; Site_1: HindIII"
BASE COUNT   177 a      78 c      123 g      116 t
ORIGIN
Query Match 81.7%; Score 18.8; DB 29; Length 494;
Best Local Similarity 90.9%; Pred. No. 3.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAA 22
    |||||
Db 95 TTGCATCCCAAGAGGATCAA 74

RESULT 6
BZ527295/c 711 bp DNA linear GSS 16-DEC-2002
LOCUS      OGAEGJ3TC.ZM2_0.7_1.5_KB Zea mays genomic clone ZMMBMA0042018,
DEFINITION genomic survey sequence.
ACCESSION  BZ527295
VERSION    BZ527295.1 GI:27067857
KEYWORDS   GSS.
SOURCE     Zea mays
            Zea mays
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
            clade; Panicoidae; Andropogoneae; Zea.
            1 (bases 1 to 711)
            Whitelaw, C.A., Quackenbush, J., Van Aken, S., Uterback, T., Resnick
            , R.W., Nundberg, A., Robbins, D. and Lakey, N.
            Consortium for Maize Genomics
            Unpublished
            Contact: Cathy Whitelaw
            TIGR
            9712 Medical Center Drive, Rockville, MD 20850, USA
            Tel: 301-838-5843
            Fax: 301-838-0208
            Email: whitelaw@tigr.org
            Seq primer: T7
            Class: shared ends.
            Location/Qualifiers
              1..711
                /organism="Zea mays"
                /mol_type="genomic DNA"
                /strain="873"
                /db_xref="taxon:4577"
                /clone="ZMMBMA0042018"
                /clone_lib="ZM2_0.7_1.5_KB"
                /note="Vector: pBSCSK-; Site_1: HincII; 0.7-1.5 kb
                methylation filtered genomic DNA library"
BASE COUNT   161 a      186 c      158 g      206 t
ORIGIN
Query Match 81.7%; Score 18.8; DB 29; Length 711;
Best Local Similarity 90.9%; Pred. No. 3.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 1 TTGCATCCCAAGAGGATCAA 22
    |||||
Db 353 TTGCATCCCAAGAGGATCAA 332

RESULT 7

```

[illegible]


```

RESULT 12
B0821234/C 483 bp mRNA linear EST 15-OCT-2002
LOCUS UB20CPG09 Populus tremula cambium cDNA library Populus tremula cDNA
DEFINITION
ACCESSION B0821234
VERSION B0821234.1 GI:23987320
KEYWORDS EST.
SOURCE Populus tremula
ORGANISM Populus tremula
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Eudicotyledons; core eudicots; rosids
; euroside 1; Malpighiales; Salicaceae; Populus.
REFERENCE
AUTHORS Uneberg,P., Bhalerao,R.R., Jansson,S. and Sterky,F.
TITLE The poplar tree transcriptome: Analysis of expressed sequence tags
from multiple libraries
JOURNAL Unpublished
COMMENT Contact: BHALERAO RUPALI R.
Umea Plant Science Center
Department of Plant Physiology
University of Umea, 901 87 Umea, Sweden
Tel: +46 90 786 5279
Fax: +46 90 786 6676
Email: rupali.bhalerao@plantphys.umu.se.
FEATURES
source
1..483
/organism="Populus tremula"
/mol_type="mRNA"
/db_xref="caxon:113636"
/tissue_type="cambium"
/clone_lib="Populus tremula cambium cDNA library"
BASE COUNT 118 a 165 c 84 g 116 t
ORIGIN
Query Match 79.1%; Score 18.2; DB 13; Length 483;
Best Local Similarity 87.0%; Pred. No. 6.4e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Cy 1 TTGATCCCAAGAGATCAAC 23
Db 479 TTGCTCCCAAGAGATCAAC 457
RESULT 13
LOCUS B0833017/c
DEFINITION B0833017 519 bp mRNA linear EST 15-OCT-2002
T040G08 Populus apical shoot cDNA library Populus tremula x Populus
tremuloides cDNA 5 prime, mRNA sequence.
ACCESSION B0833017
VERSION B0833017
KEYWORDS EST.
SOURCE Populus tremula x Populus tremuloides
ORGANISM Populus tremula x Populus tremuloides
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Eudicotyledons; core eudicots; rosids
; euroside 1; Malpighiales; Salicaceae; Populus.
REFERENCE
AUTHORS Uneberg,P., Bhalerao,R.R., Jansson,S. and Sterky,F.
TITLE The poplar tree transcriptome: Analysis of expressed sequence tags
from multiple libraries
JOURNAL Unpublished
COMMENT Contact: BHALERAO RUPALI R.
Umea Plant Science Center
Department of Plant Physiology
University of Umea, 901 87 Umea, Sweden
Tel: +46 90 786 5279
Fax: +46 90 786 6676
*Email: rupali.bhalerao@plantphys.umu.se.
Location/Qualifiers
FEATURES

```

```

source
    1..519
        /organism="Populus tremula x Populus tremuloides"
        /mol_type="mRNA"
        /db_xref="taxon:47664"
        /tissue_type="apical shoot"
        /clone_id="Populus apical shoot cDNA library"
BASE COUNT      123 a      127 c      125 g      144 t
ORIGIN
Query Match      79.1%; Score 18.2; DB 13; Length 519;
Best Local Similarity 87.0%; Pred. No. 6.5e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1 TTGCATCCCAAGAGGATCAAC 23
       ||| ||||| ||||| ||||| |||||
Db      47 TTCTCTCCCAAGAGGTATCAAC 25

RESULT_14
LOCUS      CC327702          568 bp      DNA      linear      GSS 16-MAY-2003
DEFINITION OGB0865TIBB_ZM_0.7_1.5_KB Zea mays genomic clone ZMMBma0369K09,
            genomic survey sequence.
ACCESSION   CC327702
VERSION     CC327702.1 GI:30796873
KEYWORDS    GSS.
SOURCE      Zea mays
ORGANISM    Zea mays
REFERENCE   Eukaryote; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
AUTHORS     Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
            clade; Panicoidae; Andropogoneae; Zea .
            1 (bases 1 to 568)
            Whiteaw,C.A., Quackenbush,J., Van Aken,S., Uterbacher,T., Resnick
            ,A., Frazer,C.M., Budiman,M.A., Begell,J.A., Rohlfing,T., Citek
            ,R.W., Nurnberg,A., Robbin,D. and Lakey,N.
            Consortium for Maize Genomics
TITLE       Unpublished
JOURNAL
COMMENT     Contact: Cathy Whiteaw
            TIGR
            9712 Medical Center Drive, Rockville, MD 20850, USA
            Tel: 301-838-5843
            Fax: 301-838-0208
            Email: whiteaw@tigr.org
            Seq primer: TR
            Class: sheared ends.
FEATURES
    source
        1..568
            /organism="Zea mays"
            /mol_type="genomic DNA"
            /stratn="g73"
            /db_xref="taxon:4577"
            /clone="ZMMBma0369K09"
            /clone_id="ZM_0.7_1.5_KB"
            /note="vector: pBCKS-; Site 1: HincII; 0.7-1.5 kb
                    methylation filtered genomic DNA library"
BASE COUNT      212 a      73 c      85 g      198 t
ORIGIN
Query Match      79.1%; Score 18.2; DB 29; Length 568;
Best Local Similarity 87.0%; Pred. No. 6.7e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY      1 TTGCATCCCAAGAGGATCAAC 23
       ||| ||||| ||||| ||||| |||||
Db      296 TTAGACACAAGAAGATCAAC 318

RESULT_15
BH549506      603 bp      DNA      linear      GSS 14-DEC-2001
BOHSC40TF BOHS Brassica oleracea genomic clone BOHSC40, genomic
survey sequence.
ACCESSION   BH549506
```


VERSION BH549506.1 GI:17801286
 KEYWORDS GSS.
 SOURCE Brassica oleracea
 ORGANISM Brassica oleracea

Brassicaceae
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
 ; eurosids II; Brassicales; Brassicaceae; Brassica.
 1 (bases 1 to 603)

REFERENCE Town, C.D., Van Aken, S., Utterback, T., Koo, H. and Fraser, C.M.
 TITLE Whole genome shotgun sequencing of Brassica oleracea
 JOURNAL Unpublished
 COMMENT Other GSSs: BOHSC40TR
 Contact: Chris Town

TIGR
 9712 Medical Center Drive, Rockville, MD 20850, USA.
 Tel: 301-838-3523
 Fax: 301-838-0208
 Email: cdtown@tigr.org
 DNA is from a doubled haploid provided by Tom Osborn.
 Seq primer: TF
 Class: sheared ends.

FEATURES
 Location/Qualifiers

1..603
 /organism="Brassica oleracea"
 /mol_type="genomic DNA"
 /strain="TO1000DH3"
 /db_xref="taxon:3712"
 /clone="BOHSC40"
 /note="Vector: PHOS1, site 1: BstXI; 2-3 kb sheared
 genomic DNA inserted into PHOS1 using BstXI linkers"
 BASE COUNT 189 a 147 c 94 g 173 t
 ORIGIN

Query Match 79.1%; Score 18.2; DB 28; Length 603;
 Best Local Similarity 87.0%; Pred.No. 6.8e+02;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TTCATCCCAAGAGCAATCAAC 23
 |||||
 Db 236 TTAGATTCCAGAGCAAC 258

Search completed: February 16, 2004, 13:41:01
 Job time : 92.3432 secs

This Page Blank (upto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 114.587 Seconds
(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-7

Perfect score: 24
Sequence: 1 gtagtgatgcacatgaactgaatc 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba: *
2: gb_htg: *
3: gb_in: *
4: gb_om: *
5: gb_ov: *
6: gb_pat: *
7: gb_ph: *
8: gb_pl: *
9: gb_pt: *
10: gb_ro: *
11: gb_sts: *
12: gb_sy: *
13: gb_un: *
14: gb_vi: *
15: em_ba: *
16: em_fun: *
17: em_hum: *
18: em_in: *
19: em_mu: *
20: em_om: *
21: em_ov: *
22: em_ov: *
23: em_ph: *
24: em_ph: *
25: em_pl: *
26: em_ro: *
27: em_sts: *
28: em_un: *
29: em_vi: *
30: em_htg_hum: *
31: em_htg_inv: *
32: em_htg_other: *
33: em_htg_mus: *
34: em_htg_pln: *
35: em_htg_rtd: *
36: em_htg_mam: *
37: em_htg_vrt: *
38: em_sy: *
39: em_htgo_hum: *
40: em_htgo_mus: *
41: em_htgo_other: *

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match Length	DB ID	Description
1	24	100.0	24 6 AR080673	AR080673 Sequence
2	24	100.0	24 6 AR080678	AR080678 Sequence
3	24	100.0	24 6 AR125608	AR125608 Sequence
4	24	100.0	24 6 AR287440	AR287440 Sequence
5	24	100.0	24 6 AR287442	AR287442 Polynucle
6	24	100.0	24 6 BD074426	BD074426 Polynucle
7	24	100.0	1593 6 AR210040	AR210040 Sequence
8	24	100.0	1593 6 BD136761	BD136761 Human pla
9	24	100.0	1662 4 AF281160	AF281160 Bos tau
10	24	100.0	1669 9 AF084467	AF084467 Homo sapi
11	24	100.0	1694 9 AF152376	AF152376 Homo sapi
12	24	100.0	1713 6 AR156691	AR156691 Sequence
13	24	100.0	1713 6 AX034643	AX034643 Sequence
14	24	100.0	1721 6 AR080679	AR080679 Sequence
15	24	100.0	1721 6 AR080680	AR080680 Sequence
16	24	100.0	1721 6 AR125603	AR125603 Sequence
17	24	100.0	1721 6 AR125604	AR125604 Sequence
18	24	100.0	1721 6 AR194189	AR194189 Sequence
19	24	100.0	1721 6 AR194190	AR194190 Sequence
20	24	100.0	1721 6 AR221285	AR221285 Sequence
21	24	100.0	1721 6 AR221286	AR221286 Sequence
22	24	100.0	1721 6 AR243203	AR243203 Sequence
23	24	100.0	1721 6 AR243204	AR243204 Sequence
24	24	100.0	1721 6 AR287435	AR287435 Sequence
25	24	100.0	1721 6 AR287436	AR287436 Polynucle
26	24	100.0	1721 6 BD074427	BD074427 Polynucle
27	24	100.0	1721 6 BD074428	BD074428 Polynucle
28	24	100.0	1722 6 AX136167	AX136167 Sequence
29	24	100.0	1722 6 BD123536	BD123536 Secretory
30	24	100.0	1722 9 AK075400	AK075400 Homo sapi
31	24	100.0	1723 6 AR156692	AR156692 Sequence
32	24	100.0	1723 6 AX034645	AX034645 Sequence
33	24	100.0	1724 6 AX147946	AX147946 Sequence
34	24	100.0	1724 9 AF165154	AF165154 Homo sapi
35	24	100.0	1758 9 AF144325	AF144325 Homo sapi
36	24	100.0	1810 9 BC051321	BC051321 Homo sapi
37	24	100.0	1899 6 BD074430	BD074430 Polynucle
38	24	100.0	1899 6 BD074431	BD074431 Polynucle
39	24	100.0	3726 6 AR235866	AR235866 Sequence
40	24	100.0	3726 6 AX019348	AX019348 Sequence
41	24	100.0	3726 6 BD131218	BD131218 Human hep
42	24	100.0	3726 9 AF155510	AF155510 Homo sapi
43	21.4	89.2	149188 9 AC114781	AC114781 Homo sapi
44	19.8	82.5	118890 2 AC138159	AC138159 Rattus no
45	19.8	82.5	176787 2 AC138158	AC138158 Rattus no

ALIGNMENTS

RESULT 1
LOCUS AR080673 24 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 2 from patent US 5968822.
ACCESSION AR080673
VERSION AR080673.1 GI:10007403
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Violdavsky,I. and Feinstein,E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 2 19-OCT-1999;

FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTATC 24
Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 2
LOCUS AR080678 24 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 7 from patent US 5968822.
ACCESSION AR080678
VERSION AR080678.1 GI:10007408
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I. and Feinstein,E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 7 19-OCT-1999;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTATC 24
Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 3
LOCUS AR125608 24 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 7 from patent US 6177545.
ACCESSION AR125608
VERSION AR125608.1 GI:14111670
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6177545-A 7 23-JAN-2001;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTATC 24
Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 4
LOCUS AR287440 24 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 7 from patent US 6531129.
ACCESSION AR287440
VERSION AR287440.1 GI:29725134
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6531129-A 7 11-MAR-2003;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTATGCCATGTAAGTATC 24
Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 5
LOCUS BD074421 24 bp DNA linear PAT 27-AUG-2002
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell.
ACCESSION BD074421
VERSION BD074421.1 GI:22620024
KEYWORDS JP 2001514855-A/2.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I. and Elena,F.
TITLE Polynucleotide encoding polypeptide having heparanase activity and
expression of the polypeptide in induced cell
JOURNAL Patent: JP 2001514855-A 2 18-SEP-2001;
INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES
& DEVELOPMENT LTD
OS Nucleic acid
PN JP 2001514855-A/2
PD 18-SEP-2001
PF 31-AUG-1998 JP 2000508806 09/109386 PI
PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US
IRIS PECKER, ISRAEL VLODAVSKY, FEINSTEIN ELENA
PC C12N15/09,A61K38/00,A61P9/10,A61P17/00,A61P29/00,A61P35/00, PC
A61P37/00,
PC A61P43/00,C12N5/10,C12N6/24,C12Q1/68,G01N33/15,G01N33/50// PC
A61K39/395,
PC A61K39/395,C12N15/00,A61K37/02,C12N5/00
CC Polynucleotide encoding polypeptide having
heparanase activity
and
CC expression of the polypeptide in induced cell FH key
location/Qualifiers
FT source 1..24
/organism="Nucleic acid".
FEATURES Location/Qualifiers
source 1..24
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 6
BD074426 24 bp DNA linear PAT 27-AUG-2002
LOCUS
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell.
ACCESSION BD074426
VERSION BD074426.1 GI:22620029
KEYWORDS JP 2001514855-A/7.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker, I., Vlodayevsky, I. and Elena, F.
TITLE Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell
JOURNAL Patent: JP 2001514855-A 7 18-SEP-2001;
INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD
OS Nucleic acid
PN JP 2001514855-A/7
PD 18-SEP-2001
PP 31-AUG-1998 JP 2000508806
PR 02-SEP-1997 US 08/922170, 02-JUN-1998 US 09/109386 PT
PIS PECKER, ISRAEL, VLADAVSKY, FEINSTEIN ELENA
PC C12N15/09, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC A61P37/00, PC A61P43/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC A61K39/395, PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
CC Polynucleotide encoding polypeptide having heparanase activity
CC and
CC expression of the polypeptide in induced cell FH Key
LOCATION/Qualifiers 1..24
FT source /organism='Nucleic acid'.
FEATURES location/Qualifiers 1..24
source /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT 7 a 4 c 6 g 7 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 7
AR210040 1593 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 1 from patent US 6387643.
ACCESSION AR210040
VERSION AR210040.1 GI:21512167
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1593)
AUTHORS Heintz, R. Leroy, Fairbanks, M.B. and Mildner, A.M.
TITLE Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
JOURNAL Patent: US 6387643-A 1 14-MAY-2002;
FEATURES location/Qualifiers 1..1593
source /organism='unknown'

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
855 GTAGTATGCCATGTAAGTATC 832

Db 1 GTAGTATGCCATGTAAGTATC 24

RESULT 8
BD136761 1593 bp DNA linear PAT 18-SEP-2002
LOCUS
DEFINITION Human platelet heparanase polypeptide, polynucleotide molecule encoding the same and method of identifying compound changing heparanase activity.
ACCESSION BD136761
VERSION BD136761.1 GI:23231706
KEYWORDS JP 2002504376-A/1.
SOURCE unidentified
ORGANISM unidentified

REFERENCE 1 (bases 1 to 1593)
AUTHORS Heintz, R. Leroy, Fairbanks, M.B. and Mildner, A.M.
TITLE Human platelet heparanase polypeptide, polynucleotide molecule encoding the same and method of identifying compound changing heparanase activity.
JOURNAL Patent: JP 2002504376-A 1 12-FEB-2002;
PHARMACIA & UPJOHN CO
OS Unidentified
PN JP 2002504376-A/1
PD 12-FEB-2002
PP 18-FEB-1998 JP 2000533569
PR 24-FEB-1998 US 60/075706, 26-MAR-1998 US 60/079401 PT
PIS ROBERT L. HEINTZ, MICHAEL B. FAIRBANKS, ANA M. MILDNER
PC C12N15/09, C07K16/40, C12N1/21, C12N5/10, C12N9/24, C12Q1/34, C12N15/00, C12N5/00
CC Strandedness: Double;
CC Topology: Linear;
CC Human platelet heparanase polypeptide, polynucleotide molecule
CC encoding
CC the same and method of identifying compound changing CC
FH key location/Qualifiers 1..1593
FT source /organism='Unidentified'.
FEATURES location/Qualifiers 1..1593
source /organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGTATC 24
1 GTAGTATGCCATGTAAGTATC 24

Db 855 GTAGTATGCATGTAAGTAATC 832

RESULT 9
AF281160/c 1662 bp mRNA linear MAM 12-APR-2001
LOCUS Bos taurus heparanase mRNA, complete cds.
DEFINITION AF281160
ACCESSION AF281160.2 GI:13606094
VERSION
KEYWORDS
SOURCE Bos taurus (cow)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.
REFERENCE 1 (bases 1 to 1662)
AUTHORS Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
TITLE Expression of Heparanase mRNA in Bovine Placenta During Gestation
JOURNAL Unpublished
JOURNAL 2 (bases 1 to 1662)
REFERENCE Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
AUTHORS Direct Submission
JOURNAL Submitted (22-JUN-2000) Laboratory of Reproductive Endocrinology, National Institute of Animal Industry, Tsukuba-norindanchi, PO Box 5, Tsukuba, Ibaraki 305-0901, Japan
3 (bases 1 to 1662)
REFERENCE Kizaki, K., Nakano, H., Takahashi, T., Imai, K. and Hashizume, K.
AUTHORS Direct Submission
JOURNAL Submitted (12-APR-2001) Laboratory of Reproductive Endocrinology, National Institute of Animal Industry, Tsukuba-norindanchi, PO Box 5, Tsukuba, Ibaraki 305-0901, Japan
REMARK COMMENT
FEATURES
SOURCE On Apr 12, 2001 this sequence version replaced gi:9408602.
Location/Qualifiers
1. 1662
/organism="Bos taurus"
/mol_type="mRNA"
/db_xref="taxon:9913"
/cissue_type="placenta"
25. 1662
/note="endoglycosidase"
/codon_start=1
/product="heparanase"
/protein_id="AAF87301.2"
/db_xref="GI:13606095"
/translation="MLACRKPGLRPPILLPLILGPGCGSPGPAAPADAARE
PTEPRPLIVSPFLSVTIDANLATDPRFPLIGSSKRLTLARLAAYLRFGCKGD
FLIDPKKEPFEFRSTYWSLQSNODICKSGISPSOVBKLEWPFQOVLREQYOK
KFNSTYSRSSVDLVYTFANSGDLIFGVALLRTDMHDSNAOQLLDYCSKXY
NISWELGNEPNSFORKAGIFINGROLGEDPIEFKRLGKSAFNKAKYGPDIQPRN
TVKMLKSEFLKAGGEVIDSVTHHYVNGRIATKEDPLNPDILDTFISVQKTLVER
IRPLKWLGEITSAFGGAPFLSNTFAAGFMWLDKGLSARMGIEVVMRQVFLGAN
YHIVDGNPEPLPDYWSLLEPKLKYNTKATKAMSVGSDRSKRRVYLHCTNTPRYKGS
DLTIYALNHNVTKRLPHLPHLEKQVDKILKPSGIDGLSKSVQLNGQLTKWVDQ
TLPLMEKPRPSSSLGLPAFSYSPFVIRNAKVAACI"

BASE COUNT 435 a 404 c 402 g 421 t

ORIGIN

Query Match 100.0%; Score 24; DB 4; Length 1662;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 GTAGTATGCATGTAAGTAATC 24
|||||
Db 924 GTAGTATGCATGTAAGTAATC 901
|||||

RESULT 10
AF084467/c 1669 bp mRNA linear PRI 18-OCT-2000
LOCUS Homo sapiens heparanase mRNA, complete cds.
DEFINITION AF084467
ACCESSION AF084467.1 GI:5870623
VERSION

KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1669)
AUTHORS Dempsey, L.A., Plummer, T.B., Coombes, S.L. and Platt, J.L.
TITLE Heparanase expression in invasive trophoblasts and acute vascular damage
JOURNAL Glycobiology 10 (5), 467-475 (2000)
MEDLINE 20229546
PIRMBD 10764835
REFERENCE 2 (bases 1 to 1669)
AUTHORS Dempsey, L.A., Holzkecht, R.A. and Platt, J.L.
TITLE Identification of the cDNA encoding human heparanase
JOURNAL Unpublished
JOURNAL 3 (bases 1 to 1669)
REFERENCE Dempsey, L.A., Holzkecht, R.A. and Platt, J.L.
AUTHORS Direct Submission
JOURNAL Submitted (14-AUG-1998) Surgery, Duke University, Research Dr., Rm. 401 MSRB, Durham, NC 27710, USA
FEATURES
SOURCE 1. 1669
Location/Qualifiers
1. 1669
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/cell_line="mekakaryocyte"
/tissue_type="placenta"
1. 1638
/note="endoglycosidase; expressed in placenta and platelets"
/codon_start=1
/product="heparanase"
/protein_id="AAD54516.1"
/db_xref="GI:5870624"
/translation="MLRSKRALPPILLPLILGPGCLSPALPRPAQOQVVD
FTQEPPLIVSPFLSVTIDANLATDPRFPLIGSPKRLTLARLAAYLRFGCTKD
FLIDPKKESTFEFRSYWQOQVODICKSGISPPDVEKRLRMPYQOQLLRHXYOK
KFNSTYSRSSVDLVYTFANSGDLIFGVALLRTDLOMNSNAOQLLDYCSKXY
NISWELGNEPNSFLKADIFINGSGEDPTOLHKLRSKTPNKLKYGPDVQPRK
TAKWLKSEFLKAGGEVIDSVTHHYVNGRIATKEDPLNPDILDTFISVQKQVYRS
TRPKKWLGEITSAFGGAPFLSNTFAAGFMWLDKGLSARMGIEVVMQVFGACN
YHIVDGNPEPLPDYWSLLEPKLKYNTKATKAMSVGSDRSKRRVYLHCTNTPRYKGS
DLTIYALNHNVTKRLPYFPNSKQVDKILKPSGIDGLSKSVQLNGQLTKWVDQ
TLPLMEKPRPSSSLGLPAFSYSPFVIRNAKVAACI"

BASE COUNT 445 a 396 c 388 g 440 t

ORIGIN

Query Match 100.0%; Score 24; DB 9; Length 1669;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CY 1 GTAGTATGCATGTAAGTAATC 24
|||||
Db 900 GTAGTATGCATGTAAGTAATC 877
|||||

RESULT 11
AF152376/c 1694 bp mRNA linear PRI 28-JUL-1999
LOCUS Homo sapiens heparanase mRNA, complete cds.
DEFINITION AF152376
ACCESSION AF152376.1 GI:5616196
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 1694)
AUTHORS Kussie, P.H., Hulmes, J.D., Ludwig, D.L., Patel, S., Navarro, E.C., Seddon, A.P., Giorgio, N.A. and Bohlen, P.
TITLE Cloning and functional expression of a human heparanase gene
JOURNAL Biochem. Biophys. Res. Commun. 261 (1), 183-187 (1999)

MEDLINE 9935379
LOCUS 10405343
REFERENCE 2 (bases 1 to 1694)
AUTHORS Kuesle, P.H., Humes, J.D., Ludwig, D., Patel, S., Navarro, E.C.,
Seddon, A.P., Giorgio, N.A. and Bohlen, P.
TITLE Direct Submission
JOURNAL Submitted (18-MAY-1999) Protein Chemistry, Imclone Systems Inc.,
180 Varick Street, New York, NY 10014, USA
FEATURES
source
1. 1694
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/tissue_type="placenta"
15. 1646
/codon_start=1
/product="heparanase"
/protein_id="A045669.1"
/db_xref="GI:5616197"
/translation="MLRSKPA.PPIMLLIGPLSPGAL.PPAAOADVNDLDF
TOEPLHVSFSLVITDANLATDPRLLILGSKRTTLARGSPATIRREGTIDEL
IFPDKSTFEERSYWOSQVNDICTGSIIPDVEEKLRLWEPYOEOLLRKHYOKF
KNSTYSRSVDVLYTFANCSGLDIFGLNMLRTADLQWSSNQLLDYCSSGYNI
SWEIGENPNSFLKKADIFINGSLGDEDFIQLHKLRLRSTFNKALYGPDYQPPKRTA
KMLKSPFKAGGEVIDSVTHHYVNGRTATREDPLNDVDLDFISSVOKVQVESR
PGKRWIGERTSSAYGGAAPLSDPRAGFMWLDLGSARNGIEVWNRVFFGAGNH
LVNDENPDLPDYMLSLFKLVGRTVLMASVQSKRRKRLRYLHCTTNDPRYREGIL
TLVAINLHNVTKYLRPLPFSNKQVDYLLRLPLGPHGLSKSVOLNGLTLKMDVDTL
PPLMEKRLRPGSSILGLPAFSYSPFVINAQAACI"

BASE COUNT 465 a 398 c 391 g 440 t
ORIGIN

Query Match 100.0%; Score 24; DB 9; Length 1694;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTAATC 24
Db 908 GTAGTATGCCATGTAAGTAATC 885

RESULT 12
AR156691/c
LOCUS AR156691 1713 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 12 from patent US 6242238.
ACCESSION AR156691
VERSION AR156691.1 GI:15125395
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1713)
AUTHORS Freeman, C.Geo. Jeffrey., Hulett, M.Darren., Parish, C.Richard. and
Hamdorf, B.James.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
and uses therefor
JOURNAL Patent: US 6242238-A 12 05-JUN-2001;
FEATURES
source
1. 1713
/organism="unknown"
BASE COUNT 460 a 404 c 406 g 443 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTAATC 24
Db 939 GTAGTATGCCATGTAAGTAATC 916

RESULT 13

AX034643/c
LOCUS AX034643 1713 bp DNA linear PAT 22-SEP-2000
DEFINITION Sequence 12 from Patent EP1032656.
ACCESSION AX034643
VERSION AX034643.1 GI:10303224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Hamdorf, B.J., Freeman, C.G., Hulett, M.D. and Parish, C.R.
TITLE Isolated nucleic acid molecule encoding mammalian endoglucuronidase
and uses therefor
JOURNAL Patent: EP 1032656-A 12 06-SEP-2000;
UNIV AUSTRALIAN (AU)
FEATURES
source
1. 1713
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
46. 1677
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC10139.1"
/db_xref="GI:10303225"
/translation="MLRSKPA.PPIMLLIGPLSPGAL.PPAAOADVNDLDF
TOEPLHVSFSLVITDANLATDPRLLILGSKRTTLARGSPATIRREGTIDEL
IFPDKSTFEERSYWOSQVNDICTGSIIPDVEEKLRLWEPYOEOLLRKHYOKF
KNSTYSRSVDVLYTFANCSGLDIFGLNMLRTADLQWSSNQLLDYCSSGYNI
SWEIGENPNSFLKKADIFINGSLGDEDFIQLHKLRLRSTFNKALYGPDYQPPKRTA
KMLKSPFKAGGEVIDSVTHHYVNGRTATREDPLNDVDLDFISSVOKVQVESR
PGKRWIGERTSSAYGGAAPLSDPRAGFMWLDLGSARNGIEVWNRVFFGAGNH
LVNDENPDLPDYMLSLFKLVGRTVLMASVQSKRRKRLRYLHCTTNDPRYREGIL
TLVAINLHNVTKYLRPLPFSNKQVDYLLRLPLGPHGLSKSVOLNGLTLKMDVDTL
PPLMEKRLRPGSSILGLPAFSYSPFVINAQAACI"

BASE COUNT 460 a 404 c 406 g 443 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1713;
Best Local Similarity 100.0%; Pred. No. 0.36;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTAATC 24
Db 939 GTAGTATGCCATGTAAGTAATC 916

RESULT 14
AR080679/c
LOCUS AR080679 1721 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 9 from patent US 5968822.
ACCESSION AR080679
VERSION AR080679.1 GI:10007409
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1721)
AUTHORS Pecker, I., Vlodeavsky, I. and Feinstein, E.
TITLE Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 9 19-OCT-1999;
FEATURES
source
1. 1721
/organism="unknown"
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0.36;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAGTATGCCATGTAAGAATC 24
| | | | | | | | | | | | | | | | | | | | | | | | | |
Db 956 GTAGTATGCCATGTAAGAATC 933

RESULT 15

AR080680/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

FEATURES

SOURCE

BASE COUNT

ORIGIN

Query Match

Best local similarity

Matches

QY

Db

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

956 GTAGTATGCCATGTAAGAATC 933

| | | | | | | | | | | | | | | | | | | | | | | | | |

1 GTAGTATGCCATGTAAGAATC 24

| | | | | | | | | | | | | | | | | | | | | | | | | |

Search completed: February 16, 2004, 11:43:03
Job time: 115.587 secs

PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodevsky I;
XX
XX WPI; 1999-302255/25.
XX
PT New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
XX Example 1; Page 22; 63pp; English.
XX
CC The specification describes a polypeptide having heparanase (hp)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC PCR primers AAX35642-43 were used to amplify hp3 cDNA, in the course of
CC the invention.
XX
SQ Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;
XX
Query Match 100.0%; Score 24; DB 20; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 GTAGTGATGCCATGTAACCTGATC 24
Db 1 GTAGTGATGCCATGTAACCTGATC 24
XX
RESULT 2
AAX35647
ID AAX35647 standard; DNA; 24 BP.
XX
AC AAX35647;
XX
DT 09-JUN-1999 (first entry)
XX
DE PCR primer used to amplify human hp3 cDNA.
XX
XX Heparanase; hp; modulator; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neuritis;
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KW PCR primer; ss.
XX
XX Synthetic.
OS
XX WO9911798-A1.
PN
XX 11-MAR-1999.
FD
XX 31-AUG-1998; 98WO-US17954.
PF
XX 02-JUN-1998; 98US-0109386.
PR
XX 02-SEP-1997; 97US-0922170.
PR
XX (FRIE/) FRIEDMAN M M.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodevsky I;
XX
XX WPI; 1999-302255/25.

XX
XX New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
XX Example 1; Page 23; 63pp; English.
XX
CC The specification describes a polypeptide having heparanase (hp)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC PCR primers AAX35646-47 were used to amplify hp3 cDNA, in the course of
CC the invention.
XX
SQ Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;
XX
Query Match 100.0%; Score 24; DB 20; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1 GTAGTGATGCCATGTAACCTGATC 24
Db 1 GTAGTGATGCCATGTAACCTGATC 24
XX
RESULT 3
AAX75045
ID AAX75045 standard; DNA; 24 BP.
XX
AC AAX75045;
XX
DT 15-JAN-2001 (first entry)
XX
DE PCR primer HPL229 used to amplify human cDNA encoding heparanase.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease;
KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
XX Homo sapiens.
OS
XX WO200052178-A1.
PN
XX 08-SEP-2000.
PD
XX 14-FEB-2000; 2000WO-US03542.
PF
XX 01-MAR-1999; 99US-0258892.
PR
XX (INST-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodevsky I, Feinstein E;
XX
XX WPI; 2000-579289/54.
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases
XX
XX Disclosure; Page 44; 152pp; English.
XX
XX The present PCR primer was used to amplify a human cDNA sequence,

cell interaction with plasma lipoproteins, cellular susceptibility to certain viral and some bacterial and protozoa infections, or disintegration of neurodegenerative plaques. The polynucleotide is also useful in wound healing (e.g. thermal, chemical or radiation burns), and in the treatment of angioneurosis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa infections.

SQ Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

XX Query Match 100.0%; Score 24; DB 21; Length 24;
CC Best Local Similarity 100.0%; Pred. No. 0.012;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTGATGCCCATGTAACCTGAATC 24
|||
Db 1 GTAGTGATGCCCATGTAACCTGAATC 24

RESULT 5
ID AAA75067 standard; DNA; 24 BP.
AC AAA75067;
DT 15-JAN-2001 (first entry)
DE PCR primer Hpl 229 used to amplify human cDNA encoding heparanase.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
KM heparin-binding growth factor; cytokine; neurodegenerative plaque;
KW wound healing; infection; burn; angiogenesis; restenosis;
RV atherosclerosis; inflammation; neurodegenerative disease;
XX Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
XX WO200052178-A1.
XX
PD 08-SEP-2000.
XX
PF 14-FEB-2000; 2000WO-US03542.
XX
PR 01-MAR-1999; 99US-0258892.
XX
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M W.
XX
PI Pecker I, Vlodavsky I, Feinstein B;
XX
DR WPI; 2000-579289/54.
XX
PT New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases -
XX
PS Disclosure: Page 45; 152pp; English.

The present PCR primer was used to amplify a human cDNA sequence, which encoded a protein with heparanase catalytic activity. The heparanase (hpa) polynucleotide is useful in gene therapy, particularly in treating tumour, inflammation or autoimmunity. Particularly, the polynucleotide is useful in modulating the bioavailability of heparin-binding growth factors, cellular responses to heparin-binding growth factors (e.g. bFGF) and cytokines (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins, cellular susceptibility to certain viral and some bacterial and protozoa infections, or disintegration of neurodegenerative plaques. The polynucleotide is also useful in wound healing (e.g. thermal, chemical or radiation burns), and in the treatment of angioneurosis, restenosis, atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-Strausler Syndrome

CC or Creutzfeldt-Jakob disease), and some viral, bacterial or protozoa
CC infections.

Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
ID 1 GTAGTATGCCATGTAAGTATC 24

RESULT 6
AAZ33294
ID AAZ33294 standard; DNA; 24 BP.

AC AAZ33294;
DT 21-FEB-2000 (first entry)

XX Human heparanase PCR primer Hpl-229 SEQ ID NO:7.

XX Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
KM antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
KM metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KM mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KM inflammation; haemorrhagic nephritis; nephrotic syndrome;
KM autoimmune disease; anticancer; kidney disease; PCR primer; ss.

XX Synthetic.
OS Homo sapiens.

XX MO9957153-A1.

XX 11-NOV-1999.

XX 29-APR-1999; 99WO-US09255.

XX 01-MAY-1998; 98US-0071739.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodavsky I, Friedman Y, Perets T;

XX WPI; 2000-052944/04.

XX Heparanase-specific molecular probes useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX Example; Page 30; 90pp; English.

XX The present invention describes heparanase-specific molecular probes,
CC useful for methods of detecting heparanase in situ. The probes and
CC anti-heparanase antibodies are used to detect or quantify the expression
CC of heparanase, for diagnosis and monitoring of diseases (especially
CC metastasis), for treatment of heparanase-associated diseases (e.g.
CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence represents a PCR primer for human heparanase, which
CC is used in an example from the present invention.

XX Sequence 24 BP; 7 A; 4 C; 6 G; 7 T; 0 other;

Query Match 100.0%; Score 24; DB 21; Length 24;

Best Local Similarity 100.0%; Pred. No. 0.012;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
ID 1 GTAGTATGCCATGTAAGTATC 24

RESULT 7
ABL40753/C
ID ABL40753 standard; cDNA; 1584 BP.

AC ABL40753;

DT 03-JUL-2002 (first entry)

XX Chicken signal peptide/human heparanase chimeric cDNA.

XX Heparanase; catalytic; cytostatic; antiviral; antibacterial; enzyme;
KM anti-protozoan; neuroprotective; heparin; chicken; human; chimeric; ss.

XX Synthetic.
OS Gallus gallus.
OS Homo sapiens.

XX Key Location/Qualifiers
FH CDS 1..1584
FT /*tag= a
FT /*product= "chimeric chicken-human heparanase"

FT sig_peptide 1..57
FT /*tag= b
FT /*note= "chicken heparanase signal peptide"

FT mat_peptide 58..1581
FT /*tag= c
FT /*note= "human mature heparanase"

XX US2002034810-A1.

XX 21-MAR-2002.

XX 16-AUG-2001; 2001US-0930218.

XX 20-SEP-2000; 2000US-0666390.

XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA Goldsmidt O, Pecker I, Vlodavsky I, Michal I, Zcharia E;

XX WPI; 2002-338926/37.

XX P-PSDB; ABB07815.

XX Nucleic acid encoding avian and reptile heparanase polypeptide is
PT useful to treat various heparin-related disorders and the signal
PT peptide is useful in production of membrane-targeted or secreted
PT recombinant proteins -
XX Example; Page 24-25; 39pp; English.

XX The invention relates to an isolated avian and reptile nucleic acid,
CC encoding a polypeptide with heparanase catalytic activity. The signal
CC peptide of the nucleic acid can be used to express membrane-associated or
CC secreted proteins in heterologous expression systems. The encoded
CC polypeptides can be used to prevent tumour angiogenesis, metastasis and
CC invasion, and to intervene with pathologies associated with impaired
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoa and bacterial infections or
CC cell integration of neurodegenerative plaques. The present sequence
CC represents a chicken signal peptide/human heparanase chimeric cDNA
CC sequence.

XX Sequence 1584 BP; 424 A; 361 C; 373 G; 426 T; 0 other;

Query Match 100.0%; Score 24; DB 24; Length 1584;
Best Local Similarity 100.0%; Pred. No. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTGATGCCATGTAACGATC 24
|||
Db 846 GTAGTGATGCCATGTAACGATC 823

RESULT 8

AAZ11236/c
ID AAZ11236 standard; cDNA; 1593 BP.

AC AAZ11236;

DT 15-NOV-1999 (first entry)

DE Human pre-proheparanase coding sequence.

Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
inflammation; psoriasis; diabetic retinopathy; solid tumour; arthritis;
heparin degradation; anticoagulant neutralisation; asthma; CNS disease;
inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
tumour growth; fibroproliferative disorder; neurodegenerative disease;
therapy; ds.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 1..1593
/*tag= a
/product= pre-proheparanase

XX MO9943830-A2.

XX 02-SEP-1999.

XX 18-FEB-1999; 99WO-US01489.

XX 26-MAR-1998; 98US-0079401.

XX 24-FEB-1998; 98US-0075706.

XX (PHMA) PHARMACIA & UPJOHN CO.

XX Fairbanks MB, Heinrikson RL, Mildner AM;

XX WPI; 1999-540598/45.

XX P-PSDB; AAY34173.

PT New isolated platelet heparanase polypeptides, used to develop
FT products for, e.g. wound healing and blocking angiogenesis

XX Claim 2; Fig 7; 57pp; English.

XX This sequence encodes the human pre-proheparanase of the invention. This
CC sequence was isolated from human platelets. The heparanase can be used
CC for identifying agents which alter heparanase activity. The heparanase
CC can be used for wound healing or for blocking angiogenesis or
CC inflammation. It can be used for treating e.g. psoriasis, diabetic
CC retinopathy or solid tumours, or for the degradation of heparin and the
CC neutralisation of heparin's anticoagulant properties during surgery.
CC Inhibitors of heparanase activity can be used in the treatment of
CC arthritis, asthma, and other inflammatory diseases, vascular restenosis,
CC atherosclerosis, tumour growth and progression, fibroproliferative
CC disorders, and central nervous system (CNS) and neurodegenerative
CC diseases. The products can also be used for detection and diagnosis. The
CC purified heparanase, both recombinantly produced human heparanase and
CC heparanase isolated from human platelet activity, allows for the
CC convenient selection of compounds having anti-heparanase activity,
CC i.e. inhibitors of heparanase activity, by measuring inhibition of
CC heparanase activity. Inhibition of heparanase activity can be measured by
CC blocking heparanase-mediated release of radioactive fragments from in
CC vivo radiolabelled (HSPG)/heparin.

XX SQ Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;

Query Match 100.0%; Score 24; DB 20; Length 1593;
Best Local Similarity 100.0%; Pred. No. 0.026;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 GTAGTGATGCCATGTAACGATC 24
|||
Db 855 GTAGTGATGCCATGTAACGATC 832

RESULT 9

ABZ22816/c

ID ABZ22816 standard; cDNA; 1669 BP.

AC ABZ22816;

DT 02-APR-2003 (first entry)

DE Human heparanase encoding cDNA SEQ ID NO:17.

Human; heparanase; phosphorothioate; antisense oligonucleotide;
cytostatic; gene therapy; tumour; enzyme; gene; ss.

OS Homo sapiens.

Key Location/Qualifiers

FT CDS 1..1638
/*tag= a
/product= "heparanase"

XX WO2003004705-A1.

XX 16-JAN-2003.

XX 01-JUL-2002; 2002WO-US20636.

XX 05-JUL-2001; 2001US-0899440.

XX (UYCO) UNIV COLUMBIA NEW YORK.

XX Stein C;

XX WPI; 2003-201558/19.

XX P-PSDB; ABP56822.

PT New oligonucleotide having a sequence complementary to a sequence of
FT ribonucleic acid encoding a heparanase, useful for preparing a
PT composition for treating tumor -

XX Disclosure; Fig 3; 48pp; English.

XX The present invention describes an oligonucleotide having a sequence
CC complementary to a sequence of ribonucleic acid encoding a heparanase.
CC The oligonucleotide hybridises with the ribonucleic acid under conditions
CC of high stringency and has a sequence comprising 10-40 bp. The
CC internucleoside linkages of the oligonucleotide comprise at least one
CC phosphorothioate linkage. Hybridisation of the oligonucleotide to the
CC ribonucleic acid inhibits expression of the heparanase, where inhibition
CC of heparanase means at least a 50% reduction in the quality of
CC heparanase. Also described: (1) a method of inhibiting expression of a
CC heparanase in a cell; (2) a composition comprising the above
CC oligonucleotide in an amount effective to inhibit the expression of
CC heparanase in the cell and a carrier; and (3) a method of treating a
CC tumour in a subject comprises administering to the subject an amount of
CC the above oligonucleotide effective to inhibit expression of a heparanase
CC in the subject. Heparanase antisense oligonucleotides have cytostatic
CC activity, can be used in gene therapy, and can be used for preparing a
CC composition for treating tumours. The present sequence encodes human
CC heparanase, which is given in the exemplification of the present
CC invention.

SO Sequence 1669 BP; 445 A; 396 C; 388 G; 440 T; 0 other;

Query Match 100.0%; Score 24; DB 25; Length 1669;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 900 GTAGTATGCCATGTAAGTATC 877

RESULT 10

AA37259/C

ID AA37259 standard; DNA; 1713 BP.

AC AA37259;

XX 21-JUL-1999 (first entry)

DE Human heparanase enzyme encoding DNA.

XX Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;

KW metacarcinosis; angiogenesis; wound healing; angioplasty-induced restenosis;

KW arteriosclerosis; atherosclerosis; inflammation; tissue development;

XX human; HSPG; ss.

OS Homo sapiens.

XX MO9921975-A1.

PN 06-MAY-1999.

XX 28-OCT-1998; 98WO-AU00898.

PF 09-DEC-1997; 97AU-0000812.

PR 28-OCT-1997; 97AU-0000062.

XX (AUSU) UNIV AUSTRALIAN NAT.

PA Freeman CG, Handorf BJ, Hulett MD, Parish CR;

XX WPI; 1999-312956/26.

DR P-PSDB; AAY17082.

XX Polynucleotides encoding mammalian endoglucuronidases, especially

PT heparanases, useful to promote wound healing

XX Claim 3; Page 69-73; 112pp; English.

XX The invention relates to nucleic acid sequences that encode heparanase

CC enzymes having endoglucuronidase activity. Recombinant heparanases are

CC capable of removing the HS side chain from heparan sulfate proteoglycan

CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to

CC inhibit heparanase, this is useful for treatment of a physiological or

CC medical condition associated with elevated heparanase activity, such as

CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,

CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and

CC rat heparanases can be used to enhance wound healing, especially

CC associated with tissue development and repair. The conditions mentioned

CC above can be diagnosed using specific antibodies, and also using primers

CC and probes specific for the heparanase polynucleotides. Other uses of the

CC heparanases include sequencing sulfated molecules such as HSPG. The

CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

SO Query Match 100.0%; Score 24; DB 20; Length 1713;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 939 GTAGTATGCCATGTAAGTATC 916

RESULT 11

AA35648/C

ID AA35648 standard; cDNA; 1721 BP.

XX AA35648;

XX 09-JUL-1999 (first entry)

DE cDNA encoding a human heparanase protein.

XX Heparanase; hpa; modulator; heparin-binding growth factor;

KW cellular response; cytokine; cell interaction; plasma lipoprotein;

KW cellular susceptibility; infection; disintegration;

KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;

KW atherosclerosis; inflammation; neurodegenerative disease; neuritis;

KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;

XX ss.

OS Homo sapiens.

XX MO9911798-A1.

PN 11-MAR-1999.

XX 31-AUG-1998; 98WO-US17954.

PF 02-JUL-1998; 98US-0109386.

PR 02-SEP-1997; 97US-0922170.

XX (FRIE/) FRIEDMAN M M.

PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

XX (INST-) INSIGHT STRATEGY & MARKETING LTD.

PI Feinstein E, Becker I, Vlodevsky I;

XX WPI; 1999-302255/25.

DR P-PSDB; AAY02345.

XX New human polynucleotide useful for treating angiogenesis,

PT restenosis, and inflammation

XX Claim 4; Fig 1; 63pp; English.

XX The specification describes a polypeptide having heparanase (hpa)

CC activity. The recombinant protein is used as a modulator of

CC heparin-binding growth factors, cellular responses to heparin-binding

CC growth factors and cytokines, cell interaction with plasma lipoproteins,

CC cellular susceptibility to viral, protozoal and bacterial infections

CC or disintegration of neurodegenerative plaques. Heparanase may be

CC useful for conditions such as wound healing, angiogenesis, restenosis,

CC atherosclerosis, inflammation, neurodegenerative diseases, and viral

CC infections. Mammalian heparanase can be used to neutralize plasma

CC heparin, and anti-heparanase antibodies may be applied for

CC immunodetection and diagnosis of micrometastases, autoimmune lesions,

CC and renal failure in biopsy specimens, plasma samples, and body fluids.

CC The present sequence encodes human heparanase.

XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

SO Query Match 100.0%; Score 24; DB 20; Length 1721;

Best Local Similarity 100.0%; Pred. No. 0.026;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 GTAGTATGCCATGTAAGTATC 24
|||||
DB 956 GTAGTATGCCATGTAAGTATC 933

RESULT 12

AA75051/C

ID AA75051 standard; cDNA; 1721 BP.

XX AC AA75051;
 XX 15-JAN-2001 (first entry)
 XX
 XX CDNA encoding a human heparanase polypeptide.
 XX
 XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
 XX heparin-binding growth factor; cytokine; neurodegenerative plaque;
 XX wound healing; infection; burn; angiogenesis; restenosis;
 XX atherosclerosis; inflammation; neurodegenerative disease;
 XX Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; de.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX CDS 63..1693
 XX /*tag= a
 XX /product= "heparanase"
 XX 698..724
 XX /*tag= b
 XX /note= "these nucleotides are likely to be involved
 XX in forming stem and loop structures"
 XX
 XX WO20052178-A1.
 XX
 XX 08-SEP-2000.
 XX
 XX 14-FEB-2000; 2000WO-US03542.
 XX
 XX 01-MAR-1999; 99US-0258892.
 XX
 XX (INST-) INSIGHT STRATEGY & MARKETING LTD.
 XX (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
 XX (FRIE/) FRIEDMAN M M.
 XX
 XX Pecker I, Vlodevsky I, Feinstein E;
 XX WPI; 2000-579289/54.
 XX P-PSDB; AAB08849.
 XX
 XX New polynucleotides encoding a polypeptide having heparanase activity,
 XX useful in wound healing and in gene therapy, particularly in treating
 XX tumour, inflammation, autoimmunity, neurodegenerative diseases -
 XX
 XX Claim 9; Fig 1; 152pp; English.
 XX
 XX The present sequence encodes a human protein with heparanase catalytic
 XX activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
 XX particularly in treating tumour, inflammation or autoimmunity.
 XX Particularly, the polynucleotide is useful in modulating the
 XX bioavailability of heparin-binding growth factors, cellular responses
 XX to heparin-binding growth factors (e.g. bFGF) and cytokines
 XX (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
 XX cellular susceptibility to certain viral and some bacterial and protozoa
 XX infections, or disintegration of neurodegenerative plaques. The
 XX polynucleotide is also useful in wound healing (e.g. thermal, chemical
 XX or radiation burns), and in the treatment of angiogenesis, restenosis,
 XX atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
 XX Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
 XX bacterial or protozoa infections.
 XX
 XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 XX
 XX Query Match 100.0%; Score 24; DB 21; Length 1721;
 XX Best Local Similarity 100.0%; Pred. No. 0.026;
 XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 13
 AA239195/c
 ID AA239195 standard; CDNA; 1721 BP.
 XX
 XX AA239195;
 XX
 XX 02-MAR-2000 (first entry)
 XX
 XX Human heparanase encoding CDNA.
 XX
 XX Human; heparanase; hpa; genetic modification; expression; anticancer;
 XX angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour;
 XX anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
 XX heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
 XX metastasis; wound healing; restenosis; atherosclerosis; inflammation;
 XX neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
 XX micrometastasis; autoimmune lesion; kidney failure; ss.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX CDS 63..1694
 XX /*tag= a
 XX /product= "heparanase"
 XX
 XX WO9957244-A1.
 XX
 XX 11-NOV-1999.
 XX
 XX 29-APR-1999; 99WO-US09256.
 XX
 XX 01-MAY-1998; 98US-0071618.
 XX 02-MAR-1999; 99US-0260038.
 XX
 XX (INST-) INSIGHT STRATEGY & MARKETING LTD.
 XX (FRIE/) FRIEDMAN M M.
 XX
 XX Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
 XX Shlomi Y;
 XX WPI; 2000-062144/05.
 XX P-PSDB; AAY57590.
 XX
 XX Engineered cells that express recombinant heparanase, useful
 XX therapeutically, e.g. for treating angiogenesis and to screen for
 XX specific inhibitors, potential anticancer agents -
 XX
 XX Claim 2; Page 106-107; 118pp; English.
 XX
 XX The present invention describes genetically modified cells (A) containing
 XX a polynucleotide (I) that encodes a polypeptide with heparanase activity,
 XX and expresses recombinant heparanase (II). Heparanase cleaves heparan
 XX sulphate (HS) at specific intrachain sites, resulting in release of
 XX heparin-binding growth factors, enzymes and proteins that are sequestered
 XX by HS in basement membranes, extracellular matrix or cell surfaces. It
 XX may also be implicated in tumour angiogenesis and metastases. (II) is
 XX potentially useful in wound healing and for treating angiogenesis,
 XX restenosis, atherosclerosis, inflammation, neurodegeneration, viral
 XX infection and cystic fibrosis. It can also be used to neutralise heparin
 XX (an alternative to procaine) and to screen for specific inhibitors
 XX (potentially useful for treating cancer and metastases). Antibodies
 XX raised against (II) are used for immunodetection and diagnosis of
 XX micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
 XX in large quantities, in a form that is homogeneously processed and
 XX activated/neutralised by a dedicated protease. The present sequence
 XX encodes human heparanase.
 XX
 XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 XX
 XX Query Match 100.0%; Score 24; DB 21; Length 1721;
 XX Best Local Similarity 100.0%; Pred. No. 0.026;
 XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 93.2277 Seconds
(without alignments)
.6256.802 Million cell updates/sec

Title: US-10-676-079-7

Perfect score: 24
Sequence: 1 gtatgatgcacatgaactgaac 24

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 22781392 seqs, 1215238056 residues

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

EST:
1: em_estba:*
2: em_esthum:*
3: em_estin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hic:*
9: gb_est1:*
10: gb_est2:*
11: gb_hic:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rdg:*
26: em_gss_phg:*
27: em_gss_vrt1:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	24	100.0	370	14	N41349 yw70a03.r1
C 2	24	100.0	587	14	N45367 yw7a02.r1
C 3	24	100.0	907	13	BQ438834 AGENCOURT
C 4	24	100.0	1083	13	BX398409 BX398409

5	24	100.0	1156	9	AL552151
6	24	100.0	1200	9	AL545232
7	18.8	78.3	824	28	B2114057 CH230-385
8	18.4	76.7	493	28	AQ260481 CITR1-E1-
9	18.4	76.7	642	10	BE565766 601338571
10	18.4	76.7	686	10	BB181417 BB181417
11	18.4	76.7	2733	11	AK039061 Mus muscu
12	18.2	75.8	401	28	AQ775821 HS_2006_A
13	18.2	75.8	431	28	AQ363749 nbxb00590
14	18.2	75.8	473	10	BG238460 bab51401.
15	18.2	75.8	540	28	B52785 CIT-HSP-200
16	18.2	75.8	631	13	B0352277 603526037
17	18.2	75.8	716	13	B0005587 OGG8120.Y
18	18.2	75.8	732	10	BE565192 601342769
19	18.2	75.8	755	29	CC412604 PUBJN06TD
20	18.2	75.8	757	12	BG777686 60265307
21	18.2	75.8	768	14	CB970530 CAB10003-
22	18.2	75.8	813	29	B2771989 mct83606.
23	18.2	75.8	1962	11	AK087283 Mus muscu
24	18.2	75.8	2173	11	AK040471 Mus muscu
25	18.2	75.0	114	29	AL937708 Arabidops
26	17.8	74.2	84	28	AZ939449 2M0198X20
27	17.8	74.2	246	10	BF084900 MRO-FT017
28	17.8	74.2	262	14	CB062055 401212 B
29	17.8	74.2	543	29	B2280332 CH230-344
30	17.8	74.2	565	13	BQ465842 HU04N13r
31	17.8	74.2	649	10	BB218197 BB218197
32	17.8	74.2	657	10	BF207911 601862428
33	17.8	74.2	687	10	BF029562 601765976
34	17.8	74.2	692	12	B1250835 602993460
35	17.8	74.2	727	10	BE567253 601340854
36	17.8	74.2	748	10	BG529572 602557984
37	17.8	74.2	789	10	BF211534 60181219
38	17.8	74.2	829	10	BF028342 601765135
39	17.8	74.2	843	10	BF382630 601816826
40	17.8	74.2	851	10	BG615642 602642992
41	17.8	74.2	857	10	BE865600 601677947
42	17.8	74.2	877	10	BE568413 601341993
43	17.8	74.2	878	10	BG532594 602562161
44	17.8	74.2	900	10	BG615175 602643702
45	17.8	74.2	903	10	BG615047 602644333

ALIGNMENTS

RESULT 1
N41349 370 bp mRNA linear EST 24-JAN-1996
yw70a03.r1 Soares placenta 8009weeks 2NDHP8t09w Homo sapiens cDNA
LOCUS IMAGE:257548 5', mRNA sequence.

ACCESSION N41349
VERSION N41349.1 GI:1165380
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 370)
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucab, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaastis, E., Waterston, R., Williamson, A., Wohlmann, F. and Wilson, R.
The Washu-Merck EST Project

TITLE JOURNAL
COMMENT Unpublished
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
High quality sequence stops: 279
Source: IMAGE Consortium, LNL

FEATURES
source
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: T7
High quality sequence stop: 279.
Location/Qualifiers
1..370
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3887158"
/db_xref="taxon:9606"
/clone="IMAGE:257548"
/dev_stage="two placentae: one from 8 weeks and another from 9 weeks post conception"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta 8to9weeks 2NDHP8to9W"
/note="Organ: placenta; Vector: pT7T3 (pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' TGTTACCATCTGAAGTGGAGCGCGCGCATTTTCTTTTCTTTT 3'], double-stranded cDNA was size selected, ligated to Eco RI adapters (pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT7T3 vector (pharmacia). Library constructed by Bento Soares and M.Felina Bonaldo."

BASE COUNT 113 a 64 c 83 g 103 t 7 others
ORIGIN
Query Match 100.0%; Score 24; DB 14; Length 370;
Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTAGTATGCCATGTACTGATC 24
|||||
Db 229 GTAGTATGCCATGTACTGATC 206
|||||
RESULT 2 587 bp mRNA linear EST 13-FEB-1996
N45367/c 587 bp mRNA linear EST 13-FEB-1996
LOCUS y97a02.r1 Soares placenta 8to9weeks 2NDHP8to9W Homo sapiens cDNA
DEFINITION clone IMAGE:260138 5', mRNA sequence.
ACCESSION N45367
VERSION N45367.1 GI:1186533
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 587)
AUTHORS Haller, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevasis, E., Waterston, R., Williamson, A., Wohlmann, P. and Wilson, R.
TITLE The Washu-Merck EST Project
JOURNAL Unpublished
COMMENT Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@wustl.wustl.edu
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: T7
High quality sequence stop: 369.
Location/Qualifiers
1..387
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:3889844"
/db_xref="taxon:9606"
/clone="IMAGE:260138"
/dev_stage="two placentae: one from 8 weeks and another from 9 weeks post conception"

From 9 weeks post conception"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares placenta 8to9weeks 2NDHP8to9W"
/note="Organ: placenta; Vector: pT7T3 (pharmacia) with a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' TGTTACCATCTGAAGTGGAGCGCGCGCATTTTCTTTTCTTTT 3'], double-stranded cDNA was size selected, ligated to Eco RI adapters (pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified pT7T3 vector (pharmacia). Library constructed by Bento Soares and M.Felina Bonaldo."
BASE COUNT 158 a 112 c 153 g 156 t 8 others
ORIGIN
Query Match 100.0%; Score 24; DB 14; Length 587;
Best Local Similarity 100.0%; Pred. No. 2.2;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTAGTATGCCATGTACTGATC 24
|||||
Db 173 GTAGTATGCCATGTACTGATC 150
|||||

RESULT 3 907 bp mRNA linear EST 24-MAY-2002
BQ438834/c 907 bp mRNA linear EST 24-MAY-2002
LOCUS BQ438834
DEFINITION AGENCOURT 7761619 NIH_MGC_70 Homo sapiens cDNA clone IMAGE:6017952
5', mRNA sequence.
ACCESSION BQ438834
VERSION BQ438834.1 GI:21177910
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 907)
AUTHORS NIH-MGC http://mgi.nci.nih.gov/
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
JOURNAL Unpublished
COMMENT Contact: Robert Strauberg, Ph.D.
Email: cgabbs-remail.nih.gov
Tissue Procurement: ATCC
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Agencourt Bioscience Corporation
clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNL at:
http://image.lnl.gov
Plate: L1AM13218 row: b column: 01
High quality sequence stop: 616.
Location/Qualifiers
1..907
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:6017952"
/tissue_type="epithelioid carcinoma"
/lab_host="DH10B (pnase-resistant)"
/note="Organ: pancreas; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.1 kb. Library constructed by Life Technologies."

BASE COUNT 260 a 176 c 226 g 242 t 3 others
ORIGIN
Query Match 100.0%; Score 24; DB 13; Length 907;
Best Local Similarity 100.0%; Pred. No. 2.8;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GTAGTATGCCATGTACTGATC 24
|||||

Db 576 GTAGTGATGCATGTAAGTAATC 553

RESULT 4
BX398409 1083 bp mRNA linear EST 13-MAY-2003

LOCUS BX398409 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

DEFINITION BX398409 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

ACCESSION BX398409

VERSION BX398409.1 GI:30617572

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.

TITLE Full-length cDNA libraries and normalization

JOURNAL Unpublished

COMMENT Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see
http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSODI058BI2NP1;cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODI058BI2NP1.

FEATURES
source
1..1083
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODI058BI24"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT 273 a 264 c 206 g 258 t 82 others

ORIGIN

Query Match 100.0%; Score 24; DB 13; Length 1083;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 762 GTAGTGATGCATGTAAGTAATC 785

RESULT 5
AL552151 1156 bp mRNA linear EST 31-MAY-2003

LOCUS AL552151 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

DEFINITION AL552151 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

ACCESSION AL552151

VERSION AL552151.2 GI:31273967

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.

TITLE Full-length cDNA libraries and normalization

JOURNAL Unpublished

COMMENT On Feb 15, 2001 this sequence version replaced gi:12890775.
Contact: Genoscope

Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see
http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSODI059C08NP1;cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODI059C08NP1.

FEATURES
source
1..1156
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODI059Y15"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT 305 a 251 c 233 g 323 t 44 others

ORIGIN

Query Match 100.0%; Score 24; DB 9; Length 1156;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 732 GTAGTGATGCATGTAAGTAATC 755

RESULT 6
AL545232 1200 bp mRNA linear EST 31-MAY-2003

LOCUS AL545232 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

DEFINITION AL545232 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

ACCESSION AL545232

VERSION AL545232.2 GI:31267068

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.

TITLE Full-length cDNA libraries and normalization

JOURNAL Unpublished

COMMENT On Feb 15, 2001 this sequence version replaced gi:12877713.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see
http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSODI028DC02NP1;cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODI028DC02NP1.

FEATURES
source
1..1200
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODI028YF04"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo(dT)

primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT

300 a 249 c 249 g 332 t 70 others

ORIGIN

Query Match 100.0%; Score 24; DB 9; Length 1200;
Best Local Similarity 100.0%; Pred. No. 3.1;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 GTAGTGCATGCACTGAATC 24
|||||
Db 703 GTAGTGCATGCACTGAATC 726

RESULT 7 B2114057 824 bp DNA linear GSS 11-OCT-2002
LOCUS CH230-385118.TVB CHORI-230 Segment 2 Rattus norvegicus genomic

DEFINITION CH230-385118.TVB CHORI-230 Segment 2 Rattus norvegicus genomic

ACCESSION B2114057

VERSION B2114057.1 GI:23755004

KEYWORDS GSS.

SOURCE Rattus norvegicus (Norway rat)

ORGANISM Rattus norvegicus

Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.

1 (bases 1 to 824)

Zhao, S., Shetty, J., Shatsman, S., Tsagay, G., Geer, K., Shvartsbeyn, A., Gebregregorys, E., Overton, L., Russell, D., Chen, D., Riggs, F., de Jong, P., and Frazer, C.M.
Rat BAC End Sequences from Library CHORI-230 MboI segment

Unpublished
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished

Class: BAC ends.

Seq primer: T7

Class: BAC ends.

Location/Qualifiers

1..824

/organism="Rattus norvegicus"

/mol_type="genomic DNA"

/strain="BN/SsNHsd/MCw"

/db_xref="taxon:10116"

/clone="CH230-385118"

/sex="Female"

/cell_type="Brain"

/clone_lib="CHORI-230 Segment 2"

/note="Vector: pTARBAC1.3; Site_1: MboI; Site_2: MboI; CHORI-230 Rat (BN/SsNHsd/MCw) BAC library produced by Pletzer de Jong"

BASE COUNT

293 a 133 c 163 g 235 t

ORIGIN

Query Match 78.3%; Score 18.8; DB 28; Length 824;

Best Local Similarity 90.9%; Pred. No. 6e+02;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 1 GTAGTGCATGCACTGAATC 22

|||||

Db 817 GTAGTGCATGCACTGAATC 796

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

RESULT 8 A0260481 493 bp DNA linear GSS 24-OCT-1998
LOCUS CITR1-E1-2504G20.TR CITR1-E1 Homo sapiens genomic clone 2504G20,
DEFINITION genomic survey sequence.

ACCESSION A0260481
VERSION A0260481.1 GI:3787005

KEYWORDS GSS.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.

1 (bases 1 to 493)

Adams, M.D., Rounsley, S.D., Zhao, S., Baas, S., Linher, K., Golden, K., Berry, K., Granger, D., Suh, E., Wible, C., Shizuya, H., Simon, M., and Venter, J.C.
Use of a random human BAC End Sequence Database for Sequence-Ready Map Building

Unpublished

Contact: Mark Adams

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200

Fax: 301 838 0208

Email: mdadams@tigr.org

Clones are available from Research Genetics (info@resgen.com). BAC

end search page:

http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html.

Seq primer: M13 Reverse

Class: BAC ends.

Location/Qualifiers

1..493

/organism="Homo sapiens"

/mol_type="genomic DNA"

/db_xref="taxon:9606"

/clone="2504G20"

/sex="male"

/cell_type="sperm"

/clone_lib="CITR1-E1"

/note="Vector: pBeloBAC11; Site_1: EcoRI; Site_2: EcoRI; Catrech Human BAC Library D"

BASE COUNT

180 a 80 c 95 g 138 t

ORIGIN

Query Match 76.7%; Score 18.4; DB 28; Length 493;

Best Local Similarity 95.0%; Pred. No. 7.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy 5 TGATGCATGCACTGAATC 24

|||||

Db 322 TGATGCATGCACTGAATC 341

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

|||||

FEATURES
SOURCE

FEATURES
Source

Location/Qualifiers
1. .686

```

/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="A230091D07"
/sex="male"
/cisue_type="hypothalamus"
/dev_stage="adult"
/lab_host="DH10B"

```

/note="Site_1: Sali, Site_2: Bantli, cDNA library was prepared and sequenced in Mouse Genome Encyclopedia project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN, Division of Experimental Animal Research in Riken

contributed to prepare mouse tissues. 1st strand cDNA was primed with a primer [5', GAGAGAGAGAGATCCAGAGCTTTTTTTTTTTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse

cap-trapper. cDNA went through one round of normalization to Rot = 20.0 and subtraction to Rot = 459.0. Second strand cDNA was prepared with the primer adapter of sequence 5' GAGGAGAGATTCGAGTAATTAATATCCCCCCCCCC

Query March	76.7%	Score 18.4	DB 10	Length 686
Best Local Similarity	95.0%	Pred. No. 8.3e+02		
Matches 19; Conservative	0	Mismatches 1	Indels 0	Gaps 0

OY	2 TAGTGATGCCATGTAACTGA	21
Db	33 TAGTGAATCATCTAAGTCA	14
RESULT 11		
AK039061/c		
JACOUS	AK039061	2733 bp
		mRNA
		linear
		HTC 05-DEC-2002

DEFINITION Mus musculus adult male hypothalamus cDNA, RIKEN full-length enriched library, clone:A230091D07 product:adenomatosis polyposis coli, full insert sequence.

ACCESSION AK039061

VERSION AK039061.1 GI:26086918

KEYWORDS HTC; CAP trapper.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

REFERENCE AUTHORS Carninci, P. and Hayashizaki, Y.

TITLE High-efficiency full-length cDNA cloning

JOURNAL Meth. Enzymol. 303, 19-44 (1999)

MEDLINE 99279253

PUBMED 10349636

REFERENCE AUTHORS Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.

TITLE Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes

JOURNAL Genome Res. 10 (10), 1617-1630 (2000)

MEDLINE 20499374

PUBMED 11042159

REFERENCE AUTHORS Shibata, K., Itoh, M., Aizawa, K., Nagacka, S., Sasaki, N., Carninci, P., Kono, H., Akiyama, J., Nishi, K., Kitsuana, T., Tashiro, H., Itoh, M., Suni, I., Ishii, Y., Nakamura, S., Hazama, M., Nishine, T., Harada, A., Yamamoto, R., Matsumoto, H., Sakaguchi, S., Ikegami, T., Kashiwagi, K., Fujiwaka, S., Inoue, K., Togawa, Y., Izawa, M., Ohara, E., Watabiki, M., Yoneda, Y., Ishikawa, T., Ozawa, K., Tanaka, T., Matsura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kira, A. and Hayashizaki, Y.

TITLE RIKEN integrated sequence analysis (RISA) system--384-format sequencing pipeline with 384 multicapillary sequencer

JOURNAL Genome Res. 10 (11), 1757-1771 (2000)

MEDLINE 20530913

PUBMED 11076861

REFERENCE AUTHORS Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Aizawa, K., Hara, A., Fukunishi, Y., Kono, H., Adachi, J., Fukuda, S., Aizawa, K., Izawa, M., Nishi, K., Kiyosawa, H., Kondo, S., Yamana, I., Salto, T., Okazaki, Y., Gojohori, T., Bono, H., Kaakawa, T., Salto, R., Kadota, K., Matsuda, H., Ashburner, M., Batilov, S., Casavant, T., Flischmann, W., Gaasterland, T., Gissi, C., King, B., Kochiya, H., Kuehl, P., Lewis, S., Matsuo, Y., Nikaido, I., Pesole, G., Quackenbush, J., Schriml, L. M., Stakaid, F., Suzuki, R., Tomita, M., Wagner, L., Washio, T., Sakai, K., Okido, T., Furuno, M., Aono, H., Baldarelli, R., Barsh, G., Blake, J., Boffelli, D., Bojunga, N., Carninci, P., de Bonaldo, M. F., Brownstein, M. J., Bull, C., Fletcher, C., Fujita, M., Gariboldi, M., Gustinchin, S., Hill, D., Hofmann, M., Hume, D. A., Kamiya, M., Lee, N. H., Lyons, P., Marchionni, L., Mashima, J., Mazzarelli, J., Mombereis, P., Nordone, P., Ring, B., Ringwald, M., Rodriguez, I., Sakamoto, N., Sasaki, H., Sato, K., Schonbach, C., Seya, T., Shibata, Y., Storch, K. F., Suzuki, H., Toyooka, K., Wang, K. H., Weitz, C., Whitlaker, C., Wilming, L., Wyshew-Boris, A., Yoshida, K., Hasegawa, Y., Kawaji, H., Kohlsuki, S. and Hayashizaki, Y.

TITLE Functional annotation of a full-length mouse cDNA collection

JOURNAL Nature 409 (6821), 685-690 (2001)

MEDLINE 21085660

PUBMED 11217851

REFERENCE AUTHORS The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.

TITLE Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs

JOURNAL Nature 420, 563-573 (2002)

REFERENCE AUTHORS Adachi, J., Aizawa, K., Akimura, T., Arakawa, T., Bono, H., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A., Hashizume, W., Hayashida, K., Hayatsu, N., Hiramoto, K., Hirakawa, T., Hirozane, T., Hori, F., Imotani, K., Ishii, Y., Itoh, M., Kagawa, I., Kaakawa, T., Katoh, H., Kawai, J., Kojima, Y., Kondo, S., Kono, H., Kouda, M.,

Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, M., Nishi, K., Nomura, K., Numazaki, R., Ono, M., Obata, N., Okazaki, Y., Salto, R., Salto, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Sasaki, D., Shibata, K., Shinagawa, A., Shiraki, T., Sogabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Ahira, S., Takeda, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.

TITLE Direct Submission

JOURNAL Submitted (16-JUL-2001) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama, Kanagawa 230-0045, Japan (E-mail: genome-res@gscc.riken.go.jp, URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222, Fax: 81-45-503-9216)

COMMENT cDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. Please visit our web site for further details. URL: http://genome.gsc.riken.go.jp/ URL: http://fantom.gsc.riken.go.jp/.

FEATURES

source

1..2733

/organism="Mus musculus"

/mol_type="mRNA"

/strain="C57BL/6J"

/db_xref="FANTOM DB:A230091D07"

/db_xref="taxon:10090"

/clone="A230091D07"

/sex="male"

/tissue_type="hypothalamus"

/clone_id="RIKEN full-length enriched mouse cDNA library"

/dev_stage="adult"

1..2733

/note="adenomatosis polyposis coli (MGI:88039, GB|NM_007462, evidence: BLASTN, 100%, match=3169)"

BASE COUNT 857 a 520 c 513 g 843 t

ORIGIN

Query Match 76.7%; Score 18.4; DB 11; Length 2733; Best Local Similarity 95.0%; Pred. No. 1.6e+0; Matches 19; Conservative 0; Mismatches 1; Gaps 0;

QY 2 TAGTGATGCATGACTGA 21

DB 2076 TAGTGATGCATGACTGA 2057

RESULT 12

LOCUS A0775821

DEFINITION HS_2006_A2_H02_MR_CIT Approved Human Genomic Specm Library D Homo sapiens genomic clone Plate=2006 COL=4 Row=O, genomic survey sequence.

ACCESSION A0775821

VERSION A0775821.1 GI:5655549

KEYWORDS GSS.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

REFERENCE AUTHORS Mahairas, G. G., Wallace, J. C., Smith, K., Swartzell, S., Holzman, T., Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M. D. and Hood, L.

TITLE Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome

JOURNAL Proc. Natl. Acad. Sci. U.S.A. 96 (17), 9739-9744 (1999)

MEDLINE 99380589

PUBMED 10449764

COMMENT Contact: Mahairas GG, Wallace JC, Hood L


```

/lab host="DH10B"
/clone.lib="Gm-cl043"
/note="Vector: pT73pac (Pharmacia); Site 1: EcoRI;
Site 2: NotI; This cDNA library was constructed from mRNA
isolated from hypocoely and plumule tissues of seeds
germinated for three days of the cultivar Williams.
Complementary DNA was synthesized from mRNA using a primer
consisting of a poly(dT) sequence with a NotI restriction
site. EcoRI adapters were ligated to the blunt-ended cDNA
fragments followed by digestion with EcoRI and NotI. The
cDNA fragments were directionally cloned into the
EcoRI-NotI restriction site of the pT73-pac vector. The
ligated cDNA fragments were transformed into DH10B host
cells (Gibco BRL). This library was constructed by Dr.
Randy Shoemaker."

```

BASE COUNT 138 a 73 c 98 g 164 t
ORIGIN

Query Match 75.8%; Score 18.2; DB 10; Length 473;
Best Local Similarity 87.0%; Pred. No. 8.6e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 2 TAGTGATGCCATGTACTGATC 24
Db 442 TATTGATGCCATGTACTGATC 464

RESULT 15

B52785 540 bp DNA linear GSS 20-JUN-1998
LOCUS CIT-HSP-200604.TF CIT-HSP Homo sapiens genomic clone 200604,
DEFINITION genomic survey sequence.

ACCESSION B52785
VERSION B52785.1 GI:2607119
KEYWORDS GSS.

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 540)
AUTHORS Adams,M.D., Rounsley,S.D., Field,C.E., Bass,S., Linher,K., Golden
K., Berry,K., Granger,D., Suh,E., Wible,C., Shizuya,H., Simon,M.
and Venter,J.C.
TITLE Use of a random BAC End Sequence Database for Sequence-Ready Map
Building

JOURNAL Unpublished
COMMENT Other_GSSs: CIT-HSP-200604.TF
Contact: Mark Adams
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: mdadams@tigr.org

Clones are available from Research Genetics (info@resgen.com). BAC
end search page:
http://www.tigr.org/tdb/humgen/bac_end_search/bac_end_search.html
Seq primer: M13 Reverse
Class: BAC ends.

FEATURES
Source 1..540
Location/Qualifiers

```

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="GDB:703830"
/db_xref="taxon:9606"
/clone="200604"
/sex="Male"
/cell_type="Sperm"
/clone.lib="CIT-HSP"
/note="Vector: pBel0BAC11; Site_1: HindIII; Site_2:
HindIII"

```

BASE COUNT 189 a 103 c 69 g 179 t
ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 540;
Best Local Similarity 87.0%; Pred. No. 9.2e+02;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 GTAGTGATGCCATGTACTGAT 23
Db 81 GAAAGTGATTCATGTACTGAT 103

Search completed: February 16, 2004, 13:41:05
Job time : 97.2277 secs

PA (FRIE/) FRIEDMAN M M.
 XX
 PI Ben-Attzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y,
 PI Shlom Y;
 XX WPI; 2000-062144/05.
 DR
 XX
 PT Engineered cells that express recombinant heparanase, useful
 PT therapeutically, e.g. for treating angiogenesis and to screen for
 PT specific inhibitors, potential anticancer agents -
 XX
 PS Example 1; Page 36; 118pp; English.
 XX
 CC The present invention describes genetically modified cells (A) containing
 CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
 CC and express recombinant heparanase (II). Heparanase cleaves heparan
 CC sulphate (HS) at specific intrachain sites, resulting in release of
 CC heparin-binding growth factors, enzymes and proteins that are sequestered
 CC by HS in basement membranes, extracellular matrix or cell surfaces. It
 CC may also be implicated in tumour angiogenesis and metastases. (II) is
 CC potentially useful in wound healing and for treating angiogenesis,
 CC retinosis, atherosclerosis, inflammation, neurodegeneration, viral
 CC infection and cystic fibrosis. It can also be used to neutralise heparin
 CC (an alternative to protamine) and to screen for specific inhibitors
 CC (potentially useful for treating cancer and metastases). Antibodies
 CC raised against (II) are used for immunodetection and diagnosis of
 CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
 CC in large quantities, in a form that is homogeneously processed and
 CC activated/neutralised by a dedicated protease. The present sequence
 CC represents a PCR primer for human heparanase, which is used in an
 CC example from the present invention.
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 3 G; 9 T; 0 other;
 OY Query Match 100.0%; Score 24; DB 21; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 TATGATCCTCTAGTACTTCTCGAC 24
 1 TATGATCCTCTAGTACTTCTCGAC 24
 RESULT 2
 ID AA233292 standard; DNA; 24 BP.
 XX
 AC AA233292;
 XX
 DT 21-FEB-2000 (first entry)
 XX
 DE Human heparanase PCR antisense primer SEQ ID NO:5.
 XX
 KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; hemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9957153-A1.
 XX
 PD 11-NOV-1999.
 XX
 PF 29-APR-1999; 99WO-US09255.
 XX
 PR 01-MAY-1998; 98US-0071739.
 PA (INST-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PA (FRIE/) FRIEDMAN M M.
 XX
 PI Pecker I, Vlodaevsky I, Friedman Y, Perets T;
 XX
 DR WPI; 2000-052944/04.
 XX
 PT Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 PS Example; Page 27; 90pp; English.
 XX
 CC The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, bladder, breast, ovary,
 CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
 CC drug delivery (e.g. of anticancer agents) and as research reagents.
 CC The present sequence represents a PCR primer for human heparanase, which
 CC is used in an example from the present invention for the construction of
 CC a heparanase expression vector.
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 3 G; 9 T; 0 other;
 OY Query Match 100.0%; Score 24; DB 21; Length 24;
 Best Local Similarity 100.0%; Pred. No. 0.13;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 TATGATCCTCTAGTACTTCTCGAC 24
 1 TATGATCCTCTAGTACTTCTCGAC 24
 RESULT 3
 ID ABL57029/C standard; DNA; 230 BP.
 XX
 AC ABL57029;
 XX
 DT 23-JUL-2002 (first entry)
 XX
 DE Nuclear-targeted lacZ baculovirus transfection cassette.
 XX
 KW Baculovirus; vector; gene therapy; lacZ; beta-galactosidase;
 KW enzyme; vasotropic; antiatherosclerotic; thrombolytic; cytostatic;
 KW CMV; pPABac1; ss.
 XX
 OS Baculovirus.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 6
 FT /tag= a
 FT /note= "transcription start for the polyhedrin
 FT promoter"
 FT
 PN WO200190390-A1.
 XX
 PD 29-NOV-2001.
 XX
 PF 29-MAY-2001; 2001WO-GB02383.
 XX
 PR 26-MAY-2000; 2000GB-0012997.
 XX
 PA (ARKT-) ARK THERAPEUTICS LTD.
 XX
 PI Yla-Hertuala S, Airenne KJ;
 XX
 DR WPI; 2002-401582/43.

XX Delivery of gene product, comprises applying the gene in baculovirus
 PT vector to blood-free body compartment, useful e.g. for gene therapy of
 PT vascular diseases using periaventricular collar -
 XX
 PS Example 2; Fig 1; 20pp; English.
 XX
 CC The present sequence is a portion of baculovirus transfer vector
 CC pFastBac1 (pFB). A cytomagalovirus nuclear-targeted lacZ
 CC expression cassette (see ABL57028) was inserted into the vector at
 CC an StuI site (nucleotide 121-126 of the present sequence), in
 CC opposite orientation to the vector's polyhedrin promoter, to
 CC construct a nuclear-targeted beta-galactosidase-encoding baculovirus
 CC vector. The vector was used in examples from the invention to
 CC demonstrate baculovirus-mediated gene transfer to the rabbit
 CC arterial wall, rat brain and rabbit skeletal muscle. The invention
 CC relates to the delivery of a gene product by providing the gene in
 CC a baculovirus vector and applying the vector to a body compartment
 CC which is free (or usually free) of blood. In a device for the
 CC periaventricular delivery of a gene product, the gene is provided in
 CC a baculovirus vector from which the gene is expressed. The
 CC baculovirus vector is useful for gene therapy, especially of
 CC vascular diseases such as post-angioplasty restenosis, post-bypass
 CC atherosclerosis, stenosis of vascular prosthesis anastomoses and
 CC thrombus formation. It is also useful for administration to the
 CC brain (e.g. for cancer treatment) or ex vivo injection into
 CC saline-perfused organs or vessels for transplantation.
 CC Note: The specification was published without claims.
 XX
 SQ Sequence 230 BP; 64 A; 56 C; 53 G; 57 T; 0 other;
 XX
 Query Match 100.0%; Score 24; DB 24; Length 230;
 Best Local Similarity 100.0%; Pred. No. 0.16; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TATGATCCTTAGTACTTCTCGAC 24
 DB 225 TATGATCCTTAGTACTTCTCGAC 202
 XX
 RESULT 4
 ABV77225/c
 ID ABV77225 standard; DNA; 230 BP.
 AC ABV77225;
 XX
 DT 28-MAR-2003 (first entry)
 XX
 DE Nucleotide sequence of a CMV-nt lacZ expression cassette fragment.
 XX
 KW Baculovirus; vector; spinal cord; central nervous system; CNS;
 KW periaventricular gene transfer; enzyme replacement; gene therapy;
 KW subarachnoid haemorrhage; gene delivery; cerebral choroid plexus;
 KW brain disorder; cancer; brain cancer; lacZ; ss.
 XX
 OS Synthetic.
 XX
 PN WO200296469-A2.
 PD 05-DEC-2002.
 XX
 PF 28-MAY-2002; 2002WO-GB02504.
 XX
 PR 29-MAY-2001; 2001WO-GB02383.
 PR 29-NOV-2001; 2001GB-0028620.
 XX
 PA (ARKT-) ARK THERAPEUTICS LTD.
 XX
 PI Yla-herttuala S, Airenne KJ, Lehtolainen P;
 DR WPI; 2003-129500/12.
 XX
 PT Use of baculovirus vector containing a gene, for the manufacture of a

PT medicament for treating a condition mediated by spinal cord or central
 PT nervous system, by the action of a gene or its product -
 XX
 PS Disclosure; Fig 1; 14pp; English.
 XX
 CC The specification describes the use of a baculovirus vector containing
 CC a gene, for the manufacture of a medicament for the treatment of a
 CC condition that can be mediated via the spinal cord or central nervous
 CC system (CNS), by the action of a gene or its product. Baculoviruses are
 CC capable of mediating periaventricular gene transfer. The vector is useful
 CC for treating a condition that requires enzyme replacement such as
 CC subarachnoid haemorrhage. It is useful as an efficient tool for gene
 CC delivery to cerebral choroid plexus cells and in gene therapy of several
 CC types of brain disorder. It is also useful for treating cancer e.g. in
 CC brain. To analyse the gene transfer efficiency of baculovirus and
 CC adenovirus vectors (both comprising the lacZ cassette), the viruses were
 CC injected into corpus callosum of adult rats. Expression of lacZ was
 CC analysed by reverse transcriptase (RT)-polymerase chain reaction (PCR).
 CC The present sequence represents a CMV-nt lacZ expression cassette
 CC fragment, used in adenovirus or baculovirus vectors.
 XX
 SQ Sequence 230 BP; 64 A; 56 C; 53 G; 57 T; 0 other;
 XX
 Query Match 100.0%; Score 24; DB 25; Length 230;
 Best Local Similarity 100.0%; Pred. No. 0.16;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TATGATCCTTAGTACTTCTCGAC 24
 DB 225 TATGATCCTTAGTACTTCTCGAC 202
 XX
 RESULT 5
 ABK49828/c
 ID ABK49828 standard; DNA; 432 BP.
 AC ABK49828;
 XX
 DT 15-JUL-2002 (first entry)
 XX
 DE Plasmid pFastBac1-HT region encoding MycHis tag.
 XX
 KW ds; ADAMTS; cytotactic; antidiabetic; antirheumatic; MycHis tag;
 KW antiarthritic; antitumor; antineoplastic; antineoplastic; angiotensin;
 KW diabetic omentopathy; chronic rheumatoid arthritis; gene therapy;
 KW refractory skin ulcer; gastric ulcer; post-operative healing failure;
 KW recombinant-type ZN-metalloproteinase domain; disintegrin-like domain; TSP1;
 KW thrombospondin type 1 domain; sexual cycle; tumour; 5p-syndrome deletion;
 KW chromosome 5p15.2-15.3; Cri-du-chat syndrome; pFastBac1-HT.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT CDS 255..320
 FT /tag= a
 FT /product= "MycHis tag"
 FT /note= "No start or stop codon"
 XX
 PN WO200231163-A1.
 PD 18-APR-2002.
 XX
 PF 11-OCT-2001; 2001WO-JP08913.
 XX
 PR 11-OCT-2001; 2000JP-0311309.
 PR 02-APR-2001; 2001JP-0102905.
 XX
 PA (KAZU-) KAZUSA DNA RES INST FOUND.
 PA (MITS-) MITSUBISHI PHARMA CORP.
 PI Ohara O, Nagase T, Nomura N, Yano K, Murakami K, Yasuda S;
 PI Kanazaki K;
 XX

DR WPI; 2002-372277/40.
 DR P-PSDB; AAU80152.
 XX
 PT Human brain-originated ADAMTS family polypeptide and encoded gene,
 PT applicable in diagnosis and screening compounds for drug compositions
 PT in treating diseases due to e.g. neovascularisation
 PS
 XX Example 20; Fig 16; 172pp; Japanese.
 XX
 CC The invention relates to a polypeptide belonging to the ADAMTS family is
 CC selected from sequences appearing as AAU79496, AAU79497 and AAU79499,
 CC a protein that contains the polypeptide, a protein having not less than
 CC 50% homology with the amino acid sequence of the polypeptides or a
 CC polypeptide modified from any of the polypeptides but with some amino
 CC acids deleted, substituted, added or inserted. Also included are the
 CC polynucleotides encoding the polypeptides (or their complementary
 CC strands or variants), a recombinant vector containing any of the
 CC polynucleotides, a transformant which is transformed with the recombinant
 CC vector, producing the polypeptide, protein or peptide by culturing the
 CC transformant, an antibody that can recognize the polypeptide, protein or
 CC peptide and screening compounds to promote or inhibit activity of the
 CC polypeptide or protein, or to promote or inhibit expression of the
 CC polynucleotide by using the polypeptide, protein, peptide, the
 CC polynucleotide, vector, transformant or/and antibody, particularly in
 CC the presence of a test compound for contact before evaluating the
 CC activity by measuring signal changes. The polypeptide and encoded gene
 CC are applicable in diagnosis and screening compounds for drug compositions
 CC in treating diseases due to neovascularisation, diabetic omentopathy,
 CC chronic rheumatoid arthritis, angioma, refractory skin and gastric ulcers
 CC and post-operative healing failure, including gene therapy.
 CC The gene encoding such polypeptide has conserved reprolysin-type ZN-
 CC metalloprotease domain, disintegrin-like domain and TSR1 (thrombospondin
 CC type 1) domain. Its encoded protein is characterized by high expression
 CC in ovaries, changes in expression dose depending on the sexual cycle, a
 CC decrease in tumour cell and location of the gene on the 5p-syndrome
 CC Cri-du-chat syndrome). The present sequence is a region of plasmid
 CC pFastBac1-HT used to make the expression plasmid pFastBac1-HT-P01256
 CC used to express DNA encoding an ADAMTS protein.
 CC
 XX
 SQ Sequence 432 BP; 138 A; 105 C; 82 G; 107 T; 0 other;
 Query Match 100.0%; Score 24; DB 24; Length 432;
 Best Local Similarity 100.0%; Pred. No. 0.17; 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 350 TATGATCCTCTAGTACTTCTCGAC 327
 XX
 RESULT 6
 AAA88918/C
 ID AAA88918 standard; DNA; 604 BP.
 XX
 AC AAA88918;
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of ricin toxin B chain RTB3 in pFASTBAC1.
 XX
 KM Ricin toxin B; RTB3; crystal protein; insecticide; pesticide;
 KM toxin; transgenic plant; insect resistance; crop protection;
 KM lectin; pFASTBAC1; ds.
 XX
 OS Chimeric - Ricinus communis.
 OS Chimeric - Baculovirus.
 XX
 PN WO200066755-A2.
 PD 09-NOV-2000.
 XX
 PF 27-APR-2000; 2000WO-GB01633.

XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;
 XX
 DR WPI; 2001-007228/01.
 XX
 PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests
 PS
 XX Claim 10; Fig 3e; 81pp; English.
 CC The present sequence is that of ricin toxin B chain RTB3 DNA in
 CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
 CC under the control of the polyhedrin promoter. The invention
 CC provides nucleic acids (see AAA88919-24) encoding pesticidal fusion
 CC proteins comprising a toxin domain and a heterologous binding domain
 CC capable of binding non-specifically to a cell membrane without
 CC disrupting that membrane. The toxin domain is preferably obtained
 CC from Bacillus thuringiensis crystal proteins CryIA(b) or CryIA(c),
 CC and the binding domain is preferably derived from a lectin, especially
 CC ricin toxin B chain. The use of such fusions may help to inhibit
 CC the acquisition of resistance in a pest population treated with the
 CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
 CC use in a plant), host cells, and transgenic plants (especially rice
 CC or maize) are also provided. Expression of the fusion protein in a
 CC plant is useful for influencing or affecting the toxicity of a
 CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 CC Orthoptera pests.
 CC
 XX
 SQ Sequence 604 BP; 180 A; 121 C; 134 G; 169 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 604;
 Best Local Similarity 100.0%; Pred. No. 0.17; 0; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 599 TATGATCCTCTAGTACTTCTCGAC 576
 XX
 RESULT 7
 AAA88917/C
 ID AAA88917 standard; DNA; 860 BP.
 XX
 AC AAA88917;
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of ricin toxin B chain RTB2 in pFASTBAC1.
 XX
 KM Ricin toxin B; RTB2; crystal protein; insecticide; pesticide;
 KM toxin; transgenic plant; insect resistance; crop protection;
 KM lectin; pFASTBAC1; ds.
 XX
 OS Chimeric - Ricinus communis.
 OS Chimeric - Baculovirus.
 XX
 PN WO200066755-A2.
 PD 09-NOV-2000.
 XX
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;

XX DR WPI; 2001-007228/01.
 XX PS Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 XX PT comprising a toxin and a binding domain for producing transgenic plants
 XX PT resistant to pests
 XX PS Claim 10; Fig 3d; 81pp; English.
 XX CC The present sequence is that of ricin toxin B chain RTB2 DNA in
 XX CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
 XX CC under the control of the polyhedrin promoter. The invention
 XX CC provides nucleic acids (see AAA88919-24) encoding pesticidal fusion
 XX CC proteins comprising a toxin domain and a heterologous binding domain
 XX CC capable of binding non-specifically to a cell membrane without
 XX CC disrupting that membrane. The toxin domain is preferably obtained
 XX CC from *Bacillus thuringiensis* crystal proteins CryIA(b) or CryIA(c),
 XX CC and the binding domain is preferably derived from a lectin, especially
 XX CC ricin toxin B chain. The use of such fusions may help to inhibit
 XX CC the acquisition of resistance in a pest population treated with the
 XX CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
 XX CC use in a plant), host cells, and transgenic plants (especially rice
 XX CC or maize) are also provided. Expression of the fusion protein in a
 XX CC plant is useful for influencing or affecting the toxicity of a
 XX CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 XX CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 XX CC Orthoptera pests.
 XX SQ Sequence 860 BP; 256 A; 164 C; 199 G; 241 T; 0 other;
 XX
 XX Query Match 100.0%; Score 24; DB 22; Length 860;
 XX Best Local Similarity 100.0%; Pred. No. 0.18; Mismatches 0; Indels 0; Gaps 0;
 XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 1 TATGATCCTCTAGACTTCTCGAC 24
 XX DB 855 TATGATCCTCTAGACTTCTCGAC 832
 XX
 XX RESULT 8
 XX AAA88916/c
 XX ID AAA88916 standard; DNA; 956 BP.
 XX AC AAA88916;
 XX XX
 XX DT 05-MAR-2001 (first entry)
 XX XX
 XX DE Nucleotide sequence of ricin toxin B chain RTB1 in pFASTBAC1.
 XX XX
 XX KW Ricin toxin B; RTB1; crystal protein; insecticide; pesticide;
 XX KW toxin; transgenic plant; insect resistance; crop protection;
 XX KW lectin; pFASTBAC1; ds.
 XX XX
 XX OS Chimeric - Ricinus communis.
 XX OS Chimeric - Baculovirus.
 XX XX
 XX FN WO200066755-A2.
 XX XX
 XX PD 09-NOV-2000.
 XX XX
 XX PF 27-APR-2000; 2000WO-GB01633.
 XX XX
 XX PR 28-APR-1999; 99GB-0009796.
 XX XX
 XX PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX XX
 XX PI Christou P, Mehlo L;
 XX XX
 XX DR WPI; 2001-007228/01.
 XX XX
 XX PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 XX PT comprising a toxin and a binding domain for producing transgenic plants
 XX PT resistant to pests

XX PS Claim 10; Fig 3c; 81pp; English.
 XX CC The present sequence is that of ricin toxin B chain RTB1 DNA in
 XX CC baculovirus transfer vector pFASTBAC1, in which the DNA was cloned
 XX CC under the control of the polyhedrin promoter. The invention
 XX CC provides nucleic acids (see AAA88919-24) encoding pesticidal fusion
 XX CC proteins comprising a toxin domain and a heterologous binding domain
 XX CC capable of binding non-specifically to a cell membrane without
 XX CC disrupting that membrane. The toxin domain is preferably obtained
 XX CC from *Bacillus thuringiensis* crystal proteins CryIA(b) or CryIA(c),
 XX CC and the binding domain is preferably derived from a lectin, especially
 XX CC ricin toxin B chain. The use of such fusions may help to inhibit
 XX CC the acquisition of resistance in a pest population treated with the
 XX CC protein. Vectors (e.g. baculovirus vectors or vectors suitable for
 XX CC use in a plant), host cells, and transgenic plants (especially rice
 XX CC or maize) are also provided. Expression of the fusion protein in a
 XX CC plant is useful for influencing or affecting the toxicity of a
 XX CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
 XX CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
 XX CC Orthoptera pests.
 XX SQ Sequence 956 BP; 286 A; 188 C; 214 G; 268 T; 0 other;
 XX
 XX Query Match 100.0%; Score 24; DB 22; Length 956;
 XX Best Local Similarity 100.0%; Pred. No. 0.18; Mismatches 0; Indels 0; Gaps 0;
 XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX QY 1 TATGATCCTCTAGACTTCTCGAC 24
 XX DB 951 TATGATCCTCTAGACTTCTCGAC 928
 XX
 XX RESULT 9
 XX AA164290/c
 XX ID AA164290 standard; DNA; 1189 BP.
 XX AC AA164290;
 XX XX
 XX DT 07-MAY-2002 (first entry)
 XX XX
 XX DE Protease D-G catalytic domain fusion gene construct encoding sequence.
 XX KW
 XX KW Serine protease; D-G; human; zymogen; enzyme; cytostatic;
 XX KW antinflammatory; dermatological; anticoagulation; cancer;
 XX KW skin disorder; neuropathic pain; inflammatory disorder;
 XX KW coagulation diathesis; thrombosis; laundry detergent; skin care;
 XX KW gene therapy; gene; ds.
 XX XX
 XX OS Homo sapiens.
 XX XX
 XX FH Key Location/Qualifiers
 XX FT CDS 13..891
 XX FT /*tag= a
 XX FT /product= "protease D-G"
 XX FT /transl_except= (pos: 640..642, aa: Gln)
 XX FT 13..93
 XX FT /*tag= b
 XX FT /note= "prolactin signal sequence"
 XX FT 94..888
 XX FT /*tag= c
 XX FT /note= "Mature protease D-G"
 XX XX
 XX PN WO200202011-A1.
 XX XX
 XX PD 10-JAN-2002.
 XX XX
 XX PF 08-JUN-2001; 2001WO-US18568.
 XX XX
 XX PR 30-JUN-2000; 2000US-0607745.
 XX XX
 XX PA (ORTH) ORTHO-MCNEIL PHARM INC.
 XX XX

PI Darrow AL, Qi J, Andrade-Gordon P;
XX
XX WPI; 2002-106601/14.
DR P-PSDB; AAG78578.
XX
PT Nucleic acid encoding a serine protease called D-G protein which is
PT useful for identifying modulators that are useful for treating a
PT condition which is mediated by protease D-G, e.g. cancer, skin
PT disorders, or neuropathic pain -
XX
XX
PS Claim 4; Fig 4B; 81pp; English.
XX
XX The invention relates to an isolated and purified nucleic acid that
XX encodes a serine protease called D-G protein. The activity of the protein
XX of the invention may be described as cytostatic, antiinflammatory,
XX dermatological and anticoagulation. The serine protease of the invention
XX is a member of the trypsin/chymotrypsin-like (S1) serine protease family,
XX which play an important role in processes such as digestion and
XX regulatory amplification cascades through the proteolytic activation of
XX inactive zymogen precursors. Protease D-G modulating compounds are useful
XX for treating a condition which is mediated by protease D-G, e.g. cancer,
XX skin disorders, neuropathic pain, inflammatory disorders, or coagulation
XX diathesis/thrombosis. The polynucleotide encoding the protease is useful
XX for identifying, detecting or isolating mutant forms of DNA molecules
XX encoding the protease. The protease is useful for identifying modulators
XX of the functional protease. The D-G protein can be used for formulation
XX of compositions for laundry detergents and skin care products. Protease
XX D-G gene therapy may be used to introduce protease D-G into the cells of
XX target organisms. As the D-G protein is derived from a human, it is less
XX likely to produce an allergic reaction in sensitive individuals when used
XX in formulations for laundry detergents and skin care products. The
XX current sequence represents the protease D-G catalytic domain in the
XX zymogen activation construct encoding sequence.
SQ Sequence 1189 BP; 297 A; 305 C; 307 G; 280 T; 0 other;
Query Match 100.0%; Score 24; DB 24; Length 1189;
Best Local Similarity 100.0%; Pred. No. 0.18;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 1087 TATGATCCTCTAGTACTTCTCGAC 1064
RESULT 10
AAH74721/C
ID AAH74721 standard; DNA; 1430 BP.
XX
XX AAH74721;
AC
XX
XX 29-OCT-2001 (first entry)
DT
XX
XX Nucleotide sequence of a leech active polypeptide fragment.
DE
XX
XX Active polypeptide; ectoparasitic leech; Rhynchobelliida; C3bb complex;
XX complement activation; complement factor D; haemodialysis; catheter;
XX cardio-pulmonary bypass; extra-arterial stent; transplant rejection;
XX autoimmune disease; lupus arthritis; rheumatoid arthritis; sepsis;
XX glomerulonephritis; nephritis; nephropathy; reperfusion; anaphylaxis;
XX asthma; skin reaction; infection; sickle cell anemia; haemolytic anemia;
XX ds.
XX
XX Placobdella papillifera.
OS
XX
XX WO200147963-A2.
PN
XX
XX 05-JUL-2001.
PD
XX
XX 21-DEC-2000; 2000WO-GB04971.
PF
XX
XX 24-DEC-1999; 99GB-0030659.
PR
XX

PA (BIOD-) BIO-DISCOVERY LTD.
XX
XX Finney S, Seale L, Wallis RB;
XX
XX WPI; 2001-522011/57.
DR
XX
XX Novel polypeptides from the leech Placobdella papillifera which inhibit
PT alternate pathway of complement activation, useful for treating
PT rheumatoid arthritis, sepsis, asthma involving alternate complement
PT pathway -
XX
XX
PS Claim 18; Page 53-54; 80pp; English.
XX
XX The present sequence encodes an active polypeptide fragment. The active
XX polypeptide has a molecular weight of 7000-17,000 Da (as measured by
XX mass spectrometry), and is derived from ectoparasitic leeches, of order
XX Rhynchobelliida, of genus Placobdella and especially of species
XX P. papillifera. The polypeptide inhibits the alternate route of
XX complement activation but has substantially no effect on complement
XX activation by the classical route. The polypeptide is an inhibitor of
XX complement factor D and/or C3bb complex. The active polypeptide is
XX useful for manufacturing a medicament and inhibits one or more steps
XX in the alternate pathway of complement activation. It is useful for
XX treating or preventing conditions, such as haemodialysis and
XX cardio-pulmonary bypass, the presence of in-dwelling catheters and
XX extra-arterial stents, rejection of transplanted organs or tissues,
XX autoimmune diseases including lupus arthritis, rheumatoid arthritis,
XX glomerulonephritis, nephritis, nephropathy, sepsis, injury caused to
XX tissues by reperfusion after an ischaemic period and other conditions
XX associated with activation of complement, including anaphylaxis,
XX asthma, skin reactions, infections, sickle cell anemia and haemolytic
XX anemia involving activation of alternate complement pathway in a
XX patient.
SQ Sequence 1430 BP; 419 A; 296 C; 296 G; 419 T; 0 other;
Query Match 100.0%; Score 24; DB 22; Length 1430;
Best Local Similarity 100.0%; Pred. No. 0.18;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 1126 TATGATCCTCTAGTACTTCTCGAC 1103
RESULT 11
AAA88914/C
ID AAA88914 standard; DNA; 2062 BP.
XX
XX AAA88914;
AC
XX
XX 05-MAR-2001 (first entry)
DT
XX
XX Nucleotide sequence of CRYIA(b) in PASTBAC1.
DE
XX
XX CRYIA(b); crystal protein; insecticide; pesticide; toxin;
XX transgenic plant; insect resistance; crop protection; PASTBAC1;
XX ds.
XX
XX Chimeric - Bacillus thuringiensis.
OS
XX
XX Chimeric - Baculovirus.
OS
XX
XX Key Location/Qualifiers
FH 97.1944
FT CDS /*tag= a
FT
XX
XX WO20006755-A2.
PN
XX
XX 09-NOV-2000.
PD
XX
XX 27-APR-2000; 2000WO-GB01633.
PF
XX
XX 28-APR-1999; 99GB-0009796.
PR
XX

XX	(PLAN-) PLANT BIOSCIENCE LTD.
PA	
XX	Christou P, Menlo L;
PI	
XX	WPI; 2001-007228/01.
DR	
XX	Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
PT	comprising a toxin and a binding domain for producing transgenic plants
PR	resistant to pests -
PS	
XX	Claim 9; Fig 3a; 81pp; English.
CC	
CC	The present sequence is that of Bacillus thuringiensis crystal
CC	protein CryIA(b) DNA in baculovirus transfer vector pFASTBAC1, in
CC	which the gene was cloned under the control of the polyhedrin
CC	promoter. The invention provides nucleic acids (see AAA88919-24)
CC	encoding pesticidal fusion proteins comprising a toxin domain and a
CC	heterologous binding domain capable of binding non-specifically to
CC	a cell membrane without disrupting that membrane. The toxin domain
CC	is preferably obtained from CryIA(b) or CryIA(c), and the binding
CC	domain is preferably derived from a lectin, such as ricin toxin B
CC	chain. The use of such fusions may help to inhibit the acquisition
CC	of resistance in a pest population treated with the protein.
CC	Vectors (e.g. baculovirus vectors or vectors suitable for use in a
CC	plant), host cells, and transgenic plants (especially rice or
CC	maize), are also provided. Expression of the fusion protein in a
CC	plant is useful for influencing or affecting the toxicity of a
CC	plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
CC	Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
CC	Orthoptera pests.
XX	
SQ	Sequence 2062 BP; 538 A; 552 C; 440 G; 532 T; 0 other;
Query Match	100.0%; Score 24; DB 22; Length 2062;
Best Local Similarity	100.0%; Pred. No. 0.19; 0; Indels 0; Gaps 0
Matches	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Oy	1 TATGATCCTTAGTACTTCTCGAC 24
Db	2057 TATGATCCTTAGTACTTCTCGAC 2034
RESULT 12	
ID	AAA88915/C
AC	AAA88915 standard; DNA; 2062 BP.
XX	
AC	AAA88915;
DT	
XX	
XX	05-MAR-2001 (first entry)
DE	
Nucleotide sequence of CryIA(c) in pFASTBAC1.	
KM	CryIA(c); crystal protein; insecticide; pesticide; toxin;
KW	transgenic plant; insect resistance; crop protection; pFASTBAC1;
ds.	
OS	Chimeric - Bacillus thuringiensis.
OS	Chimeric - Baculovirus.
Key	Location/Qualifiers
FH	97..1944
FT	/tag= a
XX	
PX	WO20006755-A2.
XX	
PD	09-NOV-2000.
XX	
PF	27-APR-2000; 2000WO-GB01633.
XX	
PR	28-APR-1999; 99GB-0009796.
XX	
PA	(PLAN-) PLANT BIOSCIENCE LTD.

XX Christou P., Mehlo L,
PI
XX
DR WPI; 2001-007228/01.
XX Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
PT comprising a toxin and a binding domain for producing transgenic plants
PT resistant to pests -
PS Claim 9, Fig 3b, 81pp; English.

XX The present sequence is that of Bacillus thuringiensis crystal
CC protein CryIA(c) DNA in baculovirus transfer vector pFASTBAC1, in
CC which the gene was cloned under the control of the polyhedrin
CC promoter. The invention provides nucleic acids (see AAA88919-24)
CC encoding pesticidal fusion proteins comprising a toxin domain and a
CC heterologous binding domain capable of binding non-specifically to
CC a cell membrane without disrupting that membrane. The toxin domain
CC is preferably obtained from CryIA(b) or CryIA(c), and the binding
CC domain is preferably derived from a lectin, such as ricin toxin B
CC chain. The use of such fusions may help to inhibit the acquisition
CC of resistance in a pest population treated with the protein.
CC Vectors (e.g. baculovirus vectors or vectors suitable for use in a
CC plant), host cells, and transgenic plants (especially rice or
CC maize) are also provided. Expression of the fusion protein in a
CC plant is useful for influencing or affecting the toxicity of a
CC plant to a pest, allowing control of e.g. Lepidoptera, Coleoptera,
CC Culicidae, Simuliidae, Hymenoptera, Homoptera, Diptera and
CC Orthoptera pests.

SQ Sequence 2062 BP; 544 A; 532 C; 446 G; 540 T; 0 other;

Query Match 100.0%; Score 24; DB 22; Length 2062;
Best Local Similarity 100.0%; Pred. No. 0.19;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0

OY 1 TATGATCCTTAGTACTTCCTGCAC 24
|||||
DB 2057 TATGATCCTTAGTACTTCCTGCAC 2034

RESULT 13
AAA88921/c
ID AAA88921 standard; DNA; 2436 BP.
XX
AC AAA88921;
XX
DT 05-MAR-2001 (first entry)

Nucleotide sequence of CryIA(b)-RTB3 fusion in pFASTBAC1.
DE
XX
XX
KW CryIA(b); crystal protein; ricin toxin B; RTB3; lectin;
KM insecticide; pesticide; toxin; transgenic plant; insect resistance;
KW crop protection; pFASTBAC1; ds.
XX
OS Chimeric - Bacillus thuringiensis.
OS Chimeric - Ricinus communis.
OS Chimeric - Baculovirus.
FN WO200066755-A2.
PD 09-NOV-2000.
PP 27-APR-2000; 2000WO-GBO1633.
PR 28-APR-1999; 99GB-0009796.
PA (PLAN-) PLANT BIOSCIENCE LTD.
PI Christou P., Mehlo L,
XX
XX WPI; 2001-007228/01.
XX

PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests
 XX
 PS Claim 11; Fig 3h; 81pp; English.
 XX
 CC This nucleotide sequence is that of a fusion between DNA encoding
 CC crystal protein CryIA(b) (see AA88914) of *Bacillus thuringiensis* and
 CC DNA encoding ricin toxin B RTB3 (see AA88918) in baculovirus transfer
 CC vector pFASTBAC1, in which the fusion was cloned under the control
 CC of the polyhedrin promoter. This is an example of claimed nucleic
 CC acids encoding pesticidal fusion proteins between a toxin domain
 CC and a heterologous binding domain capable of binding non-specifically
 CC to a cell membrane without disrupting that membrane. The use of such
 CC fusions may help to inhibit the acquisition of resistance in a pest
 CC population treated with the protein. Vectors (e.g. baculovirus
 CC vectors or vectors suitable for use in a plant), host cells, and
 CC transgenic plants (especially rice or maize) are also provided.
 CC Expression of the fusion protein in a plant is useful for influencing
 CC or affecting the toxicity of a plant to a pest, allowing control of
 CC e.g. Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera,
 CC Homoptera, Diptera and Orthoptera pests.
 XX
 SQ Sequence 2436 BP; 654 A; 617 C; 521 G; 644 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 2436;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 2431 TATGATCCTCTAGTACTTCTCGAC 2408
 RESULT 14
 AA88924/C
 ID AA88924 standard; DNA; 2436 BP.
 XX
 AC AAA88924;
 XX
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of CryIA(c)-RTB3 fusion in pFASTBAC1.
 XX
 KW CryIA(c); crystal protein; ricin toxin B; RTB3; lectin;
 KW insecticide; pesticide; toxin; transgenic plant; insect resistance;
 KW crop protection; pFASTBAC1; de.
 XX
 OS Chimeric - *Bacillus thuringiensis*.
 OS Chimeric - *Ricinus communis*.
 OS Chimeric - *Baculovirus*.
 XX
 PN WO200066755-A2.
 XX
 PD 09-NOV-2000.
 XX
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;
 XX
 DR WPI; 2001-007228/01.
 XX
 PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests
 XX
 PS Claim 11; Fig 3k; 81pp; English.
 XX
 CC This nucleotide sequence is that of a fusion between DNA encoding

CC crystal protein CryIA(c) (see AA88915) of *Bacillus thuringiensis* and
 CC DNA encoding ricin toxin B RTB3 (see AA88918) in baculovirus transfer
 CC vector pFASTBAC1, in which the fusion was cloned under the control
 CC of the polyhedrin promoter. This is an example of claimed nucleic
 CC acids encoding pesticidal fusion proteins between a toxin domain
 CC and a heterologous binding domain capable of binding non-specifically
 CC to a cell membrane without disrupting that membrane. The use of such
 CC fusions may help to inhibit the acquisition of resistance in a pest
 CC population treated with the protein. Vectors (e.g. baculovirus
 CC vectors or vectors suitable for use in a plant), host cells, and
 CC transgenic plants (especially rice or maize) are also provided.
 CC Expression of the fusion protein in a plant is useful for influencing
 CC or affecting the toxicity of a plant to a pest, allowing control of
 CC e.g. Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera,
 CC Homoptera, Diptera and Orthoptera pests.
 XX
 SQ Sequence 2436 BP; 660 A; 597 C; 527 G; 652 T; 0 other;
 Query Match 100.0%; Score 24; DB 22; Length 2436;
 Best Local Similarity 100.0%; Pred. No. 0.19;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 TATGATCCTCTAGTACTTCTCGAC 24
 Db 2431 TATGATCCTCTAGTACTTCTCGAC 2408
 RESULT 15
 AA88920/C
 ID AA88920 standard; DNA; 2692 BP.
 XX
 AC AAA88920;
 XX
 DT 05-MAR-2001 (first entry)
 XX
 DE Nucleotide sequence of CryIA(b)-RTB2 fusion in pFASTBAC1.
 XX
 KW CryIA(b); crystal protein; ricin toxin B; RTB2; lectin;
 KW insecticide; pesticide; toxin; transgenic plant; insect resistance;
 KW crop protection; pFASTBAC1; de.
 XX
 OS Chimeric - *Bacillus thuringiensis*.
 OS Chimeric - *Ricinus communis*.
 OS Chimeric - *Baculovirus*.
 XX
 PN WO200066755-A2.
 XX
 PD 09-NOV-2000.
 XX
 PF 27-APR-2000; 2000WO-GB01633.
 XX
 PR 28-APR-1999; 99GB-0009796.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Christou P, Mehlo L;
 XX
 DR WPI; 2001-007228/01.
 XX
 PT Novel nucleic acid molecule encoding a pesticidal fusion polypeptide
 PT comprising a toxin and a binding domain for producing transgenic plants
 PT resistant to pests
 XX
 PS Claim 11; Fig 3g; 81pp; English.
 XX
 CC This nucleotide sequence is that of a fusion between DNA encoding
 CC crystal protein CryIA(b) (see AA88914) of *Bacillus thuringiensis* and
 CC DNA encoding ricin toxin B RTB2 (see AA88917) in baculovirus transfer
 CC vector pFASTBAC1, in which the fusion was cloned under the control
 CC of the polyhedrin promoter. This is an example of claimed nucleic
 CC acids encoding pesticidal fusion proteins between a toxin domain
 CC and a heterologous binding domain capable of binding non-specifically
 CC to a cell membrane without disrupting that membrane. The use of such

CC fusions may help to inhibit the acquisition of resistance in a pest
 CC population treated with the protein. Vectors (e.g. baculovirus
 CC vectors or vectors suitable for use in a plant), host cells, and
 CC transgenic plants (especially rice or maize) are also provided.
 CC Expression of the fusion protein in a plant is useful for influencing
 CC or affecting the toxicity of a plant to a pest, allowing control of
 CC e.g. Lepidoptera, Coleoptera, Culicidae, Simuliidae, Hymenoptera,
 CC Homoptera, Diptera and Orthoptera pests.

XX
 SO Sequence 2692 BP; 730 A; 660 C; 586 G; 716 T; 0 other;

Query Match 100.0%; Score 24; DB 22; Length 2692;

Best Local Similarity 100.0%; Pred. No. 0.2;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
 |||||
 Db 2687 TATGATCCTCTAGTACTTCTCGAC 2664

Search completed: February 16, 2004, 09:18:11
 Job time : 12.7756 secs

mis Page Blank (uspio)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 93.2277 Seconds

(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-5

Perfect score: 24

Sequence: 1 tatgatccctctagctctcgac 24

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 1215238056 residues

Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

EST:*
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estm:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rnd:*
26: em_gss_phg:*
27: em_gss_vrt:*
28: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.2	80.0	820	13	BU371267 603596334
2	18.8	78.3	293	12	B1024729 RCS-MT025
3	18.8	78.3	389	28	AQ105178 HS-3000 A
4	18.4	76.7	749	28	AZ805647 2M067G12

5	18.2	75.8	491	28	AQ502165 V8B1 mtN-
6	18.2	75.8	566	9	AA660276 00145 MCR
7	18.2	75.8	600	29	B2309602 iC09C08.b
8	18.2	75.8	600	29	B2324410 iC09C08.g
9	18.2	75.8	608	28	AQ305217 HS_2019_A
10	18.2	75.8	608	28	BH022001 GH_MBD500
11	18.2	75.8	737	14	CA781659 031G1AF
12	18.2	75.8	741	29	B2506781 BONFA77F
13	18.2	75.8	799	29	B2998034 PUGFY17TD
14	18.2	75.8	815	28	AQ862478 nbe0019A
15	18.2	75.8	1661	29	B2576392 meh2_4912
16	17.8	74.2	484	9	AM573112 h132C10.x
17	17.6	73.3	195	9	AM037530 EST278857
18	17.6	73.3	327	14	CB891487 EST648456
19	17.6	73.3	493	9	A1083079 MS64C3 Me
20	17.6	73.3	504	9	A1397571 NCGC5D12T
21	17.6	73.3	533	28	AZ750896 RPT1-24-1
22	17.6	73.3	572	28	BH877505 h338e09.b
23	17.6	73.3	609	10	BF643933 NF092B11E
24	17.6	73.3	621	10	BE460948 EST412367
25	17.6	73.3	640	10	BG449733 NF007C081
26	17.6	73.3	645	9	AM586847 EST318470
27	17.6	73.3	655	10	BF646400 NF071F10E
28	17.6	73.3	659	13	BQ147235 NF038C01F
29	17.6	73.3	695	9	AV403040 AV403040
30	17.6	73.3	695	12	BP126081 BP126081
31	17.6	73.3	704	9	AV404024 AV404024
32	17.6	73.3	740	10	BG581848 EST483584
33	17.6	73.3	792	14	CB984130 AGENCOURT
34	17.6	73.3	1213	29	CC225588 CH261-57B
35	17.4	72.5	415	28	AQ556970 HS_5308 B
36	17.4	72.5	521	29	B2521578 BOKA58TR
37	17.4	72.5	728	28	BH995266 oeh17C12
38	17.2	71.7	125	12	BG945612 PM2-KN003
39	17.2	71.7	164	10	BF859022 MRO-FT018
40	17.2	71.7	188	9	AM064152 SP0586 KR
41	17.2	71.7	201	13	BU890760 P041C09 P
42	17.2	71.7	235	10	BF858704 MRO-FT019
43	17.2	71.7	252	10	BF954669 MRO-NN116
44	17.2	71.7	297	10	BF753157 MRO-BN038
45	17.2	71.7	378	9	AM181442 pa02g07.y

ALIGNMENTS

RESULT 1
BU371267
LOCUS 820 bp mRNA linear EST 28-NOV-2002
DEFINITION 603596334F1 CSEQCHN73 Gallus gallus CDNA clone CHEST564c9 5', mRNA
ACCESSION BU371267
VERSION BU371267.1 GI:25879268
KEYWORDS EST.
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
REFERENCE
AUTHORS Boardman,P.E., Sanz-Ezquerro,J., Overton,I.M., Burt,D.W., Bosch,E.,
Fong,W.T., Tickle,C., Brown,W.R.A., Wilson,S.A. and Hubbard,S.J.
TITLE A Comprehensive Collection of Chicken cDNAs
JOURNAL Curr. Biol. 12 (22), 1965-1969 (2002)
MEDLINE 22335534
PUBMED 12445392
COMMENT Contact: Simon Hubbard
Department of Biomolecular Sciences
University of Manchester Institute of Science and Technology (UMIST)

PO Box 88, Manchester, M60 10D, UK
Tel: 01612008930
Fax: 01612360409

FEATURES Email: Simon.Hubbard@unist.ac.uk.
Location/Qualifiers

SOURCE

```
1..820
/organism="Gallus gallus"
/mol_type="mRNA"
/strain="Compton line 151"
/db_xref="taxon:9031"
/clone="ChEST564c9"
/sex="Female"
/tissue_type="not cerebrum or cerebellum"
/dev_stage="Adult"
/lab_host="DH10B"
/clone.lib="CSROCHN73"
/note="Organ: Brain; Vector: pBluescript II KS(+); Site_1:
EcoRI; Site_2: NotI; This normalized library was
constructed from 1 million independent clones. cDNA
synthesis was initiated using an oligo(dT) primer, using
methylated C in the first strand synthesis reaction.
Following this first strand reaction, double-stranded cDNA
was blunt-ended, ligated to NotI adapters, digested with EcoRI
, size-selected, and cloned into the NotI and EcoRI
compatible sites of a custom modified MCS of the
pBluescript (KS+) vector. The library was normalized in 2
rounds using conditions adapted from Soares et al., PNAS
(1996) 91: 9228-9232 and Bonaldo et al., Genome Research 6
(1996): 791, except that a significantly longer
reannealing hybridization was used."
```

BASE COUNT

204 a 246 c 171 g 199 t

ORIGIN

Query Match 80.0%; Score 19.2; DB 13; Length 820;
Best Local Similarity 87.5%; Pred. No. 5.1e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 TATGATCTCTAGTACTTCTCGAC 24

Db 381 TATGCTCTCTACTTCTCTCGAC 404

RESULT 2
BI024729 293 bp mRNA linear EST 14-JUN-2001
LOCUS RCS-MT0259-300101-012-G04 MT0259 Homo sapiens CDNA, mRNA sequence.
ACCESSION BI024729
VERSION BI024729.1 GI:14431359
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 293)
Dias Neto, E., Garcia Correa, R., Verjovski-Almeida, S., Briones, M.R.,
Nagai, M.A., da Silva, W. Jr., Zago, M.A., Bordin, S., Costa, F.F.,
Goldman, G.H., Carvalho, A.F., Matukuma, A., Bala, G.S., Simpson, D.H.,
Brunstein, A., de Oliveira, P.S., Bucher, P., Jongeneel, C.V., O'Hare
, M.J., Soares, F., Brentani, R.R., Reis, L.F., de Souza, S.V. and
Simpson, A.J.

TITLE

Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags

JOURNAL MEDLINE
20202663
10737800
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the PAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL
(http://www.ludwig.org.br/scripts/gethtml2.pl?l=RC5&t2=RC5-MT0259-

300101-012-G04&t3=2001-01-30&t4=1)
Seq primer: puc 18 forward
High quality sequence start: 293.
High quality sequence stop: 293.
location/Qualifiers

FEATURES

SOURCE

```
1..293
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/dev_stage="Adult"
/clone.lib="MT0259"
/note="Organ: marrow; Vector: puc18; Site_1: SmaI; Site_2:
SmaI; A mini-library was made by cloning products derived
from ORESTES PCR (U.S. Letters Patent Application No. 196
,716 - Ludwig Institute for Cancer Research) profiles
into the puc 18 vector. Reverse transcription of tissue
mRNA and cDNA amplification were performed under low
stringency conditions."
```

BASE COUNT

70 a 76 c 73 g 74 t

ORIGIN

Query Match 78.3%; Score 18.8; DB 12; Length 293;
Best Local Similarity 90.9%; Pred. No. 5.1e+02;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 ATGATCTCTAGTACTTCTCGA 23

Db 6 ACGTCTCTAGTACTTCTCGA 27

RESULT 3
AQ105178/c 389 bp DNA linear GSS 28-AUG-1998
LOCUS HS 3000 A1 H12 MR CIT Approved Human Genomic Sperm Library D Homo
DEFINITION sapiens genomic clone Plate=3000 Col=23 Row=0, genomic survey
sequence.
ACCESSION AQ105178
VERSION AQ105178.1 GI:3480534
KEYWORDS GSS.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 389)
Mahairas, G.G., Wallace, J.C., Smith, K., Swartzell, S., Holzman, T.,
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
Hood, L.

Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome

JOURNAL MEDLINE
99380589
10449764
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 3000 row: 0 column: 23
Class: BAC ends
High quality sequence stop: 389.
location/Qualifiers

FEATURES

SOURCE

```
1..389
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=3000 Col=23 Row=0"
/sex="male"
/note="Organ: sperm; Vector: pBeloBAC11; BAC clones in  
E-Coli DH10B"
```

BASE COUNT 122 a 67 c 81 g 108 t 11 others
ORIGIN

Query Match 76.3%; Score 18.8; DB 28; Length 389;
Best Local Similarity 90.9%; Pred. No. 5.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 ATGATCCTCTAGTACTTCTGCA 23
Db 194 ATGATCTTCTAGTACTTCTCTA 173

RESULT 4

AZ805647 749 bp DNA linear GSS 20-FEB-2001
LOCUS 2M067G12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION Clone UUGC2M0067G12 F, genomic survey sequence.

ACCESSION AZ805647
VERSION AZ805647.1 GI:12966458
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 749)
AUTHORS Dunn, P., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, M., Rose, R., Stokes, R., Tinney, A., von Niederhausen, A. and Wright, D., Weis, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL COMMENT

Unpublished
Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0067 row: G column: 12
Seq primer: CGTGTAAACGACGCCACGT
Class: plasmid ends
High quality sequence stop: 749.

FEATURES

source

1. 749
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="CS7BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0067G12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/note="Vector: PMD42nv; Purified genomic DNA from M. musculus CS7BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells

BASE COUNT 211 a 203 c 144 g 191 t
ORIGIN and selected for ampicillin resistance."

Query Match 76.7%; Score 18.4; DB 28; Length 749;
Best Local Similarity 95.0%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCT 20
Db 529 TCTGATCCTCTAGTACTTCT 510

RESULT 5

AQ502165 491 bp DNA linear GSS 29-APR-1999
LOCUS V881 mtn-3xHA/lacZ insertion library Saccharomyces cerevisiae
DEFINITION genomic 5', genomic survey sequence.

ACCESSION AQ502165
VERSION AQ502165.1 GI:4707815
KEYWORDS GSS.
SOURCE Saccharomyces cerevisiae (baker's yeast)
ORGANISM Saccharomyces cerevisiae

REFERENCE Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes; Saccharomycetales; Saccharomycetaceae; Saccharomyces. 1 (bases 1 to 491)
AUTHORS Ross-Wadonald, P., Roemer, T., Coelho, P. S. R., Agarwal, S., Kumar, A., Desbages, S. A., Cheung, K. H., Sheehan, A., Symoniatidis, D., Jansen, R., Umansky, L., Heldtman, M., Nelson, K., Iwaseki, H., Kanada, D., Lugo, R., Hager, K., Miller, P., Roeder, G. S. and Snyder, M.

TITLE Large-scale analysis of the Yeast Genome by Transposon Tagging and Gene Disruption

JOURNAL COMMENT

Unpublished
Contact: Kumar A
Michael Snyder, Dept. of Mol. Cell. and Dev. Biology
Yale University
P.O. Box 208103, New Haven, CT 06520-8103, USA
Tel: 203 432 9949
Fax: 203 432 6161
Email: anuj.kumar@yale.edu

te of mtn-3xHA/lacZ insertion.
Seq primer: GGCCCTCTCTTGTGGAGTAC
Class: transposon-tagged.

FEATURES

source

1. 491
/organism="Saccharomyces cerevisiae"
/mol_type="genomic DNA"
/db_xref="taxon:4932"
/lab_host="E. coli"
/clone_lib="mtn-3xHA/lacZ insertion library"
/note="Vector: pHS56-Sal; A yeast genomic DNA library (lacking mitochondrial DNA) was prepared in pHS56-Sal; genomic DNA was size-fractionated (DNA of roughly 2-3 kb in length) prior to cloning. This library was subsequently mutagenized with a mtn-3xHA/lacZ minitransposon containing lacZ, URA3, and tect resistance."
BASE COUNT 125 a 127 c 119 g 116 t 4 others
ORIGIN

Query Match 75.8%; Score 18.2; DB 28; Length 491;
Best Local Similarity 87.0%; Pred. No. 1.1e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2 ATGATCTCTAGTACTTCTGAC 24
Db 107 ATGATCTCTAGTACTTCTGAC 129

RESULT 6

AA660276 566 bp mRNA linear EST 08-MAR-2000
LOCUS AA660276/c
DEFINITION 00145 MTRHB Medicago truncatula cDNA 5' similar to retinoblastoma binding protein p46, mRNA sequence.

ACCESSION AA660276
VERSION AA660276.1 GI:2604320
KEYWORDS EST.
SOURCE Medicago truncatula
ORGANISM Medicago truncatula (barrel medic)
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; euroside I; Fabales; Fabaceae; Papilionoideae; Trifoliaceae; Medicago.
AUTHORS 1 (bases 1 to 566)
TITLE Covitz, P.A., Smith, L.S. and Long, S.R.
JOURNAL Expressed sequence tags from a root-hair-enriched medicago truncatula cDNA library
COMMENT Plant Physiol. 117 (4), 1325-1332 (1998)
 Contact: Long SR
 Department of Biological Sciences and Howard Hughes Medical Institute
 Stanford University
 Gilbert Biology, Stanford, CA 94305-5020, USA
 Tel: 650 723 3232
 Fax: 650 725 8309
 Email: fa.srl@foreythe.stanford.edu
 Seq primer: 73.
FEATURES
 source
 location/Qualifiers
 1..566
 /organism="Medicago truncatula"
 /mol_type="mRNA"
 /culturivar="Jemalong"
 /db_xref="taxon:3880"
 /cisseu_type="Root hairs & tips"
 /dev_stage="2-3 day old seedlings"
 /clone_lib="McRHE"
 /note="Organ: Root; Vector: PBK-CMV; Site 1: EcoRI; Site 2: XhoI; cDNA was synthesized from a pooled mRNA prep from elongating root hairs (30% w/w) and 2-3cm root tips (70% w/w). XhoI-oligo-dr linker-primer and EcoRI adaptors were used. cDNAs was cloned unidirectionally into lambda ZAP Express (Stratagene), amplified, and mass-excised into PBK-CMV vector plasmids. More information is available at http://bio-sr18.stanford.edu."
BASE COUNT 178 a 121 c 135 g 127 t 5 others
ORIGIN
 Query Match 75.8%; Score 18.2; DB 9; Length 566;
 Best Local Similarity 83.3%; Pred. No. 1.2e+03;
 Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 TATGATCCTTAGTACTTCTGCAC 24
 Db 496 TATGATAGCTTGACTTCTTGAC 473
RESULT 7
LOCUS BZ309602 600 bp DNA linear GSS 06-NOV-2002
DEFINITION ic09c08.b1 WGS-ZmayrF (JM107 adapted methyl filtered) Zea mays
ACCESSION BZ309602
VERSION BZ309602.1 GI:24670634
KEYWORDS GSS.
SOURCE Zea mays
ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoidae; Andropogoneae; Zea.
REFERENCE 1 (bases 1 to 600)
AUTHORS Rabinowicz, P.D., O'Shaughnessy, A.L., Balija, V., Dedhia, N., Katzenburger, F., King, L., Miller, B., Muller, S., Nascimento, L., Zutaevern, T., McCombie, W.R. and Martienssen, R.A.
TITLE Genomic shotgun sequences from Zea mays (methyl-filtered)
JOURNAL Unpublished
COMMENT Contact: W. Richard McCombie
 Lita Annenberg Hazen Genome Sequencing Center

ACCESSION AA660276
VERSION AA660276.1 GI:2604320
KEYWORDS EST.
SOURCE Medicago truncatula
ORGANISM Medicago truncatula (barrel medic)
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; euroside I; Fabales; Fabaceae; Papilionoideae; Trifoliaceae; Medicago.
AUTHORS 1 (bases 1 to 566)
TITLE Covitz, P.A., Smith, L.S. and Long, S.R.
JOURNAL Expressed sequence tags from a root-hair-enriched medicago truncatula cDNA library
COMMENT Plant Physiol. 117 (4), 1325-1332 (1998)
 Contact: Long SR
 Department of Biological Sciences and Howard Hughes Medical Institute
 Stanford University
 Gilbert Biology, Stanford, CA 94305-5020, USA
 Tel: 650 723 3232
 Fax: 650 725 8309
 Email: fa.srl@foreythe.stanford.edu
 Seq primer: 73.
FEATURES
 source
 location/Qualifiers
 1..566
 /organism="Medicago truncatula"
 /mol_type="mRNA"
 /culturivar="Jemalong"
 /db_xref="taxon:3880"
 /cisseu_type="Root hairs & tips"
 /dev_stage="2-3 day old seedlings"
 /clone_lib="McRHE"
 /note="Organ: Root; Vector: PBK-CMV; Site 1: EcoRI; Site 2: XhoI; cDNA was synthesized from a pooled mRNA prep from elongating root hairs (30% w/w) and 2-3cm root tips (70% w/w). XhoI-oligo-dr linker-primer and EcoRI adaptors were used. cDNAs was cloned unidirectionally into lambda ZAP Express (Stratagene), amplified, and mass-excised into PBK-CMV vector plasmids. More information is available at http://bio-sr18.stanford.edu."
BASE COUNT 178 a 121 c 135 g 127 t 5 others
ORIGIN
 Query Match 75.8%; Score 18.2; DB 29; Length 600;
 Best Local Similarity 87.0%; Pred. No. 1.2e+03;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1 TATGATCCTTAGTACTTCTGCA 23
 Db 414 TATATCCTTAGTACTTCAACA 436
RESULT 8
LOCUS BZ324410/c
DEFINITION BZ324410 600 bp DNA linear GSS 06-NOV-2002
ACCESSION ic09c08.g1 WGS-ZmayrF (JM107 adapted methyl filtered) Zea mays
VERSION BZ324410
KEYWORDS Genomic clone ic09c08 5', genomic survey sequence.
SOURCE Zea mays
ORGANISM Zea mays
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD clade; Panicoidae; Andropogoneae; Zea.
REFERENCE 1 (bases 1 to 600)
AUTHORS Rabinowicz, P.D., O'Shaughnessy, A.L., Balija, V., Dedhia, N., Katzenburger, F., King, L., Miller, B., Muller, S., Nascimento, L., Zutaevern, T., McCombie, W.R. and Martienssen, R.A.
TITLE Genomic shotgun sequences from Zea mays (methyl-filtered)
JOURNAL Unpublished
COMMENT Contact: W. Richard McCombie
 Lita Annenberg Hazen Genome Sequencing Center
 Cold Spring Harbor Laboratory
 PO Box 100, Cold Spring Harbor, NY 11724, USA
 Tel: 516 367 8884
 Fax: 516 367 8874
 Email: mcombie@cshl.org
 Seq primer: -21M13UnivRev
 Plate: ic09 row: C column: 08
 High quality sequence stop: 613.
FEATURES
 source
 location/Qualifiers
 1..600
 /organism="Zea mays"
 /mol_type="genomic DNA"
 /culturivar="B73"

```

/db xref="taxon:4577"
/clone="ic09c08"
/lab host="JM107 or DH5a"
/clone_lib="WGS-zmaysf (JM107 adapted methyl filtered)"
/notes="Organ: immature ears; Site_1: Xba I; Site_2: Xba I;
The vector was digested with Xba I and one nucleotide was
added by fill in in the recessive 3' end. The genomic DNA
was nebulized, end repaired, adaptor ligated and size
fractionated using sephadex. The resulting fragments were
between 0.8 and 3 kb and were cloned into the vector
(.x/y reads in M13mp19, .b/g reads in pUC19). The same
ligation was transformed in either JM107 or DH5a."

BASE COUNT      187 a      135 c      102 g      176 t
ORIGIN

Query Match      75.8%; Score 18.2; DB 29; Length 600;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1 TATGATCCTCTAGTACTTCTCGA 23
Db      188 TAAATCTCTAGTACTTCTCGA 166

RESULT 9
ACCESSION      AQ305217
LOCUS          HS_2019_A2_D07_T7 CIT Approved Human Genomic Sperm Library D Homo
DEFINITION      sapiens genomic clone Plate=2019 Col=14 Row=G, genomic survey
sequence.
ACCESSION      AQ305217
VERSION        AQ305217.1
KEYWORDS       GSS.
SOURCE         Homo sapiens (human)
ORGANISM       Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 608)
Keller, A., Shaker, R., Furlong, J., Young, J., Zhao, S., Adams, M.D. and
Hood, L.
Sequence-tagged connectors: A sequence approach to mapping and
scanning the human genome
Proc. Natl. Acad. Sci. U.S.A. 96 (117), 9739-9744 (1999)
99380589
10449764
Contact: Mahairas GG, Wallace JC, Hood L
High Throughput Sequencing Center
University of Washington
401 Queen Anne Avenue North, Seattle, WA 98109, USA
Tel: (206) 616-3618
Fax: (206) 616-3887
Email: jwallace@u.washington.edu
Sequence Tagged Connector
Plate: 2019 row: G column: 14
Class: BAC ends
High quality sequence stop: 608.
Location/Qualifiers
1. 608
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/clone="Plate=2019 Col=14 Row=G"
/sex="male"
/clone_lib="CIT Approved Human Genomic Sperm Library D"
/notes="Organ: sperm; Vector: peloBAC11; BAC Clones in
E-Coli DH108"

BASE COUNT      168 a      150 c      136 g      140 t      14 others
ORIGIN

Query Match      75.8%; Score 18.2; DB 28; Length 608;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Oy      2 ATGATCCTCTAGTACTTCTCGAC 24
Db      236 ATGATCCTCTAGTACTTCTCGAC 214

RESULT 10
LOCUS          BH022001
DEFINITION      GH_MBB0001P10F Gossypium hirsutum L. Gossypium hirsutum genomic
clone GH_MBB0001P10F, genomic survey sequence.
ACCESSION      BH022001
VERSION        BH022001.1
KEYWORDS       GSS.
SOURCE         Gossypium hirsutum (upland cotton)
ORGANISM       Gossypium hirsutum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids
; eurosids II; Malvales; Malvaceae; Malvaceae; Malvaceae; Gossypium.
1 (bases 1 to 609)
Tomkins, J.P., Peterson, D.G., Yang, T.J., Main, D., Wilkins, T.A.,
Paterson, A.H. and Wing, R.A.
Development of Genomic Resources for Cotton (Gossypium hirsutum
L.): BAC Library Construction, Preliminary STC Analysis, and
Identification of Clones Associated with Fiber Development
Unpublished
Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: TAAATCAGCTCAGTATGAGG
Class: BAC ends
High quality sequence start: 4
High quality sequence stop: 230.
Location/Qualifiers
1. 609
/organism="Gossypium hirsutum"
/mol_type="genomic DNA"
/cultivar="Maxxa"
/db_xref="taxon:3635"
/clone="GH_MBB0001P10F"
/tissue_type="Young leaves"
/lab_host="B. coli"
/clone_lib="Gossypium hirsutum L."
/notes="Vector: pCUGIBAC-1; Site_1: HindIII; Site_2: NotI;
For more details on library preparation, ordering clones
and sequence analysis see
http://www.genome.clemson.edu/projects/btc/cotton/GH_Mbb "

BASE COUNT      152 a      156 c      81 g      220 t
ORIGIN

Query Match      75.8%; Score 18.2; DB 28; Length 609;
Best Local Similarity 87.0%; Pred. No. 1.2e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Oy      1 TATGATCCTCTAGTACTTCTCGA 23
Db      390 TACGACCTCTAGTACTTCTCTA 412

RESULT 11
LOCUS          CA781659
DEFINITION      03IG11AF Infected Arabidopsis Leaf Arabidopsis thaliana cDNA, mRNA
sequence.
ACCESSION      CA781659
VERSION        CA781659.1
KEYWORDS       EST.
SOURCE         Arabidopsis thaliana (thale cress)
ORGANISM       Arabidopsis thaliana

```

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosid II; Brassicales; Brassicaceae; Arabidopsids.

1 (bases 1 to 737)
Lundsgaard, M., Emmersen, J., Nielsen, K.L., Wilson, I., Somerville, S. and Weidner, K.G.

EST sequencing of Erysiphe cichoracearum infected Arabidopsis plants

JOURNAL
Contact: Karen G. Weidner
Institute for biotechnology
Aalborg University
Søknagårdsholmvej 49, 9000 Aalborg, Denmark
Tel: +45 96358467
Fax: +45 98141808
Email: kgw@bio.auc.dk.

FEATURES
source
1..737
/organism="Arabidopsis thaliana"
/mol_type="rRNA"
/strain="Columbia"
/db_xref="taxon:3702"
/dev_stage="plant 3 weeks old, three days post infection"
/clone_lib="infected Arabidopsis leaf"
/note="Organ: Leaf; Vector: pBluescript; Mixed cDNA library of Arabidopsis and E. cichoracearum infected leaf from three weeks old Arabidopsis plants. Plants were harvested 3 days after infection and mRNA oligo dt selected."

BASE COUNT
204 a 137 c 156 g 240 t

Query Match
Best Local Similarity 87.0%; Score 18.2; DB 14; Length 737;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGA 23
Db 668 TATGATCATCAAGTACTTCTTGA 690

RESULT 12
B2506781 741 bp DNA linear GSS 16-DEC-2002
LOCUS BONFA77TF.B0.1.6.2 KB tot Brassica oleracea genomic clone BONFA77,
DEFINITION genomic survey sequence.
ACCESSION B2506781 GI:27028149
VERSION B2506781.1 GI:27028149
KEYWORDS GSS.
SOURCE Brassica oleracea
ORGANISM Brassica oleracea
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosid II; Brassicales; Brassicaceae; Brassica.
1 (bases 1 to 741)
Town, C.D., Van Aken, S., Uteback, T., Koo, H. and Fraser, C.M.
Whole genome shotgun sequencing of Brassica oleracea
Unpublished
Other GSSs: BONFA77TR
Contact: Chris Town
TIGR
9712 Medical Center Drive, Rockville, MD 20850, USA.
Tel: 301-838-3523
Fax: 301-838-0208
Email: cdtown@tigr.org
DNA is from a doubled haploid provided by Tom Osborn.
Seq primer: TF
Class: sheared ends.

FEATURES
source
1..741
/organism="Brassica oleracea"
/mol_type="genomic DNA"
/strain="TO1000DH3"

/db_xref="taxon:3712"
/clone="BONFA77"
/clone_lib="B0.1.6.2 KB tot"
/note="Vector: pHD51; Site 1: BstXI; 1.6-2 kb sheared total DNA inserted into pHD51 using BstXI linkers"

BASE COUNT
273 a 122 c 115 g 231 t

Qy 1 TATGATCCTCTAGTACTTCTCGA 23
Db 276 TATGATCATCTAGTACTTCTCGA 298

RESULT 13
B2998034 799 bp DNA linear GSS 25-MAR-2003
LOCUS PUGFY17TD.ZM.0.6.1.0 KB Zea mays genomic clone ZMMB7A375D09,
DEFINITION genomic survey sequence.
ACCESSION B2998034 GI:29241451
VERSION B2998034.1 GI:29241451
KEYWORDS GSS.
SOURCE Zea mays
ORGANISM Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; liliopsida; Poales; Poaceae; PACCAD clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 799)
Whitelaw, C.A., Quackenbush, J., Van Aken, S., Uteback, T., Resnick, A., Fraser, C.M., Yuan, Y., San Miguel, P., Ma, J. and Bennettzen, J.
Maize Genomics Consortium
Unpublished
Other GSSs: PUGFY17TB
Contact: Cathy Whitelaw
TIGR
9712 Medical Center Drive, Rockville, MD 20850, USA
Tel: 301-838-5843
Fax: 301-838-0208
Email: whitelaw@tigr.org
Seq primer: TF
Class: sheared ends.

FEATURES
source
1..799
/organism="Zea mays"
/mol_type="genomic DNA"
/strain="B73"
/db_xref="taxon:4577"
/clone="ZMMB7A375D09"
/clone_lib="ZM.0.6.1.0 KB"
/note="Vector: pCR4-TOP0; Site 1: EcoRI; 0.6-1.0 kb high COT selected genomic DNA library"

BASE COUNT
215 a 142 c 181 g 261 t

Query Match
Best Local Similarity 87.0%; Score 18.2; DB 29; Length 799;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGA 23
Db 528 TAATATCCTCTAGTACTTCTCGA 550

RESULT 14
AO862478 815 bp DNA linear GSS 03-NOV-1999
LOCUS nbeb0019A21f CUGI Rice BAC Library (ECORI) Oryza sativa (japonica
DEFINITION cultivar-group) genomic clone nbeb0019A21f, genomic survey
sequence.
ACCESSION AO862478

KEYWORDS	VERSION
AOB62478.1	GI:6212935
ORGANISM	GSS.
SOURCE	Oryza sativa (japonica cultivar-group)
ORGANISM	Oryza sativa (japonica cultivar-group)
REFERENCE	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophytes; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.
REFERENCE	1 (bases 1 to 815)
AUTHORS	Wing,R.A. and Dean,R.A.
TITLE	A BAC End Sequencing Framework to Sequence the Rice Genome
JOURNAL	Unpublished
COMMENT	Contact: Wing RA Clemson University Genomics Institute Clemson University 100 Jordan Hall, Clemson, SC 29634, USA Tel: 864 656 7288 Fax: 864 656 4293 Email: rwing@clemson.edu Seq primer: TTAATACGACCTCACTATAGG Class: BAC ends High quality sequence start: 46 High quality sequence stop: 279. Location/Qualifiers
FEATURES	1..815
source	/organism="Oryza sativa (japonica cultivar-group)" /mol_type="genomic DNA" /strain="japonica" /cultivar="Nipponbare" /db_xref="taxon:39947" /clone="nbeb0019A21f" /issue_type="leaf" /lab_host="E. coli DH10B" /clone_id="CUGI Rice BAC library (ECORI)" /note="Vector: pBACindigo; Site 1: EcoRI; Site 2: EcoRI; Rice is the most important food crop in the world. Half of the world population, especially those inhabiting highly populated areas of the humid tropics and subtropics, rely on rice as their primary source of carbohydrate. Monocotyledonous rice is a diploid plant (2n=24) with a haploid genome equivalent of 431 Mbp (Arumuganathan and Earle, 1991). The relatively small genome of rice, three times larger than that of Arabidopsis, makes it suitable for genomic studies. In order to facilitate positional cloning, physical mapping and genome sequencing of rice, we have constructed a BAC library from Oryza sativa, Nipponbare variety using EcoRI as the cloning enzyme. The library contains 55,296 clones with an average insert size of 121 kb providing approximately 15 haploid genome equivalents. The deep coverage allows the isolation a particular sequence with a probability of 99.9 %. Three high density filters, each containing 18,432 clones (doubly spotted), represent the whole library for colony screening and can be requested from the Clemson University BAC/EST Resource Center (www.genome.clemson.edu)."
BASE COUNT	215 a 213 c 84 g 298 t 5 others
ORIGIN	
Query Match	75.8%; Score 18.2; DB 28; Length 815;
Best Local Similarity	87.0%; Pred. No. 1.4e-03;
Matches	20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY	1 TATGATCCTTAGTACTTCTCGA 23
DB	789 TATTATCCTTAATACTTCTCTGA 811
RESULT 15	BZ576392 1661 bp DNA linear GSS 17-DEC-2002
LOCUS	BZ576392
DEFINITION	msb2_4912_Y2 msh Pseudomonas aeruginosa genomic clone msh2_4912,
ACCESSION	BZ576392
VERSION	GI:27211453

```

KEYWORDS      GSS.
SOURCE        Pseudomonas aeruginosa
ORGANISM      Pseudomonas aeruginosa
REFERENCE     Bacteria; Proteobacteria; Gammaproteobacteria; Pseudomonadales;
AUTHORS       Pseudomonadaceae; Pseudomonas.
TITLE         1 (bases 1 to 1661)
              Spencer,D.H., Raymond,C.K., Smith,E.E., Sims,E.E., Hastings,M.,
              Burns,J.L., Kaul,R. and Olsen,M.V.
              Whole-Genome-Sequence variation among multiple isolates of
              Pseudomonas aeruginosa library
JOURNAL       J. Bacteriol., (2002) In press
COMMENT       Contact: Chris K. Raymond
              Genome Center
              University of Washington
              Box 352145, Seattle, WA 98105-2145, USA
              Tel: 2062216954
              Fax: 2066857244
              Email: craymond@u.washington.edu
FEATURES
source        Class: shotgun.
              location/Qualifiers
                1..1661
                  /organism="Pseudomonas aeruginosa"
                  /mol_type="genomic DNA"
                  /strain="MSH"
                  /db_xref="taxon:287"
                  /clone="mslh_4912"
                  /clone_lid="msh"
                  /note="Environmental isolate. Whole genomic shotgun
                    library."
BASE COUNT    340 a          434 c          265 g          618 t          4 others
ORIGIN
Query Match   75.8%; Score 18.2; DB 29; Length 1661;
Best local similarity 87.0%; Pred. No. 1.9e+03;
Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0.
OY            2 ATGATCCTCTAGTACTTCTGCAC 24
             ||||||| |||||||
DB            656 ATCATCCCTCCCTACTTCTGCAC 678

Search completed: February 16, 2004, 13:40:58
Job time : 97.2277 secs

```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 114.587 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-5

Perfect score: 24

Sequence: 1 tatgacctctagctactctcgac 24

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : GenEmbl:
1: gb_ba:*
2: gb_bcg:*
3: gb_in:*
4: gb_om:*
5: gb_ov:*
6: gb_pat:*
7: gb_ph:*
8: gb_pl:*
9: gb_pr:*
10: gb_ro:*
11: gb_sts:*
12: gb_sy:*
13: gb_un:*
14: gb_vi:*
15: em_ba:*
16: em_fun:*
17: em_hum:*
18: em_in:*
19: em_mu:*
20: em_om:*
21: em_or:*
22: em_ov:*
23: em_pat:*
24: em_ph:*
25: em_pl:*
26: em_ro:*
27: em_sts:*
28: em_un:*
29: em_vi:*
30: em_hcg_hum:*
31: em_hcg_inv:*
32: em_hcg_other:*
33: em_hcg_mus:*
34: em_hcg_pln:*
35: em_hcg_rod:*
36: em_hcg_mam:*
37: em_hcg_vrt:*
38: em_hcg_hum:*
39: em_hcg_mus:*
40: em_hcg_mus:*
41: em_hcg_other:*

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	24	100.0	24	6	AR125606 Sequence
2	24	100.0	24	6	AR194192 Sequence
3	24	100.0	24	6	AR221288 Sequence
4	24	100.0	24	6	AR243206 Sequence
5	24	100.0	24	6	AR287438 Sequence
6	24	100.0	604	6	AX044389 Sequence
7	24	100.0	604	6	AX044388 Sequence
8	24	100.0	956	6	AX044387 Sequence
9	24	100.0	1430	6	AX188665 Sequence
10	24	100.0	2062	6	AX044385 Sequence
11	24	100.0	2062	6	AX044386 Sequence
12	24	100.0	2436	6	AX044392 Sequence
13	24	100.0	2436	6	AX044395 Sequence
14	24	100.0	2692	6	AX044391 Sequence
15	24	100.0	2692	6	AX044394 Sequence
16	24	100.0	2788	6	AX044390 Sequence
17	24	100.0	2788	6	AX044393 Sequence
18	24	100.0	7668	6	BD170085 Novel ADA
19	24	100.0	8435	6	BD170083 Novel ADA
20	24	100.0	8505	6	BD170084 Novel ADA
21	23	95.8	934	6	AX077879 Sequence
22	18.8	78.3	164000	9	AL591682 Human DNA
23	18.4	76.7	110000	2	LMFLCHR36_22 Continuation (23 o
24	18.4	76.7	169529	2	AC131586 Mus muscu
25	18.2	75.8	404	8	ATH529465 Arabidops
26	18.2	75.8	1342	8	AY142502 Arabidops
27	18.2	75.8	2000	6	AX461217 Sequence
28	18.2	75.8	2338	8	BT005733 Arabidops
29	18.2	75.8	3006	2	AC018026 Drosophi
30	18.2	75.8	24942	8	YSCD9819 Saccharomyc
31	18.2	75.8	45980	8	ATT24818 Arabidops
32	18.2	75.8	83513	8	ATT20823 Arabidops
33	18.2	75.8	105549	10	AL844906 Mouse DNA
34	18.2	75.8	108409	14	AF083424 Ateleline h
35	18.2	75.8	153125	9	AC104456 Homo sapi
36	18.2	75.8	165617	5	AL929502 Zebrafish
37	18.2	75.8	171949	9	AC008652 Homo sapi
38	18.2	75.8	173810	10	AC083815 Mus muscu
39	18.2	75.8	198372	8	ATCHRIV66 AL161566 Arabidops
40	18.2	75.8	207639	10	AL844581 Mouse DNA
41	18.2	75.8	209114	9	AC008383 Homo sapi
42	18.2	75.8	230128	10	AC098707 Mus muscu
43	18.2	75.8	235996	2	AC096147 Rattus no
44	18.2	75.8	242679	2	AC117867 Rattus no
45	18.2	75.8	279353	2	AC120587 Rattus no

ALIGNMENTS

RESULT 1
LOCUS AR125606 24 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 5 from patent US 6177545.
ACCESSION AR125606
VERSION AR125606.1 GI:14111668
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
Pecker, I., Violdavsky, I., Friedman, Y. and Peretz, T.
Heparinase specific molecular probes and their use in research and
medical applications
JOURNAL Patent: US 6177545-A 5 23-JAN-2001;

FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 2
LOCUS AR194192 24 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5 from patent US 6348344.
ACCESSION AR194192
VERSION AR194192.1 GI:20240784
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-HersHKovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Mimon,M., Ben-Atzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6348344-A 5 19-FEB-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 3
LOCUS AR221288 24 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 5 from patent US 6426209.
ACCESSION AR221288
VERSION AR221288.1 GI:23328259
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-HersHKovitz,M., Pecker,I. and Yacoby-Zeevi,O.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6426209-A 5 30-JUL-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

Db 1 TATGATCCTCTAGTACTTCTCGAC 24

RESULT 4
LOCUS AR243206 24 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 5 from patent US 6475763.
ACCESSION AR243206
VERSION AR243206.1 GI:27290321
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Ayal-HersHKovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Mimon,M., Ben-Atzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schloni,Y.
TITLE Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
JOURNAL Patent: US 6475763-A 5 05-NOV-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 5
LOCUS AR287438 24 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 5 from patent US 6531129.
ACCESSION AR287438
VERSION AR287438.1 GI:29725132
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and medical applications
JOURNAL Patent: US 6531129-A 5 11-MAR-2003;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"

BASE COUNT 5 a 7 c 3 g 9 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 24;
Best Local Similarity 100.0%; Pred. No. 0.56;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||
1 TATGATCCTCTAGTACTTCTCGAC 24

Db

RESULT 6
LOCUS AX044389/c 604 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 5 from Patent WO0066755.
ACCESSION AX044389
VERSION AX044389.1 GI:11343267
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE 1 artificial sequences.
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 006755-A 5 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
Source
1. .604
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB3 in pFASTBAC1"
BASE COUNT 180 a 121 c 134 g 169 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 604;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TATGATCCTCTAGTACTTCTCGAC 24
Db 599 TATGATCCTCTAGTACTTCTCGAC 576
RESULT 7
AX044386/c
LOCUS AX044388 860 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 4 from Patent WO0066755.
ACCESSION AX044388
VERSION AX044388.1 GI:11343266
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 4 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
Source
1. .860
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB2 in pFASTBAC1"
BASE COUNT 255 a 165 c 200 g 240 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 860;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TATGATCCTCTAGTACTTCTCGAC 24
Db 855 TATGATCCTCTAGTACTTCTCGAC 832
RESULT 8
AX044387/c
LOCUS AX044387 956 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 3 from Patent WO0066755.
ACCESSION AX044387
VERSION AX044387.1 GI:11343265
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 3 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
Source
1. .2062
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b) in pFASTBAC1"
BASE COUNT 538 a 552 c 440 g 532 t
ORIGIN

source
1. .956
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of RTB1 in pFASTBAC1"
BASE COUNT 285 a 189 c 215 g 267 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 956;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TATGATCCTCTAGTACTTCTCGAC 24
Db 951 TATGATCCTCTAGTACTTCTCGAC 928
RESULT 9
AX188665/c
LOCUS AX188665 1430 bp DNA linear PAT 10-AUG-2001
DEFINITION Sequence 13 from Patent WO0147963.
ACCESSION AX188665
VERSION AX188665.1 GI:15142264
KEYWORDS
SOURCE Placobdella papillifera
ORGANISM Placobdella papillifera
REFERENCE 1
AUTHORS Finney, S., Seale, L. and Wallis, R.B.
TITLE Inhibitors of complement activation, their preparation and use
JOURNAL Patent: WO 0147963-A 13 05-JUL-2001;
Bio-Discovery Limited (GB)
FEATURES
Source
1. .1430
/organism="Placobdella papillifera"
/mol_type="genomic DNA"
/db_xref="taxon:168682"
BASE COUNT 419 a 296 c 296 g 419 t
ORIGIN
Query Match 100.0%; Score 24; DB 6; Length 1430;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1 TATGATCCTCTAGTACTTCTCGAC 24
Db 1126 TATGATCCTCTAGTACTTCTCGAC 1103
RESULT 10
AX044385/c
LOCUS AX044385 2062 bp DNA linear PAT 24-NOV-2000
DEFINITION Sequence 1 from Patent WO0066755.
ACCESSION AX044385
VERSION AX044385.1 GI:11343263
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 1 09-NOV-2000;
Plant Bioscience Limited (GB)
FEATURES
Source
1. .2062
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b) in pFASTBAC1"
BASE COUNT 538 a 552 c 440 g 532 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2062;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2057 TATGATCCTCTAGTACTTCTCGAC 2034

RESULT 11
AX044386/c 2062 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 2 from Patent WO0066755.
ACCESSION AX044386
VERSION AX044386.1 GI:11343264
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 2 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2062
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(c) in pFASTBAC1"

BASE COUNT 544 a 532 c 446 g 540 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2062;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2057 TATGATCCTCTAGTACTTCTCGAC 2034

RESULT 12
AX044392/c 2436 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 8 from Patent WO0066755.
ACCESSION AX044392
VERSION AX044392.1 GI:11343270
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 8 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2436
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b)-RTB3 in pFASTBAC1"

BASE COUNT 654 a 617 c 521 g 644 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2436;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
|||||

DB 2431 TATGATCCTCTAGTACTTCTCGAC 2408

RESULT 13
AX044395/c 2436 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 11 from Patent WO0066755.
ACCESSION AX044395
VERSION AX044395.1 GI:11343273
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 11 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2436
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(c)-RTB3 in pFASTBAC1"

BASE COUNT 660 a 597 c 527 g 652 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2436;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2431 TATGATCCTCTAGTACTTCTCGAC 2408

RESULT 14
AX044391/c 2692 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 7 from Patent WO0066755.
ACCESSION AX044391
VERSION AX044391.1 GI:11343269
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Christou, P. and Mehlo, L.
TITLE Pesticidal fusions
JOURNAL Patent: WO 0066755-A 7 09-NOV-2000;
Plant Bioscience Limited (GB)
LOCATION/Qualifiers

FEATURES
source 1..2692
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Nucleotide sequence of CryIA(b)-RTB2 in pFASTBAC1"

BASE COUNT 730 a 660 c 586 g 716 t
ORIGIN

Query Match 100.0%; Score 24; DB 6; Length 2692;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 TATGATCCTCTAGTACTTCTCGAC 24
DB 2687 TATGATCCTCTAGTACTTCTCGAC 2664

RESULT 15
AX044394/c 2692 bp DNA linear PAT 24-NOV-2000
LOCUS
DEFINITION Sequence 10 from Patent WO0066755.

```

ACCESSION  AX044394
VERSION     AX044394.1  GI:11343272
KEYWORDS
SOURCE      synthetic construct
ORGANISM    synthetic construct
            artificial sequences.
REFERENCE   1
AUTHORS     Christou, P. and Mehlo, L.
TITLE       Pesticidal fusions
JOURNAL     Patent: WO 006675-A 10 09-NOV-2000;
            Plant Bioscience Limited (GB)
FEATURES
  source
    1..2692
       /organism="synthetic construct"
       /mol_type="genomic DNA"
       /db_xref="taxon:32630"
       /note="Nucleotide sequence of CryIA(c)-RTB2 in pFASTBAC1"
BASE COUNT  736 a      640 c      592 g      724 t
ORIGIN
Query Match      100.0%; Score 24; DB 6; Length 2692;
Best Local Similarity 100.0%; Pred. No. 0.55;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY               1 TATGATCCTCTAGTACTTCTCGAC 24
                  |||||||
Db               2687 TATGATCCTCTAGTACTTCTCGAC 2664
                  |||||||

```

Search completed: February 16, 2004, 11:43:02
 Job time : 117.587 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:55:00 ; Search time 12.7569 Seconds
(without alignment)
5501.769 Million cell updates/sec

Title: US-10-676-079-4

Perfect score: 26
Sequence: 1 gcgcatacgcagcagctcgtgactcg 26

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 10%
Listing first 45 summaries

Database :

N Geneseq 19Jun03:*

1: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT:*
2: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT:*
3: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT:*
4: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT:*
5: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT:*
6: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT:*
7: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT:*
8: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT:*
9: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT:*
10: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT:*
11: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT:*
12: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT:*
13: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT:*
14: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT:*
15: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT:*
16: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT:*
17: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT:*
18: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT:*
19: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT:*
20: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT:*
21: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT:*
22: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT:*
23: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT:*
24: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT:*
25: /SIDSI/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26	100.0	26	21	AAZ39196 Human heparanase p
2	26	100.0	26	21	AAZ33291 Human heparanase p
3	20	76.9	30	24	ABN86005 Human heparanase g
4	19.6	75.4	474	22	AAFP9384 Primer specific fo
5	19.6	75.4	605	24	ABN86000 Human heparanase g
6	19.6	75.4	1419	24	ABN86003 Human heparanase u
7	19.6	75.4	1593	20	AAZ11236 Human pre-prohepar
8	19.6	75.4	1713	20	AAZ37259 Human heparanase e

9	19.6	75.4	1721	20	AAZ35648
10	19.6	75.4	1721	21	AAZ47501
11	19.6	75.4	1721	21	AAZ39195
12	19.6	75.4	1721	21	AAZ33290
13	19.6	75.4	1721	22	AAZ91112
14	19.6	75.4	1722	22	AAFP9388
15	19.6	75.4	1723	20	AAZ37260
16	19.6	75.4	1724	22	AAH20940
17	19.6	75.4	1899	21	AAZ35053
18	19.6	75.4	1899	21	AAZ75053
19	19.6	75.4	3726	20	AAZ86671
20	19.6	75.4	4448	21	AAZ75080
21	19.2	73.8	444	24	ABN90554
22	19.2	73.8	1369	24	ABN90553
23	19	73.1	1669	25	ABZ22816
24	18.6	71.5	35	21	AAZ39200
25	18.6	71.5	2588	25	ABT16043
26	18.6	71.5	4345	22	AAFP61716
27	18.6	71.5	11854	20	AAZ13243
28	18.6	71.5	11854	24	ABX99038
29	18.4	70.8	5770	23	AAZ84301
30	18.2	70.0	1298	24	AAZ42627
31	18.2	70.0	1302	24	AAZ9760
32	18.2	70.0	1302	24	AAZ9773
33	18.2	70.0	1304	24	AAZ42629
34	18.2	70.0	1360	24	AAZ42628
35	18	69.2	33	19	AAZ71120
36	18	69.2	33	20	AAZ30938
37	18	69.2	60	24	ABN40291
38	18	69.2	177	21	AAZ36803
39	18	69.2	177	21	AAZ82894
40	18	69.2	262	25	ABX31423
41	18	69.2	1584	24	ABT40753
42	18	69.2	2032	24	ABT92126
43	18	69.2	2032	25	ABX72051
44	18	69.2	2312	25	ABZ09890
45	18	69.2	2668	24	ABQ70896

ALIGNMENTS

RESULT 1
AAZ39196
ID AAZ39196 standard: DNA, 26 BP.
AAZ39196;
02-MAR-2000 (first entry)
Human heparanase PCR sense primer SEQ ID NO:4.
Human; heparanase; hpa; genetic modification; expression; anticancer;
angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumor;
anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
metastasis; wound healing; restenosis; atherosclerosis; inflammation;
neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
micrometastasis; autoimmune lesion; kidney failure; PCR primer; ss.
Synthetic.
Homo sapiens.
WO9957244-A1.
11-NOV-1999.
29-APR-1999; 99WO-US09256.
01-MAY-1999; 98US-0071618.
02-MAR-1999; 99US-0260038.
(INSI-) INSIGHT STRATEGY & MARKETING LTD.

CDNA encoding a hu
CDNA encoding a hu
Human heparanase e
Human heparanase n
Human heparanase
Human CDNA encodin
Seq ID No: 14 of w
Human heparanase i
CDNA encoding a hu
CDNA encoding a hu
CDNA encoding a hu
Nucleotide sequenc
Staphylococcus epi
Staphylococcus epi
Human heparanase e
Human heparanase p
NOVX related polym
Human CTAB-2-enco
Enterococcus faeca
Enterococcus faeca
DNA encoding novel
Coffee theobromine
1302nt DNA encodin
1302nt RNA encodin
Coffee theobromine
Coffee theobromine
PCR primer used to
Thermus thermophil
Human spliced tran
Human dyferlin re
Human dyferlin DN
Human GDP-mannose
Chicken signal pep
Human Tumour Endoc
DNA encoding human
Human 5' and/or re
Listeria monocytog

PA (FRIE/) FRIEDMAN M M.
XX
PI Ben-Arzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
PI Shlomi Y;
XX
DR WPI; 2000-062144/05.
XX
PT Engineered cells that express recombinant heparanase, useful
PT therapeutically, e.g. for treating angiogenesis and to screen for
PT specific inhibitors, potential anticancer agents -
XX
PS Example 1; Page 36; 118pp; English.
XX
CC The present invention describes genetically modified cells (A) containing
CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
CC and express recombinant heparanase (II). Heparanase cleaves heparan
CC sulphate (HS) at specific intrachain sites, resulting in release of
CC heparin-binding growth factors, enzymes and proteins that are sequestered
CC by HS in basement membranes, extracellular matrix or cell surfaces. It
CC may also be implicated in tumour angiogenesis and metastases. (II) is
CC potentially useful in wound healing and for treating angiogenesis,
CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
CC infection and cystic fibrosis. It can also be used to neutralise heparin
CC (an alternative to protamine) and to screen for specific inhibitors
CC (potentially useful for treating cancer and metastases). Antibodies
CC raised against (II) are used for immunodetection and diagnosis of
CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
CC in large quantities, in a form that is homogeneously processed and
CC activated/neutralised by a dedicated protease. The present sequence
CC represents a PCR primer for human heparanase, which is used in an
CC example from the present invention.
XX
SQ Sequence 26 BP; 5 A; 7 C; 9 G; 5 T; 0 other;

Query Match 100.0%; Score 26; DB 21; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.045;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGCATATGACAGAGCTGTCGACCTG 26
DB 1 CGCATATGACAGAGCTGTCGACCTG 26

RESULT 2
AAZ33291
ID AAZ33291 standard; DNA; 26 BP.
XX
AC AAZ33291;
XX

21-FEB-2000 (first entry)

Human heparanase PCR sense primer SEQ ID NO:4.

Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
KW autoimmune disease; anticancer; kidney disease; PCR primer; ss.

Synthetic.
OS Homo sapiens.

WO9957153-A1.

11-NOV-1999.

29-APR-1999; 99WO-US09255.

01-MAY-1998; 98US-0071739.

(INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PA (FRIE/) FRIEDMAN M M.
XX
PI Pecker I, Vlodavsky I, Friedman Y, Perets T;
XX
DR WPI; 2000-052944/04.
XX
PT Heparanase-specific molecular probes useful for diagnosis and
PT treatment, e.g. of tumors, and for targeted drug delivery -
XX
PS Example; Page 27; 90pp; English.

CC The present invention describes heparanase-specific molecular probes,
CC useful for methods of detecting heparanase in situ. The probes and
CC anti-heparanase antibodies are used to detect or quantify the expression
CC of heparanase, for diagnosis and monitoring of diseases (especially
CC metastasis), for treatment of heparanase-associated diseases (e.g.
CC tumour, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
CC metastases) derived from liver, prostate, bladder, breast, ovary,
CC cervix; colon, skin, intestine, stomach, uterus and pancreas, kidney
CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence represents a PCR primer for human heparanase, which
CC is used in an example from the present invention for the construction of
CC a heparanase expression vector.

SQ Sequence 26 BP; 5 A; 7 C; 9 G; 5 T; 0 other;
Query Match 100.0%; Score 26; DB 21; Length 26;
Best Local Similarity 100.0%; Pred. No. 0.045;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CGCATATGACAGAGCTGTCGACCTG 26
DB 1 CGCATATGACAGAGCTGTCGACCTG 26

RESULT 3
ABN86005
ID ABN86005 standard; DNA; 30 BP.
XX
AC ABN86005;
XX
DT 06-SEP-2002 (first entry)
XX

Human heparanase gene specific primer HP-6.

Human; heparanase; cytostatic; vasotropic; antidiabetic; anti-HIV;
KW ophthalmological; antirheumatic; antiarthritis; antipsoriatic;
KW antianemic; neuroprotective; nootropic; cerebroprotective;
KW antibacterial; virucide; protozoicide; fungicide; antiinflammatory;
KW cardiant; immunosuppressive; tumour metastasis; inflammatory disease;
KW allograft rejection; cell migration; angiogenesis; basement membrane;
KW extracellular matrix; cancer; ischaemia; diabetic retinopathy;
KW macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
KW sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
KW neurodegenerative disease; vascular disease; cardiovascular disease;
KW cystic fibrosis; stroke; gene therapy; PCR primer; ss.

Homo sapiens.

WO200244353-A2.

06-JUN-2002.

30-NOV-2001; 2001WO-US44798.

30-NOV-2000; 2000US-250690P.

(SANG-) SANGAMO BIOSCIENCES INC.
PA Wolfe AP, Qi H;

XX WPI; 2002-527708/56.
 DR Nucleic acid encoding secretory proteins/membrane proteins, useful in
 XX gene therapy or as candidate target molecules in drug development -
 PT New heparanase polynucleotide, useful for controlling disease states
 PT such as tumour metastasis, inflammatory diseases and allograft rejection
 FT
 PS Claim 4; SEQ ID 418; 72pp; English.
 XX
 XX Example 1; Page 44; 72pp; English.
 CC The invention relates to novel heparanase sequences, particularly novel
 CC sequences from the regulatory regions upstream and downstream of the
 CC coding region. The activity of polynucleotides of the invention may be
 CC described as, cytosolic, vasotropic, antidiabetic, anti-HIV,
 CC immunomodulatory, antineoplastic, antirheumatic, antiparasitic,
 CC antianemic, neuroprotective, nootropic, cerebroprotective,
 CC antibacterial, virucide, protozoacide, fungicide, antiinflammatory,
 CC cardiatic and immunosuppressive. Modulating expression of heparanase gene
 CC using constructs of the invention is useful for facilitating targeted
 CC control of disease states such as tumour metastasis, inflammatory
 CC diseases, allograft rejection, and for inhibiting processes such as cell
 CC migration, angiogenesis, and degradation of the basement membrane and/or
 CC extracellular matrix. Heparanase-targeted DNA binding domains modulates
 CC gene expression, and are useful for therapeutic or prophylactic
 CC applications, for e.g. cancer, ischaemia, diabetic retinopathy, macular
 CC degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell
 CC anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative
 CC diseases, vascular disease, cardiovascular disease, cystic fibrosis,
 CC stroke, and bacterial, protozoal, fungal and viral infection. Constructs
 CC of the invention may also be useful in gene therapy. The current sequence
 CC represents a human heparanase gene specific primer designated HP-6. This
 CC was used in the determination of nucleotide sequences in the human
 CC heparanase gene and flanking regions.
 XX
 XX Sequence 30 BP; 4 A; 9 C; 9 G; 8 T; 0 other;
 SQ
 Query Match 76.9%; Score 20; DB 24; Length 30;
 Best Local Similarity 100.0%; Pred. No. 20;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 7 TGCAGAGAGCTGCTGACCTG 26
 Db 2 TGCAGAGAGCTGCTGACCTG 21
 RESULT 4
 AAF93984 ID AAF93984 standard; DNA; 474 BP.
 AC AAF93984;
 XX
 XX 23-MAY-2001 (first entry)
 DT
 XX
 DE Primer specific for DNA encoding secretory/membrane protein SEQ ID 418.
 KW Human; secretory protein; membrane protein; vaccine; gene therapy;
 KW rheumatoid arthritis; diabetes; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 XX EP1067182-A2.
 XX
 XX 10-JAN-2001.
 PD
 XX 07-JUL-2000; 2000EP-0114090.
 PF
 XX 08-JUL-1999; 99JP-0194179.
 PR 11-JAN-2000; 2000JP-0118775.
 PR 02-MAY-2000; 2000JP-0183766.
 XX
 PA (HELI-) HELIX RES INST.
 XX
 XX Ota T, Isogai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
 XX

DR WPI; 2001-093989/11.
 XX Nucleic acid encoding secretory proteins/membrane proteins, useful in
 PT gene therapy or as candidate target molecules in drug development -
 PT
 PS Claim 4; SEQ ID 418; 609pp + CD ROM; English.
 XX
 XX This invention relates to nucleic acid sequences AAF93744 - AAF93916
 CC which encode human secretory or membrane proteins represented by
 CC AAB88317 - AAB88419. Included in the invention are primers
 CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
 CC cDNA sequences of the invention. The invention also includes methods for
 CC the production of antibodies directed against the proteins, and cDNA
 CC sequences, which can be used in vaccines. The polynucleotide sequences
 CC can be used in gene therapy. The polynucleotide sequences and the
 CC proteins they encode may be used in the prevention, treatment and
 CC diagnosis of diseases associated with inappropriate secretory
 CC protein/membrane protein expression. The nucleic acids and complementary
 CC sequences may also be used as DNA probes in diagnostic assays
 CC (e.g. polymerase chain reactions (PCR)) to detect and quantify the
 CC presence of similar nucleic acid sequences in samples. They may also be
 CC used to study the expression and function of secretory proteins/membrane
 CC polypeptides and their role in metabolism. The polypeptides may be used
 CC as antigens in the production of antibodies against them and in assays to
 CC identify modulators (agonists and antagonists) of expression and
 CC activity. The antibodies and antagonists may also be used as therapeutic
 CC agents to down regulate expression and activity. The antibodies may also
 CC be used as diagnostic agents for detecting the presence of the
 CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
 CC (ELISA). Examples of diseases which may be treated include rheumatoid
 CC arthritis and diabetes.
 XX
 XX Sequence 474 BP; 86 A; 154 C; 127 G; 101 T; 6 other;
 SQ
 Query Match 75.4%; Score 19.6; DB 22; Length 474;
 Best Local Similarity 84.6%; Pred. No. 38;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 1 CGCATATGACAGAGCTGCTGACCTG 26
 Db 161 CGCAGACACAGAGCTGCTGACCTG 186
 RESULT 5
 AABN86000 ID AABN86000 standard; DNA; 605 BP.
 AC AABN86000;
 XX
 XX 06-SEP-2002 (first entry)
 DT
 XX
 DE Human heparanase gene fragment.
 KW Human; heparanase; cytosolic; vasotropic; antidiabetic; anti-HIV;
 KW immunomodulatory; antineoplastic; antirheumatic; antiparasitic;
 KW immunomodulatory; antineoplastic; antirheumatic; antiparasitic;
 KW cardiatic; immunosuppressive; tumour metastasis; inflammatory disease;
 KW allograft rejection; cell migration; angiogenesis; basement membrane;
 KW extracellular matrix; cancer; ischaemia; diabetic retinopathy;
 KW macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
 KW sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
 KW neurodegenerative disease; vascular disease; cardiovascular disease;
 KW cystic fibrosis; stroke; gene therapy; chromosome 4; gene; ds.
 XX
 OS Homo sapiens.
 XX
 XX
 XX Key Location/Qualifiers
 FH 1..605
 FT /tag= a
 FT /product= "heparanase protein fragment"
 FT /note= "contains 2 introns; one full intron and 1 intron
 FT fragment"

FT	exon	1..105
FT	/tag= b	
FT	/number= 1	
FT	intron	106..339
FT	/tag= c	
FT	/number= 1	
FT	exon	340..602
FT	/tag= d	
FT	/number= 2	
FT	misc_signal	371..373
FT	/tag= e	
FT	/note= "start codon"	
FT	603..605	
FT	/tag= f	
FT	/number= 2	
FT	/note= "a small fragment only of this intron is given"	
XX		
PN	WO200244353-A2.	
PD		
XX	06-JUN-2002.	
PF		
XX	30-NOV-2001; 2001WO-US44798.	
PR		
XX	30-NOV-2000; 2000US-250690P.	
PA	(SANG-) SANGAMO BIOSCIENCES INC.	
XX		
PI	Wolffe AP, Qi H;	
XX		
DR	WPI; 2002-527708/56.	
PT	New heparanase polynucleotide, useful for controlling disease states	
PT	such as tumour metastasis, inflammatory diseases and allograft rejection	
PS	-	
XX		
XX	Example 1; Fig 1; 72pp; English.	
CC	The invention relates to novel heparanase sequences, particularly novel	
CC	sequences from the regulatory regions upstream and downstream of the	
CC	coding region. The activity of polynucleotides of the invention may be	
CC	described as, cytostatic, vasotropic, antidiabetic, anti-HIV,	
CC	ophthalmological, antineumatic, antiarthritic, antiproliferative,	
CC	antianemic, neuroprotective, nootropic, cerebroprotective,	
CC	antibacterial, virucide, protozoacide, fungicide, anti-inflammatory,	
CC	cardiant and immunosuppressive. Modulating expression of heparanase gene	
CC	using constructs of the invention is useful for facilitating targeted	
CC	control of disease states such as tumour metastasis, inflammatory	
CC	diseases, allograft rejection, and for inhibiting processes such as cell	
CC	migration, angiogenesis, and degradation of the basement membrane and/or	
CC	extracellular matrix. Heparanase-targeted DNA binding domains modulates	
CC	gene expression, and are useful for therapeutic or prophylactic	
CC	applications, for e.g. cancer, ischemia, diabetic retinopathy, macular	
CC	degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell	
CC	anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative	
CC	diseases, vascular disease, cardiovascular disease, cystic fibrosis,	
CC	stroke, and bacterial, protozoal, fungal and viral infection. Constructs	
CC	of the invention may also be useful in gene therapy. The current sequence	
CC	represents a human heparanase gene fragment which is located on	
CC	chromosome 4.	
SO	Sequence 605 BP; 96 A; 187 C; 230 G; 92 T; 0 other;	
Query Match	75.4%; Score 19.6; DB 24; Length 605;	
Best Local Similarity	84.6%; Pred. No. 38;	
Matches	22; Conservative 0; Mismatches 4; Indels 0; Gaps 0	
OY	1 CGCATATGAGGACGTCTGGACTTG 26 	
D5	468 CGCAAGCACAGGACGTCTGGACTTG 493 	

ID	ABN6003 standard; DNA; 1419 BP.
AC	ABN6003;
XX	
XX	06-SEP-2002 (first entry)
DE	Human heparanase upstream sequence containing exons 1 and 2.
XX	
KM	Human, heparanase; cytosolic; vasotropic; antidiabetic; anti-HIV;
KM	ophthalmological; antithematic; antiallergic; antiparasitic;
KM	antithematic; neuroprotective; nocitropic; cerebroprotective;
KM	antibacterial; virucide; protozoicide; fungicide; antiinflammatory;
KM	cardiant; immunosuppressive; tumour metastasis; inflammatory disease;
KM	allergic rejection; cell migration; angiogenesis; basement membrane;
KM	extracellular matrix; cancer; ischaemia; diabetic retinopathy;
KM	macular degeneration; rheumatoid arthritis; psoriasis; HIV infection;
KM	sickle cell anaemia; Alzheimer's disease; muscular dystrophy;
KM	neurodegenerative disease; vascular disease; cardiovascular disease;
KM	cystic fibrosis; stroke; gene therapy; ds.
XX	
OS	Homo sapiens.
XX	
PN	WO200244353-A2.
XX	
PD	06-JUN-2002.
XX	
PF	30-NOV-2001; 2001WO-US44798.
XX	
PR	30-NOV-2000; 2000US-250690P.
XX	
PA	(SANG-) SANGAMO BIOSCIENCES INC.
XX	
P1	Wolffe AP, Qi H;
XX	
DR	WPI; 2002-527708/56.
XX	
PT	New heparanase polynucleotide, useful for controlling disease states
PT	such as tumour metastasis, inflammatory diseases and allograft rejection
XX	
XX	Example 1; Fig 4; 72pp; English.
XX	
PS	The invention relates to novel heparanase sequences, particularly novel
CC	sequences from the regulatory regions upstream and downstream of the
CC	coding region. The activity of polynucleotides of the invention may be
CC	described as, cytosolic, vasotropic, antidiabetic, anti-HIV,
CC	ophthalmological, antithematic, antiallergic, antiparasitic,
CC	antithematic, neuroprotective, nocitropic, cerebroprotective,
CC	antibacterial, virucide, protozoicide, fungicide, antiinflammatory,
CC	cardiant and immunosuppressive. Modulating expression of heparanase gene
CC	using constructs of the invention is useful for facilitating targeted
CC	control of disease states such as tumour metastasis, inflammatory
CC	diseases, allograft rejection, and for inhibiting processes such as cell
CC	migration, angiogenesis, and degradation of the basement membrane and/or
CC	extracellular matrix. Heparanase-targeted DNA binding domains modulates
CC	gene expression, and are useful for therapeutic or prophylactic
CC	applications, for e.g. cancer, ischaemia, diabetic retinopathy, macular
CC	degeneration, rheumatoid arthritis, psoriasis, HIV infection, sickle cell
CC	anaemia, Alzheimer's disease, muscular dystrophy, neurodegenerative
CC	diseases, vascular disease, cardiovascular disease, cystic fibrosis,
CC	stroke, and bacterial, protozoal, fungal and viral infection. Constructs
CC	of the invention may also be useful in gene therapy. The current sequence
CC	represents the human heparanase upstream sequence containing exons 1 and
CC	2.
XX	
XX	Sequence 1419 BP; 329 A; 352 C; 452 G; 286 T; 0 other;
XX	
XX	Query Match 75.4%; Score 19.6; DB 24; Length 1419;
XX	Best Local Similarity 84.6%; Pred. No. 41;
XX	Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Db 1282 CGCAGCACAGGACGCTGTGACCTG 1307

RESULT 7

AA211236 ID AA211236 standard; cDNA, 1593 BP.

XX AA211236;

DT 15-NOV-1999 (first entry)

XX Human pre-proheparanase coding sequence.

DE Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;
 KW inflammation; psoriasis; diabetic retinopathy; solid tumor; arthritis;
 KW heparin degradation; anticoagulant neutralisation; asthma; CNS disease;
 KW inflammatory disease; vascular restenosis; atherosclerosis; diagnosis;
 KW tumour growth; fibroproliferative disorder; neurodegenerative disease;
 KW therapy; ds.

XX Homo sapiens.

OS Key Location/Qualifiers

FT CDS 1..1593

FT /tag= a

FT /product= pre-proheparanase

XX MO9943830-A2.

XX 02-SEP-1999.

XX 18-FEB-1999; 99WO-US01489.

XX 26-MAR-1998; 98US-0079401.

XX 24-FEB-1998; 98US-0075706.

XX (PHNA) PHARMACIA & UPJOHN CO.

XX Fairbanks MB, Heinrikson RL, Mildner AM;

DR WPI; 1999-540598/45.

DR P-PSDB; AAY34173.

PT New isolated platelet heparanase polypeptides, used to develop

XX products for, e.g. wound healing and blocking angiogenesis

XX Claim 2; Fig 7; 57pp; English.

CC This sequence encodes the human pre-proheparanase of the invention. This
 CC sequence was isolated from human platelets. The heparanase can be used
 CC for identifying agents which alter heparanase activity. The heparanase
 CC can be used for wound healing or for blocking angiogenesis or
 CC inflammation. It can be used for treating e.g. psoriasis, diabetic
 CC retinopathy or solid tumours, or for the degradation of heparin and the
 CC neutralisation of heparin's anticoagulant properties during surgery.
 CC Inhibitors of heparanase activity can be used in the treatment of
 CC arthritis, asthma, and other inflammatory diseases; vascular restenosis,
 CC atherosclerosis, tumour growth and progression, fibroproliferative
 CC disorders, and central nervous system (CNS) and neurodegenerative
 CC diseases. The products can also be used for detection and diagnosis. The
 CC purified heparanase, both recombinantly produced human heparanase and
 CC heparanase isolated from human platelet activity, allows for the
 CC convenient selection of compounds having anti-heparanase activity,
 CC i.e. inhibitors of heparanase activity, by measuring inhibition of
 CC heparanase activity. Inhibition of heparanase activity can be measured by
 CC blocking heparanase-mediated release of radioactive fragments from in
 CC vivo radiolabelled (HSPG)/heparin.

XX Sequence 1593 BP; 426 A; 370 C; 369 G; 428 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1593;

Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGACAGGACGCTGTGACCTG 26
 |||||
 Db 59 CGCAGCACAGGACGCTGTGACCTG 84

RESULT 8

AA37259 ID AA37259 standard; DNA, 1713 BP.

XX AA37259;

DT 21-JUL-1999 (first entry)

XX Human heparanase enzyme encoding DNA.

DE Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
 KW metastasis; angiogenesis; wound healing; angioplasty-induced restenosis;
 KW atherosclerosis; atherosclerosis; inflammation; tissue development;
 KW human; HSPG; ss.

XX Homo sapiens.

OS Key Location/Qualifiers

FT CDS 1..1593

FT /tag= a

FT /product= pre-proheparanase

XX MO9921975-A1.

XX 06-MAY-1999.

XX 28-OCT-1998; 98WO-AU00898.

XX 09-DEC-1997; 97AU-0000812.

XX 28-OCT-1997; 97AU-0000062.

XX (AUSU) UNIV AUSTRALIAN NAT.

XX Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;

DR WPI; 1999-312956/26.

DR P-PSDB; AAY17082.

PT Polynucleotides encoding mammalian endoglucuronidases, especially

XX heparanases, useful to promote wound healing

XX Claim 3; Page 69-73; 112pp; English.

CC The invention relates to nucleic acid sequences that encode heparanase
 CC enzymes having endoglucuronidase activity. Recombinant heparanases are
 CC capable of removing the HS side chain from heparan sulfate proteoglycan
 CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
 CC inhibit heparanase, this is useful for treatment of a physiological or
 CC medical condition associated with elevated heparanase activity, such as
 CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
 CC atherosclerosis, atherosclerosis and inflammation. The human, murine and
 CC rat heparanases can be used to enhance wound healing, especially
 CC associated with tissue development and repair. The conditions mentioned
 CC above can be diagnosed using specific antibodies, and also using primers
 CC and probes specific for the heparanase polynucleotides. Other uses of the
 CC heparanases include sequencing sulfated molecules such as HSPG. The
 CC present sequence represents a DNA encoding human heparanase.

XX Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1713;

Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Oy 1 CGCATATGACAGGACGCTGTGACCTG 26
 |||||
 Db 143 CGCAGCACAGGACGCTGTGACCTG 168

RESULT 9

AA355648 ID AA355648 standard; cDNA, 1721 BP.

```

XX AX35648;
AC
XX
XX 09-JUL-1999 (first entry)
DT
XX
XX cDNA encoding a human heparanase protein.
DE
XX
XX Heparanase; hpa; modulator; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiogenesis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neuritis;
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KW
XX
XX Homo sapiens.
OS
XX
XX WO911798-A1.
PN
XX
XX 11-MAR-1999.
PD
XX
XX 31-AUG-1998; 96WO-US17954.
PF
XX
XX 02-JUL-1998; 98US-0109386.
PR
XX
XX 02-SEP-1997; 97US-0922170.
PR
XX
XX (FRIE/) FRIEDMAN M M.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX Feinstein E, Pecker I, Vlodaysky I;
PI
XX
XX MPI: 1999-302255/25.
DR
XX
XX P-PSDB; AAY02345.
DR
XX
XX New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
PT
XX
XX Claim 4; Fig 1; 63pp; English.
PS
XX
XX The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.
XX
XX
XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
SQ
XX
XX
XX Query Match 75.4%; Score 19.6; DB 20; Length 1721;
XX Best Local Similarity 84.6%; Pred. No. 42;
XX Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGCAGAGCTGCTGACCTG 26
Db 160 CGCAAGCAGACGCTGCTGACCTG 185

```

```

DE cDNA encoding a human heparanase polypeptide.
XX
XX Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
XX heparin-binding growth factor; cytokine; neurodegenerative plaque;
XX wound healing; infection; burn; angiogenesis; restenosis;
XX atherosclerosis; inflammation; neurodegenerative disease;
XX Gerstmann-Straussler Syndrome; Creutzfeldt-Jakob disease; ds.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH CDS 63..1693
FT /tag= a
FT /product= "heparanase"
FT stem_loop 698..724
FT /tag= b
FT /note= "these nucleotides are likely to be involved
FT in forming stem and loop structures"
XX
XX WO200052178-A1.
PN
XX
XX 08-SEP-2000.
PD
XX
XX 14-FEB-2000; 2000WO-US03542.
PF
XX
XX 01-MAR-1999; 99US-0258892.
PR
XX
XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
PA (FRIE/) FRIEDMAN M M.
XX
XX Pecker I, Vlodaysky I, Feinstein E;
PI
XX
XX MPI: 2000-579289/54.
DR
XX
XX P-PSDB; AAB08849.
DR
XX
XX New polynucleotides encoding a polypeptide having heparanase activity,
PT useful in wound healing and in gene therapy, particularly in treating
PT tumour, inflammation, autoimmunity, neurodegenerative diseases
PT
XX
XX Claim 9; Fig 1; 152pp; English.
PS
XX
XX The present sequence encodes a human protein with heparanase catalytic
CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
CC particularly in treating tumour, inflammation or autoimmunity.
CC Particularly, the polynucleotide is useful in modulating the
CC bioavailability of heparin-binding growth factors, cellular responses
CC to heparin-binding growth factors (e.g. bFGF) and cytokines
CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
CC cellular susceptibility to certain viral and some bacterial and protozoa
CC infections, or disintegration of neurodegenerative plaques. The
CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
CC or radiation burns) and in the treatment of angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
CC Straussler Syndrome or Creutzfeldt-Jakob disease), and some viral,
CC bacterial or protozoa infections.
XX
XX
XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
SQ
XX
XX
XX Query Match 75.4%; Score 19.6; DB 21; Length 1721;
XX Best Local Similarity 84.6%; Pred. No. 42;
XX Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGCAGAGCTGCTGACCTG 26
Db 160 CGCAAGCAGACGCTGCTGACCTG 185

```

```

RESULT 10
ID AAA75051 standard; cDNA; 1721 BP.
XX
XX AAA75051;
XX
XX 15-JAN-2001 (first entry)
XX

```

```

RESULT 11
ID AAZ39195 standard; cDNA; 1721 BP.
XX
XX AAZ39195;
XX

```

XX 02-MAR-2000 (first entry)
 XX Human heparanase encoding CDNA.
 DE
 XX Human; heparanase; hpa; genetic modification; expression; anticancer;
 KW angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumor;
 KW anti-atherosclerotic; anti-inflammatory; antineurodegeneration;
 KW heparan sulphate; heparin-binding growth factor; tumour angiogenesis;
 KW metastasis; wound healing; restenosis; atherosclerosis; inflammation;
 KW neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;
 KW microvessel; autoimmune lesion; kidney failure; ss.
 KW
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH 63..1694
 FT /*tag= a
 FT /product= "heparanase"
 FT
 XX MO9957244-A1.
 XX 11-NOV-1999.
 XX 29-APR-1999; 99WO-US09256.
 XX 01-MAY-1998; 98US-0071618.
 XX 02-MAR-1999; 99US-0260038.
 XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX (FRIE/) FRIEDMAN M M.
 XX Ben-Artzi H, Ayal-Hershkovitz M, Yacoby-Zeevi O, Pecker I, Peleg Y;
 PI Shlomi Y;
 XX MPI: 2000-062144/05.
 DR P-PSDB; AAY57590.
 XX
 PT Engineered cells that express recombinant heparanase, useful
 PT therapeutically, e.g. for treating angiogenesis and to screen for
 PT specific inhibitors, potential anticancer agents -
 XX
 PS Claim 2; Page 106-107; 118pp; English.
 XX
 CC The present invention describes genetically modified cells (A) containing
 CC a polynucleotide (I) that encodes a polypeptide with heparanase activity,
 CC and express recombinant heparanase (II). Heparanase cleaves heparan
 CC sulphate (HS) at specific intrachain sites, resulting in release of
 CC heparin-binding growth factors, enzymes and proteins that are sequestered
 CC by HS in basement membranes, extracellular matrix or cell surfaces. It
 CC may also be implicated in tumour angiogenesis and metastases. (II) is
 CC potentially useful in wound healing and for treating angiogenesis,
 CC restenosis, atherosclerosis, inflammation, neurodegeneration, viral
 CC infection and cystic fibrosis. It can also be used to neutralise heparin
 CC (an alternative to protamine) and to screen for specific inhibitors
 CC (potentially useful for treating cancer and metastases). Antibodies
 CC raised against (II) are used for immunodetection and diagnosis of
 CC micrometastases, autoimmune lesions and kidney failure. (A) provide (II)
 CC in large quantities, in a form that is homogeneously processed and
 CC activated/neutralised by a dedicated protease. The present sequence
 CC encodes human heparanase.
 XX
 SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 75.4%; Score 19.6; DB 21; Length 1721;
 Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CGCATATGAGAGAGCGTGTGACCTG 26
 |||||
 DB 160 CGCAAGCACAGAGCGTGTGACCTG 185

RESULT 12
 AA233290
 ID AA233290 standard; CDNA; 1721 BP.
 XX
 XX AA233290;
 AC
 XX 21-FEB-2000 (first entry)
 DT
 XX Human heparanase nucleotide sequence.
 DE
 XX Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotoxic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; ds.
 KW
 XX Homo sapiens.
 OS
 XX Key Location/Qualifiers
 FH 63..1694
 FT /*tag= a
 FT /product= "heparanase"
 FT
 XX MO9957153-A1.
 XX 11-NOV-1999.
 XX 29-APR-1999; 99WO-US09255.
 XX 01-MAY-1998; 98US-0071739.
 XX (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 XX (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 XX (FRIE/) FRIEDMAN M M.
 XX Pecker I, Vlodaysky I, Friedman Y, Perets T;
 PI
 XX MPI: 2000-052944/04.
 DR P-PSDB; AAY52990.
 XX
 PT Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 PS Example; Page 82-84; 90pp; English.
 XX
 CC The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumours, (adeno)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, bladder, breast, ovary,
 CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted
 CC drug delivery (e.g. of anticancer agents) and as research reagents.
 CC The present sequence encodes human heparanase, which is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match 75.4%; Score 19.6; DB 21; Length 1721;
 Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CGCATATGAGAGAGCGTGTGACCTG 26
 |||||
 DB 160 CGCAAGCACAGAGCGTGTGACCTG 185

RESULT 13

```

ID      AAA91112 standard; DNA; 1721 BP.
XX
XX      AAA91112;
XX
XX      20-APR-2001 (first entry)
XX
DE      Human heparanase, coding sequence fragment isolated from EST clone.
KW      Heparanase; hnhp1; wound healing; angiogenesis; restenosis; Scrape;
KW      atherosclerosis; inflammation; pulmonary disease; Alzheimer's disease;
KW      neurodegenerative disease; Creutzfeldt-Jakob disease; viral infection;
KW      gene therapy; mouse; expressed sequence tag; ds.
XX
OS      Homo sapiens.
XX
XX      WO200100643-A2.
XX
XX      04-JAN-2001.
XX
XX      19-JUN-2000; 2000WO-IL00358.
XX
XX      25-JUN-1999; 99US-0140801.
XX
XX      (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX
XX      Pecker I, Michal I, Itzhaki H;
XX
XX      WPI; 2001-137930/14.
XX
XX      New polynucleotides and polypeptides that are distantly homologous to
XX      heparanase, useful in wound healing, as well as in gene therapy
XX      protocols for angiogenesis, restenosis, atherosclerosis, or
XX      inflammation -
XX
XX      Example 1; Page 67; 67pp; English.
XX
XX      This sequence represents a human heparanase coding sequence clone,
XX      isolated from an EST clone. The invention relates to heparanase DNA
XX      and protein sequences. The heparanase DNA and protein sequences are
XX      useful in wound healing, angiogenesis, restenosis, atherosclerosis,
XX      inflammation, pulmonary diseases, neurodegenerative diseases (such as
XX      Scrape, Alzheimer's disease, and Creutzfeldt-Jakob disease) or viral
XX      infections. The heparanase coding sequence is particularly useful in gene
XX      therapy.
XX
XX      Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
XX
XX      Query Match      75.4%; Score 19.6; DB 22; Length 1721;
XX      Best Local Similarity 84.6%; Pred. No. 42;
XX      Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0.
XX
OY      1 CGCATATGCGAGACGTCGTGACCTG 26
      ||||| ||||| ||||| |||||
Db      160 CGCAGACACGACGTCGTGACCTG 185

RESULT 14
ID      AAF93788 standard; cDNA; 1722 BP.
XX
XX      AAF93788;
XX
XX      23-MAY-2001 (first entry)
XX
DE      Human cDNA encoding a membrane or secretory protein clone PSEC0090.
XX
XX      Human; secretory protein; membrane protein; vaccine; gene therapy;
XX      rheumatoid arthritis; diabetes; ss.
XX
XX      Homo sapiens.
XX
XX      EP1067182-A2.
XX

```

```

XX PD      10-JAN-2001.
XX XX      07-JUL-2000; 2000EP-0114090.
XX PF      08-JUL-1999;   99JP-0194179.
XX PR      11-JAN-2000; 2000JP-0118775.
XX PR      02-MAY-2000; 2000JP-0183766.
XX XX      (HELI-) HELIX RES INST.
XX PA
XX Ota T, Isegai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
XX MPI: 2001-093989/11.
XX P-PEDB; AAB88361.
XX
XX Nucleic acids encoding secretory proteins/membrane proteins, useful in
XX gene therapy or as candidate target molecules in drug development -
XX PT
XX PS      Claim 1; SEQ ID 89; 603bp + CD ROM; English.
XX XX
XX CC      This invention relates to nucleic acid sequences AAF93744 - AAF93916
XX CC which encode human secretory or membrane proteins represented by
XX CC AAB88317 - AAB88419. Included in the invention are primers
XX CC AAF93917 - AAF94295 and AAF62232 - AAF62235 which are used to isolate the
XX CC cDNA sequences of the invention. The invention also includes methods for
XX CC the production of antibodies directed against the proteins, and cDNA
XX CC sequences, which can be used in vaccines. The polynucleotide sequences
XX CC can be used in gene therapy. The polynucleotide sequences and the
XX CC proteins they encode may be used in the prevention, treatment and
XX CC diagnosis of diseases associated with inappropriate secretory
XX CC protein/membrane protein expression. The nucleic acids and complementary
XX CC polymers may also be used as DNA probes in diagnostic assays
XX CC (e.g. polymerase chain reactions (PCR)) to detect and quantitate the
XX CC presence of similar nucleic acid sequences in samples. They may also be
XX CC used to study the expression and function of secretory proteins/membrane
XX CC polypeptides and their role in metabolism. The polypeptides may be used
XX CC as antigens in the production of antibodies against them and in assays to
XX CC identify modulators (agonists and antagonists) of expression and
XX CC activity. The antibodies and antagonists may also be used as therapeutic
XX CC agents to down regulate expression and activity. The antibodies may also
XX CC be used as diagnostic agents for detecting the presence of the
XX CC polypeptides in samples (e.g. by enzyme linked immunosorbant assay
XX CC (ELISA). Examples of diseases which may be treated include rheumatoid
XX CC arthritis and diabetes.
XX CC
XX SQ      Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
XX
XX Query Match          75.4%; Score 19.6; DB 22; Length 1722;
XX Best Local Similarity 84.6%; Pred. No. 42;
XX Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0.
XX
XX QY      1 CGCATATGCAGACGTCGTGGACCGC 26
XX       ||| ||||| ||||| ||||| |||||
XX Db      161 CGCAAGCACAGAGCTCTGTGAAGCTG 186
XX
XX RESULT 15
XX ID      AAX37260
XX AC      AAX37260 standard; DNA; 1723 BP.
XX XX
XX DT      21-JUL-1999 (first entry)
XX XX
XX DE      Seq ID No: 14 of WO9921975.
XX
XX KW      Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
XX KW metastasis; angiogenesis; wound healing; angiotensin-induced restenosis;
XX KW arteriosclerosis; atherosclerosis; inflammation; tissue development;
XX KW human; HSPG; ss.
XX
XX OS      Homo sapiens.

```


XX WO9921975-A1.
 XX
 XX PD 06-MAY-1999.
 XX
 XX PF 28-OCT-1998; 98WO-AU00898.
 XX
 XX PR 09-DEC-1997; 97AU-0000812.
 XX PR 28-OCT-1997; 97AU-0000062.
 XX
 XX PA (AUSU) UNIV AUSTRALIAN NAT.
 XX
 XX PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
 XX
 XX DR WPI; 1999-312956/26.
 XX DR P-PSDB; AAY17083.
 XX
 XX PT Polynucleotides encoding mammalian endoglucuronidases, especially
 XX heparanases, useful to promote wound healing
 XX
 XX PS Claim 11; Page 76-79; 112pp; English.
 XX
 CC The invention relates to nucleic acid sequences that encode heparanase
 CC enzymes having endoglucuronidase activity. Recombinant heparanases are
 CC capable of removing the HS side chain from heparan sulfate proteoglycan
 CC (HSPG). Sulfated oligosaccharides, sulphates or HSPG can be used to
 CC inhibit heparanase, this is useful for treatment of a physiological or
 CC medical condition associated with elevated heparanase activity, such as
 CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
 CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
 CC rat heparanases can be used to enhance wound healing, especially
 CC associated with tissue development and repair. The conditions mentioned
 CC above can be diagnosed using specific antibodies, and also using primers
 CC and probes specific for the heparanase polynucleotides. Other uses of the
 CC heparanases include sequencing sulfated molecules such as HSPG.
 XX
 XX SQ Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;

Query Match 75.4%; Score 19.6; DB 20; Length 1723;
 Best Local Similarity 84.6%; Pred. No. 42;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CGCATATGCAAGACGCTGTGACCTG 26
 |||||
 Db 149 CGCAAGCACAGACGCTGTGACCTG 174

Search completed: February 16, 2004, 09:18:10
 Job time : 13.7569 secs

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 100.997 Seconds
(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-4
Perfect score: 26
Sequence: 1 cgcatacgcagcagctcgtgacctg 26

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues
Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estmu:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hrc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hrc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_phg:*
27: em_gss_vrt:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.8	76.2	677	14	CD044218 pSHB013XH
2	19.6	75.4	881	14	CB988510 AGENCOURT
3	19.6	75.4	924	13	B0691142 AGENCOURT
4	19.6	75.4	1185	9	AL552174 AL552174

5	19.6	75.4	1201	9	AL545270
6	19.4	74.6	850	29	CNS0448C
7	19.4	74.6	871	12	B1754736
8	19.2	73.8	535	28	BH051472
9	19.2	73.8	613	28	AZ62831
10	19.2	73.8	617	12	BJ008199
11	19.2	73.8	627	12	BJ487056
12	19.2	73.8	711	12	BJ533801
13	19.2	73.1	1012	29	CNS026CG
14	18.6	71.5	240	9	AA398146
15	18.6	71.5	374	9	AA821887
16	18.6	71.5	434	12	BG960581
17	18.6	71.5	520	9	AL750507
18	18.6	71.5	674	9	AL750564
19	18.6	71.5	1177	11	AK009597
20	18.6	71.5	1396	14	CD387962
21	18.6	71.5	1798	10	BG110194
22	18.6	71.5	2666	11	BC030655
23	18.4	70.8	196	9	AA243145
24	18.4	70.8	226	13	BY000868
25	18.4	70.8	248	13	BY063809
26	18.4	70.8	303	9	AA811576
27	18.4	70.8	358	9	AA769475
28	18.4	70.8	364	9	AL143664
29	18.4	70.8	367	13	BY072622
30	18.4	70.8	410	9	AA732339
31	18.4	70.8	577	10	AW977606
32	18.4	70.8	707	14	BY735903
33	18.4	70.8	730	14	CB031220
34	18.4	70.8	761	12	BI649991
35	18.4	70.8	854	12	BF581403
36	18.4	70.8	884	12	BI104061
37	18.4	70.8	2078	11	BC029952
38	18.2	70.0	285	10	BB181339
39	18.2	70.0	382	9	AA288247
40	18.2	70.0	423	14	CB131946
41	18.2	70.0	530	14	CB136264
42	18.2	70.0	622	28	AZ087080
43	18.2	70.0	626	13	BU110645
44	18.2	70.0	754	10	BE897409
45	18.2	70.0	759	12	BM018081

ALIGNMENTS

RESULT 1
CD044218
LOCUS
DEFINITION
CD044218 677 bp mRNA linear EST 09-MAY-2003
pSHB013XH08f.181768 pSHB: Infected hypocotyl soybean host. 48 hrs
post infection Phytophthora sojae cDNA clone SHB013XH08 5, mRNA
sequence.

ACCESSION
CD044218.1 GI:30497811
VERSION
CD044218.1

KEYWORDS
SOURCE
ORGANISM
Phytophthora sojae
Phytophthora sojae
Eukaryota; stramenopiles; Oomycetes; Pythiales; Pythiaceae;
Phytophthora.

REFERENCE
1 (bases 1 to 677)
Tyler, B.M., Judelson, H.S., Glizem, M., Dean, R.A. and Waugh, M.E.
USDA-IFAPs: Expression of Phytophthora sojae genes during infection
and propagation

JOURNAL
COMMENT
Unpublished
Contact: Tyler B
Tyler lab

VBI
1880 Pratt Dr., Blacksburg, VA 24061, USA
Tel: 540-231-7318
Email: bmtyle@vt.edu
PCR Primers
FORWARD: BK reverse
Plate: 013 row: H column: 08

Seq primer: BK reverse
High quality sequence stop: 677.
Location/Qualifiers

1. 677
/organism="Phytophthora sojae"

/mol_type="mRNA"

/db_xref="taxon:67593"

/clone="SHB013H08"

/tissue_type="infected host tissue"

/cell_line="P6497"

/dev_stage="48 hour post infection"

/clone_1ib="pshB: Infected hypocotyl soybean host. 48 hrs post infection"

/note="Vector: PBK-CMV; Site 1: EcoRI; Site 2: XhoI; USDA-IPAFS: Expression of Phytophthora sojae genes during infection and propagation."

BASE COUNT 129 a 244 c 198 g 106 t

ORIGIN

Query Match 76.2%; Score 19.8; DB 14; Length 677;

Best Local Similarity 91.3%; Pred. No. 6.3e+02;

Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY

4 ATATGACGAGCTCGTGACCTG 26

339 AGATCAGACGAGCTCGTGACCTG 361

DB

RESULT 2

CB988510

LOCUS CB988510 881 bp mRNA linear EST 01-MAY-2003

DEFINITION

AGENCOURT 13905817 NIH MGC 147 Homo sapiens CDNA clone

IMAGE:30340461 5', mRNA sequence.

ACCESSION CB988510

VERSION CB988510.1 GI:30283030

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 881)

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cga@bbs-remail.nih.gov

Tissue Procurement: Dr. Stefan Hanson

CNA Library Preparation: Michael J. Brownstein (NHGRI) with help

and advice from Piero Carninci (RIKEN)

CNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LNL at:

http://image.lnl.gov

Plate: NDAM370 row: f column: 22

High quality sequence stop: 664.

Location/Qualifiers

1. 881

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:30340461"

/tissue_type="human placenta"

/lab_host="DH10B TONa"

/clone_1ib="NIH MGC 147"

/note="Organ: Placenta; Vector: pBluescript, site 1: all-XhoI; Site 2: BamHI; Oligo-dT primed using primer 5'-TTTTTTTTTTT-3', size-selected for average insert size 2.3 kb and normalized to 10⁶ 5. This is a primary library enriched for full-length clones and constructed using the Cap-trapper method (Carninci, in preparation). Library constructed by M. Brownstein (NIH/NHGRI, National Institutes of Health). Note: This is

BASE COUNT 200 a 244 c 229 g 208 t

ORIGIN

Query Match 75.4%; Score 19.6; DB 14; Length 881;

Best Local Similarity 84.6%; Pred. No. 8.2e+02;

Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY

1 CGCATATGACGAGCTCGTGACCTG 26

219 CGCAGACGAGCTCGTGACCTG 244

DB

RESULT 3

BO691142

LOCUS BO691142 924 bp mRNA linear EST 15-JUL-2002

DEFINITION

AGENCOURT 8343629 NIH_MGC_110 Homo sapiens CDNA clone IMAGE:6250265

5', mRNA sequence.

ACCESSION BO691142

VERSION BO691142.1 GI:21816458

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.

1 (bases 1 to 924)

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

Unpublished

Contact: Robert Strausberg, Ph.D.

Email: cga@bbs-remail.nih.gov

Tissue Procurement: ATCC

CNA Library Preparation: Rubin Laboratory

DNA Sequencing by: The I.M.A.G.E. Consortium (LNL)

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LNL at:

http://image.lnl.gov

Plate: L1CM2393 row: a column: 18

High quality sequence stop: 710.

Location/Qualifiers

1. 924

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:6250265"

/tissue_type="ductal carcinoma, cell line"

/lab_host="DH10B (phage-resistant)"

/clone_1ib="NIH MGC 110"

/note="Organ: pancreas; Vector: pOTB7; Site 1: XhoI; Site 2: EcoRI; CDNA made by oligo-dT priming. Directionally cloned into EcoRI/XhoI sites using the following 5' adaptor: GGCACGAG(G). Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-CDNA synthesis kit (Stratagene) and SuperScript II RT (Life Technologies). Note: this is a NIH_MGC Library."

BASE COUNT 203 a 271 c 227 g 219 t 4 others

ORIGIN

Query Match 75.4%; Score 19.6; DB 13; Length 924;

Best Local Similarity 84.6%; Pred. No. 8.3e+02;

Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY

1 CGCATATGACGAGCTCGTGACCTG 26

232 CGCAGACGAGCTCGTGACCTG 257

DB

RESULT 4

AL552174

LOCUS AL552174 1185 bp mRNA linear EST 31-MAY-2003

DEFINITION

AL552174 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA

clone CSOD1059YN15 5-PRIME, mRNA sequence.
 AL552174
 VERSION AL552174.2 GI:31273990
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 1 (bases 1 to 1185)
 Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
 Full-length cDNA libraries and normalization
 Unpublished
 On Feb 15, 2001 this sequence version replaced gi:12890820.
 CONTACT: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 EVRY cedex - France
 Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see
 http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSOD1059CG080P1&cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSOD1059CG080P1.

FEATURES
 source
 1..1185
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CSOD1059YN15"
 /issue_type="PLACENTA COT 25-NORMALIZED"
 /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
 /note="1st strand cDNA was primed with a NotI-oligo (dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT
 ORIGIN
 280 a 293 c 293 g 280 t 39 others

Query Match 75.4%; Score 19.6; DB 9; Length 1185;
 Best Local Similarity 84.6%; Pred. No. 8.9e+02;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

CY 1 CGCATATGCAGACGCTGTGACCTG 26
 Db 226 CGCAGACGACGACGCTGTGACCTG 251

RESULT 5
 AL545270
 LOCUS AL545270 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
 DEFINITION clone CSOD1028YF04 5-PRIME, mRNA sequence.
 ACCESSION AL545270
 VERSION AL545270.2 GI:31267106
 KEYWORDS EST.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
 1 (bases 1 to 1201)
 Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
 Full-length cDNA libraries and normalization
 Unpublished
 On Feb 15, 2001 this sequence version replaced gi:12877751.
 CONTACT: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 EVRY cedex - France
 Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see

http://www.genoscope.cns.fr/cgi-bin/cluster.cgi?seq=CSOD1028DC020P1&cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSOD1028DC020P1.

FEATURES
 source
 1..1201
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CSOD1028YF04"
 /issue_type="PLACENTA COT 25-NORMALIZED"
 /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
 /note="1st strand cDNA was primed with a NotI-oligo (dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."

BASE COUNT
 ORIGIN
 292 a 282 c 305 g 279 t 43 others

Query Match 75.4%; Score 19.6; DB 9; Length 1201;
 Best Local Similarity 84.6%; Pred. No. 8.9e+02;
 Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

CY 1 CGCATATGCAGACGCTGTGACCTG 26
 Db 219 CGCAGACGACGACGCTGTGACCTG 244

RESULT 6
 CNS0448C
 LOCUS CNS0448C
 DEFINITION CNS0448C 850 bp DNA linear GSS 01-SEP-2000
 081603 of library G from Tetraodon nigroviridis, genomic survey sequence.
 AL273765
 VERSION AL273765.1 GI:7996028
 KEYWORDS GSS; genome survey sequence.
 SOURCE Tetraodon nigroviridis
 ORGANISM Tetraodon nigroviridis
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Neoteleostei; Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Tetraodon.

REFERENCE
 1 Roest Croollius, H., Jallion, O., Dasilva, C., Bouneau, L., Fisher, C., Bernot, A., Fitzames, C., Wincker, P., Brotlier, P., Quetier, F., Saurin, W. and Weissbach, J.
 Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence
 Nat. Genet. 25 (2), 235-238 (2000)

TITLE
 JOURNAL MEDLINE
 PUBMED 20296633
 REFERENCE 10835645
 2

Roest Croollius, H., Jallion, O., Dasilva, C., Ozouf-Costaz, C., Fitzames, C., Fischer, C., Bouneau, L., Billault, A., Quetier, F., Saurin, W., Bernot, A. and Weissbach, J.
 Characterization and repeat analysis of the compact genome of the freshwater pufferfish Tetraodon nigroviridis
 Genome Res. 10 (7), 939-949 (2000)

JOURNAL MEDLINE
 PUBMED 20359837
 REFERENCE 10899143
 3 (bases 1 to 850)
 Genoscope.
 Direct Submission
 Submitted (12-APR-2000) Genoscope - Centre National de Sequencage : BP 191 91006 EVRY cedex - FRANCE (E-mail : seqref@genoscope.cns.fr)
 - Web : www.genoscope.cns.fr
 This sequence is a single read and was generated as part of a large scale clone and sequencing project of the Tetraodon nigroviridis genome. For more information, please take a look at
 http://www.genoscope.cns.fr/Tetraodon.
 Location/Qualifiers

FEATURES

source

1. 850
/organism="Tetraodon nigroviridis"
/mol_type="genomic DNA"
/db_xref="taxon:99883"
/clone_11b="G"
/note="Genoscope sequence ID : C0B081AD02SP1-end : PUC-Or1"

BASE COUNT 156 a 251 c 258 g 179 t 6 others

ORIGIN

Query Match 74.6%; Score 19.4; DB 29; Length 850;
Best Local Similarity 95.2%; Pred. No. 9.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 6 ATGCAGACGTCGTGACCTG 26
|||||
54 ATGCAGACATCGTGACCTG 74

Db

RESULT 7
LOCUS B1754736 871 bp mRNA linear EST 25-SEP-2001
DEFINITION 603025450F1 NIH_MGC_114 Homo sapiens cDNA clone IMAGE:5195845 5', mRNA sequence.
ACCESSION B1754736
VERSION B1754736.1 GI:15746314
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.
1 (bases 1 to 871)
NIH-MGC <http://mgs.nci.nih.gov/>.
National Institutes of Health, Mammalian Gene Collection (MGC)
Unpublished
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed By: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Plate: LLNL1490 row: c column: 14
High quality sequence stop: 644.
Location/Qualifiers
1. 871
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone_11b="IMAGE:5195845"
/lab_host="DH10B"
/clone_11b="NIH_MGC_114"
/note="Organ: brain; Vector: pCMV-SPORT6; Site 1: NotI; Site 2: EcoRV (destroyed); RNA source anonymous pool of 6 male brains, age range 23-27 yo. Library is oligo-dT primed and directionally cloned (EcoRV site is destroyed upon cloning). Average insert size 1.5 kb, insert size range 1-3 kb. Library is normalized and enriched for full-length clones and was constructed by C. Gruber (Invitrogen). Research Genetics tracking code 019. Note: this is a NIH_MGC Library."

BASE COUNT 174 a 268 c 277 g 152 t

ORIGIN

Query Match 74.6%; Score 19.4; DB 12; Length 871;
Best Local Similarity 95.2%; Pred. No. 9.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 6 ATGCAGACGTCGTGACCTG 26
|||||
|||||

Db

558 ATGCAGACCTCGTGACCTG 578

RESULT 8
LOCUS BH051472 535 bp DNA linear GSS 17-JUL-2001
DEFINITION RPCI-24-307N24.TV RPCI-24 Mus musculus genomic clone RPCI-24-307N24, genomic survey sequence.
ACCESSION BH051472
VERSION BH051472.1 GI:14843016
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 535)
Zhao,S., Nieman,M., Malek,J., Shatman,S., Akincet,B., Levins,M., Tsengaye,G., Geer,K., Krol,M., Shavatsbeyn,A., Gebregorgis,E., Ruesell,D., de Jong,P. and Fraser,C.M.
Mouse BAC End Sequences from Library RPCI-24
Unpublished
Other-GSSs: RPCI-24-307N24.TV
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org
Clones are derived from the mouse BAC library RPCI-24. For BAC library availability, please contact Pieter de Jong (pdejong@mail.cho.org). Clones may be purchased from BACPAC Resources (<http://www.choi.org/bacpac/orderingframe.html>). BAC end page: http://www.tigr.org/cdb/bac_ends/mouse/bac_end_intro.html
Plate: 307 row: N column: 24
Seq primer: SP6
Class: BAC ends.
Location/Qualifiers
1. 535
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="RPCI-24-307N24"
/sex="Male"
/cell_type="Spleen/Brain"
/clone_11b="RPCI-24"
/note="Vector: pTARBA1; Site 1: BamHI; Site 2: BamHI; RPCI-24 Mouse BAC Library produced by Pieter de Jong. The library was cloned in the pTARBA1 cloning vector at the BamHI sites using Mbol partially digested male C57BL/6J DNA."

BASE COUNT 114 a 148 c 166 g 107 t

ORIGIN

Query Match 73.8%; Score 19.2; DB 28; Length 535;
Best Local Similarity 87.5%; Pred. No. 1e+03;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 3 CATATGCAGACGTCGTGACCTG 26
|||||
150 CATGCAGACATCGTGACCTG 173

Db

RESULT 9
LOCUS A2362831 613 bp DNA linear GSS 02-OCT-2000
DEFINITION IM0108002F Mouse 10kb plasmid UUCG1M library Mus musculus genomic clone UUCG1M0108002 F, genomic survey sequence.
ACCESSION A2362831
VERSION A2362831.1 GI:10476531
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)

```

ORGANISM      Mus musculus
REFERENCE     Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
AUTHORS       Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly
              ,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A.
              and Wright,D.,Weise,R.
TITLE         Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
JOURNAL       Unpublished
COMMENT        Contact: Robert B. Weise
              University of Utah Genome Center
              Km. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0108 row: 0 column: 02
              Seq primer: CGTTGTAAACAGCGCCGCACT
              Class: plasmid ends
              High quality sequence stop: 613.
FEATURES      Location/Qualifiers
               ..613
               /organism="Mus musculus"
               /mol_type="genomic DNA"
               /strain="C57BL/6J"
               /db_xref="taxon:10090"
               /clone="UUCGCM108002"
               /sex="Male"
               /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
               /clone_1fb="Mouse 10kb plasmid UUCGCM library"
               /note="Vector: PWD42nv; Purified genomic DNA from M.
               musculus C57BL/6J (male) was obtained from the Jackson
               Laboratory Mouse DNA Resource
               (http://www.jax.org/resources/documents/dnares/). The DNA
               was hydrodynamically sheared by repeated passage through a
               0.005 inch orifice at constant velocity. The sheared DNA
               was blunt end-repaired with T4 DNA polymerase and T4
               polynucleotide kinase. Adaptor oligonucleotides were
               ligated to the blunt ends in high molar excess. The
               adaptor DNA was purified and size-selected for a 9.5 to
               10.5 kb range using preparative agarose gel
               electrophoresis. Vector DNA was prepared from a derivative
               of pMDA2 (gi|4732114|gb|AF129072.1)' a copy-number
               inducible derivative of plasmid R1. The vector was ligated
               with adaptors complementary to the insert adaptors and
               purified. The sheared, adaptor mouse DNA was annealed to
               adaptor vector DNA, and transformed into
               chemically-competent E. coli XL10-Gold (Stratagene) cells
               and selected for ampicillin resistance."
BASE COUNT    153 a 162 c 187 g 111 t
ORIGIN
Query Match   73.8%; Score 19.2; DB 28; Length 613;
Best Local Similarity 87.5%; Pred. No.1.le+03;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Oy            3 CATATGCAGACGTCGTGGACCTG 26
              |||||
Db            438 CATGCAGACGACGTGTGACCTG 461
RESULT 10
LOCUS      BU008199/c
DEFINITION BU008199 MF01SSA cDNA Oryzias latipes cDNA clone MF01SSA11609 5',
           mRNA sequence.
ACCESSION  BU008199.1 GI:17366522
KEYWORDS   EST.

```

```

SOURCE          Oryzias latipes (Japanese medaka)
ORGANISM        Oryzias latipes
REFERENCE        Kohara, Y., Shin-i, T., Kimura, T., Narita, T., Jindo, T. and Takeda, H.
AUTHORS         1 (bases 1 to 617)
TITLE           Medaka EST Project in Takeda's lab
JOURNAL         Unpublished
COMMENT         Contact: Tadasu Shin-i
                  Center For Genetic Resource Information
                  National Institute of Genetics
                  1111 Yata, Mishima, Shizuoka 411-8540, Japan
                  Tel: 81-559-81-6856
                  Fax: 81-559-81-6855
                  Email: tehin@genes.nig.ac.jp.
FEATURES        Location/Qualifiers
                1..617
                /organism="Oryzias latipes"
                /mol_type="mRNA"
                /strain="Hd-xr"
                /db_xref="taxon:8090"
                /clone="MF01SA116G09"
                /sex="mixture of female and male"
                /tissue_type="whole embryo"
                /dev_stage="segmentation stage 20 - 25"
                /clone_id="MF01SA cDNA"
BASE COUNT      179 a      154 c      202 g      82 t
ORIGIN
Query Match      73.8%; Score 19.2; DB 12; Length 617;
Best Local Similarity 87.5%; Pred. No. 1.1e+03;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY              2 GCATATGACGAGCGTCGTGACCT 25
Db              201 GCCTGTCAGACGTCGTGACCT 178
RESULT 11
LOCUS           BJ487056 627 bp mRNA linear EST 09-AUG-2002
DEFINITION      BJ487056 MF01FSA cDNA Oryzias latipes cDNA clone MF01FSA002C15 5',
                mRNA sequence.
ACCESSION       BJ487056
VERSION         BJ487056.1 GI:22165805
KEYWORDS        EST.
SOURCE          Oryzias latipes (Japanese medaka)
ORGANISM        Oryzias latipes
REFERENCE        Kohara, Y., Shin-i, T., Kimura, T., Narita, T., Jindo, T. and Takeda, H.
AUTHORS         1 (bases 1 to 627)
TITLE           Medaka EST Project in Takeda's lab
JOURNAL         Unpublished
COMMENT         Contact: Tadasu Shin-i
                  Center For Genetic Resource Information
                  National Institute of Genetics
                  1111 Yata, Mishima, Shizuoka 411-8540, Japan
                  Tel: 81-559-81-6856
                  Fax: 81-559-81-6855
                  Email: tehin@genes.nig.ac.jp.
FEATURES        Location/Qualifiers
                1..627
                /organism="Oryzias latipes"
                /mol_type="mRNA"
                /strain="d-xr"
                /db_xref="taxon:8090"
                /clone="MF01FSA002C15"
                /sex="mixture of female and male"

```

BASE COUNT	177 a	168 c	189 g	92 t	1 others
ORIGIN	/tissue_type="whole embryo" /dev stage="fry stage 40" /clone_lib="MF01FSA cDNA"				

Query Match	73.8%	Score 19.2	DB 12	length 627
Best Local Similarity	87.5%	Pred. No. 1.1e+03		
Matches 21, Conservative	0	Mismatches 3	Indels 0	Gaps 0

QY	2	GCATATGCAGGACGTCGTGACCT	25
Db	314	GCCTGTTCAAGACGTCGTGACCT	291

RESULT	12
BJ533801	
LOCUS	
DEFINITION	711 bp mRNA linear EST 09-AUG-2007
	BJ533801 MF01SBB CDNA Oryzias latipes clone MF01SBB018B06 3'
	mRNA Sequence.
	BJ533801
ACCESSION	BJ533801.1 GI:22192613
VERSION	EST.
KEYWORDS	Oryzias latipes (Japanese medaka)
SOURCE	

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 711)
Kohara, Y., Shn-1, T., Kimura, T., Narita, T.,
Medaka EST Project in Takeda's lab
Unpublished

Contact: Tadaeu Shin-i
Center For Genetic Resource Information
National Institute of Genetics
1111 Yata, Mishima, Shizuoka 411-8540, Japan
Tel.: 81-559-81-6856
Fax: 81-559-81-6855
Email: tehin@genes.nig.ac.jp.

FEATURES
SOURCE
1. 711
Location/Qualifiers

Oy		2 GCATATGCAGGACGTCTGGACCCT	25
Db		322 GCCTGTTCAAGACGTCGTGACCCT	345

RESULT 13					
CNS026GG/c					
LOCUS	CNS026GG	1012 bp	DNA	linear	GSS 01-SEP-2000
DEFINITION	Tetradodon nigroviridis genome survey sequence T7 end of clone 24N006 of library G from Tetradodon nigroviridis, genomic survey sequence.				
ACCESSION	AL183337				
VERSION	AL183337.1	GI:7821441			
KEYWORDS	GSS: genome survey sequence.				
SOURCE	Tetradodon nigroviridis				

ORGANISM Tetraodon nigroviridis
Bakaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei
Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
Tetraodontidae; Tetraodontidae; Tetraodon.
1

AUTHORS	Roset Crollius,H., Jallion,O., Dasilva,C., Bouneau,L., Fisher,C., Bernic,A., Fizames,C., Wincker,P., Brottier,P., Quetier,F., Saurin,W. and Weissenbach,J.
TITLE	Estimate of human gene number provided by genome-wide analysis using Tetraodon nigroviridis DNA sequence
JOURNAL	Nat. Genet. 25 (2), 235-238 (2000)
MEDLINE	20296633
PUBMED	10835645
REFERENCE	2
AUTHORS	Roset Crollius,H., Jallion,O., Dasilva,C., Ozouf-Costraz,C., Filames,C., Fischer,C., Bouneau,L., Billaud,A., Quetier,F., Saurin,W., Bernot,A. and Weissenbach,J.
TITLE	Characterization and repeat analysis of the compact genome of the freshwater pufferfish Tetraodon nigroviridis
JOURNAL	Genome Res. 10 (7), 939-949 (2000)
MEDLINE	20359837
PUBMED	10899143
REFERENCE	3 (bases 1 to 1012)
AUTHORS	Genoscope.
TITLE	Direct Submission
JOURNAL	Submitted (12-APR-2000) Genoscope - Centre National de Sequencage : BP 191 91006 Evry cedex - FRANCE (E-mail : seque@genoscope.cns.fr - Web : www.genoscope.cns.fr)
COMMENT	This sequence is a single read and was generated as part of a large scale clone and sequencing project of the Tetraodon nigroviridis genome. For more information, please take a look at http://www.genoscope.cns.fr/tetraodon .

FEATURES				
source	Location/Qualifiers			
	1. .1012			
	/organism="Tetradon nigriviridis"			
	/mol_type="genomic DNA"			
	/db_xref="taxon:99883"			
	/clone="240N06"			
	/clone_11b="G"			
	/note="Genoscope sequence ID : COAG240DG03LP1-end : T7"			
BASE COUNT	174 a	323 c	300 g	206 t
ORIGIN			9	others
Query Match	73.1%	Score 19;	DB 29;	Length 1012;
Best local Similarity	90.5%	Pred. No. 1.5e+03;		
Matches 19;	Conservative 1;	Mismatches 1;	Indels 0;	Gaps 0;

```
QY      6 ATGCAGACGTCGTGACCCTG   26  
         ||||| | :  
Db     306 ATGCAGGACATCGTGACCTS  286
```

RESULT 14
AA398146/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AA398146 240 bp mRNA linear EST 12-AUG-1997
zrebh02.r1 Soares_testis_NHT homo sapiens cDNA clone IMAGE:729459
5' mRNA sequence.
AA398146
AA398146.1 GI:2051273
EST.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 240)
Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisels, G., Jose, S.,
Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin, J., Moore, B.,
'Schellenberg, K., Stepien, M., Tan, F., Theisling, B., White, Y., Wyllie,
'T., Waterston, R. and Wilson, R.
WashU-Merck EST Project 1997
Unpublished
Contact: Wilson RK

Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: east@wustl.wustl.edu
This clone is available royalty-free through LINTL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Insert Length: 1694 Std Error: 0.00
Seq primer: -28ml3 rev1 ET from Amersham
High quality sequence stop: 130.

FEATURES

source

Location/Qualifiers

1. .240
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:5925988"
/db_xref="taxon:9606"
/clone="IMAGE:729459"
/sex="male"
/lab_host="DH10B"
/clone_lib="Soares testis NHT"
/note="Vector: pT7T3D-Pac (Pharmacia) with a modified
polylinker. Site 1: Not I; Site 2: Eco RI; 1st strand cDNA
was prepared from mRNA obtained from Clontech Laboratories
, Inc., and primed with a Not I - oligo(dT) primer [5'
TGTTACCAATCTGAGTGGAGCGCGCCCAATTTTCTTTTCTT 3']
Double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT7T3 vector. Library
went through one round of normalization to Cot5, and was
constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT

51 a 72 c 50 g 67 t

ORIGIN

Query Match 71.5%; Score 18.6; DB 9; Length 240;
Best Local Similarity 84.0%; Pred. No. 1.4e+03;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

2 GCATATGACGAGCGTGTGACCTG 26

227 GCATATGACGAGCGTGTGACCTG 203

RESULT 15
AA821887 374 bp mRNA linear EST 17-FEB-1998
LOCUS
DEFINITION
vp23a05.r1 StrataGene mouse diaphragm (#937303) Mus musculus cDNA
ACCESSION
AA821887
VERSION
AA821887.1 GI:2891755
KEYWORDS
EST.
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 374)
Marras, M., Hallier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T.,
Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M.,
Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B.,
Teisling, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and
Waterston, R.
The WashU-HHMI Mouse EST Project
Unpublished
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.wustl.edu
This clone is available royalty-free through LINTL; contact the
IMAGE Consortium (info@image.lnl.gov) for further information.
Seq primer: -28ml3 rev1 ET from Amersham

FEATURES
source
High quality sequence stop: 371.
Location/Qualifiers
1. .374
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="IMAGE:1077488"
/tissue_type="diaphragm"
/dev_stage="adult"
/lab_host="SOIR (kanamycin resistant)"
/clone_lib="StrataGene mouse diaphragm (#937303)"
/note="Organ: diaphragm; Vector: pBluescript SK-; Site 1:
EcoRI; Site 2: XhoI; Cloned unidirectionally from mRNA
prepared from diaphragm muscle. Primer: Oligo dT. Average
insert size: 1.5 kb. Uni-ZAP XR Vector; ~5' adaptor
sequence: 5' GAATTCGGCAGAG 3' ~3' adaptor sequence: 5'
CTCGAGTTTCTTTTCTTTTCTTTT 3"

BASE COUNT 72 a 113 c 130 g 59 t

ORIGIN

Query Match 71.5%; Score 18.6; DB 9; Length 374;
Best Local Similarity 84.0%; Pred. No. 1.6e+03;
Matches 21; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

2 GCATATGACGAGCGTGTGACCTG 26

99 GCCTGTGACGAGAGTCTCGACCTG 123

Search completed: February 16, 2004, 13:40:54
Job time : 105.997 secs

This Page Blank (uspto)

FEATURES
source
location/Qualifiers
1..26
/organism="unknown"

BASE COUNT 5 a 7 c 9 g 5 t

ORIGIN

Query Match 100.0%; Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

RESULT 2
AR194191
LOCUS AR194191 26 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4 from patent US 6348344.
ACCESSION AR194191
VERSION AR194191.1 GI:20240783
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 26)
Ayal-Hershkovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Miron,M.,
Ben-Artzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schlomi,Y.
Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
Patent: US 6348344-A 4 19-FEB-2002;
Location/Qualifiers
1..26
/organism="unknown"

BASE COUNT 5 a 7 c 9 g 5 t

ORIGIN

Query Match 100.0%; Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

RESULT 3
AR221287
LOCUS AR221287 26 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 4 from patent US 6426209.
ACCESSION AR221287
VERSION AR221287.1 GI:23328258
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 26)
Ayal-Hershkovitz,M., Pecker,I. and Yacoby-Zeevi,O.
Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
Patent: US 6426209-A 4 30-JUL-2002;
Location/Qualifiers
1..26
/organism="unknown"

BASE COUNT 5 a 7 c 9 g 5 t

ORIGIN

Query Match 100.0%; Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

Db 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

RESULT 4
AR243205
LOCUS AR243205 26 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 4 from patent US 6475763.
ACCESSION AR243205
VERSION AR243205.1 GI:27290320
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 26)
Ayal-Hershkovitz,M., Moskowitz,H., Miron,D., Gilboa,A., Miron,M.,
Ben-Artzi,H., Yacoby-Zeevi,O., Pecker,I., Peleg,Y. and Schlomi,Y.
Genetically modified cells and methods for expressing recombinant
heparanase and methods of purifying same
Patent: US 6475763-A 4 05-NOV-2002;
Location/Qualifiers
1..26
/organism="unknown"

BASE COUNT 5 a 7 c 9 g 5 t

ORIGIN

Query Match 100.0%; Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

RESULT 5
AR287437
LOCUS AR287437 26 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 4 from patent US 6531129.
ACCESSION AR287437
VERSION AR287437.1 GI:29725131
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 26)
Pecker,I., Violdavsky,I., Friedman,Y. and Peters,T.
Heparanase specific molecular probes and their use in research and
medical applications
Patent: US 6531129-A 4 11-MAR-2003;
Location/Qualifiers
1..26
/organism="unknown"

BASE COUNT 5 a 7 c 9 g 5 t

ORIGIN

Query Match 100.0%; Score 26; DB 6; Length 26;
Best Local Similarity 100.0%; Pred. No. 1.3;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CGCATATGCAGACGCTGTCGACCTG 26
|||||
1 CGCATATGCAGACGCTGTCGACCTG 26

RESULT 6
AX557108
LOCUS AX557108 30 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 6 from Patent W00244353.
ACCESSION AX557108
VERSION AX557108.1 GI:25900161
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

REFERENCE 1 artificial sequences.
AUTHORS Wolffe, A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 6 06-JUN-2002;
Sangamo Biosciences Inc. (US)
FEATURES
source Location/Qualifiers
1. 30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Primer Hp-6"
BASE COUNT 4 a 9 c 9 g 8 t
ORIGIN
Query Match 76.9%; Score 20; DB 6; Length 30;
Best Local Similarity 100.0%; Pred. No. 5.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 7 TGCAGACGTCGTGACCTG 26
2 TGCAGACGTCGTGACCTG 21
Db
RESULT 7
AE006005/c 10328 bp DNA linear BCT 12-JUN-2002
LOCUS Caulobacter crescentus CB15 section 331 of 359 of the complete
DEFINITION genome.
ACCESSION AE006005 AE005673
VERSION AE006005.1 GI:13425180
KEYWORDS
SOURCE
ORGANISM Caulobacter crescentus CB15
Caulobacter crescentus CB15
Bacteria; Proteobacteria; Alphaproteobacteria; Caulobacterales;
Caulobacteraceae; Caulobacter.
REFERENCE 1 (bases 1 to 10328)
AUTHORS Nierman, W.C., Feldblum, T.V., Laub, M.T., Paulsen, I.T., Nelson, K.E.,
Eisen, J., Heidelberg, J.F., Alley, M.R.K., Ohta, N., Maddock, J.R.,
Potocka, I., Nelson, W.C., Newton, A., Stephens, C., Phadke, N.D.,
Ely, B., DeBoy, R.T., Dodson, R.J., Durkin, A.S., Gwinn, M.L.,
Hart, D.H., Kolonay, J.F., Smit, J., Craven, M., Khouli, H., Shetty, J.,
Berry, K., Uterback, T., Tran, K., Wolf, A., Vamathevan, J.,
Ermolaeva, M., White, O., Salzberg, S.L., Venter, J.C., Shapiro, L. and
Fraser, C.M.
TITLE Complete genome sequence of Caulobacter crescentus
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 98 (7), 4136-4141 (2001)
MEDLINE 11259647
PUBMED
REFERENCE 2 (bases 1 to 10328)
AUTHORS Nierman, W.C., Feldblum, T.V., Paulsen, I.T., Nelson, K.E., Eisen, J.,
Heidelberg, J.F., Alley, M.R.K., Ohta, N., Maddock, J.R., Potocka, I.,
Nelson, W.C., Newton, A., Stephens, C., Phadke, N.D., Ely, B.,
Laub, M.T., DeBoy, R.T., Dodson, R.J., Durkin, A.S., Gwinn, M.L.,
Hart, D.H., Kolonay, J.F., Smit, J., Craven, M., Khouli, H., Shetty, J.,
Berry, K., Uterback, T., Tran, K., Wolf, A., Vamathevan, J.,
Ermolaeva, M., White, O., Salzberg, S.L., Shapiro, L., Venter, J.C. and
Fraser, C.M.
TITLE Direct Submission
JOURNAL Submitted (31-JUN-2001) The Institute for Genomic Research, 9712
Medical Center Dr, Rockville, MD 20850, USA
FEATURES
source Location/Qualifiers
1. 10328
/organism="Caulobacter crescentus CB15"
/mol_type="genomic DNA"
/strain="CB15"
/db_xref="taxon:190650"
complement (90. 2633)
/gene="CC3461"
complement (90. 2633)
/gene="CC3461"
/note="Identified by match to protein family HMM"
/codon_start=1

gene
CDS
/transl_table=11
/product="TonB-dependent receptor"
/protein_id="AAK25423.1"
/db_xref="GI:13425181"
/translation="MTYVLSVSNALLIMPSFRVDFHODEGEPQRCVSGNSKAKNTR
EEITMTIVSSGRAPALFGASALSSLLAGVIALPSVATAQADNNAIAETIIVATKRD
ATIQDIPFSINAQTEKDIQSGAVTLEDLERNVAGLITQMLPGQSQVSVGSAGV
VRDQPKVEQGVYLDSEVLSLFTFDVDFLMDLRVETLRPGSLFGSGSVGGTIR
YINQPKLGYSEGFEEANANLVODDAGGVKAVNPIEDKILAMRAVGLTYGGFPI
DAREGEGKVDKVNNDGRRGGRGLSFYIEPVEQVNFPRVYVQEIIRAGFRQETNFI
ANNNTTRPKIQGGERQYILDERBEDNTLMDMTNKLFPDAITLTLSVTSFISDIT
VSRDASALTGVSVDYDGYPAAVILPSNLNEDDTLDEQFOTELRLASTTDDFLQVYIG
FSKVDKRVNQRLPTTGVDYTDVAVLAGSAAVANGFQSDSPYNALPYDIIQKALP
GELNYIVGKLTATAGGRYDPSFETRGKFGSGLPANGMDRDTKTSIDGTFPFLSYRA
SDFTVFAASKSGFRGLGVNDPLNIPICSAQDRAIFGGYQNYDETLMEYGVKSRF
GRVTLNAAFTYDIKNLTQTLDAGSGSRVFNVPKATKRGVAEALFARLANGIDIL
SGSLIEMAFSTYKDGITGAVITGIRBENRILPSPKRVSDYVTSKRVGVNGLA
SLQHVGNRFTQASDQENNPRILFVSNLFGGATGVPAVNLALPSYETIVLSAGLEMQ
DGVDTLTLYNNLPDENALLSPDRERGRARLGYAVGQPRTMGVTVRSF"
2758. 3945
/gene="CC3462"
2758. 3945
/gene="CC3462"
/note="Identified by match to protein family HMM"
/codon_start=1
/transl_table=11
/product="thiolase family protein"
/protein_id="AAK25424.1"
/db_xref="GI:13425182"
/translation="MREAVIVSARTGLAKSVRGFNNTGAMAGHAIQHAVSRACL
EGAEVEDVNVIGCGPEGATGMNVARNAMAGAPVTTSQGTINRFGSSGLQALATAAN
YVANDGVANVAIGGVESISLVNAGHNRHIEEKMLQHPALMMADITADIVAR
YVSRXYODEYVALRQORIAAOAGLFXEIVPMATKMNVTNETSEEPVAVDK
DECNRAPTTLEGLASLKPVMGKRTTAGNAGLSQSLDAAVVMVEAEAKRGILTPG
AFRGPAVAGCEPPEMKGIVPNAVPRLLERGLKXDDIDIELNAPASQCLYSRDLG
IDPEKYNVNGSIAIGHPFMTGARCGHLLLEGKRRKALGVVTMCIGGAGAGLF
EIP"
complement (3998. 4279)
/gene="CC3463"
complement (3998. 4279)
/gene="CC3463"
/note="Identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAK25425.1"
/db_xref="GI:13425183"
/translation="MMELTRMEILVLRQAQDEDFLRTANSRPHPELVEGRGLLRGD
QHPTSKQPKERPETAQAKVSGLFQSFSLSDCAVNRKISNRPAAPLWIA"
complement (4343. 7246)
/gene="CC3464"
complement (4343. 7246)
/gene="CC3464"
/note="Identified by match to protein family HMM"
/codon_start=1
/transl_table=11
/product="DNA polymerase I"
/protein_id="AAK25426.1"
/db_xref="GI:13425184"
/translation="MLPAMTDAAAPLPNASELTODGPAVRLFLVDSAGVILFRAYNAL
PPLTRKSDGLPVGAVGFCNMLWKLRLMDGDEPPTHLAVIMSEKFRNALXYQYKA
HRPPPEPDLPOPLVREATLARGVPIELRGVADDLIAAYCAKADIGEALIVSS
DKOLMOLVGVGVSMYOMKGVRIERREVEFKRGPVPRKVVQVADLCGSDVNDVAGG
IGIKTAQQLITTEGDDTLARAGELIKQPKRRTILNFAQIRLSRLVYLDCTPIR
QPLDALTRPPDEBALAALFLEQMFSLARVDDGSAATPGTLDRPAAPKAAVSV
SYMGAAARAAPHVEPKVIDAAVACVRDITATKAWAKATDGLVAFDETPALISA
TAGLCAVSLAIAPGEACYIPISHCERKDGAFAPADIEQIPLADYATIKPLIEDPA
TLKVAONAKYDIAVLARHGIOVAPIETPTMISYLELGGHGDSEILHKKPFP
PKOVASGKGOISFKYVALPEATVAAEDVDVTLRYHNHKKPLARSLSTVYETLER
PMFPAVLAMENNGRVDPBALRLISNEFSIRMAQFERRADELIGRPNLSSPKOIGV
LFSGMQKGGKRTATQGWSTDSVLSLAEHLPRVLMDWRQLSKGTGYTEQILAA
IAPSTGVHTSVLAATTTGRLSSSDPNLQNIIVREBGRKIRKAPAAAGHVALISAD
YSQIEIRLTLAHIGDIPOLKKAFOEGDLIHAMTASEMDPPIEGMDPMIRRRAXAINFG

```
IVGISAFLANOLGISQAGAYIKTYFERPGLQAYMDATKAFVREHGVTITFGR
KINIPDIKASARHROPERRAIIINPIOGAADWRMRIMPVALAAGISTMLLO
VHDELVEAPEAEERACAVRAVMEKAEPAVALSIPITVEAASAASWDAH"
7355..9202
/gene="CC3465"
/355..9202
/gene="CC3465"
/notice="identified by match to protein family HMM"
/codon_start=1
/transl_table=11
/product="ATP-dependent DNA helicase RecQ"
/protein_id="AAK25427.1"
/db_xref="GI:13425185"
/translaction="MYVPPESPPELDRADVLRRTFGHNPGLQAGVITHELTGSHSM
AVLPTGGKSLCYQIPSPISRPGLGVISPLIALMADYQGRGQVNAERDINSMD
ERSDIWRIDAGEVDLTLSPBGLMOPMLRLSTPLALAVDSAHCVSGWGHFRP
EYRMIGRLAELFPDAPRLAVTADARTRDDIRLELRIOGAEPDSFARBELLSAR
RKRGKGRVVELVLEPRGSGVYAGSDGTETKLAERLNEGVPALAVHAGLDKAVR
ARLEDFLEADAAVWVATIAFGMGVDEKDVYVHADPPALIEAVMOEVBGRDQGP
AEGITIVGSADMAAARIETREAPDEVKQOSRLQOFVAMLEGVTCRAAAVRVYG
EEGVHCGVCDCICSPPTGIDATQAQKALAVHRLGRLGRVITHELMKTDVTP
QEAQPLTIGIFERSQPTWRDLFTLLIFEGLRDPNGRPLIGLDVEGVQVYRNE
RKVALRQTTDAPDSGGAGGMRKRREGRAVLTIPANQLFEALRSWKREQAOLQHP
PYVIFHDATTIAEIAARPATLALGKAGVGCGKLDRYGEAVLKVREN"
9247..9555
/gene="CC3466"
/9247..9555
/gene="CC3466"
/notice="identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="hypothetical protein"
/protein_id="AAK25428.1"
/db_xref="GI:13425186"
/translaction="MTHVNSLTPSDITSVAVDVENTRKAQDALDAVKSARDTATEV
AQRTRFAEQARAGAAWTKQAKAHVHVDHPWGLGAFALGIGLIFLSHMLAR
"
gene
complement(9792..10250)
/gene="CC3467"
complement(9792..10250)
/gene="CC3467"
/notice="identified by Glimmer2; putative"
/codon_start=1
/transl_table=11
/product="conserved hypothetical protein"
/protein_id="AAK25429.1"
/db_xref="GI:13425187"
/translaction="MWDVIELAPSRPETTLAVTRGARLLVDLYGAPLAPEVTLPNGR
ADMLAGKGVILIVEKSGLEDPRDKMGDVAPFCDAFYFAVAVSPDPGLPDPG
LLVADPGGAVVREAPLTPPLAPARKALTALFGRILAAWRAGVNAERLSL"
BASE COUNT 1665 a 3459 c 3503 g 1701 t
ORIGIN
Query Match 76.2%; Score 19.8; DB 1; Length 10328;
Best Local Similarity 91.3%; Pred. No. 5.7e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 4 ATATGACGACGCTGTCGACCTG 26
|||||
Db 247 AGATGACGACGACGCTGTCGACCTG 225
|||||
RESULT 8
AXI36496 474 bp DNA linear PAT 30-MAY-2001
LOCUS Sequence 418 from Patent EP1067182.
DEFINITION AXI36496
ACCESSION AXI36496
VERSION AXI36496.1 GI:14272900
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
```

```
REFERENCE 1
AUTHORS Ota,T., Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and
Hayashi,K.
TITLE Secretory protein or membrane protein
JOURNAL Patent: EP 1067182-A 418 10-JUN-2001;
Helix Research Institute (JP)
FEATURES
source 1..474
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 86 a 154 c 127 g 101 t 6 others
ORIGIN
Query Match 75.4%; Score 19.6; DB 6; Length 474;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGACGACGCTGTCGACCTG 26
|||||
Db 161 CGCAGACGACGACGCTGTCGACCTG 186
|||||
RESULT 9
BD123736 474 bp DNA linear PAT 18-SEP-2002
LOCUS Secretory protein or membrane protein.
DEFINITION BD123736
ACCESSION BD123736.1 GI:23218681
VERSION JP 2002017376-A/245.
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 474)
AUTHORS Ota,T., Isogai,T., Nishikawa,T., Kawai,Y., Sugiyama,T. and
Hayashi,K.
TITLE Secretory protein or membrane protein
JOURNAL Patent: JP 2002017376-A 245 22-JUN-2002;
HELIX RESEARCH INSTITUTE
COMMENT OS Homo sapiens (human)
PN JP 2002017376-A/245
PD 22-JAN-2002
PF 07-JUL-2000 JP 2000253173
PI TOSHIO OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, YURI KAWAI, TOMOYASU
PI SUGIYAMA,
PI KOJI HAYASHI
PC C12N15/09,C07K16/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21,C12N5/ PC
10, C12P21/02,C12Q1/68//C12P21/08,C12N15/00,C12N5/00 CC
Secretory protein or membrane protein
FT Key Location/Qualifiers
FT source 1..474
FT location/Qualifiers
1..474
/organism="Homo sapiens (human)".
FEATURES
source 1..474
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
BASE COUNT 86 a 154 c 127 g 101 t 6 others
ORIGIN
Query Match 75.4%; Score 19.6; DB 6; Length 474;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1 CGCATATGACGACGCTGTCGACCTG 26
|||||
Db 161 CGCAGACGACGACGCTGTCGACCTG 186
|||||
RESULT 10
```

AX557103
LOCUS AX557103 605 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 1 from Patent WO0244353.
ACCESSION AX557103
VERSION AX557103.1 GI:25900156
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Wolffe,A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 1 06-JUN-2002;
Sangamo BioSciences Inc. (US)
FEATURES
source
1. 605
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="first and second exons of human heparanase gene"
BASE COUNT 96 a 187 c 230 g 92 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 605;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CGCATATCGACGACGTGTCGACCTG 26
Db 468 CGCAGACACGACGACGTGTCGACCTG 493

RESULT 11
LOCUS AX557106 1419 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 4 from Patent WO0244353.
ACCESSION AX557106
VERSION AX557106.1 GI:25900159
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1
AUTHORS Wolffe,A.P.
TITLE Human heparanase gene regulatory sequences
JOURNAL Patent: WO 0244353-A 4 06-JUN-2002;
Sangamo BioSciences Inc. (US)
FEATURES
source
1. 1419
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="human heparanase gene in the vicinity of the
upstream region"

BASE COUNT 329 a 352 c 452 g 286 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1419;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CGCATATCGACGACGTGTCGACCTG 26
Db 1282 CGCAGACACGACGACGTGTCGACCTG 1307

RESULT 12
LOCUS AR210040 1593 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 1 from patent US 6387643.
ACCESSION AR210040
VERSION AR210040.1 GI:21512167
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 1593)
AUTHORS Heinrichson,R,Levoy,, Fairbanks,M.B. and Mildner,A.M.
TITLE Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
JOURNAL Patent: US 6387643-A 1 14-MAY-2002;
FEATURES
source
1. 1593
/organism="unknown"
BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1593;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CGCATATCGACGACGTGTCGACCTG 26
Db 59 CGCAGACACGACGACGTGTCGACCTG 84

RESULT 13
LOCUS BD136761 1593 bp DNA linear PAT 18-SEP-2002
DEFINITION Human platelet heparanase polypeptide, polynucleotide molecule encoding the same and method of identifying compound changing heparanase activity.
ACCESSION BD136761
VERSION BD136761.1 GI:23231706
KEYWORDS JP 2002504376-A/1.
SOURCE unidentified
ORGANISM unidentified
REFERENCE
1 (bases 1 to 1593)
AUTHORS Heinrichson,R.L., Fairbanks,M.B. and Mildner,A.M.
TITLE Human platelet heparanase polypeptide, polynucleotide molecule encoding the same and method of identifying compound changing
JOURNAL Patent: JP 2002504376-A 1 12-FEB-2002;
PHARMACIA & UPJOHN CO
COMMENT
OS Unidentified
PN JP 2002504376-A/1
PD 12-FEB-2002
PF 18-FEB-1999 JP 2000533569
PR 24-FEB-1998 US 60/075706,26-MAR-1998 US 60/079401 PI
ROBERT L. HEINRICHSON,MICHAEL B FAIRBANKS,ANA M MILDNER PC
C12N15/09,C07K16/40,C12N1/21,C12N5/10,C12N9/24,C12Q1/34,C12N15/00,C12N5/00
CC Strandedness: Double;
CC Topology: linear;
CC Human platelet heparanase polypeptide, polynucleotide molecule

CC encoding
CC the same and method of identifying compound changing CC
FH key location/Qualifiers
FT source 1. 1593
FT location/Qualifiers
FEATURES
source
1. 1593
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

BASE COUNT 426 a 370 c 369 g 428 t
ORIGIN

Query Match 75.4%; Score 19.6; DB 6; Length 1593;
Best Local Similarity 84.6%; Pred. No. 7.2e+02;
Matches 22; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 1 CGCATATCGACGACGTGTCGACCTG 26

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using SW model

Run on: February 16, 2004, 07:55:00 ; Search time 844.407 Seconds
(without alignments)
5501.769 Million cell updates/sec

Title: US-10-676-079-1

Perfect score: 1721
Sequence: 1 ctgagccttcgactctccg.....atctactgctcgcactg 1721

Scoring table: IDENTITY_NUC
Gapop 10.0, Gapext 1.0

Searched: 2552756 seqs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Listing first 45 summaries

Database : N Geneseq 19Jun03:*

1: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1980.DAT:*
2: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1981.DAT:*
3: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1982.DAT:*
4: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1983.DAT:*
5: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1984.DAT:*
6: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1985.DAT:*
7: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1986.DAT:*
8: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1987.DAT:*
9: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1988.DAT:*
10: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1989.DAT:*
11: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1990.DAT:*
12: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1991.DAT:*
13: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1992.DAT:*
14: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1993.DAT:*
15: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1994.DAT:*
16: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1995.DAT:*
17: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1996.DAT:*
18: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1997.DAT:*
19: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1998.DAT:*
20: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA1999.DAT:*
21: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA2000.DAT:*
22: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA2001A.DAT:*
23: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA2001B.DAT:*
24: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA2002.DAT:*
25: /SIDSI/gcgdata/geneseq/geneeqn-emb1/NA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1721	100.0	1721	20	AA35648
2	1721	100.0	1721	21	AA75051
3	1721	100.0	1721	21	AA23195
4	1721	100.0	1721	21	AA233290
5	1721	100.0	1721	22	AA91112
6	1719.4	99.9	1899	20	AA35650
7	1719.4	99.9	1899	21	AA75053
8	1713	99.5	1722	22	AA93788

9	1694.6	98.5	1713	20	AA37259
10	1688.8	98.1	1723	20	AA37260
11	1686.8	98.0	3726	20	AA36671
12	1682.6	97.8	1724	22	AA20940
13	1631.4	94.8	1669	25	AB222816
14	1585	92.1	1593	20	AA211236
15	1535	89.2	1584	24	ABL40753
16	1092	63.5	2396	21	AA75081
17	1092	63.5	2396	22	AA31113
18	802.2	46.6	1380	20	AA37261
19	786.2	45.7	1192	20	AA37262
20	595	34.6	1605	24	ABL40748
21	486.8	28.3	553	24	ABL68772
22	453	26.3	824	21	AA35649
23	453	26.3	824	20	AA75052
24	435.2	25.3	474	22	AA93984
25	433.6	25.2	504	22	AA94131
26	313.8	18.2	428	25	ABX51804
27	287.8	16.7	605	24	ABN66003
28	287.8	16.7	1419	24	ABN66003
29	287.8	16.7	44848	21	AA75080
30	285.2	16.6	2060	22	AA91097
31	284.8	16.5	1847	24	AA29202
32	284.8	16.5	2636	22	AAH2671
33	284.6	16.5	2496	24	AA170849
34	282	16.4	1779	22	AA31848
35	278.8	16.2	1779	22	AA75080
36	270.6	15.7	1685	24	AA29204
37	269.4	15.7	1898	22	AA91098
38	230.6	13.4	385	21	AA75082
39	197.6	11.5	1511	24	AA29205
40	196.4	11.4	1724	22	AA91099
41	196.4	11.4	1930	22	AA31843
42	196.4	11.4	2300	22	AA23673
43	195.6	11.4	1674	24	AA29203
44	195	11.3	3943	22	AAH28347
45	194.4	11.3	1891	24	AB211527

ALIGNMENTS

RESULT 1
ID AA35648 standard: CDNA; 1721 BP.

AA35648;
09-JUL-1999 (first entry)

CDNA encoding a human heparanase protein.

Heparanase; hpa; modulator; heparin-binding growth factor;
cellular response; cytokine; cell interaction; plasma lipoprotein;
cellular susceptibility; infection; disintegration;
neurodegenerative plaque; wound healing; angiogenesis; restenosis;
atherosclerosis; inflammation; neurodegenerative disease; neutralise;
plasma heparin; micrometastasis; autoimmune lesion; renal failure;
88.

Homo sapiens.

WO9911798-A1.

11-MAR-1999.

31-AUG-1998; 98WO-US17954.

02-JUL-1998; 98US-0109386.

02-SEP-1997; 97US-0922170.

(FRIE/) FRIEDMAN M M.
(HADA-) HADASIT MEDICAL RES SERVICES & DEV.

Human heparanase e
Seq ID No: 14 of W
CDNA encoding a hu
Human heparanase i
Human heparanase i
Human heparanase e
Human pre-prohepar
CDNA encoding a mu
Mouse heparanase c
Mouse heparanase
Rat heparanase enz
Chicken heparanase
Kidney cancer rela
3' untranslated re
Murine EST which i
Primer specific fo
Bovine EST associa
Human heparanase g
Human heparanase u
Nucleotide sequenc
Human heparanase-2
Human heparanase-2
Heparanase-like pr
Human heparanase I
DNA encoding hepar
Human heparanase-2
Human heparanase-2
Human heparanase-2
Human heparanase,
Rat EST which is h
Human heparanase-2
Human heparanase,
DNA encoding novel
Heparanase-like pr
Human heparanase-2
Nucleotide sequenc
Human polynucleoti

PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
XX Feinstein E, Pecker I, Vlodavsky I;
XX WPI: 1999-302255/25.
DR P-PSDB; AA02345.
XX
PT New human polynucleotide useful for treating angiogenesis,
PT restenosis, and inflammation
XX
PS Claim 4; Fig 1; 63pp; English.
XX
CC The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins,
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.
XX
SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other:

Query Match 100.0%; Score 1721; DB 20; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTAGAGCTTTGACCTCTCCGCGCGGAGCTGGCGGGGAGACAGCCAGTGAAGCCCA 60
DB 1 CTAGAGCTTTGACCTCTCCGCGCGGAGCTGGCGGGGAGACAGCCAGTGAAGCCCA 60
QY 61 AGATCTCTGCGCTGCAAGCCTGCGCTGCCCGCCGCTGATGCTGCTCTGAGGAC 120
DB 61 AGATCTCTGCGCTGCAAGCCTGCGCTGCCCGCCGCTGATGCTGCTCTGAGGAC 120
QY 121 CGCTGGTCCCTCTCCGCGCGCTGGCGCCCGCACTGCGGACACAGAGCTGTGG 180
DB 121 CGCTGGTCCCTCTCCGCGCGCTGGCGCCCGCACTGCGGACACAGAGCTGTGG 180
QY 121 CGCTGGTCCCTCTCCGCGCGCTGGCGCCCGCACTGCGGACACAGAGCTGTGG 180
DB 121 CGCTGGTCCCTCTCCGCGCGCTGGCGCCCGCACTGCGGACACAGAGCTGTGG 180
QY 181 ACCTGGAATTCTTCAACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGCA 240
DB 181 ACCTGGAATTCTTCAACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGCA 240
QY 181 ACCTGGAATTCTTCAACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGCA 240
DB 181 ACCTGGAATTCTTCAACCCAGAGGCGGCTGCACTGTGAGCCCTCTCTCTCCGCA 240
QY 241 CCATTGAGCGCAACCTGGCGACGACCCCGGTTCTCATCTCTCTGGGTTCTCCAAAGC 300
DB 241 CCATTGAGCGCAACCTGGCGACGACCCCGGTTCTCATCTCTCTGGGTTCTCCAAAGC 300
QY 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGTGTGGACCAAGAG 360
DB 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGTGTGGACCAAGAG 360
QY 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGTGTGGACCAAGAG 360
DB 301 TTTCGATCTTGGCGCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGTGTGGACCAAGAG 360
QY 361 ACTTCTCAATTTTGCATCCCAAGAGGATCAACTTTGAAGAAGAAATTACTGGCAAT 420
DB 361 ACTTCTCAATTTTGCATCCCAAGAGGATCAACTTTGAAGAAGAAATTACTGGCAAT 420
QY 421 CTCAAGTCAACAGAGATATTTGCAATATGATTCATCCCTCTGATGTGGAGGAAAGT 480
DB 421 CTCAAGTCAACAGAGATATTTGCAATATGATTCATCCCTCTGATGTGGAGGAAAGT 480
QY 481 TACGGTTGGAATGGCCCTACAGAGCAATTGCTACTCCGAGAAACACTACAGAAAAGT 540
DB 481 TACGGTTGGAATGGCCCTACAGAGCAATTGCTACTCCGAGAAACACTACAGAAAAGT 540
QY 541 TCAAGAACAGCACTTACTCAAGAGCTGTGATGTGTATACCTTTTGGCAACTGCT 600
DB 541 TCAAGAACAGCACTTACTCAAGAGCTGTGATGTGTATACCTTTTGGCAACTGCT 600
QY 601 CAGAGCTGAGACTTATCTTGGCCTAAATGCGTTATTAAGAACAGACAGATTGGAGTGA 660

DB 601 CAGAGCTGAGACTTATCTTGGCCTAAATGCGTTATTAAGAACAGACAGATTGGAGTGA 660
QY 661 ACAGTTCTAATGCTCAGTGTCTCTCGACCTACTCTCTCCAAAGGATATACTTTCTT 720
DB 661 ACAGTTCTAATGCTCAGTGTCTCTCGACCTACTCTCTCCAAAGGATATACTTTCTT 720
QY 721 GGGAACTAGGAACTGAACCTTAACAGTTCTCTTAAGAAGGCTGATATTTTCATCATGGGT 780
DB 721 GGGAACTAGGAACTGAACCTTAACAGTTCTCTTAAGAAGGCTGATATTTTCATCATGGGT 780
QY 781 CGCAGTTAGAGAAATTAATTCATTTGCAATTAACCTTGAAGAAAGTCCACTTTCAAAA 840
DB 781 CGCAGTTAGAGAAATTAATTCATTTGCAATTAACCTTGAAGAAAGTCCACTTTCAAAA 840
QY 841 ATGCAAACTCTATGCTCTGATGTGTGCTGAGCTCCGAGAAAGAAACAGGCTAAAGTCTGA 900
DB 841 ATGCAAACTCTATGCTCTGATGTGTGCTGAGCTCCGAGAAAGAAACAGGCTAAAGTCTGA 900
QY 901 AGAGCTTCTGAAGGCTGTGAGAGATGATGATTCAGTATGATGATGATGATGATGATGAT 960
DB 901 AGAGCTTCTGAAGGCTGTGAGAGATGATGATTCAGTATGATGATGATGATGATGATGAT 960
QY 961 TGAATGACGAGACTGCTACACAGGAGATTTTCTTAAACCTGATGATTTGACATTTTGA 1020
DB 961 TGAATGACGAGACTGCTACACAGGAGATTTTCTTAAACCTGATGATTTGACATTTTGA 1020
QY 1021 TTTTATCTGTGCAAAAAGTTTTCAGAGTGTGTGAGAGACACAGGCTGGCAAGAGCTCT 1080
DB 1021 TTTTATCTGTGCAAAAAGTTTTCAGAGTGTGTGAGAGACACAGGCTGGCAAGAGCTCT 1080
QY 1081 GGTTAGAGAAACAAGCTCTGATATGAGAGGCGGAGGCGCTGTGATTCGACACTTTG 1140
DB 1081 GGTTAGAGAAACAAGCTCTGATATGAGAGGCGGAGGCGCTGTGATTCGACACTTTG 1140
QY 1141 CAGCTGGCTTTATGCTGATTAATTTGGCTGTGAGAGAGAGAGAGAGAGAGAGAGAG 1200
DB 1141 CAGCTGGCTTTATGCTGATTAATTTGGCTGTGAGAGAGAGAGAGAGAGAGAGAGAG 1200
QY 1201 TGATGAGGCAAGATATCTTGTGAGAGAGAACTACATTTAGTGAATGAAAACTTCGATC 1260
DB 1201 TGATGAGGCAAGATATCTTGTGAGAGAGAACTACATTTAGTGAATGAAAACTTCGATC 1260
QY 1261 CTTTACCTGATTTATGCTATCTCTCTGCTCAAGAAATGAGTGGGACCAAGGTTTAA 1320
DB 1261 CTTTACCTGATTTATGCTATCTCTCTGCTCAAGAAATGAGTGGGACCAAGGTTTAA 1320
QY 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
DB 1321 TGGCAAGGCTCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
QY 1381 CTGACATTCGAAGATTAAGAGAGAGATTAACCTGTATGCAATTAACCTCCATAACG 1440
DB 1381 CTGACATTCGAAGATTAAGAGAGAGATTAACCTGTATGCAATTAACCTCCATAACG 1440
QY 1441 TCACCAAGTACTTGGGTTACCTATCTTTCTTCAACCAAGAGTGAATTAATACCTTC 1500
DB 1441 TCACCAAGTACTTGGGTTACCTATCTTTCTTCAACCAAGTGAATTAATACCTTC 1500
QY 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAATCTGTCAACCTCAATGATGTCTAATC 1560
DB 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAATCTGTCAACCTCAATGATGTCTAATC 1560
QY 1561 TAAAGATGATGATTAATTAAGAGAGAGATTAACCTTTAATGAAAACTCTCCGCGCAGAA 1620
DB 1561 TAAAGATGATGATTAATTAAGAGAGAGATTAACCTTTAATGAAAACTCTCCGCGCAGAA 1620
QY 1621 GTTCACTGGGCTTGGCAGCTTCTCATATATTTTGTGATGATGATGATGATGATGATG 1680
DB 1621 GTTCACTGGGCTTGGCAGCTTCTCATATATTTTGTGATGATGATGATGATGATGATG 1680
QY 1681 CTGCTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

Db 1681 CTGCTTGCACTGAAAATAAAATATACTAGTCTGCACTG 1721

RESULT 2

ID AAA75051 standard; cDNA; 1721 BP.

AC AAA75051;

DT 15-JAN-2001 (first entry)

DE CDNA encoding a human heparanase polypeptide.

KW Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;

KW wound healing; infection; burn; angiogenesis; restenosis;

KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease;

OS Homo sapiens.

FH	Key	Location/Qualifiers
1	1	1
2	2	2
3	3	3
4	4	4
5	5	5
6	6	6
7	7	7
8	8	8
9	9	9
10	10	10
11	11	11
12	12	12
13	13	13
14	14	14
15	15	15
16	16	16
17	17	17
18	18	18
19	19	19
20	20	20
21	21	21
22	22	22
23	23	23
24	24	24
25	25	25
26	26	26
27	27	27
28	28	28
29	29	29
30	30	30
31	31	31
32	32	32
33	33	33
34	34	34
35	35	35
36	36	36
37	37	37
38	38	38
39	39	39
40	40	40
41	41	41
42	42	42
43	43	43
44	44	44
45	45	45
46	46	46
47	47	47
48	48	48
49	49	49
50	50	50
51	51	51
52	52	52
53	53	53
54	54	54
55	55	55
56	56	56
57	57	57
58	58	58
59	59	59
60	60	60
61	61	61
62	62	62
63	63	63
64	64	64
65	65	65
66	66	66
67	67	67
68	68	68
69	69	69
70	70	70
71	71	71
72	72	72
73	73	73
74	74	74
75	75	75
76	76	76
77	77	77
78	78	78
79	79	79
80	80	80
81	81	81
82	82	82
83	83	83
84	84	84
85	85	85
86	86	86
87	87	87
88	88	88
89	89	89
90	90	90
91	91	91
92	92	92
93	93	93
94	94	94
95	95	95
96	96	96
97	97	97
98	98	98
99	99	99
100	100	100

ET

```
FT      stem_loop      698..724
```

FT

XX

✕✕

XX

XX

XX

PA (HADA-) HADASTIT

XX

XX

DR P-PSDB; AAB08849.

PT New polynucleotides encoding a polypeptide

PT tumour, inflammation, autoimmunity, neurodegeneration

PS Claim 9; Fig 1; 152pp

CC The present sequence encodes a human

CC particularly in treat

bioavailability c

CC (e.g., interleukin (IL)-8), cell interaction with plasma lipoproteins,

CC infections, or disintegration of

CC or radiation burns), and in the treatment of angiogenesis, restenosis,

CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,

XX

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

Best Local Similarity 100.0%; Pred. No. 0;

QY	1	CTAAGACTTTTGA	CTCTCCGCTGGCGGCGAGCTGGCGGGGGAGCAAGCCAGGTGAAGCCCA	60
Db	1	CTAAGAGCTTTCGACTCTCCGCTGGCGGAGCTGGCGGGGGAGAGCAAGGTGAAGCCCA	60	
QY	61	AGATGCTGCTGGCGGTGAGAGCTGGCGGTGGCGCGCGCGCGCTGATATGCTGCTCTCTGGGGC	120	
Db	61	AGATGCTGCTGGCGGTGAGAGCTGGCGGTGGCGCGCGCGCGCTGATATGCTGCTCTCTGGGGC	120	
QY	121	CGCTGGGTCCCTCTCTCCCTGGCGGCGCCCTGGCCCGGACTGTGGCAAGACAAGAGCTGTGG	180	
Db	121	CGCTGGGTCCCTCTCTCCCTGGCGGCGCCCTGGCCCGGACTGTGGCAAGACAAGAGCTGTGG	180	
QY	181	ACCTGAGCTTCTTCA	CCCAAGAGAGCTGTGACCTCTGTCTGTCCGTCA	240
Db	181	ACCTGAGCTTCTTCA	CCCAAGAGAGCTGTGACCTCTGTCTGTCCGTCA	240
QY	241	CCATTGAGCGCAACCTTGGCCACCGGAGCGCGGGGTTCCATCTCTCTGGGTTCTCCAAAGC	300	
Db	241	CCATTGAGCGCAACCTTGGCCACCGGAGCGCGGGGTTCTCATCTCTCTGGGTTCTCCAAAGC	300	
QY	301	TTCTGACTTGGCCAGAGGCTTGTCTCTCGTACCTGAGGTTTGGTGGCACCAGAAGAG	360	
Db	301	TTCTGACTTGGCCAGAGGCTTGTCTCTCGTACCTGAGGTTTGGTGGCACCAGAAGAG	360	
QY	361	ACTTCTTAATTTTGCATCCCAAGAGGAATCAACTTTGAAAGAGAGATTACTGGCAAT	420	
Db	361	ACTTCTTAATTTTGCATCCCAAGAGGAATCAACTTTGAAAGAGAGATTACTGGCAAT	420	
QY	421	CTCAAGTCAACCAAGATATTTGGCAATATGGAATCCATCCTCTGTATGTGGAGAGAAAGT	480	
Db	421	CTCAAGTCAACCAAGATATTTGGCAATATGGAATCCATCCTCTGTATGTGGAGAGAAAGT	480	
QY	481	TACGGTTGGAATGGCCCTCAACAGAGAGAAATTTGCTACTCCGAGAACTACACAGAAAAAGT	540	
Db	481	TACGGTTGGAATGGCCCTCAACAGAGAGAAATTTGCTACTCCGAGAACTACACAGAAAAAGT	540	
QY	541	TCAAGAACAGCACTTCAAGAAAGCTCTGTAGATGTCTATACATTTTGGCAACTGCT	600	
Db	541	TCAAGAACAGCACTTCAAGAAAGCTCTGTAGATGTCTATACATTTTGGCAACTGCT	600	
QY	601	CAGACCTGAGACTTGTATCTTTGGCCTTAATATCGTTATTAAGAACAGCAGATTTGCAGTGA	660	
Db	601	CAGACCTGAGACTTGTATCTTTGGCCTTAATATCGTTATTAAGAACAGCAGATTTGCAGTGA	660	
QY	661	ACAGTTCTTAATGCTCAGTGTGCTCTGTGAATATGCTCTTCCAAAGGGGTATTAACATTTCTT	720	
Db	661	ACAGTTCTTAATGCTCAGTGTGCTCTGTGAATATGCTCTTCCAAAGGGGTATTAACATTTCTT	720	
QY	721	GGGAACCTAAGCAATGAAGCTTACAGTTTCTTTAAGAGCGCTGATATTTTATCAATGGGT	780	
Db	721	GGGAACCTAAGCAATGAAGCTTACAGTTTCTTTAAGAGCGCTGATATTTTATCAATGGGT	780	
QY	781	CGCAGTTAAGAGAAAGATTATATTCATTTGATTAATAACTTTCTTAAGAAAGTCCACTTCAAAA	840	
Db	781	CGCAGTTAAGAGAAAGATTATATTCATTTGATTAATAACTTTCTTAAGAAAGTCCACTTCAAAA	840	
QY	841	ATGCAAAAACCTATATGTCTGTATGTGTGTGACGCTCGAAGAAAGACGGCTTAATAGCTGA	900	
Db	841	ATGCAAAAACCTATATGTCTGTATGTGTGTGACGCTCGAAGAAAGACGGCTTAATAGCTGA	900	
QY	901	AGAGCTTCTTAAGAGCGCTGTGGAGAGAAAGTGAATTGATTAATAGTGAATCACTAATTT	960	
Db	901	AGAGCTTCTTAAGAGCGCTGTGGAGAGAAAGTGAATTGATTAATAGTGAATCACTAATTT	960	
QY	961	TGAATGAGCGGACTGTCTACCAAGGAGATTTTCTAAACCCTGATGTATTTGGACATTTTAA	1020	
Db	961	TGAATGAGCGGACTGTCTACCAAGGAGATTTTCTAAACCCTGATGTATTTGGACATTTTAA	1020	
QY	1021	TTTCACTGTGTGCAAAAAGTTTTCAGAGTGGTTGAGAGCACCAAGGCTGTGGCAAGAGCTCT	1080	
Db	1021	TTTCACTGTGTGCAAAAAGTTTTCAGAGTGGTTGAGAGCACCAAGGCTGTGGCAAGAGCTCT	1080	

Oy		1081	GGTTAGAGAAACAAGCTCTGATATGTAGAGCGGAGGCCCTTGCTATCCGACACTTGG	1140
Db		1081	GATTAGAGAAAACAAGCTCTGTGATAATGAGGGGAGCGCCCTTGCTATCCGACACTTGG	1140
Oy		1141	CAGCTGGCTTTATATGTGGCTGTGATAAATTGGGCTGTCA GCCGAATGGGAATAGAAGTGG	1200
Db		1141	CAGCTGGCTTTATATGTGGCTGTGATAAATTGGGCTGTCA GCCGAATGGGAATAGAAGTGG	1200
Oy		1201	TGATGAGGCAGATATTCTTTGGAGCAGGAACTACCATTTATGTGATGAAAACTTCGATC	1260
Db		1201	TGATGAGGCAGATATTCTTTGGAGCAGGAACTACCATTTATGTGATGAAAACTTCGATC	1260
Oy		1261	CTTTACCTGATTAATTTGGGCTATCTCTTGTTCAAGAAATTTGGTGGGCAACAAGGTTAA	1320
Db		1261	CTTTACCTGATTAATTTGGGCTATCTCTTGTTCAAGAAATTTGGTGGGCAACAAGGTTAA	1320
Oy		1321	TGGCAAGCGTCGACAGTTCAAAGAGAAAGAGCTTCGAGTATACCTTCATTGCAACAACA	1380
Db		1321	TGGCAAGCGTCGACAGTTCAAAGAGAAAGAGCTTCGAGTATACCTTCATTGCAACAACA	1380
Oy		1381	CTGACATATCCAAGTATATAAGAGAGATTTAATCTGTATGCCATAAACCTCCATAACG	1440
Db		1381	CTGACATATCCAAGTATATAAGAGAGATTTAATCTGTATGCCATAAACCTCCATAACG	1440
Oy		1441	TCACCAATPACTTGGGGTTACCCTATCCCTTTTTCTTAACAAGCAAGTGATTAATCTCTTC	1500
Db		1441	TCACCAATPACTTGGGGTTACCCTATCCCTTTTTCTTAACAAGCAAGTGATTAATCTCTTC	1500
Oy		1501	TAAAGACCTTTGGGAGCCTCATGGATTACTTTCCAAATCTGTCCAATGGTGTCTTAATC	1560
Db		1501	TAAAGACCTTTGGGAGCCTCATGGATTACTTTCCAAATCTGTCCAATGGTGTCTTAATC	1560
Oy		1561	TAAAGATGTGATGATCAAACTTTGCCACCTTTAATGAAAAAACTCTCCGGCCAGGAA	1620
Db		1561	TAAAGATGTGATGATCAAACTTTGCCACCTTTAATGAAAAAACTCTCCGGCCAGGAA	1620
Oy		1621	GTTCACTGGGCTTGGCACCTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1680
Db		1621	GTTCACTGGGCTTGGCACCTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1680
Oy		1681	CTGCTTGCAATCGAAATTAATAATATACATAGTCTGACACTG 1721	
Db		1681	CTGCTTGCAATCGAAATTAATAATATACATAGTCTGACACTG 1721	
<hr/>				
RESULT 3				
AAZ39195				
ID	AAZ39195	standard:	cDNA; 1721 BP.	
XX	AAZ39195;			
AC				
XX				
DT	-02-MAR-2000	(first entry)		
XX				
DE	Human heparanase encoding cDNA.			
XX				
KW	Human; heparanase; hpa; genetic modification; expression; anticancer;			
KM	angiogenesis; anti-angiogenic; antiproliferative; antiviral; antitumour;			
KW	anti-atherosclerotic; anti-inflammatory; antineurodegeneration;			
KM	heparan sulphate; heparin-binding growth factor; tumour angiogenesis;			
KW	metastasis; wound healing; revascularisation; atherosclerosis; inflammation;			
KM	neurodegeneration; viral infection; cystic fibrosis; cancer; diagnosis;			
KW	micrometastasis; autoimmune lesion; kidney failure; se.			
XX				
OS	Homo sapiens.			
XX				
FH	Key	Location/Qualifiers		
FT	CDS	63..1694		
FT		/tag= .a		
FT		/product= "heparanase"		
XX				
RN	WO9557244-A1.			
XX				
PD	11-NOV-1999.			

QY 421 CTCAAGTCACACAGATATTTGGCAAAATATGATCCATCCCTCTGATGTGAGGAAAGT 480
 DB 421 CTCAAGTCACACAGATATTTGGCAAAATATGATCCATCCCTCTGATGTGAGGAAAGT 480
 QY 481 TAGGGTTGGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAAACACTACCAAGAAAAGT 540
 DB 481 TAGGGTTGGAAATGGCCCTTACCAAGAGCAATGCTACTCCGAGAAACACTACCAAGAAAAGT 540
 QY 541 TCAAGAACAGACACCTCACTCAAGAAAGCTGTAGATGTGCTATACACTTTTGCAAACTGCT 600
 DB 541 TCAAGAACAGACACCTCACTCAAGAAAGCTGTAGATGTGCTATACACTTTTGCAAACTGCT 600
 QY 601 CAGGACTGAGACTTATCTTTGGCTTAAATGCGTTATTAAGAAACAGCAGATTTGCACTGGA 660
 DB 601 CAGGACTGAGACTTATCTTTGGCTTAAATGCGTTATTAAGAAACAGCAGATTTGCACTGGA 660
 QY 661 ACACTTCTAATGCTCAGTTGCTCTGAGACTCTGCTCTTCCAAAGGGGTATTAACATTTCTT 720
 DB 661 ACACTTCTAATGCTCAGTTGCTCTGAGACTCTGCTCTTCCAAAGGGGTATTAACATTTCTT 720
 QY 721 GGGAACTAGAGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTTCATCAATGGGT 780
 DB 721 GGGAACTAGAGCAATGAACCTTAACAGTTTCTTAAGAAAGCTGATATTTTTCATCAATGGGT 780
 QY 781 CGCAGTTAGAGAAATATATATTCATATTCATTAATCAATTAACCTTCAAGAAAGTCCACTTCAAAA 840
 DB 781 CGCAGTTAGAGAAATATATATTCATATTCATTAATCAATTAACCTTCAAGAAAGTCCACTTCAAAA 840
 QY 841 ATGCAGAACTCTATATGCTCTGATATGTTGGTCAAGCTCGAAGAAAGACGGCTTAAGATGCTGA 900
 DB 841 ATGCAGAACTCTATATGCTCTGATATGTTGGTCAAGCTCGAAGAAAGACGGCTTAAGATGCTGA 900
 QY 901 AGAGCTTCCCTGAAGGCTGTGAGAAAGTGAATGATTCAGTCAATGAGATCACTATCTATT 960
 DB 901 AGAGCTTCCCTGAAGGCTGTGAGAAAGTGAATGATTCAGTCAATGAGATCACTATCTATT 960
 QY 961 TGAATGAGACGAGCTGCTACACAGGAAAGATTTTCTTAACCTCGATATTTGACATTTTGA 1020
 DB 961 TGAATGAGACGAGCTGCTACACAGGAAAGATTTTCTTAACCTCGATATTTGACATTTTGA 1020
 QY 1021 TTTGATCTGTGCAAAAAGTTTTTCCAGGTGTGAGAGCAACAGGCTGGCAAGAAAGTCT 1080
 DB 1021 TTTGATCTGTGCAAAAAGTTTTTCCAGGTGTGAGAGCAACAGGCTGGCAAGAAAGTCT 1080
 QY 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCCCTTGTATTCGACACCTTTG 1140
 DB 1081 GGTATGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCCCTTGTATTCGACACCTTTG 1140
 QY 1141 CAGCTGCTTATATGCTGTGATTAATTTGGGCTGTCAAGCCCGAATGGGAATGAAGTGG 1200
 DB 1141 CAGCTGCTTATATGCTGTGATTAATTTGGGCTGTCAAGCCCGAATGGGAATGAAGTGG 1200
 QY 1201 TGATGAGGCAAGTATCTTTTGGAGCAGAGAACTACCATTTAGTGAATGAAAACCTTCGATC 1260
 DB 1201 TGATGAGGCAAGTATCTTTTGGAGCAGAGAACTACCATTTAGTGAATGAAAACCTTCGATC 1260
 QY 1261 CTTTACTGCTATTTATGCTGCTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGGTGTTAA 1320
 DB 1261 CTTTACTGCTATTTATGCTGCTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGGTGTTAA 1320
 QY 1321 TGGCAAGGTGCAAGGTTCAAGAGAGAGAGCTTCGAGTATACCTTCAATGTCACAAACA 1380
 DB 1321 TGGCAAGGTGCAAGGTTCAAGAGAGAGAGCTTCGAGTATACCTTCAATGTCACAAACA 1380
 QY 1381 CTGCAATCCCAAGTATTAAGAGAGATTTAACTCTGTATGCAATTAACCTCCATAACG 1440
 DB 1381 CTGCAATCCCAAGTATTAAGAGAGATTTAACTCTGTATGCAATTAACCTCCATAACG 1440
 QY 1441 TCACCAAGTACTTGGGTTACCTTATCTCTTTTCTTAACAAGCAAGTGAATTAATCTTTC 1500
 DB 1441 TCACCAAGTACTTGGGTTACCTTATCTCTTTTCTTAACAAGCAAGTGAATTAATCTTTC 1500
 QY 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACCTCAATGCTTAACCTC 1560

DB 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCCAAATCTGTCCAACCTCAATGCTTAATCTC 1560
 QY 1561 TAAAGTGTGTGAGATCAAAACCTTGCACCTTAAATGAGAAAACCTTCCGCGCAGAGAA 1620
 DB 1561 TAAAGTGTGTGAGATCAAAACCTTGCACCTTAAATGAGAAAACCTTCCGCGCAGAGAA 1620
 QY 1621 GTTCACTGGGCTTCCAGCTTTCATATATGTTTTTGTGATTAAGAAATGCCAAAGTTG 1680
 DB 1621 GTTCACTGGGCTTCCAGCTTTCATATATGTTTTTGTGATTAAGAAATGCCAAAGTTG 1680
 QY 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
 DB 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 4
 AA233290
 ID AA233290 standard; cDNA; 1721 BP.
 XX
 AC AA233290;
 XX
 DT 21-FEB-2000 (first entry)
 XX
 DE Human heparanase nucleotide sequence.
 XX
 KW Human; heparanase; hpa; diagnosis; therapy; tumour; cytostatic;
 KW antidiabetic; immunomodulatory; anti-inflammatory; nephrotropic;
 KW metastasis; adenocarcinoma; squamous cell carcinoma; teratocarcinoma;
 KW mesothelioma; melanoma; lymphoma; leukemia; cancer; sepsis; diabetes;
 KW inflammation; haemorrhagic nephritis; nephrotic syndrome;
 KW autoimmune disease; anticancer; kidney disease; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key
 FT CDS Location/Qualifiers
 FT CDS 63..1694
 FT /tag= a
 FT /product= "heparanase"
 XX
 PN W09957153-A1.
 XX
 PD 11-NOV-1999.
 XX
 PE 29-APR-1999; 99WO-US09255.
 XX
 PR 01-MAY-1998; 98US-0071739.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADAST MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.
 XX
 PI Pecker I, Violdavsky I, Friedman Y, Perets T;
 XX
 DR WPI: 2000-052944/04.
 XX
 DR P-P8DB; AAY52990.
 XX
 PT Heparanase-specific molecular probes useful for diagnosis and
 PT treatment, e.g. of tumors, and for targeted drug delivery -
 XX
 PS Example; Page 82-84; 90pp; English.
 XX
 CC The present invention describes heparanase-specific molecular probes,
 CC useful for methods of detecting heparanase in situ. The probes and
 CC anti-heparanase antibodies are used to detect or quantify the expression
 CC of heparanase, for diagnosis and monitoring of diseases (especially
 CC metastasis), for treatment of heparanase-associated diseases (e.g.
 CC tumours, (aden)carcinoma, squamous cell carcinoma, teratocarcinoma,
 CC mesothelioma, melanoma, lymphoma or leukemia, a solid cancer (or its
 CC metastases) derived from liver, prostate, breast, ovary,
 CC cervix, colon, skin, intestine, stomach, uterus and pancreas, kidney
 CC disease, diabetes and inflammation, haemorrhagic nephritis, nephrotic
 CC syndrome, sepsis and inflammatory or autoimmune disease), for targeted

CC drug delivery (e.g. of anticancer agents) and as research reagents.
CC The present sequence encodes human heparanase, which is used in the
CC exemplification of the present invention.

SQ Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;

Query Match	Score	DB	Length
100.0%	1721	21	1721

Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	CTAAGAGCTTTCGACTCTCCGTCACGGGACAGCTGAGCGGGGGAGACAGCCAGAGTGAAGCCA	60
Db	1	CTAAGAGCTTTCGACTCTCCGTCACGGGACAGCTGAGCGGGGGAGACAGCCAGAGTGAAGCCA	60
QY	61	AGATGCTGCTGGAGCTGGAAGCCGCGGTGCGCGCGCGCTGATGCTGCTCTGGGGC	120
Db	61	AGATGCTGCTGGAGCTGGAAGCCGCGGTGCGCGCGCGCTGATGCTGCTCTGGGGC	120
QY	121	CGCTGGGTTCCCTCTCTCCCTGGCGCCTTGCCGACTGCGGAAGCAAGAGTGTGTGG	180
Db	121	CGCTGGGTTCCCTCTCTCCCTGGCGCCTTGCCGACTGCGGAAGCAAGAGTGTGTGG	180
QY	181	ACCTGGACTTCTTCAACCCAGAGAGCGGTGCACTGGTGAAGCCCTGTTCTGTCCGCTCA	240
Db	181	ACCTGGACTTCTTCAACCCAGAGAGCGGTGCACTGGTGAAGCCCTGTTCTGTCCGCTCA	240
QY	241	CCATTGACGCAACCTGGCCACGGAACCCGCGTTCCTCATCTCTGGTTCCTCAAAAGC	300
Db	241	CCATTGACGCAACCTGGCCACGGAACCCGCGTTCCTCATCTCTGGTTCCTCAAAAGC	300
QY	301	TTTCGTAACCTTGGCCAGAGGCTGTCTTCCTGCGTAACCTGAGTTCGTTGGTGGCAACAAGCAG	360
Db	301	TTTCGTAACCTTGGCCAGAGGCTGTCTTCCTGCGTAACCTGAGTTCGTTGGTGGCAACAAGCAG	360
QY	361	ACTTCCTTAATTTTCATCCCAAGAAGAAATCAACTTTGAAGAGAGAATCTACGCGCAAT	420
Db	361	ACTTCCTTAATTTTCATCCCAAGAAGAAATCAACTTTGAAGAGAGAATCTACGCGCAAT	420
QY	421	CTCAAGTCAACCAAGATATTTGGCAATATGATTCATCCCTCCTGATGTGGAGAGAGAGT	480
Db	421	CTCAAGTCAACCAAGATATTTGGCAATATGATTCATCCCTCCTGATGTGGAGAGAGAGT	480
QY	481	TACGGTTGGAATGCGCCCTTACACAGAGCAATTGCTACTCCGAGAACACTACACAGAAAAAGT	540
Db	481	TACGGTTGGAATGCGCCCTTACACAGAGCAATTGCTACTCCGAGAACACTACACAGAAAAAGT	540
QY	541	TCAAGAACAGCAACTCTCAAGAAAGCTGTATATGTCATATCACTTTGGCAACCTGCT	600
Db	541	TCAAGAACAGCAACTCTCAAGAAAGCTGTATATGTCATATCACTTTGGCAACCTGCT	600
QY	601	CAGGACTGACCTTGATCTTTGGCGCTAAATGCGTTATTAAGAACAGCAGATTTGCAGTGA	660
Db	601	CAGGACTGACCTTGATCTTTGGCGCTAAATGCGTTATTAAGAACAGCAGATTTGCAGTGA	660
QY	661	ACAGTTCTATATGCTCAGTTGCTCTCGACTACTGCTCTTCCAAAGGGGTATTAACATTTCTT	720
Db	661	ACAGTTCTATATGCTCAGTTGCTCTCGACTACTGCTCTTCCAAAGGGGTATTAACATTTCTT	720
QY	721	GGGAAGCTGGGCATGAACTCAACAGTTTCCTTAAGAAAGGTGATATTTTCATCAATGGGT	780
Db	721	GGGAAGCTGGGCATGAACTCAACAGTTTCCTTAAGAAAGGTGATATTTTCATCAATGGGT	780
QY	781	CGCAGTTTGGAGAGAGATTATTTCAATTCAGTCAATACTTCAAGAAAAGTCCACCTTCAAAA	840
Db	781	CGCAGTTTGGAGAGAGATTATTTCAATTCAGTCAATACTTCAAGAAAAGTCCACCTTCAAAA	840
QY	841	ATGCAAAACTCTATGCTCTGTATGTTGTCAGCTTCGAAAGAAAGACGGCTTAAGATGCTGA	900
Db	841	ATGCAAAACTCTATGCTCTGTATGTTGTCAGCTTCGAAAGAAAGACGGCTTAAGATGCTGA	900
QY	901	AGAGCTTCTGAAAGCTGTGTGGAAGATATATTCAGTTAATATGGCATCACTATCATTT	960
Db	901	AGAGCTTCTGAAAGCTGTGTGGAAGATATATTCAGTTAATATGGCATCACTATCATTT	960

QY	961	GGAAATGAGCGACATGCTTACCAAGGGAAAGTTTCTTAAACCCGATGATATGGACATTTTAA	1023
Db	961	TGAATGAGCGACATGCTTACCAAGGGAAAGTTTCTTAAACCCGATGATATGGACATTTTAA	1020
QY	1021	TTTCAATCTGTGCAGAAAAGTTTTTCCAGGTGTTGAGAGCACCAGGCTTGGCAAGAAGTCT	1086
Db	1021	TTTCAATCTGTGCAGAAAAGTTTTTCCAGGTGTTGAGAGCACCAGGCTTGGCAAGAAGTCT	1088
QY	1081	GATTATGAGAAAACAAGCTCTGCATATGAGAGCGGAGCCCTTCGTATCCACACTTTTG	1146
Db	1081	GATTATGAGAAAACAAGCTCTGCATATGAGAGCGGAGCCCTTCGTATCCACACTTTTG	1146
QY	1141	CAGCTGCTTTATATGAGCTGATATTAATTTGGCCCTGTACAGCCCGAATGGGAATPAGAATGG	1200
Db	1141	CAGCTGCTTTATATGAGCTGATATTAATTTGGCCCTGTACAGCCCGAATGGGAATPAGAATGG	1200
QY	1201	TGATGAGCGCAAGTATTTCTTTGAGCAGAGAACTACATTATAGTGATTAATACTTCGATC	1266
Db	1201	TGATGAGCGCAAGTATTTCTTTGAGCAGAGAACTACATTATAGTGATTAATACTTCGATC	1266
QY	1261	CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATGATGAGCACAAGGTGTTAA	1320
Db	1261	CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATGATGAGCACAAGGTGTTAA	1320
QY	1321	TGGCAAGGCTGCAGAGTTCAAGAGAGAGAGCTTCGAGTATPACTTATATGGCACAACA	1380
Db	1321	TGGCAAGGCTGCAGAGTTCAAGAGAGAGAGCTTCGAGTATPACTTATATGGCACAACA	1380
QY	1381	CTGACAAATCCAAAGTATTAAGAGAGATTTAACTGTATATGCATTAACCTCCATAAG	1446
Db	1381	CTGACAAATCCAAAGTATTAAGAGAGATTTAACTGTATATGCATTAACCTCCATAAG	1446
QY	1441	TCACCAAGTACTTGGCGTTACCCCTATCTTTTTCTAACACAGAGTGATTAATACCTTC	1500
Db	1441	TCACCAAGTACTTGGCGTTACCCCTATCTTTTTCTAACACAGAGTGATTAATACCTTC	1500
QY	1501	TAAAGCCTTTGGGACCTCATGATTAACCTTCCAAATCTGTCCAACTCATATGCTTACTTC	1566
Db	1501	TAAAGCCTTTGGGACCTCATGATTAACCTTCCAAATCTGTCCAACTCATATGCTTACTTC	1566
QY	1561	TAAAGATGATGGATGATCAAACTTTGCAACCTTTAATGGAATAAACTTCCGGCCAGGAA	1620
Db	1561	TAAAGATGATGGATGATCAAACTTTGCAACCTTTAATGGAATAAACTTCCGGCCAGGAA	1620
QY	1621	GTTCACTGGGCTTGCACGCTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1686
Db	1621	GTTCACTGGGCTTGCACGCTTCTCATATAGTTTTTTTGTGATTAAGAAATGCCAAAGTTG	1686
QY	1681	CTGCTTGATCTGAAAATAAAAATATACATAGTCCGACACTG 1721	
Db	1681	CTGCTTGATCTGAAAATAAAAATATACATAGTCCGACACTG 1721	

RESULT

ID AAA9112 standard; DNA; 1721 BP.

AC AAA91112;

DT 20-APR-2001 (first entry)

DE

KCM

KM

XX

XX

XX

XX

PD 04-JAN-2001.
 XX 19-JUN-2000; 2000MO-IL00358.
 XX 25-JUN-1999; 99US-0140801.
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PI Pecker I, Michal I, Itzhaki H;
 XX WPI; 2001-137930/14.
 DR
 XX
 XX New polynucleotides and polypeptides that are distantly homologous to
 PT heparanase, useful in wound healing, as well as in gene therapy
 PT protocols for angiogenesis, restenosis, atherosclerosis, or
 PT inflammation -
 XX
 XX Example 1; Page 67; 67pp; English.
 CC This sequence represents a human heparanase coding sequence clone,
 CC isolated from an EST clone. The invention relates to heparanase DNA
 CC and protein sequences. The heparanase DNA and protein sequences are
 CC useful in wound healing, angiogenesis, restenosis, atherosclerosis,
 CC inflammation, pulmonary diseases, neurodegenerative diseases (such as
 CC scrapie, Alzheimer's disease, and Creutzfeldt-Jakob disease) or viral
 CC infections. The heparanase coding sequence is particularly useful in gene
 CC therapy.
 CC
 XX
 XX Sequence 1721 BP; 451 A; 413 C; 410 G; 447 T; 0 other;
 SQ
 Query Match 100.0%; Score 1721; DB 22; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	601	CAGACTGACCTTATCTTTGGCTAAATGCGTATTAAGAACAGCAGATTGGAGTGA	660
DB	601	CAGACTGACCTTATCTTTGGCTAAATGCGTATTAAGAACAGCAGATTGGAGTGA	660
QY	661	ACAGTTCTAATGCTCAGTGTCTCTGAGCTACTGCTCTCCAAAGGGATTAACATTTCTT	720
DB	661	ACAGTTCTAATGCTCAGTGTCTCTGAGCTACTGCTCTCCAAAGGGATTAACATTTCTT	720
QY	721	GGGAACCTAGGCAATGAACCTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT	780
DB	721	GGGAACCTAGGCAATGAACCTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT	780
QY	781	CGCAGTTAGGAGAAATTAATTCATTTGCAATTAACCTTTAAGAAAGTCCACTTCAAAA	840
DB	781	CGCAGTTAGGAGAAATTAATTCATTTGCAATTAACCTTTAAGAAAGTCCACTTCAAAA	840
QY	841	ATGCAAACTGTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGCGCTTAAGATGCTGA	900
DB	841	ATGCAAACTGTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGCGCTTAAGATGCTGA	900
QY	901	AGAGTTTCTGAAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT	960
DB	901	AGAGTTTCTGAAGGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGAT	960
QY	961	TGAATGAGCGGACTGCTACAGGAGAAATTTCTAAACCTGATGATTTGACATTTTGA	1020
DB	961	TGAATGAGCGGACTGCTACAGGAGAAATTTCTAAACCTGATGATTTGACATTTTGA	1020
QY	1021	TTTCATCTGTGCAAAAATTTTTCAGAGTGTGAGAGCAGAGCTGGCAAGAGTCT	1080
DB	1021	TTTCATCTGTGCAAAAATTTTTCAGAGTGTGAGAGCAGAGCTGGCAAGAGTCT	1080
QY	1081	GATTAGAGAAACAAGCTCTGATATGAGAGCGGAGCGCTTGTATCCGACACTTTTG	1140
DB	1081	GATTAGAGAAACAAGCTCTGATATGAGAGCGGAGCGCTTGTATCCGACACTTTTG	1140
QY	1141	CAGCTGCTTTATGAGCTGATTAATTTGGGCTGTGAGGCGGAGTGGAAATAGAGTGG	1200
DB	1141	CAGCTGCTTTATGAGCTGATTAATTTGGGCTGTGAGGCGGAGTGGAAATAGAGTGG	1200
QY	1201	TGATGAGCAAGATATTTCTTGGAGAGAGAACTACATTTAGTGGATGAAACTTCGATC	1260
DB	1201	TGATGAGCAAGATATTTCTTGGAGAGAGAACTACATTTAGTGGATGAAACTTCGATC	1260
QY	1261	CTTTAAGTATTTGCTATCTCTTCTTGAAGAAATTTGTTGGGACCAAGGTGTTAA	1320
DB	1261	CTTTAAGTATTTGCTATCTCTTCTTGAAGAAATTTGTTGGGACCAAGGTGTTAA	1320
QY	1321	TGGCAAGGCTCAGAGTTCAGAGAGAGAGAGTTCGATATACCTTATGACCAAAACA	1380
DB	1321	TGGCAAGGCTCAGAGTTCAGAGAGAGAGAGTTCGATATACCTTATGACCAAAACA	1380
QY	1381	CTGACAAATCCAAAGATTAATAAGAGAGATTAACCTGTATGCCATAAACCCTCCATAAG	1440
DB	1381	CTGACAAATCCAAAGATTAATAAGAGAGATTAACCTGTATGCCATAAACCCTCCATAAG	1440
QY	1441	TCACCAAGTACTTGGGTTACCTTATCTTTTCTAACAGCAAGTGAATAATCTTTC	1500
DB	1441	TCACCAAGTACTTGGGTTACCTTATCTTTTCTAACAGCAAGTGAATAATCTTTC	1500
QY	1501	TAAAGCTTTGGGACCTCATGATTAATTTCCAAATCTGTCCAACTCAATGCTTAATCTC	1560
DB	1501	TAAAGCTTTGGGACCTCATGATTAATTTCCAAATCTGTCCAACTCAATGCTTAATCTC	1560
QY	1561	TAAAGATGATGATGATCAAACTTGCACCTTTAATGAGAAACCTTCGCGCAGAGAA	1620
DB	1561	TAAAGATGATGATGATCAAACTTGCACCTTTAATGAGAAACCTTCGCGCAGAGAA	1620
QY	1621	GTTCACTGGGCTTGGCAGCTTTCTCATATAGCTTTTGTATTAAGAAATCCAAAGTTG	1680
DB	1621	GTTCACTGGGCTTGGCAGCTTTCTCATATAGCTTTTGTATTAAGAAATCCAAAGTTG	1680

Oy	1681	CTGCTGCATCTGAAAATAAATACTAGTCCTGACACTG	1721
Db	1681	CTGCTGCATCTGAAAATAAATACTAGTCCTGACACTG	1721

RESULT 6
AA35650
ID AA35650 standard; cDNA; 1899 BP.
...

AC AAX35650;

DT 09-JUL-1999 (first entry)

DE CDNA encoding a human heparanase protein.

KW Hepernase; hpa; modular; heparin-binding growth factor;
KW cellular response; cytokine; cell interaction; plasma lipoprotein;
KW cellular susceptibility; infection; disintegration;
KW neurodegenerative plaque; wound healing; angiosclerosis; restenosis;
KW atherosclerosis; inflammation; neurodegenerative disease; neutralise
KW plasma heparin; micrometastasis; autoimmune lesion; renal failure;
KW ss.

OS Homo sapiens.

PN WO9911798-A1.

PD 11-MAR-1999.

PF 31-AUG-1998; 98WO-US17954

PR 02-JUL-1998; 98US-0109386

PR .02-SEP-1997; 97US-0922170

PA (FRIE/) FRIEDMAN M. M.
PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.

PI Feinstein E, Pecker I, Vlodavsky I;

DR WPI; 1999-302255/25.

DR P-PSDB; AAY02346.

PT New human polynucleotide useful for treating angiogenesis, restenosis, and inflammation

PS Claim 4; Page 64-65; 63pp; English.

CC The specification describes a polypeptide having heparanase (hpa)
CC activity. The recombinant protein is used as a modulator of
CC heparin-binding growth factors, cellular responses to heparin-binding
CC growth factors and cytokines, cell interaction with plasma lipoproteins
CC cellular susceptibility to viral, protozoal and bacterial infections
CC or disintegration of neurodegenerative plaques. Heparanase may be
CC useful for conditions such as wound healing, angiogenesis, restenosis,
CC atherosclerosis, inflammation, neurodegenerative diseases, and viral
CC infections. Mammalian heparanase can be used to neutralize plasma
CC heparin, and anti-heparanase antibodies may be applied for
CC immunodetection and diagnosis of micrometastases, autoimmune lesions,
CC and renal failure in biopsy specimens, plasma samples, and body fluids.
CC The present sequence encodes human heparanase.

SQ Sequence 1899 BP; 495 A; 433 C; 510 G; 461 T; 0 other;

Query Match	99.98;	Score 1719.4;	DB 20;	Length 1899;
-------------	--------	---------------	--------	--------------

Best Local Similarity 99.9%; Pred. No. 0;
Matches 1720; Conservative 0; Mismatches 1; Indels 0; Gaps 0

[illegible]

Db	229	AGATGCTGCTGCGCTCCAAAGCTGCGCTGCGCGCGCGCTGATGCTGCTCTGGGGC	298
Qy	121	CGTGGGTCCCTCTCCCTGGCGCCTTGCCCGACCTGGCGAAGCAAGAGCTGCTGG	180
Db	299	CGTGGGTCCCTCTCCCTGGCGCCTTGCCCGACCTGGCGAAGCAAGAGCTGCTGG	358
Qy	131	ACCTGGAATTTTTCACCCAGAGAGCGCTGCACTGCTGAGAGCCCTCGTCTGCTGCA	240
Db	359	ACCTGGAATTTTTCACCCAGAGAGCGCTGCACTGCTGAGAGCCCTCGTCTGCTGCA	418
Qy	241	CCATTGACGCAACCTGGCCACCGAGCCGCTGCTCATCTCTGGGTTCTTCAAGC	300
Db	419	CCATTGACGCAACCTGGCCACCGAGCCGCTGCTCATCTCTGGGTTCTTCAAGC	478
Qy	301	TTGCTACTTGGCCAGAGGCTTGTCTCTCGCTACTGAGGTTTGTGGCACCAAGCAG	360
Db	479	TTGCTACTTGGCCAGAGGCTTGTCTCTCGCTACTGAGGTTTGTGGCACCAAGCAG	538
Qy	361	ACTTCTTAATTTTGGATGCCAAGAAAGATTAACCTTTGAAAGAGAAGTTACTGGCAAT	420
Db	539	ACTTCTTAATTTTGGATGCCAAGAAAGATTAACCTTTGAAAGAGAAGTTACTGGCAAT	598
Qy	421	CTCAAGTCAACAGAGATTTTGGCAATATGATGATCATCCCTCGTAGTGGAGAGAAT	480
Db	599	CTCAAGTCAACAGAGATTTTGGCAATATGATGATCATCCCTCGTAGTGGAGAGAAT	658
Qy	481	TACGGTTGGAATGGCCCTACAGAGAGCAATTCTACTCCGAGAACACTACCCAGAAAAAT	540
Db	659	TACGGTTGGAATGGCCCTACAGAGAGCAATTCTACTCCGAGAACACTACCCAGAAAAAT	718
Qy	541	TCAGAAACAGACCTACTACAAGAAAGCTGTGATATGCTATATACATTTTGGCAACTGCT	600
Db	719	TCAGAAACAGACCTACTACAAGAAAGCTGTGATATGCTATATACATTTTGGCAACTGCT	778
Qy	601	CAGAGCTGGACTGATCTTTGGCCCTAAATGCGTTATTAAGAACAGCAATTTGACGTGA	660
Db	779	CAGAGCTGGACTGATCTTTGGCCCTAAATGCGTTATTAAGAACAGCAATTTGACGTGA	838
Qy	661	ACAGTTCTAATGCTCAGTTGCTCTCTGCACTACTGCTCTTCCAGGGGTATTAACATTTCTT	720
Db	839	ACAGTTCTAATGCTCAGTTGCTCTCTGCACTACTGCTCTTCCAGGGGTATTAACATTTCTT	898
Qy	721	GGGAACTTAGGCAATGAACCTTAAAGCTTCTTAAAGAGCGTGAATTTTTCATCAATGGCT	780
Db	899	GGGAACTTAGGCAATGAACCTTAAAGCTTCTTAAAGAGCGTGAATTTTTCATCAATGGCT	958
Qy	781	CGCAGTTAGGAGAAGATTATATTCATTTGCAATAACTCTTAAGAAAGTCCACCTTCAAA	840
Db	959	CGCAGTTAGGAGAAGATTATATTCATTTGCAATAACTCTTAAGAAAGTCCACCTTCAAA	1018
Qy	841	ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGACGGCTAAGATGCTGA	900
Db	1019	ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGACGGCTAAGATGCTGA	1078
Qy	901	AGAGTCTCTGAAGGCTGGTGGAGAGATGATTAATTCAGTTACATGGCATCACTAATTT	960
Db	1079	AGAGTCTCTGAAGGCTGGTGGAGAGATGATTAATTCAGTTACATGGCATCACTAATTT	1138
Qy	961	TGAATGACGGAACGTGCTACACAGGGAAGTTTCTAAACCCCTGAATGATTTGACATTTTTA	1020
Db	1139	TGAATGACGGAACGTGCTACACAGGGAAGTTTCTAAACCCCTGAATGATTTGACATTTTTA	1198
Qy	1021	TTTCACTCTGTCAAAAAGTTTTCAGAGTGGTTGAGACACACAGGCTGGCAAGAGCTCT	1080
Db	1199	TTTCACTCTGTCAAAAAGTTTTCAGAGTGGTTGAGACACACAGGCTGGCAAGAGCTCT	1258
Qy	1081	GATTAGAGAAAACAAGCTCTGCAATATGAGAGCGAGCGCCTTGTCTATCCGACACTTTTG	1140
Db	1259	GATTAGAGAAAACAAGCTCTGCAATATGAGAGCGAGCGCCTTGTCTATCCGACACTTTTG	1318
Qy	1141	CAGCTGGCTTATATGTGGTGGATTAATTGGGCTGTCAAGCCCAATGGGAATTAAGTGG	1200

Db 1319 CAGCTGCTTATGTGCTGATTAATTTGGCTGTGACCCGCAATGGGAATAGAACTGG 1378
 Qy 1201 TGATGAGGCAAGTATTTCTTTGAGAGAGAACTACATTTATGATGATGAAATCTTCATC 1260
 Db 1379 TGATGAGGCAAGTATTTCTTTGAGAGAGAACTACATTTATGATGATGAAATCTTCATC 1438
 Qy 1261 CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGGTGGCCCAAGGTGTTAA 1330
 Db 1439 CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGGTGGCCCAAGGTGTTAA 1498
 Qy 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAAAGCTTCAGATTAATCTTATCTTATGCAACAA 1380
 Db 1499 TGGCAAGGCTGCAAGGTTCAAGAGAGAAAGCTTCAGATTAATCTTATGCAACAA 1558
 Qy 1381 CTGCAATTCGAAGGATTAAGAGAGATTAATCTTATGCAACAAAGCTTCATACG 1440
 Db 1559 CTGCAATTCGAAGGATTAAGAGAGATTAATCTTATGCAACAAAGCTTCATACG 1618
 Qy 1441 TCACCAAGTACTTGGCTTACCTTATCTTCTTCTTCAACAGCAAGTGAATAATCTTC 1500
 Db 1619 TCACCAAGTACTTGGCTTACCTTATCTTCTTCTTCAACAGCAAGTGAATAATCTTC 1678
 Qy 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACTCAATGCTTAATC 1560
 Db 1679 TAAAGCTTTGGGACCTCATGATTAATCTTCAAAATCTGTCCAACTCAATGCTTAATC 1738
 Qy 1561 TAAAGATGATGATGATCAAACTTGGCACTTTAATGGAATAATCTTCCGGCCAGGAA 1620
 Db 1739 TAAAGATGATGATGATCAAACTTGGCACTTTAATGGAATAATCTTCCGGCCAGGAA 1798
 Qy 1621 GTTCACTGGGCTTGGCCAGCTTCTCATATAGTTTTTTTGTGATAAGAAATGCCAAAGTTG 1680
 Db 1799 GTTCACTGGGCTTGGCCAGCTTCTCATATAGTTTTTTTGTGATAAGAAATGCCAAAGTTG 1858
 Qy 1681 CTGCTTGATCTGAATAATTAATATATAGTCTGACACTG 1721
 Db 1859 CTGCTTGATCTGAATAATTAATATATAGTCTGACACTG 1899
 RESULT 7
 AAA75053
 ID AAA75053 standard; cDNA, 1899 BP.
 AC AAA75053;
 XX
 DT 15-JAN-2001 (first entry)
 XX
 DE cDNA encoding a human heparanase polypeptide.
 XX
 KW Human; heparanase; gene therapy; tumour; inflammation; autoimmunity;
 KW heparin-binding growth factor; cytokine; neurodegenerative plaque;
 KW wound healing; infection; burn; angiogenesis; restenosis;
 KW atherosclerosis; inflammation; neurodegenerative disease;
 KW Gerstmann-Strausler Syndrome; Creutzfeldt-Jakob disease; ds.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 94..1872
 FT /*tag= a
 FT /product= "heparanase"
 XX
 EN WO200052178-A1.
 XX
 PD 08-SEP-2000.
 XX
 PF 14-FEB-2000; 2000WO-US03542.
 XX
 PR 01-MAR-1999; 99US-0258892.
 XX
 PA (INSI-) INSIGHT STRATEGY & MARKETING LTD.
 PA (HADA-) HADASIT MEDICAL RES SERVICES & DEV.
 PA (FRIE/) FRIEDMAN M M.

XX Pecker I, Vlodaysky I, Feinstein E;
 PI MPI: 2000-579289/54.
 DR P-PSDB; AAB08850.
 XX
 PT New polynucleotides encoding a polypeptide having heparanase activity,
 PT useful in wound healing and in gene therapy, particularly in treating
 PT tumour, inflammation, autoimmunity, neurodegenerative diseases
 XX
 PS Claim 9; Page 121-122; 152pp; English.
 XX
 CC The present sequence encodes a human protein with heparanase catalytic
 CC activity. The heparanase (hpa) polynucleotide is useful in gene therapy,
 CC particularly in treating tumour, inflammation or autoimmunity.
 CC Particularly, the polynucleotide is useful in modulating the
 CC bioavailability of heparin-binding growth factors, cellular responses
 CC to heparin-binding growth factors (e.g. bFGF) and cytokines
 CC (e.g. interleukin (IL)-8), cell interaction with plasma lipoproteins,
 CC cellular susceptibility to certain viral and some bacterial and protozoa
 CC infections, or disintegration of neurodegenerative plaques. The
 CC polynucleotide is also useful in wound healing (e.g. thermal, chemical
 CC or radiation burns), and in the treatment of angiogenesis, restenosis,
 CC atherosclerosis, inflammation, neurodegenerative diseases (Gerstmann-
 CC Strausler Syndrome or Creutzfeldt-Jakob disease), and some viral,
 CC bacterial or protozoa infections.
 XX
 SQ Sequence 1899 BP; 495 A; 433 C; 510 G; 461 T; 0 other;

Query Match 99.9%; Score 1719.4; DB 21; Length 1899;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1720; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 CTAGAGCTTTGACTCTCCGCTGGCGGAGCTGGCGGGGAGACAGCAGTAGGCCA 60
 Db 179 CTAGAGCTTTGACTCTCCGCTGGCGGAGCTGGCGGGGAGACAGCAGTAGGCCA 238
 Qy 61 AGATGCTGCTGCGCTGCAAGGCTGCGCGCGCGCGCTGATCTGCTGCTGCGGAGC 120
 Db 239 AGATGCTGCTGCGCTGCAAGGCTGCGCGCGCGCGCTGATCTGCTGCTGCGGAGC 298
 Qy 121 CGTGGGCTCCCTCTCCCTGGCGCCCTGCGCGCGCGCGCTGATCTGCTGCTGCGGAGC 180
 Db 299 CGTGGGCTCCCTCTCCCTGGCGCCCTGCGCGCGCGCGCTGATCTGCTGCTGCGGAGC 358
 Qy 181 ACCTGACTTTTCAACCCAGAGAGCCGCTGACCTGCTGAGGCGCCCTGCTGCTGCTGCA 240
 Db 359 ACCTGACTTTTCAACCCAGAGAGCCGCTGACCTGCTGAGGCGCCCTGCTGCTGCTGCA 418
 Qy 241 CCATTGACGCCAACCTGGCCACGAGACCGCGGCTTCTCATCTCTGGGTTCTCCAAAGC 300
 Db 419 CCATTGACGCCAACCTGGCCACGAGACCGCGGCTTCTCATCTCTGGGTTCTCCAAAGC 478
 Qy 301 TTGCTACCTTGGCCAGAGGCTTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCA 360
 Db 479 TTGCTACCTTGGCCAGAGGCTTCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCA 538
 Qy 361 ACTTCTTAATTTTGGATCCCAAGAGATTAACCTTTGAAGAAGAAAGTTACTGGCAAT 420
 Db 539 ACTTCTTAATTTTGGATCCCAAGAGATTAACCTTTGAAGAAGAAAGTTACTGGCAAT 598
 Qy 421 CTCGAAGTCAACAGAGATTTTGAATAATGATCATCCCTCGATGTGGAGGAGAGT 480
 Db 599 CTCGAAGTCAACAGAGATTTTGAATAATGATCATCCCTCGATGTGGAGGAGAGT 658
 Qy 481 TACGTTGGAATGGCCCTTACAGAGAGCAATTTCTTCCAGAACATCAACCAAGAAAAGT 540
 Db 659 TACGTTGGAATGGCCCTTACAGAGAGCAATTTCTTCCAGAACATCAACCAAGAAAAGT 718
 Qy 541 TCAAGAACAGCACTTCAAGAAAGCTGTGATGTGCTATCACTTTTGAACATGCTCT 600
 Db 719 TCAAGAACAGCACTTCAAGAAAGCTGTGATGTGCTATCACTTTTGAACATGCTCT 778

```

Qy 601 CAGACTGAGTGTATCTTTGGCTTAAATGCGTTATTAAGAACACAGATTGTCAGTGA 660
Db 779 CAGACTGAGTGTATCTTTGGCTTAAATGCGTTATTAAGAACACAGATTGTCAGTGA 838
Qy 661 ACAGTTCTAATGCTCAAGTTGCTCTGAGTACTGCTCTTCCAGGGGATTAACATTTCTT 720
Db 839 ACAGTTCTAATGCTCAAGTTGCTCTGAGTACTGCTCTTCCAGGGGATTAACATTTCTT 898
Qy 721 GGGAACTAGGCAATGACCTTAACAGTTTCTTAAGAAAGGCTGATATTTTCAATGAGGT 780
Db 899 GGGAACTAGGCAATGACCTTAACAGTTTCTTAAGAAAGGCTGATATTTTCAATGAGGT 958
Qy 781 CGCAGTTAGAGAGATTATATTCATTGATGATTAACCTTAAAGAAAGTCCACTTCAAAA 840
Db 959 CGCAGTTAGAGAGATTATATTCATTGATGATTAACCTTAAAGAAAGTCCACTTCAAAA 1018
Qy 841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTGAAGAAAGCGCTAAGATGCTGA 900
Db 1019 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTTGAAGAAAGCGCTAAGATGCTGA 1078
Qy 901 AGAGCTTCTGTAAGGCTGGTGGAGAAAGTATGATTGATTCAGTTACATGAGCATCTATTT 960
Db 1079 AGAGCTTCTGTAAGGCTGGTGGAGAAAGTATGATTGATTCAGTTACATGAGCATCTATTT 1138
Qy 961 TGAATGACGCACTGCTACACAGGAAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1020
Db 1139 TGAATGACGCACTGCTACACAGGAAAGATTTTCTAAACCTGATGATTTGACATTTTAA 1198
Qy 1021 TTTTATCTGTGCAAAAAGTTTCCAGGTGTTGAAGACACAGGCTTGGCAAGAAAGTCT 1080
Db 1199 TTTTATCTGTGCAAAAAGTTTCCAGGTGTTGAAGACACAGGCTTGGCAAGAAAGTCT 1258
Qy 1081 GGTGAGGAAACAAGCTCTGCAATGAGAGCGAGCGCCCTTGTATCCGACACTTTTG 1140
Db 1259 GGTGAGGAAACAAGCTCTGCAATGAGAGCGAGCGCCCTTGTATCCGACACTTTTG 1318
Qy 1141 CAGCTGCTTATATGCTGTGATTAATTGGGCTGTCAAGCCCGCAATGGGAATGAAAGTGG 1200
Db 1319 CAGCTGCTTATATGCTGTGATTAATTGGGCTGTCAAGCCCGCAATGGGAATGAAAGTGG 1378
Qy 1201 TGATGAGCAAGTATCTTTGGAGACAGAACTACCATTTAGTGATGAAAACTTGCATC 1260
Db 1379 TGATGAGCAAGTATCTTTGGAGACAGAACTACCATTTAGTGATGAAAACTTGCATC 1438
Qy 1261 CTTTACCTGATTTGGGATCTCTCTGTTCAAGAAATGGTGGGCAACAAAGTGTAA 1320
Db 1439 CTTTACCTGATTTGGGATCTCTCTGTTCAAGAAATGGTGGGCAACAAAGTGTAA 1498
Qy 1321 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAGCTTCAAGTATACCTTCAATGGCAACAA 1380
Db 1499 TGGCAAGCGTGCAGAGTTCAAGAGAGAGAGCTTCAAGTATACCTTCAATGGCAACAA 1558
Qy 1381 CTGACAAATCCAAAGTATTAAGAGAGATTTAAGTGTGCAATTAACCTTCCATAACG 1440
Db 1559 CTGACAAATCCAAAGTATTAAGAGAGATTTAAGTGTGCAATTAACCTTCCATAACG 1618
Qy 1441 TCACCAAGTACTGGGGTTAACCTTCTTTTCAACAGAGAAAGTGAATTAATCCTTC 1500
Db 1619 TCACCAAGTACTGGGGTTAACCTTCTTTTCAACAGAGAAAGTGAATTAATCCTTC 1678
Qy 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCAAACTGTCCAACTCAATGCTTAATCTC 1560
Db 1679 TAAAGCTTTGGGACCTCATGATTAATCTTCAAACTGTCCAACTCAATGCTTAATCTC 1738
Qy 1561 TAAAGATGATGATGATCAAACTTGGCACTTTAATGAAAAAAGCTTCCGGCCAGAA 1620
Db 1739 TAAAGATGATGATGATCAAACTTGGCACTTTAATGAAAAAAGCTTCCGGCCAGAA 1798
Qy 1621 GTTACCTGGGCTGTCAGCTTTCTCATATAGTTTTTTTGTGATAGAAATGCCAAGTGG 1680
Db 1799 GTTACCTGGGCTGTCAGCTTTCTCATATAGTTTTTTTGTGATAGAAATGCCAAGTGG 1858
Qy 1681 CTGCTTGATCTGAATAATTAATATATAGTCTGACACTG 1721

```

```

Db 1859 CTGCTTGATCTGAATAATTAATATACTAGTCTGACACTG 1899
RESULT 8
AAFP3788
ID AAFP3788 standard; cDNA; 1722 BP.
XX
XX AAFP3788;
AC
XX 23-MAY-2001 (first entry)
DT
XX Human cDNA encoding a membrane or secretory protein clone PSEC0090.
DE
XX Human; secretory protein; membrane protein; vaccine; gene therapy;
KW rheumatoid arthritis; diabetes; ss.
XX
XX Homo sapiens.
OS
XX EP167182-A2.
PN
XX 10-JAN-2001.
PD
XX 07-JUL-2000; 2000EP-0114090.
PF
XX 08-JUL-1999; 99JP-0194179.
PR 11-JAN-2000; 2000JP-0118775.
PR 02-MAY-2000; 2000JP-0163766.
XX
XX (HELI-) HELIX RES INST.
PA
XX Ota T, Isegai T, Nishikawa T, Kawai Y, Sugiyama T, Hayashi K;
PI WPI: 2001-093989/11.
DR P-PSDB; AAB88361.
XX
XX Nucleic acids encoding secretory proteins/membrane proteins, useful in
PT gene therapy or as candidate target molecules in drug development -
XX
XX Claim 1; SEQ ID 89; 609bp + CD ROM; English.
PS
XX
XX This invention relates to nucleic acid sequences AAFP3744 - AAFP3916
CC which encode human secretory or membrane proteins represented by
CC AAB88317 - AAB88419. Included in the invention are primers
CC AAFP3917 - AAFP4295 and AAFP6232 - AAFP6235 which are used to isolate the
CC cDNA sequences of the invention. The invention also includes methods for
CC the production of antibodies directed against the proteins, and cDNA
CC sequences, which can be used in vaccines. The polynucleotide sequences
CC can be used in gene therapy. The polynucleotide sequences and the
CC proteins they encode may be used in the prevention, treatment and
CC diagnosis of diseases associated with inappropriate secretory
CC protein/membrane protein expression. The nucleic acids and complementary
CC sequences may also be used as DNA probes in diagnostic assays
CC (e.g. polymerase chain reactions (PCR)) to detect and quantify the
CC presence of similar nucleic acid sequences in samples. They may also be
CC used to study the expression and function of secretory proteins/membrane
CC polypeptides and their role in metabolism. The polypeptides may be used
CC as antigens in the production of antibodies against them and in assays to
CC identify modulators (agonists and antagonists) of expression and
CC activity. The antibodies and antagonists may also be used as therapeutic
CC agents to down regulate expression and activity. The antibodies may also
CC be used as diagnostic agents for detecting the presence of the
CC polypeptides in samples (e.g. by enzyme linked immunosorbent assay
CC (ELISA). Examples of diseases which may be treated include rheumatoid
CC arthritis and diabetes.
XX
XX Sequence 1722 BP; 449 A; 414 C; 412 G; 447 T; 0 other;
SQ
Query Match 99.5%; Score 1713; DB 22; Length 1722;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1716; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
Qy 1 CTAAGCTTTGACTTCCGCTGCGGCAAGCTGGCGGGGAGACAGCCAGTAGGCCCA 60

```

Db 2 CTAGAGCTTCGACCTCTCCGCTGCGGAGCTGGCGGGGAGAGCCAGGAGGCCCA 61
 Qy 61 AGATCTGTGCGCTGAGAGCTTGCCTGCGCGCGCGCTGATGTCTGCTCTGCGGC 120
 Db 62 AGATCTGTGCGCTGAGAGCTTGCCTGCGCGCGCGCTGATGTCTGCTCTGCGGC 121
 Qy 121 CGCTGGGTCCTCTCTCCCTGCGCGCGCTGCGCGAGCTGCGAGAGAGAGCTGCG 180
 Db 122 CGCTGGGTCCTCTCTCCCTGCGCGCGCTGCGCGAGCTGCGAGAGAGAGCTGCG 181
 Qy 181 ACCTGAGCTTCTTCAACCGAGAGCGCTGCACTGCTGAGCGCCCTGCTCTCTCTCA 240
 Db 182 ACCTGAGCTTCTTCAACCGAGAGCGCTGCACTGCTGAGCGCCCTGCTCTCTCTCA 241
 Qy 241 CCATTGAGCGCAACCTGCGCAGAGAGCGGCTTCTCTCACTCTCTGCGCTTCCAAAGC 300
 Db 242 CCATTGAGCGCAACCTGCGCAGAGAGCGGCTTCTCTCACTCTCTGCGCTTCCAAAGC 301
 Qy 301 TTCTGATCTTGGCGCAGAGGCTTGTCTCTGCGTACCTGAGGTTTGGTGGCAGCAAGAG 360
 Db 302 TTCTGATCTTGGCGCAGAGGCTTGTCTCTGCGTACCTGAGGTTTGGTGGCAGCAAGAG 361
 Qy 361 ACTTCTTAATTTTGCATCCCAAGAGAGATCAACCTTTGAGAGAGAGATTAAGTCAAT 420
 Db 362 ACTTCTTAATTTTGCATCCCAAGAGAGATCAACCTTTGAGAGAGAGATTAAGTCAAT 421
 Qy 421 CTCAAGTCAACAGAGATTTTGCATTAATGATTCATCCCTCTGATGAGAGAGAGT 480
 Db 422 CTCAAGTCAACAGAGATTTTGCATTAATGATTCATCCCTCTGATGAGAGAGAGT 481
 Qy 481 TAGCGTTGGAATGGCCCTTACAGAGAGCAATTTCTACTCCGAGAGCACTACAGAAAAGT 540
 Db 482 TAGCGTTGGAATGGCCCTTACAGAGAGCAATTTCTACTCCGAGAGCACTACAGAAAAGT 541
 Qy 541 TCAGAGAGAGAGAGCTTACTCAAGAGAGCTGTGATGATGTGTATACCTTTTGCAGAGTGT 600
 Db 542 TCAGAGAGAGAGAGCTTACTCAAGAGAGCTGTGATGATGTGTATACCTTTTGCAGAGTGT 601
 Qy 601 CAGAGCTGAGACTTGAATCTTGGCCTTAAATGCGTTATTAAGAGAGAGAGTTTGCAGTGA 660
 Db 602 CAGAGCTGAGACTTGAATCTTGGCCTTAAATGCGTTATTAAGAGAGAGAGTTTGCAGTGA 661
 Qy 661 ACAGTTCTTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCAAGGGGATTAACATTTCTT 720
 Db 662 ACAGTTCTTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCAAGGGGATTAACATTTCTT 721
 Qy 721 GGGAGCTGAGAGAGAGCTTAAACAGTTTCTTAAGAGAGCTGATATTTTCAATCAATGCGT 780
 Db 722 GGGAGCTGAGAGAGAGCTTAAACAGTTTCTTAAGAGAGCTGATATTTTCAATCAATGCGT 781
 Qy 781 CGCAGTTGAGAGAGATTAATTAATGAGAGAGAGCTTCTTAAGAGAGAGAGCTTCAAAA 840
 Db 782 CGCAGTTGAGAGAGATTAATTAATGAGAGAGAGCTTCTTAAGAGAGAGAGCTTCAAAA 841
 Qy 841 ATGCAAAAATCTATGCTGCTGATGTGTGAGAGAGCTTCAAGAGAGAGAGAGAGAGTGA 900
 Db 842 ATGCAAAAATCTATGCTGCTGATGTGTGAGAGAGCTTCAAGAGAGAGAGAGAGAGTGA 901
 Qy 901 AGAGCTTCTGAGAGAGCTGAGAGAGAGATTAATGAGAGAGAGAGAGAGAGAGAGTGA 960
 Db 902 AGAGCTTCTGAGAGAGCTGAGAGAGAGATTAATGAGAGAGAGAGAGAGAGAGAGTGA 961
 Qy 961 TGAATGAGAGAGAGCTGAGAGAGAGAGATTAATGAGAGAGAGAGAGAGAGAGAGTGA 1020
 Db 962 TGAATGAGAGAGAGCTGAGAGAGAGAGATTAATGAGAGAGAGAGAGAGAGAGAGTGA 1021
 Qy 1021 TTTCAATCTGAGAGAGAGATTTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1080
 Db 1022 TTTCAATCTGAGAGAGAGATTTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1081
 Qy 1081 GGTGAGAGAGAGAGCTTCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1140

Db 1082 GGTGAGAGAGAGAGCTTCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1141
 Qy 1141 CAGCTGGCTTATATGAGCTGAGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1200
 Db 1142 CAGCTGGCTTATATGAGCTGAGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1201
 Qy 1201 TGATGAGAGAGAGATTTCTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1260
 Db 1202 TGATGAGAGAGAGATTTCTTGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1261
 Qy 1261 CTTTACCTGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1320
 Db 1262 CTTTACCTGATTAATGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1321
 Qy 1321 TGGCAGTGA 1380
 Db 1322 TGGCAGTGA 1381
 Qy 1381 CTGACATTCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1440
 Db 1382 CTGACATTCAGAGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1441
 Qy 1441 TCACCAAGTACTTGGGCTTACCTTCTCTTCTTCAAGAGAGAGAGAGAGAGAGAGTGA 1500
 Db 1442 TCACCAAGTACTTGGGCTTACCTTCTCTTCTTCAAGAGAGAGAGAGAGAGAGAGTGA 1501
 Qy 1501 TAAAGTGA 1560
 Db 1502 TAAAGTGA 1561
 Qy 1561 TAAAGTGA 1620
 Db 1562 TAAAGTGA 1621
 Qy 1621 GTTACCTGGGCTTGGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1680
 Db 1622 GTTACCTGGGCTTGGCAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1681
 Qy 1681 CTGCTTGCATCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1721
 Db 1682 CTGCTTGCATCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGTGA 1722

RESULT 9
 AAX37259
 ID AAX37259 standard: DNA: 1713 BP.
 XX
 AC AAX37259;
 XX
 DT 21-JUL-1999 (first entry)
 XX
 DE Human heparanase enzyme encoding DNA.
 XX
 KW Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
 KW metastasis; angiogenesis; wound healing; angioplasticity-induced restenosis;
 KW arteriosclerosis; atherosclerosis; inflammation; tissue development;
 KW human; HSPG; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09921975-A1.
 XX
 PD 06-MAY-1999.
 XX
 PF 28-OCT-1998; 98WO-AU00898.
 XX
 PR 09-DEC-1997; 97AU-0000812.
 PR 28-OCT-1997; 97AU-0000062.
 XX
 PA (AUSU) UNIV AUSTRALIAN NAT.
 XX
 PI Freeman CG, Hamdorf BJ, Hulett MD, Parish CR;
 XX

DR WPI: 1999-312956/26.
DR P-PSDB: AAY17082.

PT Polynucleotides encoding mammalian endoglucuronidases, especially
heparanases, useful to promote wound healing

PS Claim 3; Page 69-73; 112pp; English.

XX The invention relates to nucleic acid sequences that encode heparanase
enzymes having endoglucuronidase activity. Recombinant heparanases are
capable of removing the HS side chain from heparan sulfate proteoglycan
(HSPG). Sulfated oligosaccharides, sulfonates or HSPG can be used to
inhibit heparanase, this is useful for treatment of a physiological or
medical condition associated with elevated heparanase activity, such as
metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
arteriosclerosis, atherosclerosis and inflammation. The human, murine and
rat heparanases can be used to enhance wound healing, especially
associated with tissue development and repair. The conditions mentioned
above can be diagnosed using specific antibodies, and also using primers
and probes specific for the heparanase polynucleotides. Other uses of the
heparanases include sequencing sulfated molecules such as HSPG. The
present sequence represents a DNA encoding human heparanase.

CC Sequence 1713 BP; 460 A; 404 C; 406 G; 443 T; 0 other;

Query Match 98.5%; Score 1694.6; DB 20; Length 1713;

Best Local Similarity 99.8%; Pred. No. 0; Mismatches 4; Indels 0; Gaps 0;

Matches 1697; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 18 CCGCTGCGCGGAGCTGGGCGGGGAGCAGCCAGGTGAGCCCAAGATGTGTGCGCTCG 77
DB 1 CCGCTGCGCGGAGCTGGGCGGGGAGCAGCCAGGTGAGCCCAAGATGTGTGCGCTCG 60
QY 78 AAGCTTGGGCTGCGCGCGCGCTGATGCTGCTCTGCGGCGCGCTGGGTCCCTTC 137
DB 61 AAGCTTGGGCTGCGCGCGCGCTGATGCTGCTCTGCGGCGCGCTGGGTCCCTTC 120
QY 138 CCGTGGCGCGCTGCGCGCGCGCTGAGCAGCAGGAGCTGTGAGCCTGCTTCAACC 197
DB 121 CCGTGGCGCGCTGCGCGCGCGCTGAGCAGCAGGAGCTGTGAGCCTGCTTCAACC 180
QY 198 CAGGAGCGCGCTGAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 257
DB 181 CAGGAGCGCGCTGAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 240
QY 258 GCCACGAGCGCGCGCTGCTCATCTCTGCGCTTCCAAAGCTTGATCTTGGCCAGA 317
DB 241 GCCACGAGCGCGCGCTGCTCATCTCTGCGCTTCCAAAGCTTGATCTTGGCCAGA 300
QY 318 GCGCTGCTGCTGCGCGCTGAGCTGAGCTGAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 377
DB 301 GCGCTGCTGCTGCGCGCTGAGCTGAGCTGAGCAGCAGCAGCAGCAGCAGCAGCAGCAG 360
QY 378 CCAAGAGAGATCAACCTTTGAAGAGAGATTAAGTGAATCAATCAAGCAGAGAT 437
DB 361 CCAAGAGAGATCAACCTTTGAAGAGAGATTAAGTGAATCAATCAAGCAGAGAT 420
QY 438 ATTTCGAATATGATGATCAATCTCTGATGTGAGAGAGATTAAGTGAATGAGCC 497
DB 421 ATTTCGAATATGATGATCAATCTCTGATGTGAGAGAGATTAAGTGAATGAGCC 480
QY 498 TACCGAGAGATTTGCTACTCCGAGAACCTACAGAAAAAGTTCAAGAACGACCTAC 557
DB 481 TACCGAGAGATTTGCTACTCCGAGAACCTACAGAAAAAGTTCAAGAACGACCTAC 540
QY 558 TCAAGAGAGCTGTAGATGCTATACCTTTTGCAACTGCTCAGAGATGAGCTGATC 617
DB 541 TCAAGAGAGCTGTAGATGCTATACCTTTTGCAACTGCTCAGAGATGAGCTGATC 600
QY 618 TTTGGCTTAATGCGTTATTAAGAACAGAGATTTGCAAGTCTAATGCTGAG 677
DB 601 TTTGGCTTAATGCGTTATTAAGAACAGAGATTTGCAAGTCTAATGCTGAG 660

QY 678 TTGCTCTGAGCTACTGCTCTTCCAGAGGGTATTAACATTTCTGGGAACTAGCCATGAA 737
DB 661 TTGCTCTGAGCTACTGCTCTTCCAGAGGGTATTAACATTTCTGGGAACTAGCCATGAA 720
QY 738 CCTAACGTTTCCCTAAGAGGCTGATATTTTCAATAGGCTGCGAGTGAAGAGAT 797
DB 721 CCTAACGTTTCCCTAAGAGGCTGATATTTTCAATAGGCTGCGAGTGAAGAGAT 780
QY 798 TATATCAATGCTATTAACCTTCTAAGAAAGTCACCTTCAAAAAATGCAAACTCTATGCT 857
DB 781 TTTATCAATGCTATTAACCTTCTAAGAAAGTCACCTTCAAAAAATGCAAACTCTATGCT 840
QY 858 CCGATGTTGGTCAAGCTTCGAGAAAGAGCGCTAAGTCTGAAGAGCTTCTGAAGCT 917
DB 841 CCGATGTTGGTCAAGCTTCGAGAAAGAGCGCTAAGTCTGAAGAGCTTCTGAAGCT 900
QY 918 GGTGAGAGAGATTTGATTTCAATGATGATACATGATTAATTTGATGAGCGGAGCT 977
DB 901 GGTGAGAGAGATTTGATTTCAATGATGATACATGATTAATTTGATGAGCGGAGCT 960
QY 978 ACCAGGAGATTTTCTAACCCTGATGATTTGAGCAATTTTATTTCTGTCGCAAAA 1037
DB 961 ACCAGGAGATTTTCTAACCCTGATGATTTGAGCAATTTTATTTCTGTCGCAAAA 1020
QY 1038 GTTTTCCAGGTGTTGAGAGCAGCAGGCTGCGAAGAGTCTGTTAGAGAAACAAGC 1097
DB 1021 GTTTTCCAGGTGTTGAGAGCAGCAGGCTGCGAAGAGTCTGTTAGAGAAACAAGC 1080
QY 1098 TCTGATATGAGAGCGGAGCGCTTGTCTATCCGACACCTTTGAGAGCTGCTTATGCTG 1157
DB 1081 TCTGATATGAGAGCGGAGCGCTTGTCTATCCGACACCTTTGAGAGCTGCTTATGCTG 1140
QY 1158 CTGATTAATTTGGGCTGTGAGCGGAGGAGTGAAGTGAAGTGAAGGAGGAGTATTC 1217
DB 1141 CTGATTAATTTGGGCTGTGAGCGGAGGAGTGAAGTGAAGTGAAGGAGGAGTATTC 1200
QY 1218 TTTGAGAGAGAACTACATTTATGATGATGAAACTTCGATCTTACCTGATTTATGG 1277
DB 1201 TTTGAGAGAGAACTACATTTATGATGATGAAACTTCGATCTTACCTGATTTATGG 1260
QY 1278 CTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGTGTATATGCGAAGGTGCAAGGT 1337
DB 1261 CTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGTGTATATGCGAAGGTGCAAGGT 1320
QY 1338 TCAAGAGAGAGCTTGAATGCTGATGCTTCAATGCTCAATGCTCAATGCTCAATGCT 1397
DB 1321 TCAAGAGAGAGCTTGAATGCTGATGCTTCAATGCTCAATGCTCAATGCTCAATGCT 1380
QY 1398 AAAGAGAGATTTAAGCTGATGCTTCAATGCTCAATGCTCAATGCTCAATGCTCAATGCT 1457
DB 1381 AAAGAGAGATTTAAGCTGATGCTTCAATGCTCAATGCTCAATGCTCAATGCTCAATGCT 1440
QY 1458 TTACCTTATCTTTTCTAACAAGAGTGAATTAATCTTCTTCAAGCTTTTGGAGCT 1517
DB 1441 TTACCTTATCTTTTCTAACAAGAGTGAATTAATCTTCTTCAAGCTTTTGGAGCT 1500
QY 1518 CATGATTAATCTTCAATGCTGCTCAATGCTCAATGCTCAATGCTCAATGCTCAATGCT 1577
DB 1501 CATGATTAATCTTCAATGCTGCTCAATGCTCAATGCTCAATGCTCAATGCTCAATGCT 1560
QY 1578 CAACCTTGCACCTTTATGAGAAACCTCTCGGCGCAGAGAGTTCATCGGCTTGCA 1637
DB 1561 CAACCTTGCACCTTTATGAGAAACCTCTCGGCGCAGAGAGTTCATCGGCTTGCA 1620
QY 1638 GCTTCTCATATAGTTTCTTGTGATTAAGAAATGCAAGTGTGCTGCTGATCTGAAGA 1697
DB 1621 GCTTCTCATATAGTTTCTTGTGATTAAGAAATGCAAGTGTGCTGCTGATCTGAAGA 1680
QY 1698 TAAATATATAGTCCAGACA 1718
DB 1681 TAAATATATAGTCCAGACA 1701

RESULT 10
 AAX37260
 ID AAX37260 standard; DNA; 1723 BP.
 XX
 AC AAX37260;
 XX
 DT 21-JUL-1999 (first entry)
 XX
 DE Seq ID No: 14 of W09921975.
 XX
 KM Heparanase; endoglucuronidase; heparan sulfate proteoglycan; enzyme;
 KM metachasis; angiogenesis; wound healing; angioplasty-induced restenosis;
 KM arteriosclerosis; atherosclerosis; inflammation; tissue development;
 KM human; HSPG; ss.
 XX
 OS Homo sapiens.
 XX
 PN W09921975-A1.
 XX
 PD 06-MAY-1999.
 XX
 PE 28-OCT-1998; 98WO-AU00898.
 XX
 PR 09-DEC-1997; 97AU-0000812.
 PR 28-OCT-1997; 97AU-0000062.
 XX
 PA (AUSU) UNIV AUSTRALIAN NAT.
 XX
 P1 Freeman CG, Handorf BJ, Hulett MD, Parish CR;
 DR WPI; 1999-312956/26.
 DR P-PSDB; AAY17083.
 XX
 PT Polynucleotides encoding mammalian endoglucuronidases, especially
 PT heparanases, useful to promote wound healing
 PS
 PS Claim 11; Page 76-79; 112pp; English.
 XX
 CC The invention relates to nucleic acid sequences that encode heparanase
 CC enzymes having endoglucuronidase activity. Recombinant heparanases are
 CC capable of removing the HS side chain from heparan sulfate proteoglycan
 CC (HSPG). Sulfated oligosaccharides, sulphonates or HSPG can be used to
 CC inhibit heparanase, this is useful for treatment of a physiological or
 CC medical condition associated with elevated heparanase activity, such as
 CC metastasis, angiogenesis, wound healing, angioplasty-induced restenosis,
 CC arteriosclerosis, atherosclerosis and inflammation. The human, murine and
 CC rat heparanases can be used to enhance wound healing, especially
 CC associated with tissue development and repair. The conditions mentioned
 CC above can be diagnosed using specific antibodies, and also using primers
 CC and probes specific for the heparanase polynucleotides. Other uses of the
 CC heparanases include sequencing sulfated molecules such as HSPG.
 CC
 XX
 SQ Sequence 1723 BP; 461 A; 407 C; 412 G; 443 T; 0 other;
 Query Match 98.1%; Score 1688.8; DB 20; Length 1723;
 Best Local Similarity 99.8%; Pred. No. 0; Mismatches 2; Indels 1; Gaps 1;
 Matches 1701; Conservative 0;

QY 258 GCACGAGCCCGCGTTCTTCATCCTCTCGGGTTCTCCAAAGCTTCGATCCTTGCCAGA 317
 DB 247 GCACGAGCCCGCGGTTCCTCATCCTCGGGTTCTCCAAAGCTTCGATCCTTGCCAGA 306
 QY 318 GCGTTGTCTCTGCGTACCTGAGGTTTGTGGCACCAAGACAGACTTCTTAATTTTGAT 377
 DB 307 GCGTTGTCTCTGCGTACCTGAGGTTTGTGGCACCAAGACAGACTTCTTAATTTTGAT 366
 QY 378 CCCAAGAGGAATCACTTGAAGAGAACTGAGCAATCTCAAGTCAACAGGAT 437
 DB 367 CCCAAGAGGAATCACTTGAAGAGAACTGAGCAATCTCAAGTCAACAGGAT 426
 QY 438 ATTGCAATATGATCATCCTCTGATGTGAGGAAAGTTACGGTTGAATGGCCC 497
 DB 427 ATTGCAATATGATCATCCTCTGATGTGAGGAAAGTTACGGTTGAATGGCCC 486
 QY 498 TACGAGAGCAATGCTACTCCGAGAACCTACCAAGAAAAGTTCAAGACAGCACTTAC 557
 DB 487 TACGAGAGCAATGCTACTCCGAGAACCTACCAAGAAAAGTTCAAGACAGCACTTAC 546
 QY 558 TCAAGAGCTCTGATGATGCTATACCTTTGCAACCTGCTAGGACTGAGCTGATC 617
 DB 547 TCAAGAGCTCTGATGATGCTATACCTTTGCAACCTGCTAGGACTGAGCTGATC 606
 QY 618 TTTGGCCTTAATGCGTTATTAAGAACAGCAATTTGCGAAGACAGTTCTAATGCTCAG 677
 DB 607 TTTGGCCTTAATGCGTTATTAAGAACAGCAATTTGCGAAGACAGTTCTAATGCTCAG 666
 QY 678 TTGCTCTGAGCTACCTGCTCTTCCAGAGGGATTAACATTTCTTGGAACTAGGCAATGA 737
 DB 667 TTGCTCTGAGCTACCTGCTCTTCCAGAGGGATTAACATTTCTTGGAACTAGGCAATGA 726
 QY 738 CCTACAGTTTCTTGAAGAGCGTGATTTTTCATCAATGGGTGGCAATTAGGAAAT 797
 DB 727 CCTACAGTTTCTTGAAGAGCGTGATTTTTCATCAATGGGTGGCAATTAGGAAAT 786
 QY 798 TATATCAATTCATTAACCTTGAAGAAAGTCCACCTTCAAAAATGCAAACTATGAT 857
 DB 787 TATATCAATTCATTAACCTTGAAGAAAGTCCACCTTCAAAAATGCAAACTATGAT 846
 QY 858 CCTGATGTTGTGACGCTCGAAGAAAGACGCTAAGATGCTGAAGAGCTTCTGAAGGCT 917
 DB 847 CCTGATGTTGTGACGCTCGAAGAAAGACGCTAAGATGCTGAAGAGCTTCTGAAGGCT 906
 QY 918 GGTGAGAGATGATGATTCAGTTACATGCACTACATCTTGAATGACGACCTGCT 977
 DB 907 GGTGAGAGATGATGATTCAGTTACATGCACTACATCTTGAATGACGACCTGCT 966
 QY 978 ACCAGGGAATTTTCTTAACCTGATGATTTGACATTTTATTTTCACTGTGCAAAA 1037
 DB 967 ACCAGGGAATTTTCTTAACCTGATGATTTGACATTTTATTTTCACTGTGCAAAA 1026
 QY 1038 GTTTTCCAGTGTTGAGAGACAGAGCTGCGAAGAAAGTCTGTGTTAGAGAAACAAGC 1097
 DB 1027 GTTTTCCAGTGTTGAGAGACAGAGCTGCGAAGAAAGTCTGTGTTAGAGAAACAAGC 1086
 QY 1098 TCTGATATGAGAGGCGGAGCGCTTGTATCCGACACTTTTGACGTGCTTATGTGG 1157
 DB 1087 TCTGATATGAGAGGCGGAGCGCTTGTATCCGACACTTTTGACGTGCTTATGTGG 1146
 QY 1158 CTGATTAATTTGGGCTGTACGCCGCAATGGAATAGAAAGTGATAGAGCAAGTATTC 1217
 DB 1147 CTGATTAATTTGGGCTGTACGCCGCAATGGAATAGAAAGTGATAGAGCAAGTATTC 1206
 QY 1218 TTTGAGAGGAAATCACTTATGATGATGAAAACCTTCGATCTTATCTGATTAATGG 1277
 DB 1207 TTTGAGAGGAAATCACTTATGATGATGAAAACCTTCGATCTTATCTGATTAATGG 1266
 QY 1278 CTATCTCTTCTTCAAGAAATTTGTGGGCAACAAGGTGTTAATGCAAGGCTGCAAGT 1337
 DB 1267 CTATCTCTTCTTCAAGAAATTTGTGGGCAACAAGGTGTTAATGCAAGGCTGCAAGT 1326


```

Qy 752 TAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAGATTATTCATTCGA 811
Db 826 TAAAGAGGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAGATTATTCATTCGA 885
Qy 812 TAACTTCTAAGAAAGTCCACTTCAAAAATGCAAAATCTATAGTCTCTGATGTTGGCA 871
Db 886 TAACTTCTAAGAAAGTCCACTTCAAAAATGCAAAATCTATAGTCTCTGATGTTGGCA 945
Qy 872 GCCTCGAAGAAAGACGGCTAAGATGCTGAGAGGCTCTGAGAGCTGGTGGAGAAAGTAT 931
Db 946 GCCTCGAAGAAAGACGGCTAAGATGCTGAGAGGCTCTGAGAGCTGGTGGAGAAAGTAT 1005
Qy 932 TGATTCAGTTACATGCGATCACTACTATTTGATGAGACGAGCTGCTACAGAGAAATTT 991
Db 1006 TGATTCAGTTACATGCGATCACTACTATTTGATGAGACGAGCTGCTACAGAGAAATTT 1065
Qy 992 TCTAACCCTGATGATTTGACATTTTATTTTCATCTGTGCAAAAAGTTTCCAGGTGCT 1051
Db 1066 TCTAACCCTGATGATTTGACATTTTATTTTCATCTGTGCAAAAAGTTTCCAGGTGCT 1125
Qy 1052 TGAGAGCAACGAGGCTGGCAAGAGGTCTGGTTAGAGAAACAAGCTGCTGATATGAGG 1111
Db 1126 TGAAGAGCAACGAGGCTGGCAAGAGGTCTGGTTAGAGAAACAAGCTGCTGATATGAGG 1185
Qy 1112 CGAGAGCGGCTTGTCTATCCGACACCTTTCAGAGCTGGCTTTATGTTGGCTGATTAATTTGG 1171
Db 1186 CGAGAGCGGCTTGTCTATCCGACACCTTTCAGAGCTGGCTTTATGTTGGCTGATTAATTTGG 1245
Qy 1172 CCGTGCAGCCCGGAATGGGAATGAAAGTGTGATGAGGCAAGTATCTTTGAGACAGGAA 1231
Db 1246 CCGTGCAGCCCGGAATGGGAATGAAAGTGTGATGAGGCAAGTATCTTTGAGACAGGAA 1305
Qy 1232 CTACACATTTAGTGAATGAAAATCTCGATCTTTACCTGATATGAGGATCTCTCTGCTT 1291
Db 1306 CTACACATTTAGTGAATGAAAATCTCGATCTTTACCTGATATGAGGATCTCTCTGCTT 1365
Qy 1292 CAAGAAATTTGGTGGGCAACCAAGTGTATGAGCAAGCTGCAAGGTTCAAGAGAGGAA 1351
Db 1366 CAAGAAATTTGGTGGGCAACCAAGTGTATGAGCAAGCTGCAAGGTTCAAGAGAGGAA 1425
Qy 1352 GCTTCGAGTATACCTTCATTCGACAAACACCTGACCAATCCAGATTAAGAGAGATTT 1411
Db 1426 GCTTCGAGTATACCTTCATTCGACAAACACCTGACCAATCCAGATTAAGAGAGATTT 1485
Qy 1412 AACTCTGATATGCAATAACTTCATTAAGTCAACCAAGTACTTGGGTTACCTTATCTTT 1471
Db 1486 AACTCTGATATGCAATAACTTCATTAAGTCAACCAAGTACTTGGGTTACCTTATCTTT 1545
Qy 1472 TTCTAACAAGCAAGTGAATTAATACCTTCTAAGACCTTGGGACCTCAATGATTACTTTC 1531
Db 1546 TTCTAACAAGCAAGTGAATTAATACCTTCTAAGACCTTGGGACCTCAATGATTACTTTC 1605
Qy 1532 CAATCTGTCCAACTCAATGCTCTAATCTTAAGATGATGATGATCAAACTTCCACAC 1591
Db 1606 CAATCTGTCCAACTCAATGCTCTAATCTTAAGATGATGATGATCAAACTTCCACAC 1665
Qy 1592 TTTAATGAAAAAATCTTCCGGCCAGAAAGTTCACTGGGCTTCCAGCTTTCTCATATAG 1651
Db 1666 TTTAATGAAAAAATCTTCCGGCCAGAAAGTTCACTGGGCTTCCAGCTTTCTCATATAG 1725
Qy 1652 TTTTCTTGTGATTAAGAAATGCAAAAGTTCGCTGATGCAATGAAAATATATCTAGT 1711
Db 1726 TTTTCTTGTGATTAAGAAATGCAAAAGTTCGCTGATGCAATGAAAATATATCTAGT 1785
Qy 1712 CCTGCACATG 1721
Db 1786 CCTGCACATG 1795

```

RESULT 12
AAH20940
ID AAH20940 standard; cDNA; 1724 BP.
XX

```

AC AAH20940;
XX
XX 24-AUG-2001 (first entry)
XX
XX Human heparanase inhibitor cDNA.
DE
XX Heparanase; inhibitor; cardiac insufficiency; cardiatic; nephrotropic;
KW hepatocytic; veterinary medicine; congestive heart failure; dyspnoea;
KW primary cardiomyopathy; peripheral odema; pulmonary congestion;
KW hepatic congestion; hydrothorax; ascites; nocturia; human; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH 52..1683
FT CDS /*tag= a
FT /product= "heparanase"
FT
XX DE19955803-A1.
XX
XX 23-MAY-2001.
XX
XX 19-NOV-1999; 99DE-1055803.
XX
XX 19-NOV-1999; 99DE-1055803.
XX
XX (KNOL ) KNOL AG.
XX
XX Herr D, Hahn A, Laux V;
XX
XX WPI; 2001-368371/39.
XX
XX P-PSDB; AAB86206.
XX
XX Treatment or prevention of cardiac insufficiency and related
XX conditions, e.g. pulmonary congestion and dyspnoea, comprises
XX administration of heparanase inhibitor
XX
XX Disclosure; Page 8-11; 16pp; German.
XX
XX This invention describes a novel heparanase inhibitor which can be used
XX for the treatment or prevention of cardiac insufficiency and associated
XX indications, symptoms and/or malfunctions. The heparanase inhibitor of
XX the invention has cardiatic, nephrotropic and hepatocytic activity. The
XX products of the invention can be used in human and veterinary medicine,
XX for the treatment or prevention of congestive heart failure e.g. primary
XX cardiomyopathy. Associated conditions treated or prevented with the
XX inhibitor are especially peripheral odemas, pulmonary and hepatic
XX congestion, dyspnoea, hydrothorax and ascites. Renal problems, e.g.
XX nocturia can also be treated. This sequence encodes the human heparanase
XX protein described in the method of the invention.
XX
XX Sequence 1724 BP; 466 A; 405 C; 410 G; 443 T; 0 other;
SQ

```

Query Match 97.8%; Score 1682.6; DB 22; Length 1724;
Best Local Similarity 99.7%; Pred. No. 0;
Matches 1696; Conservative 0; Mismatches 4; Indels 1; Gaps 1;

```

Qy 18 CCGCTGCGCGACGTGGCGGGGAGAGCAGCGTGAAGCCCAAGATGCTGCGCTCG 77
Db 8 CCGCTGCGCGACGTGGC -GGGGAGAGCAGCGTGAAGCCCAAGATGCTGCGCTCG 66
Qy 78 AAGCTGCGCGCGCGCGCGCGCTGATGCTGCTCCCGGGGGCGCGGTGCTCCCTCC 137
Db 67 AAGCTGCGCGCGCGCGCGCGCTGATGCTGCTCCCGGGGGCGCGGTGCTCCCTCC 126
Qy 138 CCGGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 197
Db 127 CCGTGTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 186
Qy 198 CAGAGCGCGCTGCACTGCTGAGCGCCCTGTTCTGTCTGCTGACCATTTAGCCCACTG 257
Db 187 CAGAGCGCGCTGCACTGCTGAGCGCCCTGTTCTGTCTGCTGACCATTTAGCCCACTG 246

```


QY 258 GCCACGAGACCGCGGCTCTCATCTCTGAGGTTCTCCAAAGCTTCTGATCTGGCCAGA 317
 DB 247 GCCACGAGACCGCGGCTCTCATCTCTGAGGTTCTCCAAAGCTTCTGATCTGGCCAGA 306
 QY 318 GGGTTGTCCTGCGTACCTGAGGTTGGTGACCAAGACAGACTTCTTAATTTTGCAT 377
 DB 307 GGGTTGTCCTGCGTACCTGAGGTTGGTGACCAAGACAGACTTCTTAATTTTGCAT 366
 QY 378 CCCAAGAGGAATCAACCTTTGAGAGAGAGAGTTCTGGCAATCTCAGTCAACAGAT 437
 DB 367 CCCAAGAGGAATCAACCTTTGAGAGAGAGTTCTGGCAATCTCAGTCAACAGAT 426
 QY 438 ATTGCAATATGATTCATCCCTCTGATGAGAGAGAGTTACGGTTGGATGGCCC 497
 DB 427 ATTGCAATATGATTCATCCCTCTGATGAGAGAGAGTTACGGTTGGATGGCCC 486
 QY 498 TACAGAGCAATGCTACTCCGAGACACTACAGAAAAGTTCAAGAACAGCACTAC 557
 DB 487 TACAGAGCAATGCTACTCCGAGACACTACAGAAAAGTTCAAGAACAGCACTAC 546
 QY 558 TCAGAAAGCTCTGATGATGCTATACACTTTTGCAAACTGCTCAGACTGATGATC 617
 DB 547 TCAGAAAGCTCTGATGATGCTATACACTTTTGCAAACTGCTCAGACTGATGATC 606
 QY 618 TTGGCCTTAAATGCGTTATTAAGACAGACAGATTGACAGTGAAGAGTTCTTAATGCTCAG 677
 DB 607 TTGGCCTTAAATGCGTTATTAAGACAGACAGATTGACAGTGAAGAGTTCTTAATGCTCAG 666
 QY 678 TTGCTCTGACTGACTGCTTTCAGAGGGATTAACATTTCTTGGAACTAGGCAATGAA 737
 DB 667 TTGCTCTGACTGACTGCTTTCAGAGGGATTAACATTTCTTGGAACTAGGCAATGAA 726
 QY 738 CCTAACAGTTCTTAAAGAGCTGATATTTTCAATCAATGGGTCCGAGTAGAGAAAGAT 797
 DB 727 CCTAACAGTTCTTAAAGAGCTGATATTTTCAATCAATGGGTCCGAGTAGAGAAAGAT 786
 QY 798 TATATTCAATTGATTAACCTTCTAAGAAAGTCCACTTCAAAAATGCAAAAATCTATGAT 857
 DB 787 TATATTCAATTGATTAACCTTCTAAGAAAGTCCACTTCAAAAATGCAAAAATCTATGAT 846
 QY 858 CCTGATGTTGGTCAGCTCGAAGAAAGACGGCTAAGATGCTGAAAGGCTTCTGAAAGCT 917
 DB 847 CCTGATGTTGGTCAGCTCGAAGAAAGACGGCTAAGATGCTGAAAGGCTTCTGAAAGCT 906
 QY 918 GGTGAGAAAGTATGATTCAGTTCATGAGCACTACTATTTTGAATGAGACGACTGCT 977
 DB 907 GGTGAGAAAGTATGATTCAGTTCATGAGCACTACTATTTTGAATGAGACGACTGCT 966
 QY 978 ACCAGGAGAAATTTCTAAACCTGATGATGACATTTTATTTCAATCTGTGCAAAA 1037
 DB 967 ACCAGGAGAAATTTCTAAACCTGATGATGACATTTTATTTTCAATCTGTGCAAAA 1026
 QY 1038 GTTTTCCAGGTGTTGAGAGCACAGGCTGCGCAAGAAAGTCTGTTAGAGAAACAAAGC 1097
 DB 1027 GTTTTCCAGGTGTTGAGAGCACAGGCTGCGCAAGAAAGTCTGTTAGAGAAACAAAGC 1086
 QY 1098 TCTGATATGAGAGGCGAGCGCTTCTGATTCGACACCTTTGACGCTGCTTATGTTGG 1157
 DB 1087 TCTGATATGAGAGGCGAGCGCTTCTGATTCGACACCTTTGACGCTGCTTATGTTGG 1146
 QY 1158 CTGGATTAATTTGGGCTGTACAGCCGGAATGGGAATGAGAGTGTATGAGGCAATATTC 1217
 DB 1147 CTGGATTAATTTGGGCTGTACAGCCGGAATGGGAATGAGAGTGTATGAGGCAATATTC 1206
 QY 1218 TTTGGAGCAGAACTACATTTAGTGAATGAAACCTTGATCTTTTACCTGATTTATGG 1277
 DB 1207 TTTGGAGCAGAACTACATTTAGTGAATGAAACCTTGATCTTTTACCTGATTTATGG 1266
 QY 1278 CTATCTCTTCTGTTAAAGAAATTTGGTGGCACCAAGTGTATATGCAAGCTGCAAGGT 1337
 DB 1267 CTATCTCTTCTGTTAAAGAAATTTGGTGGCACCAAGTGTATATGCAAGCTGCAAGGT 1326
 QY 1338 TCAGAGAGAGAGAGCTTCAAGTATACCTTATTCACAAACACTGACAAATCAAGGTAT 1397

DB 1327 TCAGAGAGAGAGAGCTTCAGATATACCTTATTCACAAACACTGACAAATCAAGGTAT 1386
 QY 1398 AAGAGAGAGATTTAATCTGTATAGCCATAAACCTCCATAACGTACATCTGGG 1457
 DB 1397 AAGAGAGAGATTTAATCTGTATAGCCATAAACCTCCATAACGTACATCTGGG 1446
 QY 1458 TTACCTTATCTTTTCTTAAAGAGAGTGAATAATCTTCTTAAGACTTTGGGACT 1517
 DB 1447 TTACCTTATCTTTTCTTAAAGAGAGTGAATAATCTTCTTAAGACTTTGGGACT 1506
 QY 1518 CATGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATCAATGATGATGAT 1577
 DB 1507 CATGATTAATCTTCCAAATCTGTCCAACTCAATGCTTAATCAATGATGATGAT 1566
 QY 1578 CAACCTTCCACCTTTAATGAGAAACCTTCCGCGCAGAGAGTTCACTGGGCTTGGCA 1637
 DB 1567 CAACCTTCCACCTTTAATGAGAAACCTTCCGCGCAGAGAGTTCACTGGGCTTGGCA 1626
 QY 1638 GCTTCTCATATGATTTTGTGATTAAGAAATGCAAGTTGCTGCTGATCTGAATA 1697
 DB 1627 GCTTCTCATATGATTTTGTGATTAAGAAATGCAAGTTGCTGCTGATCTGAATA 1686
 QY 1698 TAAATATATCTAGTCTGACA 1718
 DB 1687 TAAATATATCTAGTCTGAAA 1707

RESULT 13
 ABZ22816
 ID ABZ22816 standard; cDNA, 1669 BP.
 XX
 AC ABZ22816;
 XX
 DT 02-APR-2003 (first entry)
 XX
 DE Human heparanase encoding cDNA SEQ ID NO:17.
 XX
 DE Human, heparanase; phosphorothioate; antisense oligonucleotide;
 KM cytosolic; gene therapy; tumour; enzyme; gene; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT CDS 1..1638
 FT /tag= a
 FT /product= "heparanase"
 XX
 PN MO200304705-A1.
 XX
 PD 16-JAN-2003.
 XX
 PF 01-JUL-2002; 2002WO-US20636.
 XX
 PR 05-JUL-2001; 2001US-0899440.
 XX
 PA (UNCO) UNIV COLUMBIA NEW YORK.
 XX
 PI Stein C;
 XX
 DR WPI; 2003-201558/19.
 DR P-PDB; ABP56822.
 XX
 PT New oligonucleotide having a sequence complementary to a sequence of
 PT ribonucleic acid encoding a heparanase, useful for preparing a
 PT composition for treating tumor -
 XX
 PS Disclosure; Fig 3; 48pp; English.
 CC The present invention describes an oligonucleotide having a sequence
 CC complementary to a sequence of ribonucleic acid encoding a heparanase.
 CC The oligonucleotide hybridises with the ribonucleic acid under conditions
 CC of high stringency and has a sequence comprising 10-40 bp. The

CC internucleoside linkages of the oligonucleotide comprise at least one
 CC phosphorothioate linkage. Hybridisation of the oligonucleotide to the
 CC ribonucleic acid inhibits expression of the heparanase, where inhibition
 CC of heparanase means at least a 50% reduction in the quality of a
 CC heparanase. Also described: (1) a method of inhibiting expression of a
 CC heparanase in a cell; (2) a composition comprising the above
 CC oligonucleotide in an amount effective to inhibit the expression of
 CC heparanase in the cell and a carrier; and (3) a method of treating a
 CC tumour in a subject comprising administering to the subject an amount of
 CC the above oligonucleotide effective to inhibit expression of a heparanase
 CC in the subject. Heparanase antisense oligonucleotides have cytostatic
 CC activity, can be used in gene therapy, and can be used for preparing a
 CC composition for treating tumours. The present sequence encodes human
 CC heparanase, which is given in the exemplification of the present
 CC invention.

XX Sequence 1669 BP; 445 A; 396 C; 388 G; 440 T; 0 other;

Query Match 94.8%; Score 1631.4; DB 25; Length 1669;

Best Local Similarity 99.6%; Pred. No. 0;

Matches 1658; Conservative 0; Mismatches 1; Indels 6; Gaps 2;

Qy	63	ATGCTGCTGCGCTGAGAGCTGCGTGCCTGCGCGCC--GCTGATCTGCTGCTCTGGGG	119
Db	1	ATGCTGCTGCGCTGAGAGCTGCGTGCCTGCGCGCCGCTGATGCTGCTGCTCTGGGG	60
Qy	120	CCGCTGGGCTCCCTCTCCCTGGGCGCGTGCCTGCGCGAGCTGGGCAAGCA--CAGAGGTC	176
Db	61	CCGCTGGGCTCCCTCTCCCTGGGCGCGTGCCTGCGCGAGCTGGGCAAGCAAGCTTC	120
Qy	177	GTGACCTGGAATCTTTCACCCAGAGAGCGCTGACCTGTGTGAGGCGCTGCTGCTGCTC	236
Db	121	GTGACCTGGAATCTTTCACCCAGAGAGCGCTGACCTGTGTGAGGCGCTGCTGCTGCTC	180
Qy	237	GTCAACATTGAGCGCAACCTTGGCCAGAGACCGCGGCTTCTTCATCTCTGCGTTTCTCA	296
Db	181	GTCAACATTGAGCGCAACCTTGGCCAGAGACCGCGGCTTCTTCATCTCTGCGTTTCTCA	240
Qy	297	AAGCTTCTACCTTGGCCAGAGGCTTGTCTCTGTGTACCTGAGTTTGTGTGACCAAG	356
Db	241	AAGCTTCTACCTTGGCCAGAGGCTTGTCTCTGTGTACCTGAGTTTGTGTGACCAAG	300
Qy	357	ACAGACTTCTTAATTTTGCATCCCAAGAGAAATCACTTTGAAGAGAAAGTTACTTG	416
Db	301	ACAGACTTCTTAATTTTGCATCCCAAGAGAAATCACTTTGAAGAGAAAGTTACTTG	360
Qy	417	CAATCTCAAGTCAACAGAGATATTGCAATATGAGTCCATCCCTCTGATGTGAGAG	476
Db	361	CAATCTCAAGTCAACAGAGATATTGCAATATGAGTCCATCCCTCTGATGTGAGAG	420
Qy	477	AAGTTACGCTTGGAAATGGCCCTTACAGAGCAATTTGCTATCCGAGAACATACAGAA	536
Db	421	AAGTTACGCTTGGAAATGGCCCTTACAGAGCAATTTGCTATCCGAGAACATACAGAA	480
Qy	537	AAGTTACAGAACAGACCTAATCAAGAACTGTAGATGTGCTATACCTTTTCAAC	596
Db	481	AAGTTACAGAACAGACCTAATCAAGAACTGTAGATGTGCTATACCTTTTCAAC	540
Qy	597	TGCTCAGAGCTGAGCTTGTATCTTTGGCTTAAATGCGTTATTAAGAACAGCAATTTG	656
Db	541	TGCTCAGAGCTGAGCTTGTATCTTTGGCTTAAATGCGTTATTAAGAACAGCAATTTG	600
Qy	657	TGGAACATTTCTAATGCTCAAGTGTCTCTGAGCTACTGCTTCCAAAGGGGATTAACAT	716
Db	601	TGGAACATTTCTAATGCTCAAGTGTCTCTGAGCTACTGCTTCCAAAGGGGATTAACAT	660
Qy	717	TCTTGGGAATGAGCAATGAACTTAACAGTTTCTTAAGAAAGCTGATATTTTCATCAT	776
Db	661	TCTTGGGAATGAGCAATGAACTTAACAGTTTCTTAAGAAAGCTGATATTTTCATCAT	720
Qy	777	GGGTGCAAGTTAGAGAAAGATTATATCAATTGATAAACTTTTAAGAAAGTCCACTTC	836
Db	721	GGGTGCAAGTTAGAGAAAGATTATATCAATTGATAAACTTTTAAGAAAGTCCACTTC	780

Qy	837	AAAATGCAAAACTATATGCTCTGATGTTGGTCAGCCTCGAAGAAAGCGCTAAGATG	896
Db	781	AAAATGCAAAACTATATGCTCTGATGTTGGTCAGCCTCGAAGAAAGCGCTAAGATG	840
Qy	897	CTGAAGAGCTTCTGAAGAGCTGTGTGAGAAAGTATTTGATTCATGCTCATCACTAC	956
Db	841	CTGAAGAGCTTCTGAAGAGCTGTGTGAGAAAGTATTTGATTCATGCTCATCACTAC	900
Qy	957	TATTTGAATGAGACGACCTGTACCAAGGAGATTTTCTAAACCTGATATGAGACAT	1016
Db	901	TATTTGAATGAGACGACCTGTACCAAGGAGATTTTCTAAACCTGATATGAGACAT	960
Qy	1017	TTTATTTTCATCTGTGCAAAAAGTTTTCAGAGTGTGAGAGACACAGGCTGTGCAAG	1076
Db	961	TTTATTTTCATCTGTGCAAAAAGTTTTCAGAGTGTGAGAGACACAGGCTGTGCAAG	1020
Qy	1077	GTCTGTTTGAAGAAACAGCTTGTGATATGAGAGCGAGCGCTTGTCTATCCGACACC	1136
Db	1021	GTCTGTTTGAAGAAACAGCTTGTGATATGAGAGCGAGCGCTTGTCTATCCGACACC	1080
Qy	1137	TTTGACGTGCTTATGTGTGCTGATTAATTTGGCGCTGTACGCGCAATGGAATAGAA	1196
Db	1081	TTTGACGTGCTTATGTGTGCTGATTAATTTGGCGCTGTACGCGCAATGGAATAGAA	1140
Qy	1197	GTGTGATGAGCAAGTATCTTTTGAAGCAAGAACTTATAGTGAATGAAAACTTC	1256
Db	1141	GTGTGATGAGCAAGTATCTTTTGAAGCAAGAACTTATAGTGAATGAAAACTTC	1200
Qy	1257	GATCCTTTACCTGATATATGAGCTATCTCTCTGTTCAAGAAATGTGTGGCAACAGGTG	1316
Db	1201	GATCCTTTACCTGATATATGAGCTATCTCTCTGTTCAAGAAATGTGTGGCAACAGGTG	1260
Qy	1317	TTAATGGAACCGTGCAGAGTTTCAAGAGAAAGAGTTCAGATATACCTTCAATGACA	1376
Db	1261	TTAATGGAACCGTGCAGAGTTTCAAGAGAAAGAGTTCAGATATACCTTCAATGACA	1320
Qy	1377	AAACTGCAATTCAGAGTATTAAGAGAGAGATTTAACTGTATGCCATAACCTGCAT	1436
Db	1321	AAACTGCAATTCAGAGTATTAAGAGAGAGATTTAACTGTATGCCATAACCTGCAT	1380
Qy	1437	AACGTCAACAAATCTTGGGTTACCTTATCTTTTCTTCAACAGCAAGGATTAATAC	1496
Db	1381	AACGTCAACAAATCTTGGGTTACCTTATCTTTTCTTCAACAGCAAGGATTAATAC	1440
Qy	1497	CTTCTAAGACCTTTGGGACCTCATAGATTAATCTTTTCAAAATCTGTCAACTCAATGCTCA	1556
Db	1441	CTTCTAAGACCTTTGGGACCTCATAGATTAATCTTTTCAAAATCTGTCAACTCAATGCTCA	1500
Qy	1557	ACTCTAAGATGTGAGATGATCAAACTTGGCACCTTATATGAGAAAACTCTCCGGGCA	1616
Db	1501	ACTCTAAGATGTGAGATGATCAAACTTGGCACCTTATATGAGAAAACTCTCCGGGCA	1560
Qy	1617	GGAAGTCACTGAGGCTTGCACAGCTTCTCATATAGTTTCTTGTGTAGAAATGCCAA	1676
Db	1561	GGAAGTCACTGAGGCTTGCACAGCTTCTCATATAGTTTCTTGTGTAGAAATGCCAA	1620
Qy	1677	GTTGCTGCTTGCATTTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTA	1721
Db	1621	GTTGCTGCTTGCATTTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTA	1665

RESULT 14

AAZ11236 standard; cDNA; 1593 BP.

AAZ11236;

15-NOV-1999 (first entry)

Human pre-proheparanase coding sequence.

Human; pre-proheparanase; platelet; wound healing; angiogenesis blocker;

Db	782	AGATGCTGAGAGAGCTTCTGTAAGGCTGTGAGAAAGTATGATTCAGTTACATGSCATC	841
Qy	952	ACTACTATTGTAATGGAAGGACTGCTACACAGGGAAGATTTCTAAACCTGATGATTTGG	1011
Db	842	ACTACTATTGTAATGGAAGGACTGCTACACAGGGAAGATTTCTAAACCTGATGATTTGG	901
Qy	1012	ACATTTTATTTTCATCTGTGCAAAAAAGTTTTCCAGGTGTTGAGACACAGGCTTGCA	1071
Db	902	ACATTTTATTTTCATCTGTGCAAAAAAGTTTTCCAGGTGTTGAGACACAGGCTTGCA	961
Qy	1072	AGAAGTCTGTGTAAGAGAAACAAGCTGTGCATATGAGGCGAGGCTTGTATCCG	1131
Db	962	AGAAGTCTGTGTAAGAGAAACAAGCTGTGCATATGAGGCGAGGCTTGTATCCG	1021
Qy	1132	ACACCTTTGACGCTGCTTATGAGCTGGAATAAATTGGGCGCTGTACGCGGAATGGGAA	1191
Db	1022	ACACCTTTGACGCTGCTTATGAGCTGGAATAAATTGGGCGCTGTACGCGGAATGGGAA	1081
Qy	1192	TAGAAGTGTGATGAGGCAAGTATCTTTGAGCAGAAACTACATTTAGTGATGAAA	1251
Db	1082	TAGAAGTGTGATGAGGCAAGTATCTTTGAGCAGAAACTACATTTAGTGATGAAA	1141
Qy	1252	ACTTGATCTTTACCTGATTAATTGGCTATCTCTTCTGTTCAAGAAATTGGTGGACCA	1311
Db	1142	ACTTGATCTTTACCTGATTAATTGGCTATCTCTTCTGTTCAAGAAATTGGTGGACCA	1201
Qy	1312	AGGTGTATGAGGCAAGCTGCAAGGTTCAAGAGAAAGGCTTGAGTATACCTTCATT	1371
Db	1202	AGGTGTATGAGGCAAGCTGCAAGGTTCAAGAGAAAGGCTTGAGTATACCTTCATT	1261
Qy	1372	GCACAAACATGACATCCAGGTATMAAGAGAGATTTAACTGTATGCCATMAAC	1431
Db	1262	GCACAAACATGACATCCAGGTATMAAGAGAGATTTAACTGTATGCCATMAAC	1321
Qy	1432	TCCATTAAGTCAACAAGTACTTGGGTTACCTTATCTTTTCTAACAAGAGTGATA	1491
Db	1322	TCCATTAAGTCAACAAGTACTTGGGTTACCTTATCTTTTCTAACAAGAGTGATA	1381
Qy	1492	AATACCTTCTAAGACCTTTGGGACCTCANTGATTACTTCCAAATCTGTCCAACCAATG	1551
Db	1382	AATACCTTCTAAGACCTTTGGGACCTCANTGATTACTTCCAAATCTGTCCAACCAATG	1441
Qy	1552	GTCTAACTCTAAGAAGTGTGATGATCAAAACCTTGCACTTTAATGAAAAACCTCTCC	1611
Db	1442	GTCTAACTCTAAGAAGTGTGATGATCAAAACCTTGCACTTTAATGAAAAACCTCTCC	1501
Qy	1612	GGCCAGGAAGTTCACCTGGGCTTGCCAGCTTCTCAATATAGTTTTTTGTGATAGAATG	1671
Db	1502	GGCCAGGAAGTTCACCTGGGCTTGCCAGCTTCTCAATATAGTTTTTTGTGATAGAATG	1561
Qy	1672	CCAAAGTTGCTGCTTGCACTGTA	1694
Db	1562	CCAAAGTTGCTGCTTGCACTGTA	1584

Search completed: February 16, 2004, 09:18:09
 Job time : 850.407 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 08:49:50 ; Search time 6685.2 Seconds
(without alignments)
6256.802 Million cell updates/sec

Title: US-10-676-079-1
Perfect score: 1721
Sequence: 1 ctgagcttcgactctccg.....atatactagctcgcacactg 1721

Scoring table: IDENTITY NUC
Gapop 10.0, Gapext 1.0

Searched: 22781392 seqs, 12152238056 residues
Total number of hits satisfying chosen parameters: 45562784

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :
EST:
1: em_estba:*
2: em_esthum:*
3: em_estlin:*
4: em_estm:*
5: em_estov:*
6: em_estpl:*
7: em_estro:*
8: em_hlc:*
9: gb_est1:*
10: gb_est2:*
11: gb_hlc:*
12: gb_est3:*
13: gb_est4:*
14: gb_est5:*
15: em_estfun:*
16: em_estom:*
17: em_gss_hum:*
18: em_gss_inv:*
19: em_gss_pln:*
20: em_gss_vrt:*
21: em_gss_fun:*
22: em_gss_mam:*
23: em_gss_mus:*
24: em_gss_pro:*
25: em_gss_rtd:*
26: em_gss_dhg:*
27: em_gss_vrt1:*
28: gb_gss1:*
29: gb_gss2:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1093.6	63.5	2173	11	AK040471 Mus muscu
2	954.2	55.4	1156	9	AL552151 AL552151
3	933.4	54.2	1962	11	AK087283 Mus muscu
4	923.6	53.7	1185	9	AL552174 AL552174

5	902.6	52.4	1201	9	AL545270
6	866.4	50.3	1200	9	AL545232
7	844.8	49.1	1083	13	BX398409
8	804.6	46.8	914	13	BX373611
9	761.6	44.3	881	14	CB988510
10	750.2	43.6	907	13	BO691142
11	689.8	40.1	907	13	BQ438834
12	687.8	40.0	708	13	BQ775819
13	615.2	35.7	682	12	BM996417
14	614.8	35.7	682	12	BM996417
15	553.4	32.2	556	9	AI342512
16	541	31.4	549	10	BF197674
17	537.4	31.2	540	10	AI582254
18	486.8	28.3	553	14	N30824
19	486.4	28.3	495	9	AI660639
20	470.4	27.3	484	9	AI033490
21	468.2	27.2	479	9	AI824984
22	466.2	27.1	488	13	B0617228
23	465.8	27.1	587	14	N45367
24	456.6	26.5	518	14	N30845
25	426.4	24.8	629	14	CB483444
26	410.2	23.8	427	9	AI928508
27	404.8	23.5	412	9	AI027968
28	371.2	21.6	480	9	AW465382
29	369.6	21.5	386	9	AI393542
30	352	20.5	370	14	N41349
31	348.4	20.2	367	9	AW015299
32	341	19.8	445	10	BF040685
33	332	19.3	484	14	N41373
34	327.2	19.0	632	10	BB636167
35	320.4	18.6	506	10	BF419897
36	317.4	18.4	341	9	AI189657
37	314.4	18.3	327	9	AA948627
38	310.4	18.0	408	14	N32056
39	304.6	17.7	431	9	AA177901
40	304.4	17.7	453	9	AA429437
41	299	17.4	451	9	AA674378
42	271.2	15.8	447	10	BB815166
43	263.4	15.3	452	10	BG663158
44	254.4	14.8	283	9	AI207288
45	253.8	14.7	777	9	AL718139

ALIGNMENTS

RESULT 1
LOCUS AK040471
DEFINITION Mus musculus 0 day neonate thymus cDNA, RIKEN full-length enriched library, clone: A43010M04 product: heparanase, full insert sequence.
ACCESSION AK040471
VERSION AK040471.1 GI:26333764
KEYWORDS HTC; CAP trapper.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 Carninci, P. and Hayashizaki, Y.
High-efficiency full-length cDNA cloning
Meth. Enzymol. 303, 19-44 (1999)
99279253
MEDLINE
PUBMED
10349636
2
Carninci, P., Shibata, Y., Hayatsu, N., Sugahara, Y., Shibata, K., Itoh, M., Kono, H., Okazaki, Y., Muramatsu, M. and Hayashizaki, Y.
Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes
Genome Res. 10 (10), 1617-1630 (2000)
20499374
MEDLINE
PUBMED
11042159
REFERENCE


```

Oy 683 CCTGACTACTGCTCTTCCAGAGGGTATTAACATTTCTTGGAACTAGCAATGAACCTAA 742
Db 687 CTTGACTACTGCTCTTCCAGAGGGTATTAACATTTCTTGGAACTAGCAATGAACCTAA 746
Oy 743 CAGTTTCTTAAAGAGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAAATTAAT 802
Db 747 CAGTTTCTTAAAGAGCTGATATTTTCATCAATGGGTGCGAGTTAGAGAAATTAAT 806
Oy 803 TCAATTCATTAATCTTCAAGAAAGTCACTTCAAAAATGCAAACTCTTATGCTCCGA 862
Db 807 GGAAGTTGATTAATCTTCAAGAAAGTCACTTCAAAAATGCAAACTCTTATGCTCCGA 866
Oy 863 TGTGTGAGGCTGCAAGAAAGAGCGGCTAAGATGCTGAAGAGCTTCTGAAGAGCTGAG 922
Db 867 CATGCTGAGGCTGCAAGAAAGAGCGGCTAAGATGCTGAAGAGCTTCTGAAGAGCTGAG 926
Oy 923 AGAAGTATGATTCAGTTACATGAGCATCACTATATTTGAATGAGACGAGCTGATACCA 982
Db 927 AGAAGTATGATTCAGTTACATGAGCATCACTATATTTGAATGAGACGAGCTGATACCA 986
Oy 983 GGAAGATTTTAAACCTGATATTTGAATGAGCATCACTATATTTGAATGAGACGAGCTG 1042
Db 987 AGAAGATTTTCTGAGCTGATATTTGAATGAGCATCACTATATTTGAATGAGACGAGCTG 1046
Oy 1043 CCAGTGTGAGAGCAACGAGGCTGCAAGAAAGTCTGTTAGAGAAACAAGCTGAG 1102
Db 1047 GAAAGTCACTAAGAGATCAACCTGCAAGAAAGTCTGTTAGAGAAACAAGCTGAG 1106
Oy 1103 ATATGAGGCGGAGCGGCTTGTATCCAGACCTTTGCAAGCTGCTTATGAGCTGGA 1162
Db 1107 TTAGGTTGGGGTGGAGCTTGTGTGCTGCAACCTTTGCAAGCTGCTTATGAGCTGGA 1166
Oy 1163 TAAATGGGCTGTGAGCCCGAATGGAAATGAAGTGTGATGAGGCAATTTCTTTGG 1222
Db 1167 TAAATGGGCTGTGAGCCCGAATGGAAATGAAGTGTGATGAGGCAATTTCTTTGG 1226
Oy 1223 AGCAGGAACTACCACTTAGGATGAAACCTTGATCCTTTAAGCTGATTTAGGCTATG 1282
Db 1227 AGCAGGCACTACCACTTAGGATGAAACCTTGATCCTTTAAGCTGATTTAGGCTATG 1286
Oy 1283 TCTTCTGTTCAAGAAATGTGGGCAACCAAGGTGTTAATGGCAAGCTGTTCAA 1342
Db 1287 TCTTCTGTTCAAGAAATGTGGGCAACCAAGGTGTTAATGGCAAGCTGTTCAA 1346
Oy 1343 GAGAGGAGCTTGGAGTATACCTTCAATGCAAAACCTGACCAATCCAGATTAAGA 1402
Db 1347 GAGAGGAGCTTGGAGTATACCTTCAATGCAAAACCTGACCAATCCAGATTAAGA 1406
Oy 1403 AGGAGATTAATCTGATATGCAATTAACCTCATTAAGCTGCAAGCTGCGGTTAAC 1462
Db 1407 AGGAGATTAATCTGATATGCAATTAACCTCATTAAGCTGCAAGCTGCGGTTAAC 1466
Oy 1463 CTATCTTTTCTTAACAAGCAAGTGAATTAATCTTCAAGACCTTTGGGAGCTCATAG 1522
Db 1467 GCTTCCTGTTTCAAGAAACCAAGTGAATTAATCTTCAAGACCTTTGGGAGCTCATAG 1526
Oy 1523 ATTAATTTTCAAAATGTGTCACCTCAATGCTTAACTCTAAGAGTGGATGATCAAC 1582
Db 1527 ATTAATTTTCAAAATGTGTCACCTCAATGCTTAACTCTAAGAGTGGATGATCAAC 1586
Oy 1583 CTGTCACCTTAAATGAGAAACCTTCCGCGCAAGAAAGTTCAGTGGTGGCCAGCTTT 1642
Db 1587 CTTGACACCTTGAAGAAACCTTCCGCGCAAGAAAGTTCAGTGGTGGCCAGCTTT 1646
Oy 1643 CTCAATATGATTTTCTTGAATGAAGATGCAAGATGCTGCTCATCTGAATTAATA 1702
Db 1647 TTCTATGATTTTCTTGAATGAAGATGCAAGATGCTGCTCATCTGAATTAATA 1706

```

RESULT 2
AL552151/c
LOCUS AL552151 1156 bp mRNA linear EST 31-MAY-2003

```

DEFINITION AL552151 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA
ACCESSION clone CSODI059YN15 3-PRIME, mRNA sequence.
VERSION AL552151.2 GI:1273967
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
TITLE 1 (bases 1 to 1156)
JOURNAL Full-length cDNA libraries and normalization
COMMENT On Feb 15, 2001 this sequence version replaced gi:12890775.
Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 Evry cedex - France
Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of
Invitrogen. This sequence belongs to sequence cluster 2469.r for
more information about this cluster, see
http://www.genoscope.cns.fr/
cgi-bin/cluster.cgi?seq=CSODI059CG08NP1&cluster=2469.r. Contact :
Feng Liang Email : fliang@lifetech.com URL :
http://fulllength.invitrogen.com/Invitrogen Corporation 1600
Faraday Avenue Genoscope sequence ID : CSODI059CG08NP1.
location/Qualifiers
1. 1156
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODI059YN15"
/issue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo (dT)
primer. Five prime end enriched, double-strand cDNA was
digested with Not I and cloned into the Not I and BclI V
sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT 305 a 251 c 233 g 323 t 44 others
ORIGIN
Query Match 55.4%; Score 954.2; DB 9; Length 1156;
Best Local Similarity 98.0%; Pred. No. 1.5e-252;
Matches 970; Conservative 5; Mismatches 14; Indels 1; Gaps 1;
Oy 698 TTCAGAGGGGTATACATTTCTTGGGAACTAGGCAATGACCTTAACAGTTCTTAAGA 757
Db 989 YTTCCAGGGTATACATTTCTTGGGAACTAGGCAATGACCTTAACAGTTCTTAAGA 931
Oy 758 GGCATATTTTCAATCAATGGGTGCGAGTGAAGAAATTAATTAATGATGATTAAC 817
Db 930 GGCATATTTTCAATCAATGGGTGCGAGTGAAGAAATTAATTAATGATGATTAAC 871
Oy 818 TCTAAGAAAGTCAACCTTCAAAAATGCAAACTATGATGCTGATGTTGGTCAAGCTCG 877
Db 870 TCTAAGAAAGTCAACCTTCAAAAATGCAAACTATGATGCTGATGTTGGTCAAGCTCG 811
Oy 878 AAGAAAGCGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGGTGAAGAGATGATGATTC 937
Db 810 AAGAAAGCGGTAAAGATGCTGAAGAGCTTCTGAAGGCTGGTGAAGAGATGATGATTC 751
Oy 938 AGTTACATGGGATCACTACTATTTGAATGAGCGGCTGCTACAGAGAAAGATTTCTAAA 997
Db 750 AGTTACATGGGATCACTACTATTTGAATGAGCGGCTGCTACAGAGAAAGATTTCTAAA 691
Oy 998 CCTGATATTTGAGCATTTTATTTATTCATCTGTGCAAAAGTTTTCAGAGTGTGAGAG 1057
Db 690 CCTGATATTTGAGCATTTTATTTATTCATCTGTGCAAAAGTTTTCAGAGTGTGAGAG 631
Oy 1058 CACCAAGGCTTGGCAAGAGGTCTGTTGAGAGAAACAAGCTCTGATATGAGAGGGAGC 1117
Db 630 CACCAAGGCTTGGCAAGAGGTCTGTTGAGAGAAACAAGCTCTGATATGAGAGGGAGC 571

```

OY		1118	GCCCTTGCATACCGACACCTTTGGAGCCTGCGCTTTATGTGGCGATAAATTGGGCGTAGC	1177
Db		570	GCCCTTGTCATCCGACACTTTGGACGTGGCTTTATGTGGCTGATAAATTGGGCGTAGC	511
OY		1178	AGCCCGAATGGGAATAGAAGTGGTATGATGAGCAAGTAATCTTTGGAGCAGAACTACCA	1237
Db		510	AGCCCGAATGGGAATAGAAGTGGTATGATGAGCAAGTAATCTTTGGAGCAGAACTACCA	451
OY		1238	TTTAACTGATGAAAACCTTGATCCTTTACCTGATTTATGGCTATCTCTTGTGTCAGAA	1297
Db		450	TTTAACTGATGAAAACCTTGATCCTTTACCTGATTTATGGCTATCTCTTGTGTCAGAA	391
OY		1298	ATTGTGGGGCACCAAGGTTTATGGCAAGCGTGAAGGTTCAAAGAGAGAGAGCTTCG	1357
Db		350	ATTGTGGGGCACCAAGGTTTATGGCAAGCGTGAAGGTTCAAAGAGAGAGAGAGCTTCG	331
OY		1358	AGTATACCTTCATTCGACAAACACTGCACATCCAAGTATCAATAAAGAGAGATTAACTCT	1417
Db		330	AGTATACCTTCATTCGACAAACACTGCACATCCAAGTATCAATAAAGAGAGATTAACTCT	271
OY		1418	GTAATCCCATPAAACCTTCATACGTCACCAAGTACTTGGGTTAACCTTATCCTTTTTCTAA	1477
Db		270	GTAATCCCATPAAACCTTCATACGTCACCAAGTACTTGGGTTAACCTTATCCTTTTTCTAA	211
OY		1478	CAAGCAAGTGAATAAATACCTTCCTPAAAGCTTTGGGACCTCAATGATTAATCTTCCAAATC	1537
Db		210	CAAGCAAGTGAATAAATACCTTCCTPAAAGCTTTGGGACCTCAATGATTAATCTTCCAAATC	151
OY		1538	TGTCCAACTCATGCTGTCTTAACCTPAAAGATGGTGTGATGATCAAACTTGCACACTTTAAT	1597
Db		150	TGTCCAACTCATGCTGTCTTAACCTPAAAGATGGTGTGATGATCAAACTTGCACACTTTAAT	91
OY		1598	GGAATAAACCTCTCCGCGCCAGGAAGTTCACTGGGCTTGCACGCTTCTCATATAGTTTTT	1657
Db		90	GGAATAAACCTCTCCGCGCCAGGAAGTTCACTGGGCTTGCACGCTTCTCATATAGTTTTT	31
OY		1658	TGTGATGAAGAAATGCCAAAGTTCGTCGCTTG 1687	
Db		30	TGTGATGAAGAAATGCCAAAGTTCGTCGCTKG 1	
RESULT_3				
AK087283				
LOCUS				
DEFINITION		AK087283	1962 bp mRNA linear HTC 05-DEC-2002	
ACCESSION		Mus musculus J day neonate lung cDNA, RIKEN full-length enriched library, clone:EO30042C09 product:heparanase, full insert sequence.		
VERSION		AK087283		
KEYWORDS		AK087283.1 GI:26104170		
SOURCE		HTC; CAP trapper.		
ORGANISM		Mus musculus (house mouse)		
AUTHORS		Mus musculus		
REFERENCE		Eutheria; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.		
AUTHORS		1 Carninci,P. and Hayashizaki,Y.		
TITLE		High-efficiency full-length cDNA cloning		
JOURNAL MEDLINE		Meth. Enzymol. 303, 19-44 (1999)		
PUBMED		99279253		
REFERENCE		10349636		
AUTHORS		2		
TITLE		Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K., Itoh,M., Komno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.		
JOURNAL MEDLINE		Normalizatiion and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes		
PUBMED		Genome Res. 10 (10), 1617-1630 (2000)		
REFERENCE		20499374		
AUTHORS		3		
TITLE		Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P., Komno,H., Akiyama,J., Nishi,K., Kitsuana,T., Tashiro,H., Itoh,M., Suni,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A., Yamamoto,R., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kasaiwagi,K., Fujiwara,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watanuki,M.,		

JOURNAL
PUBMED
REFERENCE
AUTHORS

Yoneda, Y., Ishikawa, T., Osawa, K., Tanaka, T., Matsunura, S., Kawai, J., Okazaki, Y., Muramatsu, M., Inoue, Y., Kita, A. and Hayashizaki, Y.
RIKEN Integrated sequence analysis (RISA) system-384-format
Genome Res. 10 (11), 1757-1771 (2000)

JOURNAL
PUBMED
REFERENCE
AUTHORS

Kawai, J., Shinagawa, A., Shibata, K., Yoshino, M., Itoh, M., Ishii, Y., Arakawa, T., Hara, A., Fukunishi, Y., Konno, H., Adachi, D., Fukuda, S., Atzawa, K., Ozawa, M., Nishi, K., Kiyosawa, H., Kondo, S., Yamanaoka, I., Salto, T., Okazaki, Y., Gotohori, T., Bono, H., Kasukawa, T., Salto, R., Kadota, K., Matsuda, H., Ashburner, M., Batalov, S., Casavant, T., Fleischmann, W., Gaasterland, T., Gissi, C., King, B., Kochwa, H., Kunhi, P., Lewis, S., Matsuo, Y., Nikaido, T., Peeble, G., Quackenbush, J., Schriml, L.M., Stabili, F., Suzuki, R., Tomita, M., Wagner, L., Washio, T., Sakai, K., Okido, T., Furuno, M., Aono, H., Baldarelli, R., Barsh, G., Blake, J., Boffelli, D., Bojunga, N., Carninci, P., de Bonaldo, M.F., Brownstein, M.J., But, C., Fletcher, C., Fujita, M., Gariboldi, M., Gestblom, S., Hill, D., Hotamoni, L., Hume, D.A., Kamuya, M., Lee, N.H., Lyons, P., Marchionni, L., Mashima, J., Mazzarelli, J., Mommaerts, P., Nordone, P., Ring, B., Ringwald, M., Rodriguez, I., Sakamoto, N., Sasaki, H., Sato, K., Schonbach, C., Seya, T., Shibata, Y., Storch, K.F., Suzuki, H., Toyooka, K., Wang, K.H., Weitz, C., Whitaker, C., Wilming, L., Wynshaw-Boris, A., Yoshida, K., Hasegawa, Y., Kawai, J., Kohetsuki, S. and Hayashizaki, Y.

JOURNAL
PUBMED
REFERENCE
AUTHORS

Functional annotation of a full-length mouse cDNA collection
Nature 409 (6821), 685-690 (2001)

JOURNAL
PUBMED
REFERENCE
AUTHORS

The FANTOM Consortium and the RIKEN Genome Exploration Research Group Phase I & II Team.
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs
Nature 420, 563-573 (2002)

JOURNAL
PUBMED
REFERENCE
AUTHORS

Adachi, J., Atzawa, K., Akimura, T., Arai, T., Bono, H., Carninci, P., Fukuda, S., Furuno, M., Hanagaki, T., Hara, A., Hashizume, W., Hayashida, K., Hayatsu, N., Hiramoto, K., Hirooka, T., Hirozane, T., Horii, F., Imocari, K., Ishii, Y., Itoh, M., Kagawa, I., Kasukawa, T., Katoh, H., Kawai, J., Kojima, Y., Kondo, S., Konno, H., Kouda, M., Koya, S., Kurihara, C., Matsuyama, T., Miyazaki, A., Murata, M., Nakamura, Y., Nishi, K., Nomura, K., Numasaki, R., Ohno, M., Ohsato, N., Okazaki, Y., Salto, R., Satoh, H., Sakai, C., Sakai, K., Sakazume, N., Sano, H., Saesaki, D., Shibata, K., Shinagawa, A., Shitaki, T., Sobabe, Y., Tagami, M., Tagawa, A., Takahashi, F., Takaku-Akaira, S., Takeda, Y., Tanaka, T., Tomaru, A., Toya, T., Yasunishi, A., Muramatsu, M. and Hayashizaki, Y.

JOURNAL
PUBMED
REFERENCE
AUTHORS

Direct Submission
Submitted (16-APR-2002) Yoshihide Hayashizaki, The Institute of Physical and Chemical Research (RIKEN), Laboratory for Genome Exploration Research Group, RIKEN Genomic Sciences Center (GSC), RIKEN Yokohama Institute, 1-7-22 Suhiro-cho, Tsurumi-ku, Yokohama Kanagawa 230-0045, Japan (E-mail: genome-res@gsc.riken.go.jp)
URL: http://genome.gsc.riken.go.jp/, Tel: 81-45-503-9222,
Fax: 81-45-503-9216

JOURNAL
PUBMED
REFERENCE
AUTHORS

CDNA library was prepared and sequenced in Mouse Genome Encyclopedia Project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues.
Please visit our web site for further details.
URL: http://genome.gsc.riken.go.jp/
URL: http://fantom.gsc.riken.go.jp/.
Location/Qualifiers

FEATURES

Source

1..1962

/organism="Mus musculus"

/mol_type="mRNA"

/subset="C57BL/6J"

/db_xref="RANTOM DB:E03042C09"

/db_xref="taxon:10090"


```

source
1..1185
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CS0D1059Y15"
/tissue_type="PLACENTA COT 25-NORMALIZED"
/clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
/note="1st strand cDNA was primed with a NotI-oligo (dt) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT      280 a      293 c      293 g      280 t
ORIGIN
Query Match      53.7%; Score 923.6; DB 9; Length 1185;
Best Local Similarity 98.4%; Pred. No. 4,6e-244;
Matches 956; Conservative 7; Mismatches 6; Indels 3; Gaps 3;
1  CTAGAGCTTTGACCTCTCCGCTGCGGCGAGCTGGGGGAGAGCAGGAGAGCCCA 60
Db  CTAAGAGCTCTGACTCTCCGCTGCGC -GAGCTGGCGGGGAGAGCAGGAGAGCCCA 126
Qy  AGATGCTGCTGCTGGAAGCTGCGCTGCGCGCGCGCTGATGCTGCTCTGGGAC 120
Db  AGATGCTGCTGCTGGAAGCTGCGCTGCGCGCGCGCTGATGCTGCTCTGGGAC 186
Qy  CGCTGGGCTCCCTCCCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 180
Db  CGCTGGGCTCCCTCCCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCG 246
Qy  ACCTGAGCTTCTACCCAGAGAGCGCTGCACTGTGAGCCCTGTTCTCTGCTGCA 240
Db  ACCTGAGCTTCTCTACCCAGAGAGCGCTGCACTGTGAGCCCTGTTCTCTGCTGCA 306
Qy  CCATTGAGCCCACTGCGCCAGAGAGCGCGCTGCTCTGCTGCTGCTGCTGCAAGC 300
Db  CCATTGAGCCCACTGCGCCAGAGAGCGCGCTGCTCTGCTGCTGCTGCTGCTGCAAGC 366
Qy  TTGCTGACTTGGCGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
Db  TTGCTGACTTGGCGAGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 426
Qy  ACTTCTCTATTTTTCATCCCAAGAGATCACTTGAAGAGAGAGATTACTGGCAAT 420
Db  ACTTCTCTATTTTTCATCCCAAGAGATCACTTGAAGAGAGAGATTACTGGCAAT 486
Qy  CTCAAGTCAACCAAGATATTTGCAATATGATTCATCTCTGATGTGAGAGAAAGT 480
Db  CTCAAGTCAACCAAGATATTTGCAATATGATTCATCTCTGATGTGAGAGAAAGT 546
Qy  TAGCGTTGGATGGCGCTTACCAAGAGCAATTTCTCTCCAGAGAACATCAAGAAAGT 540
Db  TAGCGTTGGATGGCGCTTACCAAGAGCAATTTCTCTCCAGAGAACATCAAGAAAGT 606
Qy  TCAAGAGCAGACCTACTCAAGAGCTGTGATGTGCTATACATTTTGAAGAACTGCT 600
Db  TCAAGAGCAGACCTACTCAAGAGCTGTGATGTGCTATACATTTTGAAGAACTGCT 666
Qy  CAGAGCTGAGCTGATCTTTGGCTTAAATGCGTTATTAAGAAACAGACAGATTTGAGTGA 660
Db  CAGAGCTGAGCTGATCTTTGGCTTAAATGCGTTATTAAGAAACAGACAGATTTGAGTGA 726
Qy  ACAATTTCTAATGCTCAAGTTGCTCTGAGCTACTGCTTTCCAAAGGGGATTAATTTTCTT 720
Db  ACAATTTCTAATGCTCAAGTTGCTCTGAGCTACTGCTTTCCAAAGGGGATTAATTTTCTT 786
Qy  GGAAGCTAGGCAATTAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGGT 780
Db  GGAAGCTAGGCAATTAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGGT 846
Qy  CGCAGTTAGGAGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 840
Db  CGCAGTTAGGAGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 906

```

```

Qy  841 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGACGGCTAAGATGCTG- 899
Db  907 ATGCAAACTCTATGCTCTGATGTTGGTCAAGCTCGAAGAAAGACGGCTAAGATGCTGCA 966
Qy  900 AAGAGCTTCTGAAGAGCTGTGAGAGAAAGTATTAATTAATTAATTAATTAATTAATTAAT 959
Db  967 AAGAGCTTCTGAAGAGCTGTGAGAGAAAGTATTAATTAATTAATTAATTAATTAATTAAT 1025
Qy  960 TTGAATGACCG 971
Db  1026 TTGAATGACGMSR 1037

RESULT 5
AL545270
LOCUS      AL545270 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA
DEFINITION
ACCESSION  AL545270 GI:31267106
VERSION    AL545270.2
KEYWORDS   EST.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE  1 (bases 1 to 1201)
AUTHORS   Li, W.B., Gruber, C., Jessee, J. and Polyes, D.
TITLE     Full-length cDNA libraries and normalization
JOURNAL   Unpublished
COMMENT    On Feb 15, 2001 this sequence version replaced gi:12877751.
Contact:  Genoscope
          Genoscope - Centre National de Sequencage
          BP 191 91006 Evry cedex - France
          Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
          Library was constructed by Life Technologies, a division of
          Invitrogen. This sequence belongs to sequence cluster 2469.r For
          more information about this cluster, see
          http://www.genoscope.cns.fr/
          cgi-bin/cluster.cgi?seq=CS0D1028DC02P1&cluster=2469.r. Contact :
          Feng Liang Email : fliang@lifetech.com URL :
          http://fulllength.invitrogen.com/Invitrogen Corporation 1600
          Faraday Avenue Genoscope sequence ID : CS0D1028DC02P1.
FEATURES
    source
        1..1201
        /organism="Homo sapiens"
        /mol_type="mRNA"
        /db_xref="taxon:9606"
        /clone="CS0D1028YF04"
        /tissue_type="PLACENTA COT 25-NORMALIZED"
        /clone_lib="Homo sapiens PLACENTA COT 25-NORMALIZED"
        /note="1st strand cDNA was primed with a NotI-oligo (dt)
        primer. Five prime end enriched, double-strand cDNA was
        digested with Not I and cloned into the Not I and EcoR V
        sites of the pCMVSPORT 6 vector. Library was normalized."
BASE COUNT      292 a      282 c      305 g      279 t
ORIGIN
Query Match      52.4%; Score 902.6; DB 9; Length 1201;
Best Local Similarity 99.3%; Pred. No. 3e-238;
Matches 916; Conservative 0; Mismatches 5; Indels 1; Gaps 1;
1  GAGCTTGAATCTCCGCTGCGGCGAGCTGGCGGGGAGACACCGAGTGAAGCCAAAGA 63
Db  GGGATCTGACTCTCCGCTGCGGCGAGCTGGCGGGGAGACACCGAGTGAAGCCAAAGA 122
Qy  TGCGTCTGCGCTCAAGAGCTGCGCTGCGCGCGCGCTGATCTGCTCTGCGGCGCGC 123
Db  TGCGTCTGCGCTCAAGAGCTGCGCTGCGCGCGCGCGCTGATCTGCTCTGCGGCGCGC 182
Qy  TGGGTCCCTCTCCCTGCGCGCGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC 183
Db  TGGGTCCCTCTCCCTGCGCGCGCTGCGCGCGCGCGCGCGCGCGCGCGCGCGCGCGC 242

```


QY	1425	TTAAACCTCCAAAGTACCAAGTACCTGGGTTACCTTACCTTTTCTTAACAAGCA	1488
Db	234	ATAAACCTTCAATAAGTACCAAGTACTTGGGTTACCTTACCTTTTCTTAACAAGCA	175
QY	1485	GTGATTAATAATACCTTCTAAGACCTTTGGGACCTCATGATTAATCTTCCAAATCTGTCCA	1544
Db	174	GTGATTAATAATACCTTCTAAGACCTTTGGGACCTCATGATTAATCTTCCAAATCTGTCCA	115
QY	1545	CTCAATGCTCTAATCTTAAGATGGTGATGATCAACCTTGGCACCTTTAATGGAAAA	1604
Db	114	CTCAATGCTCTAATCTTAAGATGGTGATGATCAACCTTGGCACCTTTAATGGAAAA	55
QY	1605	CCTCTCCGGCCAGGAAGTTCATCGGCGCTTGCACGCTTCTCATATAGTTTTTTT	1658
Db	54	CCTCTCCGGCCAGGAAGTTCATCGGCGCTTGCACGCTTCTCATATATTTT	1
RESULT 7			
LOCUS	BX398409/c	1083 bp	mRNA linear EST 13-MAY-2003
DEFINITION	BX398409 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens CDNA clone CS0DI058Y124 3-PRIME, mRNA sequence.		
ACCESSION	BX398409		
VERSION	BX398409.1	GI:30617572	
KEYWORDS	EST.		
SOURCE	Homo sapiens (human)		
ORGANISM	Homo sapiens		
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		
AUTHORS	Li W.B., Gruber,C., Jessee,J. and Polayes,D.		
TITLE	Full-length cDNA libraries and normalization		
JOURNAL	Unpublished		
COMMENT	Contact: Genoscope Genoscope - Centre National de Sequencage BP 191 91006 EVRY cedex - France Email: seqref@genoscope.cns.fr Web : www.genoscope.cns.fr Library was constructed by life technologies, a division of Invitrogen. This sequence belongs to sequence cluster 2469.r For more information about this cluster, see http://www.genoscope.cns.fr/ cgi-bin/cluster.cgi?seq=CS0DI058B12NP1;cluster=2469.r. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CS0DI058B12NP1.		
FEATURES			
Source	1. 1083 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="CS0DI058Y124" /cuisine_type="PLACENTA COT 25-NORMALIZED" /clone_1fb="Homo sapiens PLACENTA COT 25-NORMALIZED" /note="1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoR V sites of the pCMVSPORT 6 vector. Library was normalized."		
BASE COUNT	273 a 264 c 206 g 258 t		
ORIGIN			
Query Match	49.1%;	Score 844.8;	DB 13; Length 1083;
Best Local Similarity	89.6%;	Pred. No. 2.9e-222;	
Matches 928;	Conservative 18;	Mismatches 75;	Indels 15; Gaps 6;
QY	670	ATGCTCAGTTGCTCTGAGACTACCTCTTCCAAAGGGGATATAATTTCTTGGGAACTAG	729
Db	1045	ATGCTCAAGTGTCTCT- GACTACTGCTC-TCGMAAGGGGATATAACTTTCTTGGGAACTAG	988
QY	730	GCAATGAACCTTAACAGTTTCCCTTAAGAAGCGTGAATATTTCTCATGAGGGTGCAGTTAG	789
Db	987	GCAATGAACCTTAACAGTTTCCCTTAAGAAGCGTGAAT-TTTATTCATAGGGTGCAGTTAG	929
QY	790	GAGAAAGTATATTTCAATTCATGAATACTTTAAGAAAGTCACCTTCAAAAATTCAAAC	849

Db	928	GAGAAAGATTTTATTCATTTGATTCATTAACCTTTAGAAAGTCCA	CTTCAAAAATGCCAAAC	869
Qy	850	TCTATGATCTCGATGTTGGTCAGCCTCGAAGAAAAGCGGCTA	AGATGCTGAAGGCTTCC	909
Db	868	TCTATGGTCTCGATGTTGGTCAGCCTCGAAGAAAAGCGGCTA	AGATGCTGAAGGCTTCC	809
Qy	910	TGAAGGCTGCTGAGAGAAAGTGAATGATTCATGATTAACATG	GCATCACTACTATTTTGAATGAGC	969
Db	808	TGAAGGCTGCTGAGAGAAAGTGAATGATTCATGATTAACATG	GCATCACTACTATTTTGAATGAGC	749
Qy	970	GGATCGCTACCAAGGAGATTTTCTAAACCCCTGATGATTTGA	CACTTTTATTTTCATCTG	1029
Db	748	GSATCGCTACCAAGGAGATTTTCTAAACCCCTGATGATTTGA	CACTTTTATTTTCATCTG	689
Qy	1030	TGCAAAAAGTTTTCCAGGTGGTTGAGACACAGGCCCTGGCA	AGAAAGCTCTGTTAGAG	1089
Db	688	TGCAAAAAGTTTTCCAGGTGGTTGAGACACAGGCCCTGGCA	AGAAAGCTCTGTTAGAG	629
Qy	1090	AAACAAGCTCTGATATGAGAGCGGAGCGCCCTTGCTATCC	GACACCTTTGACGTGCT	1149
Db	628	AAACAAGCTCTGATATGAGAGCGGAGCGCCCTTGCTATCC	GACACCTTTGACGTGCT	569
Qy	1150	TTATGCTGCTGGATTAATTTGGGCGCTGTCAGGCCGAAATG	GAATGAGTGTGATGAGC	1209
Db	568	TTATGCTGCTGGATTAATTTGGGCGCTGTCAGGCCGAAATG	GAATGAGTGTGATGAGC	509
Qy	1210	AAGTATCTTTTGGAGCAGAAACTACATTTAGTGAATGA	AAACCTTGATCCTTTACCTG	1269
Db	508	AAGTATCTTTTGGAGCAGAAACTACATTTAGTGAATGA	AAACCTTGATCCTTTACCTG	449
Qy	1270	ATTAT-----TTGGCTATCTCTTCTGTTCAAGAAATTTG	TGGGCGACCAAGCTTTAT	1321
Db	448	ATTATGKGGGKGGTGGCGCKGKGGKGGKGGKGGKGGKGG	CGACCAAGCTTTAT	389
Qy	1322	GGCAAGCGGTGAAGGTTCAAGAGAGAGAGAGCTTGAATAT	CACTTACCAAAAC	1381
Db	388	GGCAAGCGGTGAAGGTTCAAGAGAGAGAGAGCTTGAATAT	CACTTACCAAAAC	329
Qy	1382	TGACATCTCAAGATATAAAGAGAGATTTAACTCTGTATCC	ATAAACCTTCATTAACGT	1441
Db	328	TGACATCTCAAGATATAAAGAGAGATTTAACTCTGTATCC	ATAAACCTTCATTAACGT	269
Qy	1442	CACCAAGTACTTGGCGTTACCTTATCCTTTTCTTAAACA	GAGTGTATAATACCTTCT	1501
Db	268	CACCAAGTACTTGGCGTTACCTTATCCTTTTCTTAAACA	GAGTGTATAATACCTTCT	209
Qy	1502	AAGAC---TTTGGGACCTCATGATTAATCTTCCAAATCTG	TCCAACTGATGATTAAC	1558
Db	208	GGGACCGTGTGGGCGCTGCATGATTAATCTTCCAAATCTG	TCCAACTGATGATTAAC	149
Qy	1559	TCTAAAGATGCTGATGATCAAACTTGGCCACCTTTAATG	AAAAAACCCTTCGCGCAGG	1618
Db	148	TCTAAAGATGCTGATGATCAAACTTGGCCACCTTTAATG	AAAAAACCCTTCGCGCAGG	89
Qy	1619	AAGTCACTGGGCTTGGCCAGCTTTCTCATATATGTTT	TTTGTGATTAAG-AAATGCCAAG	1677
Db	88	AAGTCACTGGGCTTGGCCAGCTTTCTCATATATGTTT	TTTGTGATTAAG-AAATGCCAAG	29
Qy	1678	TTGCTGCTGATGATCTG	1693	
Db	28	NTGNCGCTTGCMTNNB	13	

RESULT 8

BX373611/c 914 bp mRNA linear EST 08-MAY-2003

LOCUS BX373611 Homo sapiens PLACENTA COT 25-NORMALIZED Homo sapiens cDNA

DEFINITION clone CS010581Y124 3-PRIME, mRNA sequence.

ACCESSION BX373611

VERSION BX373611.1 GI:30446136

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 914)
 AUTHORS Li, W.B., Gruber, C., Jessee, J. and Polayes, D.
 TITLE Full-length cDNA libraries and normalization
 JOURNAL Unpublished
 COMMENT Contact: Genoscope
 Genoscope - Centre National de Sequencage
 BP 191 91006 Evry cedex - France
 Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
 Library was constructed by Life Technologies, a division of
 Invitrogen. This sequence belongs to sequence cluster 2469.r For
 more information about this cluster, see
 http://www.genoscope.cns.fr/
 cgi-bin/cluster.cgi?seq=CS0BAK06DC08NM1&cluster=2469.r. Contact :
 Feng Liang Email : fliang@lifetech.com URL :
 http://fulllength.invitrogen.com/Invitrogen Corporation 1600
 Faraday Avenue Genoscope sequence ID : CS0BAK06DC08NM1.
 FEATURES
 SOURCE
 1. 914
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="CS0D1058Y124"
 /issue_type="PLACENTA COT 25-NORMALIZED"
 /note="18c strand cDNA was primed with a NotI-oligo (dT)
 primer. Five prime end enriched, double-strand cDNA was
 digested with Not I and cloned into the Not I and EcoR V
 sites of the pCMVSPORT 6 vector. Library was normalized."
 BASE COUNT 260 a 191 c 188 g 275 t
 ORIGIN
 Query Match 46.8%; Score 804.6; DB 13; Length 914;
 Best Local Similarity 95.3%; Pred. No. 3.6e-211;
 Matches 872; Conservative 0; Mismatches 39; Indels 4; Gaps 4;

1344 AGAAGAAAGCTTCAGATATACCTTCATGTGACAAACACTGACAAATCCAGGTATTAAGAA 1403
 374 AGAAGAAAGCTTCAGATATACCTTCATGTGACAAACACTGACAAATCCAGGTATTAAGAA 315
 1404 GGAATTTAACTCTGTATGCCATTAACCTCCATTAAGCTCACCAGATCTGGGTTACCC 1463
 314 GGAATTTAACTCTGTATGCCATTAACCTCCATTAAGCTCACCAGATCTGGGTTACCC 255
 1464 TATCCTTTTCTAACAAGCAAGTGATTAATACCTTGAAGCTTTGGAGCTCATGGA 1523
 254 TATCCTTTTCTAACAAGCAAGTGATTAATACCTTGAAGCTTTGGAGCTCATGGA 195
 1524 TTACTTTCCAAATCTGTCCAACTCAATGCTTAACCTTAAGATGATGATCAAAACC 1583
 194 TTACTTTCCAAATCTGTCCAACTCAATGCTTAACCTTAAGATGATGATCAAAACC 135
 1584 TTGCACTCTTAATGAAAAAAGCTCTCCGAGCAAGATTCAGTGGCTTCCAGCTTTC 1643
 134 TTGCACTCTTAATGAAAAAAGCTCTCCGAGCAAGATTCAGTGGCTTCCAGCTTTC 75
 1644 TCATATAGTTTTTTTGTATGAAGAAATCCAAAGTTGCTGCTGCATCTGAATTAAT 1703
 74 TCATATAGTTTTTTTGT-ATAAGAAATGCCAAAGTTGCTGCTGCATCTGAATTAAT 16
 1704 ATACTAGTCTGACA 1718
 15 ATACCACTGCCGAAA 1
 RESULT 9
 CB988510
 LOCUS
 DEFINITION
 AGENCOURT 13905817 NIH_MGC 147 Homo sapiens cDNA clone
 IMAGE:30340461 5', mRNA sequence.
 ACCESSION
 CB988510
 VERSION
 CB988510.1 GI:30283030
 KEYWORDS
 EST.
 SOURCE
 Homo sapiens (human)
 ORGANISM
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 1 (bases 1 to 881)
 AUTHORS NIH-MGC http://imgc.nci.nih.gov/
 TITLE National Institutes of Health, Mammalian Gene Collection (MGC)
 JOURNAL Unpublished
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-remail.nih.gov
 Tissue Procurement: Dr. Stefan Hansson
 cDNA Library Preparation: Michael J. Brownstein (NHGRI) with help
 and advice from Piero Carninci (RIKEN)
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNLN)
 DNA sequencing by: Agencourt Bioscience Corporation
 Clone distribution: MGC clone distribution information can be
 found through the I.M.A.G.E. Consortium/LNLN at:
 http://imgc.lnl.gov
 Plate: NDAM370 row: f column: 22
 High quality sequence stop: 664.
 FEATURES
 SOURCE
 1. 881
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:30340461"
 /issue_type="Human Placenta"
 /lab_host="DH10B Tora"
 /clone.lib="NIH MGC 147"
 /note="Organ: Placenta; Vector: pluscriptR; Site: 1:
 all-XhoI; Site 2: BamH; Oligo-dT primed using primer
 5'-TTTTTTTTTTTTTTVN-3', size-selected for average
 insert size 2.3 kb and normalized to ROT 5. This is a
 primary library enriched for full-length clones and
 constructed using the Cap-trapper method (Carninci, in

QY 452 ATCCATCCCTCTGATGTGAGAGAGATGCGTTGGAATGGCCCTACAGAGCAATT 511
DB 524 ATCCATCCCTCTGATGTGAGAGAGATGCGTTGGAATGGCCCTACAGAGCAATT 583
QY 512 GCTCTCCGAGAACCTTCCAGAAAAGTTCAAGAACAGCACTTCTAAGAGCTCTGT 571
DB 584 GCTCTCCGAGAACCTTCCAGAAAAGTTCAAGAACAGCACTTCTAAGAGCTCTGT 643
QY 572 AGATGTGCTATACCTTTTGGAACTGCTCAGAGCTGAGCTTATCTTTGGCTTAATGC 631
DB 644 AGATGTGCTATACCTTTTGGAACTGCTCAGAGCTGAGCTTATCTTTGGCTTAATGC 703
QY 632 GTTATTAGAACAGAGATTGTCAGTGAACAGTTCTATGTCTAGTTCTCTGAGCTA 691
DB 704 GTTATTAGAACAGAGATTGTCAGTGAACAGTTCTATGTCTAGTTCTCTGAGCTA 763
QY 692 CTGCTCTTCCAGAGGGGTATTAACATTTCTTTGGAACTAGGCAATGAAGTTTCTT 751
DB 764 CTGCTCTTCCAGAGGGGTATTAACATTTCTTTGGAACTAGGCAATGAAGTTTCTT 822
QY 752 TAAAGAGCTGATATTTTTCATCAATGAGTGGAGTGAAGATTAATTCATTCGA 811
DB 823 TAAAGAGCTGATATTTTTCATCAATGAGTGGAGTGAAGATTAATTCATTCGA 882
QY 812 TAACTTCTAAGAAAGTCCACCTTCAAAAATGCAAACT 850
DB 883 TAACTTCTAAGAAAGTCCACCTTCAAAAATGCAAACTCT 921

RESULT 11
BQ438834 907 bp mRNA linear EST 24-MAY-2002
LOCUS AGENCOURT_7761619 NIH_MGC_70 Homo sapiens cDNA clone IMAGE:6017952
DEFINITION 5', mRNA sequence.

ACCESSION BQ438834.1 GI:21177910
VERSION BQ438834.1
KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1 (bases 1 to 907)

NIH-MGC http://mgi.nci.nih.gov/.

National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL

COMMENT

Contact: Robert Strausberg, Ph.D.

Email: cga@bbs-rcmail.nih.gov

Tissue Procurement: ATCC

cDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: Agencourt Bioscience Corporation

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/MLNI at:

http://image.llnl.gov

Plate: ILAM13218 row: b column: 01

High quality sequence stop: 616.

Location/Qualifiers

1. 907

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:6017952"

/tissue_type="epithelioid carcinoma"

/lab_host="DH10B (phage-resistant)"

/clone_1ib="NIH MGC 70"

/note="Organ: pancreas; Vector: pCMV-SPORT6; Site 1: NCI;
Site 2: Sall; Cloned unidirectionally. Primer: Oligo dT.
Average insert size 1.1 kb. Library constructed by Life
Technologies."

BASE COUNT 260 a 176 c 226 g 242 t 3 others

ORIGIN

Query Match 40.1%; Score 689.8; DB 13; Length 907;

Best Local Similarity 94.8%; Pred. No. 2.2e-119;
Matches 778; Conservative 0; Mismatches 34; Indels 9; Gaps 6;

QY 385 AGAATCAACCTTTGAAGAGAGAGTACTGGCAATCTCAAGTCAACAGAGATTTTSCA 444

DB 5 AAGATCAACCTTTGAAGAGAGAGTACTGGCAATCTCAAGTCAACAGAGATTTTSCA 64

QY 445 AATATGATCCATCCCTCTGATGTGAGAGAGATTAAGTTGAATGAGCCCTACAGG 504

DB 65 AATATGATCCATCCCTCTGATGTGAGAGAGATTAAGTTGAATGAGCCCTACAGG 124

QY 505 AGCAATGCTACTCCGAGAACACTTACAGAAAAGTTCAAGAACAGCACTTACTAGAA 564

DB 125 AGCAATGCTACTCCGAGAACACTTACAGAAAAGTTCAAGAACAGCACTTACTAGAA 184

QY 565 GCTCTGATAGTGTCTATACCTTTTGGAACTGCTCAGAGCTGAGCTTATCTTTGGCC 624

DB 185 GCTCTGATAGTGTCTATACCTTTTGGAACTGCTCAGAGCTGAGCTTATCTTTGGCC 244

QY 625 TAAATGCGTATTAAGAACAGACAGATTGTCAGTGAACAGTTCTATATGCTGCTCC 684

DB 245 TAAATGCGTATTAAGAACAGACAGATTGTCAGTGAACAGTTCTATATGCTGCTCC 304

QY 685 TGAATCTGCTCTTCCAGAGGGGTATTAACATTTCTTTGGAACTAGGCAATGAACCTAACA 744

DB 305 TGAATCTGCTCTTCCAGAGGGGTATTAACATTTCTTTGGAACTAGGCAATGAACCTAACA 364

QY 745 GTTTCCTTAAGAGGCTGATATTTTTCATCAATGGTGGCAGTGTAGAGAAATTAATTC 804

DB 365 GTTTCCTTAAGAGGCTGATATTTTTCATCAATGGTGGCAGTGTAGAGAAATTAATTC 424

QY 805 AATTGCAATTAACCTTAAAGAAAGTCAACCTTCAAAAATGCAAACTATATGCTGCTGATG 864

DB 425 AATTGCAATTAACCTTAAAGAAAGTCAACCTTCAAAAATGCAAACTATATGCTGCTGATG 484

QY 865 TTGGTCAACCTTCAAGAAAGAGCGCTAAGATGCTGAAGAGCTTCTGAAAGCTGGTGAG 924

DB 485 TTGGTCAACCTTCAAGAAAGAGCGCTAAGATGCTGAAGAGCTTCTGAAAGCTGGTGAG 544

QY 925 AAGTATGATTCATCAATGATGATGATGATGATGATGATGATGATGATGATGATGATG 982

DB 545 AAGTATGATTCATCAATGATGATGATGATGATGATGATGATGATGATGATGATGATG 604

QY 983 GGAAGATTTTCTAACCCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1040

DB 605 GGAAGATTTTCTAACCCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 664

QY 1041 TTCCAGGTGTTGAGAGACAGAGCTTGGCAAG-AAAGTCTGTTAGAGAAACAGCTC 1099

DB 665 TTCCAGGTGTTGAGAGACAGAGCTTGGCAAG-AAAGTCTGTTAGAGAAACAGCTC 724

QY 1100 TGCATAT-GAGAGCGAGAGCGCTTGTCTATCCGACCTTTGACAGCTGCTTATGTCG 1158

DB 725 TGCATATGAGAGCGAGAGCGCTTGTCTATCCGACCTTTGACAGCTGCTTATGTCG 784

QY 1159 T---GATTAATTTGGGCTGCTGACGCCGGAATGGGAATGAA 1196

DB 785 TTGGATTAATTTGGGCTGCTGACGCCGGAATGGGAATGAA 825

RESULT 12

LOCUS BQ775819/c

DEFINITION UI-H-FH0-bcg-a-07-0-UI.s1 NCI CGAP FH0 Homo sapiens cDNA clone

ACCESSION BQ775819

VERSION BQ775819.1 GI:21984295

KEYWORDS EST.

SOURCE

ORGANISM Homo sapiens (human)

REFERENCE

1 (bases 1 to 708) 708 bp mRNA linear EST 26-JUL-2002

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.
 TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 JOURNAL Unpublished
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-remail.nih.gov
 Tissue Procurement: James Martin
 cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
 DNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
 DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
 Clone Distribution: Clone distribution information can be obtained
 from Dr. M. Bento Soares, bento-soares@uiowa.edu
 Seq primer: M13 FORWARD
 POLYA=Yes.

FEATURES
 source Location/Qualifiers
 1..708
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="UI-H-FH0-Dc9-a-07-0-UI"
 /tissue_type="Human Chondrosarcoma Cell Line"
 /dev_stage="Adult"
 /lab_host="DH10B (Life Technologies)"
 /clone_lib="NCI CGAP FH0"
 /note="Organ: Bone; Vector: pT773-Pac (Pharmacia) with a
 modified polylinker; Site 1: EcoR I; Site 2: Not I;
 NCI CGAP FH0 is a cDNA library containing the following
 tissue(s): Human Grade I Chondrosarcoma Cell Line The
 library was constructed according to Bonaldo, Lennon and
 Soares, Genome Research, 6:791-806, 1996. First strand
 cDNA synthesis was primed with an oligo-dT primer
 containing a Not I site. Double stranded cDNA was ligated
 to an EcoR I adaptor, digested with Not I, and cloned
 directionally into pT773-Pac vector. The oligonucleotide
 used to prime the synthesis of first-strand cDNA contains
 a library tag sequence that is located between the Not I
 site and the (dT)18 tail. The sequence tag for this
 library is AGAATCCGGC. The cell line was provided by Dr
 James Martin from University of Iowa
 TAG_LIB=UI-H-FH0
 TAG_TISSUE=Human Chondrosarcoma Cell Line C58 - Grade 1
 Chondrosarcoma
 TAG_SEQ=AGAATCCGGC"

BASE COUNT 190 a 157 c 144 g 215 t 2 others
 ORIGIN

Query Match 40.0%; Score 687.8; DB 13; Length 708;
 Best Local Similarity 99.4%; Pred. No. 6.8e-179;
 Matches 689; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1026 TCTGTGCAAAAAGTTTCCAGGTGTTGAGACACAGCCCTGGCAAGAAGTCTGCTTA 1085
 DB 708 TCTGTGCAAAAAGTTCACAGGTGTTGAGACACAGCCCTGGCAAGAAGTCTGCTTA 649
 QY 1086 GGAGAAACAGCTTCGATATGAGAGCGGCGCTTCATCCGACACCTTTGACGT 1145
 DB 708 GGAGAAACAGCTTCGATATGAGAGCGGCGCTTCATCCGACACCTTTGACGT 589
 QY 648 GGAGAAACAGCTTCGATATGAGAGCGGCGCTTCATCCGACACCTTTGACGT 589
 QY 1146 GCGTTATGTGGCTGGATTAATTTGGCCCTGTGACCCGGAATGGAATGAGTGTGATG 1205
 DB 588 GCGTTATGTGGCTGGATTAATTTGGCCCTGTGACCCGGAATGGAATGAGTGTGATG 529
 QY 1206 AGGCAAGATTTTCTTGGAGCAGGAACTTCCATTATGAGTGAATGAAACTTCATCTTTA 1265
 DB 528 AGGCAAGATTTTCTTGGAGCAGGAACTTCCATTATGAGTGAATGAAACTTCATCTTTA 469
 QY 1266 CCGATTTATGGCTATCTCTCTGTTCAAGAAATGTTGGGACCAAGGTGTTAATGGA 1325
 DB 468 CCGATTTATGGCTATCTCTCTGTTCAAGAAATGTTGGGACCAAGGTGTTAATGGA 409
 QY 1326 AGCGTCAAGGTTCAAAGAGAGAGCTTCAGATATACCTTCATGCAACAACACTGAC 1385
 DB 409 AGCGTCAAGGTTCAAAGAGAGAGCTTCAGATATACCTTCATGCAACAACACTGAC 349

QY 1386 AATCCAGATATTAAGAGAGATTTAACTCTGTATGCCATTAACCTTCATATGCTACC 1445
 DB 348 AATCCAGATATTAAGAGAGATTTAACTCTGTATGCCATTAACCTTCATATGCTACC 289
 QY 1446 AAGTACTTGGCGTTACCTTATCTTTTCTTCAACAAGCAGTGATTAATACCTTTAAGA 1505
 DB 288 AAGTACTTGGCGTTACCTTATCTTTTCTTCAACAAGCAGTGATTAATACCTTTAAGA 229
 QY 1506 CCTTTGGAGACCTCATGATTACTTTCCAAATCTGTCACATCATGCTCACTTAAG 1565
 DB 228 CCTTTGGAGACCTCATGATTACTTTCCAAATCTGTCACATCATGCTCACTTAAG 169
 QY 1566 ATGTGATGATCAAACTTCCACCTTTAAATGAAAAACCTTCGCGCCAGAAAGTTCA 1625
 DB 168 ATGTGATGATCAAACTTCCACCTTTAAATGAAAAACCTTCGCGCCAGAAAGTTCA 109
 QY 1626 CTGGGCTTGGCAGCTTCTCATATATGTTTTTTGTGATGAATAATGCCAAGTTGCT 1685
 DB 108 CTGGGCTTGGCAGCTTCTCATATATGTTTTTTGTGATGAATAATGCCAAGTTGCT 49
 QY 1686 TGCATCTGAATAAATAATATCTAGTCTGACA 1718
 DB 48 TGCATCTGAATAAATAATATCTAGTCTGACA 16

RESULT 13
 BX107633
 LOCUS BX107633 Soares_placenta_8to9weeks_2NBH8to9w Homo sapiens cDNA
 DEFINITION clone IMAGP998B16561; IMAGE:257583, mRNA sequence.
 ACCESSION BX107633
 VERSION BX107633
 KEYWORDS EST, B107633.1 GI:27847484
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens

REFERENCE
 AUTHORS Ebert, L., Heil, O., Hennig, S., Neubert, P., Patsch, E., Peters, M.,
 Radelof, U., Schneider, D. and Korn, B.
 Human Unigeneset - RZPD3
 Unpublished

TITLE
 JOURNAL
 COMMENT RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
 Im Neuenheimer Feld 580, D-69120 Heidelberg, Germany
 RZPD; IMAGP998B16561.
 RZPDLIB; I.M.A.G.E. cDNA Clone Collection;
 Human Unigeneset - RZPD3 (RZPDLIB No.972)
<http://www.rzpd.de/cloneCards/cg1-bin/showLib.pl.cgi/response?libNo=972> Contact: Ina Rolfs
 RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH
 Heubnerweg 6, D-14059 Berlin, Germany
 Tel: +49 30 32639 101
 Fax: +49 30 32639 111
 www.rzpd.de

FEATURES
 source This clone is available royalty-free from RZPD.
 contact RZPD (clone@rzpd.de) for further information. Seq primer:
 M13r, Primer sequence: TTTCAACACAGAAACACTATGAC.
 location/Qualifiers
 1..652

/organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGP998B16561; IMAGE:257583"
 /dev_stage="two placenta; one from 8 weeks and another
 from 9 weeks post conception"
 /lab_host="DH10B (ampicillin resistant)"
 /clone_lib="Soares_placenta_8to9weeks_2NBH8to9w"
 /note="Organ: placenta; Vector: pT773D (Pharmacia) with a
 modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
 strand cDNA was primed with a Not I - oligo(dT) primer [5'
 TGTTACCAATCTGAAGTGGAGCGCGCATTTTTTTTTTTTTTTT 3'],

double-stranded cDNA was size selected, ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of a modified p773 vector (Pharmacia). Library constructed by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 181 a 138 c 149 g 182 t 2 others
ORIGIN

Query Match 35.7%; Score 615.2; DB 13; Length 652;
Best Local Similarity 98.9%; Pred. No. 8.4e-159;
Matches 639; Conservative 0; Mismatches 5; Indels 2; Gaps 2;

1016 TTTTATTTCTGTCGCAAAAAGTTTCCAGTGTGAGACACCGAGCTGGCAAGAA 1075
7 TTTTATTTATCTGCAAAAAGTTTCCAGTGTGAGACACCGAGCTGGCAAGAA 66
1076 GGTCTGTAGAGAAACAAGCTGCAATGAGAGCGGAGCGCTTGTCTATCCGACAC 1135
67 GGTCTGTAGAGAAACAAGCTGCAATGAGAGCGGAGCGCTTGTCTATCCGACAC 126
1136 CTTTGACCTGGCTTTATGTCGCTGATTAATTTGGGCTGTGAGCCCGAATGGATAGA 1195
127 CTTTGACCTGGCTTTATGTCGCTGATTAATTTGGGCTGTGAGCCCGAATGGATAGA 186
1196 AGTGTGATGAGGCAAGTATCTTTGGAGCAGAAACTACATTAAGTGAATAACTT 1255
187 AGTGTGATGAGGCAAGTATCTTTGGAGCAGAAACTACATTAAGTGAATAACTT 246
1256 CGATCTTTAAGCTGATTAATGCTATCTCTTGTTCAGAAATTTGGGAGCAAGCT 1315
247 CGATCTTTAAGCTGATTAATGCTATCTCTTGTTCAGAAATTTGGGAGCAAGCT 306
1316 GTTAATGAGCAGCGTCAGAGTTCAAGAGAGAGAGCTTCGATATACCTTCATTGCA 1375
307 GTTAATGAGCAGCGTCAGAGTTCAAGAGAGAGAGCTTCGATATACCTTCATTGCA 366
1376 AAACATGACATCCAAAGTATTAAGAGAGAGAGATTAACCTGTATGCAATTAACCTCA 1435
367 AAACATGACATCCAAAGTATTAAGAGAGAGAGATTAACCTGTATGCAATTAACCTCA 426
1436 TAAAGTACCAAGTACTGCGGTTACCTTATCTTTTCAACAGCAAGTGGATTAATA 1495
427 TAAAGTACCAAGTACTGCGGTTACCTTATCTTTTCAACAGCAAGTGGATTAATA 486
1496 CTTTGAAGCTTTGGGACCTCATGATTAATCTTCCAAATGTCGAATGATGCT 1555
487 CTTTGAAGCTTTGGGACCTCATGATTAATCTTCCAAATGTCGAATGATGCT 546
1556 AACTTAAAGATGTGATGATCAAA-CCTTGCCACCTTTAATGGAAGAAA-CCTCTCCGG 1613
547 AACTTAAAGATGTGATGATCAAA-CCTTGCCACCTTTAATGGAAGAAA-CCTCTCCGG 606
1614 CCAGAGAGTCACTGGGCTTGGCCAGCTTTCTCATATAGTTTTTTG 1659
607 CCAGAGAGTCACTGGGCTTGGCCAGCTTTCTCATATAGTTTTTTG 652

RESULT 14
BM996417/c 682 bp mRNA linear EST 17-JUN-2002
LOCUS UI-H-DT0-av1-m-03-0-UI.s1 NCI CGAP_DTO Homo sapiens cDNA clone
DEFINITION IMAGE:5881130 3', mRNA sequence.
ACCESSION BM996417
VERSION BM996417.1 GI:19721318
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE 1 (bases 1 to 682)
NCI-GenBank <http://www.ncbi.nlm.nih.gov/ncicgap>.
AUTHORS National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
TITLE Tumor Gene Index

JOURNAL COMMENT

Unpublished
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-remail.nih.gov
Tissue Procurement: Dr. Jose Mercuende
cDNA Library preparation: Dr. M. Bento Soares, University of Iowa
DNA Library Arrayed by: Dr. M. Bento Soares, University of Iowa
DNA Sequencing by: Dr. M. Bento Soares, University of Iowa
Clone Distribution: Clone distribution information can be found through the I.M.A.G.E. Consortium/LINL at: <http://image.lnl.gov>
Seq primer: M13 FORWARD
POLYA=Yes.

FEATURES

source

Location/Qualifiers

1..682
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5881130"
/tissue_type="Metastatic Chondrosarcoma"
/dev_stage="Adult"
/lab_host="DH10B (Life Technologies)"
/clone_id="NCI CGAP DTO"
/note="Organ: Lung; Vector: p773-Pac (Pharmacia) with a modified polylinker; Site 1: EcoR I; Site 2: Not I; NCI CGAP DTO is a cDNA library containing the following tissue(s): Metastatic Chondrosarcoma in lung. The library was constructed according to Bonaldo, Lennon and Soares, Genome Research, 6:791-806, 1996. First strand cDNA synthesis was primed with an oligo-dT primer containing a Not I site. Double stranded cDNA was ligated to an EcoR I adaptor, digested with Not I, and cloned directionally into p773-Pac vector. The oligonucleotide used to prime the synthesis of first-strand cDNA contains a library tag sequence that is located between the Not I site and the (dT)18 tail. The sequence tag for this library is AACTGTCGG.
TAG_LIB=UI-H-DT0
TAG_TISSUE=Lung metastatic chondrosarcoma
TAG_SEQ=AACTGTCGG"

BASE COUNT 182 a 146 c 139 g 210 t 5 others
ORIGIN

Query Match 35.7%; Score 614.8; DB 12; Length 682;
Best Local Similarity 98.8%; Pred. No. 1.1e-158;
Matches 660; Conservative 0; Mismatches 4; Indels 4; Gaps 4;

1054 AGAGCACCAGGCTGGCAAGAGCTGTGAGAGAAACAAGCTTCGATATGAGGGC 1113
682 AGAGCACCAGGCTGGCAAGAGAGCTGTGAGAGAAACAAGCTTCGATATGAGGGC 624
1114 GAGCGCCCTTGCTATCCGACACCTTTGACGCTGCTTATGCTGATTAATTTGGGC 1173
623 GAGCGCCCTTGCTATCCGACACCTTTGACGCTGCTTATGCTGATTAATTTGGGC 564
1174 TGTGAGCCCGAATGGAATAGAGTGTGATGAGCAAGTATCTTTGAGCAGAAACT 1233
563 TGTGAGCCCGAATGGAATAGAGTGTGATGAGCAAGTATCTTTGAGCAGAAACT 504
1234 ACCATTATGATTAATAAATCTTGATCCTTTATACCTGATTAATGCTATCTCTGTTCA 1293
503 ACCATTATGATTAATAAATCTTGATCCTTTATACCTGATTAATGCTATCTCTGTTCA 444
1294 -AGAAATGTTGGGACCAAA-GGTGTATATGAGCAGCGTCAAGGTTCAAGAGAGGAA 1351
443 NAGAAATGTTGGGACCAAAAGGTGTATATGAGCAGCGTCAAGGTTCAAGAGAGGAA 384
1352 GCTTGAGATATACCTTCAATGACCAACAAGTCAATCAAGTATTAAGAGAGGATTT 1411
383 GCTTGAGATATACCTTCAATGACCAACAAGTCAATCAAGTATTAAGAGAGGATTT 324
1412 AACTGTGATGATTAACCTTCATTAAGTCAACCAAGTACTTGGGTTACCTTATCCCTT 1471
324 AACTGTGATGATTAACCTTCATTAAGTCAACCAAGTACTTGGGTTACCTTATCCCTT 264

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: February 16, 2004, 07:56:25 ; Search time 8216.88 Seconds

(without alignments)
8568.399 Million cell updates/sec

Title: US-10-676-079-1

Perfect score: 1721

Sequence: 1 ctgaagcttcgactctccg.....atactactgctgacactg 1721

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 2888711 seqs, 2045481386 residues

Total number of hits satisfying chosen parameters: 5777422

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl: *
1: gb_ba: *
2: gb_hcg: *
3: gb_in: *
4: gb_om: *
5: gb_ov: *
6: gb_pat: *
7: gb_ph: *
8: gb_pl: *
9: gb_pr: *
10: gb_ro: *
11: gb_sts: *
12: gb_sy: *
13: gb_un: *
14: gb_vl: *
15: em_ba: *
16: em_fun: *
17: em_hum: *
18: em_in: *
19: em_mu: *
20: em_om: *
21: em_ov: *
22: em_ph: *
23: em_pat: *
24: em_pl: *
25: em_ro: *
26: em_sts: *
27: em_sy: *
28: em_un: *
29: em_vl: *
30: em_hcg_hum: *
31: em_hcg_inv: *
32: em_hcg_other: *
33: em_hcg_mus: *
34: em_hcg_pln: *
35: em_hcg_rod: *
36: em_hcg_mam: *
37: em_hcg_vrt: *
38: em_sy: *
39: em_hcgo_hum: *
40: em_hcgo_mus: *
41: em_hcgo_other: *

score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1721	100.0	1721	6 AR080679	AR080679 Sequence
2	1721	100.0	1721	6 AR080680	AR080680 Sequence
3	1721	100.0	1721	6 AR125603	AR125603 Sequence
4	1721	100.0	1721	6 AR125604	AR125604 Sequence
5	1721	100.0	1721	6 AR194189	AR194189 Sequence
6	1721	100.0	1721	6 AR194190	AR194190 Sequence
7	1721	100.0	1721	6 AR221285	AR221285 Sequence
8	1721	100.0	1721	6 AR221286	AR221286 Sequence
9	1721	100.0	1721	6 AR243203	AR243203 Sequence
10	1721	100.0	1721	6 AR243204	AR243204 Sequence
11	1721	100.0	1721	6 AR287435	AR287435 Sequence
12	1721	100.0	1721	6 AR287436	AR287436 Sequence
13	1721	100.0	1721	6 BD074427	BD074427 Polynucle
14	1721	100.0	1721	6 BD074428	BD074428 Polynucle
15	1719.4	99.9	1899	6 BD074430	BD074430 Polynucle
16	1719.4	99.9	1899	6 BD074431	BD074431 Polynucle
17	1717.8	99.8	1758	9 AF144325	AF144325 Homo sapi
18	1713	99.5	1722	6 AX136167	AX136167 Sequence
19	1713	99.5	1722	6 BD123536	BD123536 Secretary
20	1713	99.5	1722	9 AK075400	AK075400 Homo sapi
21	1694.6	98.5	1713	6 AR156691	AR156691 Sequence
22	1694.6	98.5	1713	6 AX034643	AX034643 Sequence
23	1688.8	98.1	1723	6 AR156692	AR156692 Sequence
24	1688.8	98.1	1723	6 AX034645	AX034645 Sequence
25	1686.8	98.0	3726	6 AR235866	AR235866 Sequence
26	1686.8	98.0	3726	6 AX019348	AX019348 Sequence
27	1686.8	98.0	3726	6 BD131218	BD131218 Human hep
28	1686.8	98.0	3726	6 AF155510	AF155510 Homo sapi
29	1683.8	97.8	1810	9 BC051321	BC051321 Homo sapi
30	1682.6	97.8	1724	6 AX147946	AX147946 Sequence
31	1682.6	97.8	1724	9 AF165154	AF165154 Homo sapi
32	1660.8	96.5	1694	9 AF152376	AF152376 Homo sapi
33	1631.4	94.8	1669	9 AF084467	AF084467 Homo sapi
34	1585	92.1	1593	6 AR210040	AR210040 Sequence
35	1585	92.1	1593	6 BD136761	BD136761 Human pla
36	1254.4	72.9	1662	4 AF281160	AF281160 Bos tauru
37	1099.2	63.9	1736	10 AY077467	AY077467 Mus muscu
38	1081.6	62.8	3177	10 AF184967	AF184967 Rattus no
39	802.2	46.6	1380	6 AR156693	AR156693 Sequence
40	802.2	46.6	1380	6 AX034647	AX034647 Sequence
41	786.2	45.7	1191	6 AR156694	AR156694 Sequence
42	786.2	45.7	1191	6 AX034649	AX034649 Sequence
43	595	34.6	1605	5 AY037007	AY037007 Gallus ga
44	486.8	28.3	553	6 AX336600	AX336600 Sequence
45	453	26.3	824	6 AR080681	AR080681 Sequence

ALIGNMENTS

RESULT 1
AR080679
LOCUS AR080679 1721 bp DNA linear PAT 31-AUG-2000
DEFINITION Sequence 9 from patent US 5968822.
ACCESSION AR080679
VERSION AR080679.1 GI:10007409
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1721)
Pecker, I., Vlodavsky, I. and Feinstein, E.
Polynucleotide encoding a polypeptide having heparanase activity
and expression of same in transduced cells
JOURNAL Patent: US 5968822-A 9 19-OCT-1999;

FEATURES		Location/Qualifiers	
Source		1..1721	
BASE COUNT		451 a 413 c 410 g 447 t	
ORIGIN		100.0%; Score 1721; DB 6; Length 1721;	
Query Match		Best Local Similarity 100.0%; Pred. No. 0;	
Matches 1721; Conservative		0; Mismatches 0; Indels 0; Gaps 0;	
QY	1	CTAAGGCTTTGACCTCTCCGCTGCGGAGAGCTGGGGGGGAGAGCCAGCTGAGCCCA	60
DB	1	CTAAGGCTTTGACCTCTCCGCTGCGGAGAGCTGGGGGGGAGAGCCAGCTGAGCCCA	60
QY	61	AGATGCTGCTGCGCTGAGAGCCCTGCGCGCGCGCTGATGCTGCTCTGCGGAGC	120
DB	61	AGATGCTGCTGCGCTGAGAGCCCTGCGCGCGCGCTGATGCTGCTCTGCGGAGC	120
QY	121	CGCTGGGTCCTCTCCCTGCGCGCGCTGCGCGCGCTGCGCGAGCAGCAGAGCTGCTG	180
DB	121	CGCTGGGTCCTCTCCCTGCGCGCGCTGCGCGCGCTGCGCGAGCAGCAGAGCTGCTG	180
QY	181	ACCTGAGCTTTCTTCAACCAGAGCGCTGACCTGGTGAGCCCTGCTCTGCTGCTCA	240
DB	181	ACCTGAGCTTTCTTCAACCAGAGCGCTGACCTGGTGAGCCCTGCTCTGCTGCTCA	240
QY	241	CCATTGAGCGCAACCTGGCGAGAGCCGGGGTCTCATCTCTGGGTTCTCCAAAGC	300
DB	241	CCATTGAGCGCAACCTGGCGAGAGCCGGGGTCTCATCTCTGGGTTCTCCAAAGC	300
QY	301	TTTCGTAACCTTGGCCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGGTGCAACAGACG	360
DB	301	TTTCGTAACCTTGGCCAGAGGCTTGTCTCTGCTGACCTGAGGTTTGGTGCAACAGACG	360
QY	361	ACTTCTTAATTTTTCATCCCAAGAGAGATCAACTTTTGAAGAGAGATTAAGTCAAT	420
DB	361	ACTTCTTAATTTTTCATCCCAAGAGAGATCAACTTTTGAAGAGAGATTAAGTCAAT	420
QY	421	CTCAAGTCAACGAGATTTTGAATATGATGATCCATCCCTCTGATGAGAGAGAGT	480
DB	421	CTCAAGTCAACGAGATTTTGAATATGATGATCCATCCCTCTGATGAGAGAGAGT	480
QY	481	TACGCTTGAATGCGCTTACACGAGAGCAATGCTACTCCGAGAGCACTACAGAAAAGT	540
DB	481	TACGCTTGAATGCGCTTACACGAGAGCAATGCTACTCCGAGAGCACTACAGAAAAGT	540
QY	541	TCAGAGACGACCTACTCAAGAGCTGTGATGATGTCTATPACATTTTGCAGAACTGCT	600
DB	541	TCAGAGACGACCTACTCAAGAGCTGTGATGATGTCTATPACATTTTGCAGAACTGCT	600
QY	601	CAGGACTGAGCTTGAATCTTGGCTTAAAGCGCTTATTAAGAACAGAGTTTGGAGTGA	660
DB	601	CAGGACTGAGCTTGAATCTTGGCTTAAAGCGCTTATTAAGAACAGAGTTTGGAGTGA	660
QY	661	ACAGTTCTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCAAGGGGTATACATTTCTT	720
DB	661	ACAGTTCTAATGCTCAGTTGCTCTGAGACTACTGCTCTTCAAGGGGTATACATTTCTT	720
QY	721	GGGAACTAGGCAATGAACCTAACAGTTTCTTAAAGAGCTGATATTTTCAATCAATGAGT	780
DB	721	GGGAACTAGGCAATGAACCTAACAGTTTCTTAAAGAGCTGATATTTTCAATCAATGAGT	780
QY	781	CGCAGTTAGGAGAAATTTATTTCAATGCTAATACTTTAAGAAAGTCCACTTCAAAA	840
DB	781	CGCAGTTAGGAGAAATTTATTTCAATGCTAATACTTTAAGAAAGTCCACTTCAAAA	840
QY	841	ATGCAAACTATGATGCTGATGTTTGGCAGCTCGAAGAGAGAGCGGTAAAGATGCTGA	900
DB	841	ATGCAAACTATGATGCTGATGTTTGGCAGCTCGAAGAGAGAGCGGTAAAGATGCTGA	900
QY	901	AGAGCTTCTGTAAGGCTGGTGAGAGATGATTTCAATTCATGATCAATGATCACTATTT	960
DB	901	AGAGCTTCTGTAAGGCTGGTGAGAGATGATTTCAATTCATGATCAATGATCACTATTT	960

QY	961	TGAATGACGAGCTGCTACCAAGGAGATTTTCTAATCCCTGATGATTTGACATTTTGA	1020
DB	961	TGAATGACGAGCTGCTACCAAGGAGATTTTCTAATCCCTGATGATTTGACATTTTGA	1020
QY	1021	TTTCAATCTGTGCAAAAAGTTTTCAGGTGCTTGAAGACACCAAGGCTGCGCAAGAGTCT	1080
DB	1021	TTTCAATCTGTGCAAAAAGTTTTCAGGTGCTTGAAGACACCAAGGCTGCGCAAGAGTCT	1080
QY	1081	GGTTAGAGAAACAAGCTCTGATATGAGAGCGAGCGCCCTGCTATCCGACACTTGG	1140
DB	1081	GGTTAGAGAAACAAGCTCTGATATGAGAGCGAGCGCCCTGCTATCCGACACTTGG	1140
QY	1141	CAGCTGGCTTTATGTGCTGATTAATTTGGGCTGTGACCCGAGATGGGAATAGAATGG	1200
DB	1141	CAGCTGGCTTTATGTGCTGATTAATTTGGGCTGTGACCCGAGATGGGAATAGAATGG	1200
QY	1201	TGATGAGCAAGATATTTCTTTGAGAGAGAACTACCATTTATGATGATGAAAACTTCGATC	1260
DB	1201	TGATGAGCAAGATATTTCTTTGAGAGAGAACTACCATTTATGATGATGAAAACTTCGATC	1260
QY	1261	CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGGTGCGCAAGAGTGTAA	1320
DB	1261	CTTTACCTGATTTATGCTATCTCTTCTGTTCAAGAAATTTGGTGCGCAAGAGTGTAA	1320
QY	1321	TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGCTTCAAGTATACCTTCAATGCACAACA	1380
DB	1321	TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGCTTCAAGTATACCTTCAATGCACAACA	1380
QY	1381	CTGACATTCAGAGTATTAAGAGAGATTTACTCTGATGATCCATAAACCCTCATAACG	1440
DB	1381	CTGACATTCAGAGTATTAAGAGAGATTTACTCTGATGATCCATAAACCCTCATAACG	1440
QY	1441	TCACCAATTAATCTGGGTTAACCTATCCTTTTCTAACAAGAGTGAATTAATCCTTC	1500
DB	1441	TCACCAATTAATCTGGGTTAACCTATCCTTTTCTAACAAGAGTGAATTAATCCTTC	1500
QY	1501	TAAAGCTTTTGGGACCTCATGATTAATCTTCAAACTGTCCAACTCAATGATGATCACTC	1560
DB	1501	TAAAGCTTTTGGGACCTCATGATTAATCTTCAAACTGTCCAACTCAATGATGATCACTC	1560
QY	1561	TAAAGATGATGATGATCAAACTTTCGACCTTTAATGAGAAAACTTCCGGCCAGGAA	1620
DB	1561	TAAAGATGATGATGATCAAACTTTCGACCTTTAATGAGAAAACTTCCGGCCAGGAA	1620
QY	1621	GTTCACTGGGCTTGGCAGCTTTCTCATATAGTTTGTGATTAAGAAATGCCAAAGTTG	1680
DB	1621	GTTCACTGGGCTTGGCAGCTTTCTCATATAGTTTGTGATTAAGAAATGCCAAAGTTG	1680
QY	1681	CTGCTTGATCTGAAAAATTAATAATATACATGATGATGATGATGATGATGATGATG	1721
DB	1681	CTGCTTGATCTGAAAAATTAATAATATACATGATGATGATGATGATGATGATGATG	1721

RESULT 2

AR080680 1721 bp DNA linear PAT 31-AUG-2000

LOCUS AR080680 Sequence 11 from patent US 5968822.

DEFINITION AR080680

VERSION AR080680.1 GI:10007410

KEYWORDS

SOURCE

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 1721)

AUTHORS

TITLE

JOURNAL

Patent: US 5968822-A 11-19-OCT-1999;

FEATURES

Source

BASE COUNT 451 a 413 c 410 g 447 t

ORIGIN

Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CTAGAGCTTTGCACTCTCCGCTGCGCGGAGCTGGCGGGGGAGACACCGAGTGAGCCCA 60
 DB 1 CTAGAGCTTTGCACTCTCCGCTGCGCGGAGCTGGCGGGGGAGAGACGAGCGAGTGAGCCCA 60
 QY 61 AGATCTGCTGCTGCGAGAGCTGGCGCGCGCGCGCGCTGATGCTGCTGCTGCTGCGGCG 120
 DB 61 AGATCTGCTGCTGCGAGAGCTGGCGCGCGCGCGCGCTGATGCTGCTGCTGCTGCGGCG 120
 QY 121 CGCTGGGCTCCCTCTCCCTGGCGCGCTGCGCGAGCTGGCGAGACACGAGACGCTGCG 180
 DB 121 CGCTGGGCTCCCTCTCCCTGGCGCGCTGCGCGAGCTGGCGAGACACGAGACGCTGCG 180
 QY 181 ACCTGGAATCTTTCACCCAGAGCGCGCTGCACTGGTGAAGCCCTGCTGCTGCTGCTCA 240
 DB 181 ACCTGGAATCTTTCACCCAGAGCGCGCTGCACTGGTGAAGCCCTGCTGCTGCTGCTCA 240
 QY 241 CCATGAGCGCCCACTGGCGAGAGACCGCGGTTCTCATCTCTGCTGCTGCTGCTGCTCAAGC 300
 DB 241 CCATGAGCGCCCACTGGCGAGAGACCGCGGTTCTCATCTCTGCTGCTGCTGCTGCTCAAGC 300
 QY 301 TTGCGAATCTGGCGAGAGGCTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
 DB 301 TTGCGAATCTGGCGAGAGGCTTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
 QY 361 ACTTCTTAATTTTGCATCCCAAGAGATCAACCTTTGAGAGAGAGATTACTGGCAAT 420
 DB 361 ACTTCTTAATTTTGCATCCCAAGAGATCAACCTTTGAGAGAGAGATTACTGGCAAT 420
 QY 421 CTCAAGTCAACCGAGATATTTGCAATATGATTCATCTCTGCTGCTGCTGCTGCTGCTGCT 480
 DB 421 CTCAAGTCAACCGAGATATTTGCAATATGATTCATCTCTGCTGCTGCTGCTGCTGCTGCT 480
 QY 481 TACGGTGAATGCGCTACCGAGAGCAATGCTCTCCGAGAGACCTACCGAGAGAGT 540
 DB 481 TACGGTGAATGCGCTACCGAGAGCAATGCTCTCCGAGAGACCTACCGAGAGAGT 540
 QY 541 TCAAGAACAGCACTACTCAAGAGCTCTGATGCTGCTATACATTTTGGCAACTGCT 600
 DB 541 TCAAGAACAGCACTACTCAAGAGCTCTGATGCTGCTATACATTTTGGCAACTGCT 600
 QY 601 CAGGACTGGAATCTTTTGGCTTAATGCTTATTAAGAACAGCAATTTGCACTGGA 660
 DB 601 CAGGACTGGAATCTTTTGGCTTAATGCTTATTAAGAACAGCAATTTGCACTGGA 660
 QY 661 ACAGTTCAATGCTGAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720
 DB 661 ACAGTTCAATGCTGAGTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720
 QY 721 GGGAACTAGGCAATGACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGT 780
 DB 721 GGGAACTAGGCAATGACCTTAACAGTTTCTTAAGAGGCTGATATTTTCAATGAGT 780
 QY 781 CGCAGTTAGAGAGATTATTAATTCATGATTAACCTTTCAAGAAAGTCCACTTCAAAA 840
 DB 781 CGCAGTTAGAGAGATTATTAATTCATGATTAACCTTTCAAGAAAGTCCACTTCAAAA 840
 QY 841 ATGCAAACTCTATGCTCTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
 DB 841 ATGCAAACTCTATGCTCTGATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
 QY 901 AGAGCTTCTGAGAGCTGGTGAAGAGATGATTCATGCTGCTGCTGCTGCTGCTGCTGCT 960
 DB 901 AGAGCTTCTGAGAGCTGGTGAAGAGATGATTCATGCTGCTGCTGCTGCTGCTGCTGCT 960
 QY 961 TGAATGAGCGAGCTCTACAGAGAGAGATTTCTAAACCTGATGATGAGCATTTTGA 1020
 DB 961 TGAATGAGCGAGCTCTACAGAGAGAGATTTCTAAACCTGATGATGAGCATTTTGA 1020

QY 1021 TTTCACTGTGCAAAAAGTTTCCAGTGTGTTGAGAGACAGAGGCTGGCAAGAGTCT 1080
 DB 1021 TTTCACTGTGCAAAAAGTTTCCAGTGTGTTGAGAGACAGAGGCTGGCAAGAGTCT 1080
 QY 1081 GGTTCGAGAAAAGAGCTCTGATATGAGAGGCGAGCGCCCTTGTATTCGACACTTTG 1140
 DB 1081 GGTTCGAGAAAAGAGCTCTGATATGAGAGGCGAGCGCCCTTGTATTCGACACTTTG 1140
 QY 1141 CAGTGGCTTATATGCGTGAATTAATTGGGCTGTGACCCGGAATGGGAATGAGAGTGG 1200
 DB 1141 CAGTGGCTTATATGCGTGAATTAATTGGGCTGTGACCCGGAATGGGAATGAGAGTGG 1200
 QY 1201 TGATGAGCAAGATATCTTTTGGAGCAGAGAACTACATTTATGATGAGAAACTTCGATC 1260
 DB 1201 TGATGAGCAAGATATCTTTTGGAGCAGAGAACTACATTTATGATGAGAAACTTCGATC 1260
 QY 1261 CTTTACCTGATTAATGCTATCTCTTCTGTTCAAGAAATGGTGGCACCAAGTGTAA 1320
 DB 1261 CTTTACCTGATTAATGCTATCTCTTCTGTTCAAGAAATGGTGGCACCAAGTGTAA 1320
 QY 1321 TGGCAAGGTCGAGGTTCAAGAGAGAGCTTGAGATACCTGATGCAAGAA 1380
 DB 1321 TGGCAAGGTCGAGGTTCAAGAGAGAGCTTGAGATACCTGATGCAAGAA 1380
 QY 1381 CTGACATTCGAAGTATTAAGAGAGATTTACTCTGATGCAATTAACCTCCATAAGC 1440
 DB 1381 CTGACATTCGAAGTATTAAGAGAGATTTACTCTGATGCAATTAACCTCCATAAGC 1440
 QY 1441 TCACCAAGTACTTGGGTTACCTTATCTTTTCTTAACAGCAAGTGATTAATCTTC 1500
 DB 1441 TCACCAAGTACTTGGGTTACCTTATCTTTTCTTAACAGCAAGTGATTAATCTTC 1500
 QY 1501 TTAAGCTTTTGGAGCTGATGATTAATCTTTTCCAAATCTGTCCAACTCAATGCTTAATC 1560
 DB 1501 TTAAGCTTTTGGAGCTGATGATTAATCTTTTCCAAATCTGTCCAACTCAATGCTTAATC 1560
 QY 1561 TAAAGATGATGATGATCAAACTTGGACCTTTAATGGAAGAACTCTCGGCGAGAGA 1620
 DB 1561 TAAAGATGATGATGATCAAACTTGGACCTTTAATGGAAGAACTCTCGGCGAGAGA 1620
 QY 1621 GTTCACTGGGCTTGGCAGCTTCTCATATAGTTTGTGATTAAGAAATGCGAAAGTTG 1680
 DB 1621 GTTCACTGGGCTTGGCAGCTTCTCATATAGTTTGTGATTAAGAAATGCGAAAGTTG 1680
 QY 1681 CTGCTTGATCTGAAGATTAATATATCTAGTCTGACACTG 1721
 DB 1681 CTGCTTGATCTGAAGATTAATATATCTAGTCTGACACTG 1721

RESULT 3
 AR125603 1721 bp DNA linear PAT 16-MAY-2001
 LOCUS
 DEFINITION Sequence 1 from patent US 6177545.
 ACCESSION AR125603
 VERSION AR125603.1 GI:14111665
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.

REFERENCE 1 (bases 1 to 1721)
 AUTHORS Pecker, I., Vlodavsky, I., Friedman, Y. and Peretz, T.
 TITLE Hepiranase specific molecular probes and their use in research and medical applications
 JOURNAL Patent: US 6177545-A 1 23-JAN-2001;
 FEATURES
 source 1..1721
 location/Qualifiers
 BASE COUNT 451 a 413 c 410 g 447 t

ORIGIN
 Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;


```

Db      ||| 120
61 AGATCTGCTGCGCTGCAAGCTGCGCTGCGCGCGCTGATGCTGCTGCTGCGGCG 120
Qy      ||| 180
121 CGCTGGGTCCTCTCTCCCTGCGCGCTGCGCGCGCTGCGCGCGCTGCGCGCGCT 180
Db      ||| 180
121 CGCTGGGTCCTCTCTCCCTGCGCGCTGCGCGCGCTGCGCGCGCTGCGCGCGCT 180
Qy      ||| 240
181 ACCTGGAATCTTCTCAACCGAGAGCGCTGCACTGATGAGCGCTGCTGCTGCTGCA 240
Db      ||| 240
181 ACCTGGAATCTTCTCAACCGAGAGCGCTGCACTGATGAGCGCTGCTGCTGCTGCA 240
Qy      ||| 300
241 CCATTGAGCGCAACCTGCGCAGAGCGCGGCTCTCATCTCTGCTGCTGCTGCA 300
Db      ||| 300
241 CCATTGAGCGCAACCTGCGCAGAGCGCGGCTCTCATCTCTGCTGCTGCTGCA 300
Qy      ||| 360
301 TTCTGATCTTGGCGAGAGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
Db      ||| 360
301 TTCTGATCTTGGCGAGAGCGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 360
Qy      ||| 420
361 ACTTCTAATTTTCTGATCCCAAGAGAAATCAACCTTTGAGAGAGAGTTACTGCA 420
Db      ||| 420
361 ACTTCTAATTTTCTGATCCCAAGAGAAATCAACCTTTGAGAGAGAGTTACTGCA 420
Qy      ||| 480
421 CTCAAGTCAACCGAGAGATATTTGCAATATGATTCATCCCTCTGATGAGAGAG 480
Db      ||| 480
421 CTCAAGTCAACCGAGAGATATTTGCAATATGATTCATCCCTCTGATGAGAGAG 480
Qy      ||| 540
481 TACGGTGGAAATGCGCTTACCGAGAGCAATTTGCTACTCCGAGAACATCCAGAAA 540
Db      ||| 540
481 TACGGTGGAAATGCGCTTACCGAGAGCAATTTGCTACTCCGAGAACATCCAGAAA 540
Qy      ||| 600
541 TCAAGAACGAGCACTACTCAAGAGCTGTGATGCTGTATATGAAAGAGAGTTGCA 600
Db      ||| 600
541 TCAAGAACGAGCACTACTCAAGAGCTGTGATGCTGTATATGAAAGAGAGTTGCA 600
Qy      ||| 660
601 CAGGACTGGAATCTTGTGCTTGAAGAGCTGCTGCTGCTGCTGCTGCTGCTGCT 660
Db      ||| 660
601 CAGGACTGGAATCTTGTGCTTGAAGAGCTGCTGCTGCTGCTGCTGCTGCTGCT 660
Qy      ||| 720
661 ACAGTTCTAATGCTCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720
Db      ||| 720
661 ACAGTTCTAATGCTCAAGTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 720
Qy      ||| 780
721 GGGAACTGAGCAATGAACTTAACAGTTCTTAAGAGAGCTGATATTTTCAATGAG 780
Db      ||| 780
721 GGGAACTGAGCAATGAACTTAACAGTTCTTAAGAGAGCTGATATTTTCAATGAG 780
Qy      ||| 840
781 CGCAGTTAGAGAGATTAATTAATTCATTAATGCTTAAGAGAGCTGCTGCTGCT 840
Db      ||| 840
781 CGCAGTTAGAGAGATTAATTAATTCATTAATGCTTAAGAGAGCTGCTGCTGCT 840
Qy      ||| 900
841 ATGCAAACTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
Db      ||| 900
841 ATGCAAACTCTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 900
Qy      ||| 960
901 AGAGCTTCTGTAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 960
Db      ||| 960
901 AGAGCTTCTGTAAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 960
Qy      ||| 1020
961 TGAATGAGCGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
Db      ||| 1020
961 TGAATGAGCGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1020
Qy      ||| 1080
1021 TTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
Db      ||| 1080
1021 TTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1080
Qy      ||| 1140
1081 GGTGAGAGAAACAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
Db      ||| 1140
1081 GGTGAGAGAAACAAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1140
Qy      ||| 1200
1141 CAGTGGCTTTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1200

```

```

Db      ||| 1200
1141 CAGTGGCTTTATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1200
Qy      ||| 1260
1201 TGATGAGCAAGATATTTCTTTGAGAGAGAAATCAACATTTATGATGATAAACTTCATC 1260
Db      ||| 1260
1201 TGATGAGCAAGATATTTCTTTGAGAGAGAAATCAACATTTATGATGATAAACTTCATC 1260
Qy      ||| 1320
1261 CTTTACCTGATTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Db      ||| 1320
1261 CTTTACCTGATTAATGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1320
Qy      ||| 1380
1321 TGGCAAGCTGCAAGCTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Db      ||| 1380
1321 TGGCAAGCTGCAAGCTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Qy      ||| 1440
1381 CTGACATCCAGATGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1440
Db      ||| 1440
1381 CTGACATCCAGATGATTAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1440
Qy      ||| 1500
1441 TCACCAAGTACTTGGGCTTACCTTATCTTTTCTTACAGAGAGAGAGAGAGAG 1500
Db      ||| 1500
1441 TCACCAAGTACTTGGGCTTACCTTATCTTTTCTTACAGAGAGAGAGAGAGAG 1500
Qy      ||| 1560
1501 TAAAGCTTTGGAGAGCTGATGATTAATTTGCAATCTGCTGCTGCTGCTGCTGCT 1560
Db      ||| 1560
1501 TAAAGCTTTGGAGAGCTGATGATTAATTTGCAATCTGCTGCTGCTGCTGCTGCT 1560
Qy      ||| 1620
1561 TAAAGATGATGATGATTAACCTTTGCAACCTTTTAAAGAGAGAGAGAGAGAG 1620
Db      ||| 1620
1561 TAAAGATGATGATGATTAACCTTTGCAACCTTTTAAAGAGAGAGAGAGAGAG 1620
Qy      ||| 1680
1621 GTTCACTGGGCTTGGCAGCTTCTCATATAGTTTGTGATTAAGAGAGAGAGAG 1680
Db      ||| 1680
1621 GTTCACTGGGCTTGGCAGCTTCTCATATAGTTTGTGATTAAGAGAGAGAGAG 1680
Qy      ||| 1720
1681 CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1720
Db      ||| 1720
1681 CTGCTTGCATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1720

RESULT 6
ARI94190 1721 bp DNA linear PAT 20-APR-2002
LOCUS ARI94190
DEFINITION Sequence 3 from patent US 6348344.
ACCESSION ARI94190
VERSION ARI94190.1 GI:20240782
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 1721)
AUTHORS Ayal-Hersbkovitz, M., Moskowitz, H., Miron, D., Gilboa, A., Mimon, M., Ben-Artzi, H., Yacoby-Zeevi, O., Pecker, I., Peleg, Y. and Schloimi, Y.
TITLE Genetically modified cells and methods for expressing recombinant heparinase and methods of purifying same
JOURNAL Patent: US 6348344-A 3 19-FEB-2002;
FEATURES
source location/Qualifiers
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      ||| 60
1 CTAGAGCTTTGACTCTCTCGCTGCGGCACTGCGGAGAGAGAGAGAGAGAGAGAGAG 60
Db      ||| 60
1 CTAGAGCTTTGACTCTCTCGCTGCGGCACTGCGGAGAGAGAGAGAGAGAGAGAGAG 60
Qy      ||| 120
61 AGATCTGCTGCGCTGCAAGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCT 120
Db      ||| 120
61 AGATCTGCTGCGCTGCAAGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCTGCGGCT 120

```



```

QY 121 CGCTGGGTCCTCTCTCCCTGGCGCCCTGCGCCGACCTGCGCAGACAGACGTCGTGG 180
Db 121 CGCTGGGTCCTCTCTCCCTGGCGCCCTGCGCCGACCTGCGCAGACAGACGTCGTGG 180
QY 181 ACCGTGACTCTTTCACCCAGAGCGCGCTGCACTGTGTAGCCCGCTCTCTCTCTCTCTCA 240
Db 181 ACCGTGACTCTTTCACCCAGAGCGCGCTGCACTGTGTAGCCCGCTCTCTCTCTCTCTCA 240
QY 241 CCATTGAGCGCCAACTGGCCACGAGACCGCGGTTCTCTCATCTCTCTGGTTCTCCAAAGC 300
Db 241 CCATTGAGCGCCAACTGGCCACGAGACCGCGGTTCTCTCATCTCTCTGGTTCTCCAAAGC 300
QY 301 TTCTGATCTTGGCCAGAGCGTTGTCTCTGCGTACCTGAGGTTTGTGGCACCAAGACG 360
Db 301 TTCTGATCTTGGCCAGAGCGTTGTCTCTGCGTACCTGAGGTTTGTGGCACCAAGACG 360
QY 361 ACTTCTTAATTTTGCATCCCAAGAGAAATCAACTTTGAAGAGAGAAATTACTGGCAAT 420
Db 361 ACTTCTTAATTTTGCATCCCAAGAGAAATCAACTTTGAAGAGAGAAATTACTGGCAAT 420
QY 421 CTCAGTCAACCAAGGATATTTGCAATATGATTCATCCCTCTGATGTGAGAGAAAT 480
Db 421 CTCAGTCAACCAAGGATATTTGCAATATGATTCATCCCTCTGATGTGAGAGAAAT 480
QY 481 TACGGTTGGAATGGCCCTACACAGAGCAATGCTACTCCGAGACACTACCAAGAAAGT 540
Db 481 TACGGTTGGAATGGCCCTACACAGAGCAATGCTACTCCGAGACACTACCAAGAAAGT 540
QY 541 TCAAGAACAGCACCTACTACAGAGAGCTGTGTATGTGTATACCTTTTGCAAACTGCT 600
Db 541 TCAAGAACAGCACCTACTACAGAGAGCTGTGTATGTGTATACCTTTTGCAAACTGCT 600
QY 601 CAGGACTGGAATCTTGTATCTTGGCTTAATGCGTTATTAAGAACAGCAATTTGCACTGA 660
Db 601 CAGGACTGGAATCTTGTATCTTGGCTTAATGCGTTATTAAGAACAGCAATTTGCACTGA 660
QY 661 ACAGTTCTAATGCTCAGTTGCTCTGAGACTACCTGCTCTTCCAAAGGATTAACATTTCT 720
Db 661 ACAGTTCTAATGCTCAGTTGCTCTGAGACTACCTGCTCTTCCAAAGGATTAACATTTCT 720
QY 721 GGGAACTGAGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATATGGT 780
Db 721 GGGAACTGAGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTCAATATGGT 780
QY 781 CGCAGTTGAGAGAAATTAATATTAATGCAATTAACCTTAAGAAAGTCAACTCAAAA 840
Db 781 CGCAGTTGAGAGAAATTAATATTAATGCAATTAACCTTAAGAAAGTCAACTCAAAA 840
QY 841 ATGCAAAAATCTATGATGCTGATGTGTGCTCAGCTCGAAGAAAGACGGCTAAGATGCTGA 900
Db 841 ATGCAAAAATCTATGATGCTGATGTGTGCTCAGCTCGAAGAAAGACGGCTAAGATGCTGA 900
QY 901 AGAGCTTCTCGAAGGCTGTGAGAGAGTGAATGATTCAGTTACATGCAATCACTAAT 960
Db 901 AGAGCTTCTCGAAGGCTGTGAGAGAGTGAATGATTCAGTTACATGCAATCACTAAT 960
QY 961 TGAATGAGCGGACCTGCTACCGAGGAAATTTCTAAACCTGATATTTGACATTTTGA 1020
Db 961 TGAATGAGCGGACCTGCTACCGAGGAAATTTCTAAACCTGATATTTGACATTTTGA 1020
QY 1021 TTTTCACTGTGCAAAAAGTTTTCAGAGTGTGTGAGAGCACAGGCTGCGCAAGAGCT 1080
Db 1021 TTTTCACTGTGCAAAAAGTTTTCAGAGTGTGTGAGAGCACAGGCTGCGCAAGAGCT 1080
QY 1081 GGTTCGAGGAAACAAGCTCTGATATGAGGCGAGCGCTTGTCTATCCGACACTTTG 1140
Db 1081 GGTTCGAGGAAACAAGCTCTGATATGAGGCGAGCGCTTGTCTATCCGACACTTTG 1140
QY 1141 CAGCTGGCTTATATGAGGCTGATTAATGGGCTGTGACCGCGGAGGAAATGAAGAGTGG 1200
Db 1141 CAGCTGGCTTATATGAGGCTGATTAATGGGCTGTGACCGCGGAGGAAATGAAGAGTGG 1200
QY 1201 TGATGAGGCAAGTATTTCTTTGAGAGCAAGAACTACCATTTATGTGATGAAAACTTCGATC 1260

```

```

Db 1201 TGATGAGGCAAGTATTTCTTTGAGAGCAAGAACTACCATTTATGTGATGAAAACTTCGATC 1260
QY 1261 CTTTACCGATTAATTTGCTATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1320
Db 1261 CTTTACCGATTAATTTGCTATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1320
QY 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGAGTTCAGTATACCTCTTATGCAACAA 1380
Db 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGAGTTCAGTATACCTCTTATGCAACAA 1380
QY 1381 CTGACATCCAAAGTATTAAGAGAGATTTACTCTGTATGCAATTAACCTCCATAAG 1440
Db 1381 CTGACATCCAAAGTATTAAGAGAGATTTACTCTGTATGCAATTAACCTCCATAAG 1440
QY 1441 TCACCAATCTCTGGGTTACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1500
Db 1441 TCACCAATCTCTGGGTTACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 1500
QY 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCCAAATCTGTCCTCAATGATGCTAATCTC 1560
Db 1501 TAAAGCTTTGGGACCTCATGATTAATCTTCCAAATCTGTCCTCAATGATGCTAATCTC 1560
QY 1561 TAAAGATGATGATGATCAAACTTTGCCAATCTTAATGAGAAACCTCTCCGCGCAGGAA 1620
Db 1561 TAAAGATGATGATGATCAAACTTTGCCAATCTTAATGAGAAACCTCTCCGCGCAGGAA 1620
QY 1621 GTTCACTGGGCTGCGACCTTCTCATATATTTTGTGTATGATTAAGAAATGCAAGTTG 1680
Db 1621 GTTCACTGGGCTGCGACCTTCTCATATATTTTGTGTATGATTAAGAAATGCAAGTTG 1680
QY 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
Db 1681 CTGCTTGATCTGAAATTAATATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 7
AR221285 1721 bp DNA linear PAT 26-SEP-2002
LOCUS AR221285
DEFINITION Sequence 1 from patent US 6426209.
ACCESSION AR221285
VERSION AR221285.1 GI:23328256
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1721)
AUTHORS Ayal-HersHKovitz,M., Pecker,I. and Yacoby-Zeevi,O.
TITLE Genetically modified cells and methods for expressing recombinant
JOURNAL heparinase and methods of purifying same
FEATURES
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CTAGAGCTTTGAGACTCTCGGCTGCGCGGACCTGCGGAGGAGAGCAGGAGGAGCCCA 60
Db 1 CTAGAGCTTTGAGACTCTCTCGGCTGCGCGGACCTGCGGAGGAGAGCAGGAGGAGCCCA 60
QY 61 AGATGCTGCTGCGCTGCAAGCCTGCGCTGCGCGCGCTGATGCTGCTCTCTGAGGC 120
Db 61 AGATGCTGCTGCGCTGCAAGCCTGCGCTGCGCGCGCTGATGCTGCTCTCTGAGGC 120
QY 121 CGCTGGGTCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 180
Db 121 CGCTGGGTCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 180

```

OY	181	ACCTGGACTTCCTTCAACCCAGAGACGGCTGCACCTGGTAGAGCCCTCGTTCCTGTCGCCGA	240
Db	181	ACCTGGACTTCCTTCAACCCAGAGACGGCTGCACCTGGTAGAGCCCTCGTTCCTGTCGCCGA	240
OY	241	CCATTGACGGCAACCTGGCCACCGAACCCGGGGTTCCTCATCCTCTGGGGTTCCTCAAGC	300
Db	241	CCATTGACGGCAACCTGGCCACCGAACCCGGGGTTCCTCATCCTCTGGGGTTCCTCAAGC	300
OY	301	TTTCGTACTTGGCCACAGAGCTTGTCCTCGGCTACCTGAGGTTTGGTGGCACACAGACG	360
Db	301	TTTCGTACTTGGCCACAGAGCTTGTCCTCGGCTACCTGAGGTTTGGTGGCACACAGACG	360
OY	361	ACTTCCTAATTTTGGATCCCAAGAGAAATCAACTTTGAAGAGAAAGTTAATGGCAAT	420
Db	361	ACTTCCTAATTTTGGATCCCAAGAGAAATCAACTTTGAAGAGAAAGTTAATGGCAAT	420
OY	421	CTCAAGTCAACACGAGATATTTGGCAATATNGATTCATCCTCTCTATGTGAGAGAGAGT	480
Db	421	CTCAAGTCAACACGAGATATTTGGCAATATNGATTCATCCTCTCTATGTGAGAGAGAGT	480
OY	481	TACGGTTGGAATGGCCCTTACACGAGACAAATGCTAATCCGAGAACATCACAGAAAAAGT	540
Db	481	TACGGTTGGAATGGCCCTTACACGAGACAAATGCTAATCCGAGAACATCACAGAAAAAGT	540
OY	541	TCMAAACAAGACCTCAATCTCAAGAAACTCTGTAGATGTGTCTATACCTTTTGCAACCTGCT	600
Db	541	TCMAAACAAGACCTCAATCTCAAGAAACTCTGTAGATGTGTCTATACCTTTTGCAACCTGCT	600
OY	601	CAGACTGGAACCTTGATCTTTGGCCTTAATAGCGTTATTAAGAACACACAGATTTGCAGTGA	660
Db	601	CAGACTGGAACCTTGATCTTTGGCCTTAATAGCGTTATTAAGAACACAGATTTGCAGTGA	660
OY	661	ACAAGTCTAATGCTCAGTTGCTCCTGCACACTAGCTCTTCCAAAGGGATATAACATTCTT	720
Db	661	ACAAGTCTAATGCTCAGTTGCTCCTGCACACTAGCTCTTCCAAAGGGATATAACATTCTT	720
OY	721	GGGAACCTAGGCAATGAACTTCAACATTTCTTAAGAAGGCTGATATTTTCATCAATGGGT	780
Db	721	GGGAACCTAGGCAATGAACTTCAACATTTCTTAAGAAGGCTGATATTTTCATCAATGGGT	780
OY	781	CGCAGTTAGGAGAGATATATTTCAATTTGCATPAACCTTCAAGAAAGTCCACCTTCAAA	840
Db	781	CGCAGTTAGGAGAGATATATTTCAATTTGCATPAACCTTCAAGAAAGTCCACCTTCAAA	840
OY	841	ATGCAAAACTCTATGCTCCTGATGTTGGTGCACGCTCGAAGAAAGACGGCTAAGATGCTGA	900
Db	841	ATGCAAAACTCTATGCTCCTGATGTTGGTGCACGCTCGAAGAAAGACGGCTAAGATGCTGA	900
OY	901	AGAGCTTCTGAAAGGCTGGTGGAGAAAGTATGATTCACTTACATNGCATCACTACTATT	960
Db	901	AGAGCTTCTGAAAGGCTGGTGGAGAAAGTATGATTCACTTACATNGCATCACTACTATT	960
OY	961	TGAATGAGACGGACTGCTACACAGGAAGATTTTCTAAACCTTGATGTATTTGGACATTTT	1020
Db	961	TGAATGAGACGGACTGCTACACAGGAAGATTTTCTAAACCTTGATGTATTTGGACATTTT	1020
OY	1021	TTTCAATCTGTGCAAAAAGTTTTCAGATGGTTGAGAGACACAGGCTTGCAAGAGGCTCT	1080
Db	1021	TTTCAATCTGTGCAAAAAGTTTTCAGATGGTTGAGAGACACAGGCTTGCAAGAGGCTCT	1080
OY	1081	GGTTAGAGAAACAAGCTCTGCAATATGAGGCGGAGCGCCCTTGCTATCCGACACTTTG	1140
Db	1081	GGTTAGAGAAACAAGCTCTGCAATATGAGGCGGAGCGCCCTTGCTATCCGACACTTTG	1140
OY	1141	CAGCTGGCTTATATGAGGCTGGAATAATGGGCGCTGACGCCCCGAATGGGAATAGAAAGTG	1200
Db	1141	CAGCTGGCTTATATGAGGCTGGAATAATGGGCGCTGACGCCCCGAATGGGAATAGAAAGTG	1200
OY	1201	TGATAGGCAATATTTCTTTGGAGACGAAACTACATTTAGTGTGATGAAAACCTTCGATC	1260
Db	1201	TGATAGGCAATATTTCTTTGGAGACGAAACTACATTTAGTGTGATGAAAACCTTCGATC	1260
OY	1261	CTTAACTGATATATGGCTATCTCTTCTGTTCAAGAAATTTGGTGGCACCAAGGTGTTA	1320

Db 1261 CTTTACCGATTTATGGCTATCTTCTGTTCAAGAAATTGGTGGCCCAAGGTGTTAA 1320

Qy 1321 TGGCAAGCGTGCAGAGTTCAAGAAGAAAGCTTCCGAGTATACCTTCATTGCAAAACA 1380

Db 1321 TGGCAAGCGTGCAGAGTTCAAGAAGAAAGAAAGCTTCCGAGTATACCTTCATTGCAAAACA 1380

Qy 1381 CTGACAAATCCCAAGGTATTAAGAAAGAAATTTAACTCTGTATGACATTAACCTCCATTAAG 1440

Db 1381 CTGACAAATCCCAAGGTATTAAGAAAGAAATTTAACTCTGTATGACATTAACCTCCATTAAG 1440

Qy 1441 TCACCAAGTACTTGGCGTTACCTATCCCTTTCTTAAACAAGCAAGTGGATTAATACCTTC 1500

Db 1441 TCACCAAGTACTTGGCGTTACCTATCCCTTTCTTAAACAAGCAAGTGGATTAATACCTTC 1500

Qy 1501 TAAGACCTTTGGGACCTCATGAGTTACTTTCCAAATCTGTCCAACTCAATGTCYAACTC 1560

Db 1501 TAAGACCTTTGGGACCTCATGAGTTACTTTCCAAATCTGTCCAACTCAATGTCYAACTC 1560

Qy 1561 TAAAGATGATGATGATCAAACTTGGCCACTTTTAATGAAAAAAACCTCTCCGGCCAGGAA 1620

Db 1561 TAAAGATGATGATGATCAAACTTGGCCACTTTTAATGAAAAAAACCTCTCCGGCCAGGAA 1620

Qy 1621 GTTCACTGGGCTTGCAGCTTCTCCATAACTTTTTTTTGGATGAAATGSCAAAGTTG 1680

Db 1621 GTTCACTGGGCTTGCAGCTTCTCCATAACTTTTTTTTGGATGAAATGSCAAAGTTG 1680

Qy 1681 CTGCTTGATCTGAAATTAATAATATTAATCTAGTCCAGCACTG 1721

Db 1681 CTGCTTGATCTGAAATTAATAATATTAATCTAGTCCAGCACTG 1721

AR2121286	RESULT 8				
LOCUS	AR2121286	1721 bp	DNA	linear	PAT 26-SEP-2002
DEFINITION	Sequence 3 from patent US 6426209.				
ACCESSION	AR2121286				
VERSION	AR2121286.1	GI:23328257			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 1721)				
TITLE	Ayal-Hershkovitz,M., Pecker,I. and Yacoby-Zeevi,O.				
JOURNAL	Genetically modified cells and methods for expressing recombinant				
FEATURES	heparanase and methods of purifying same				
Source	Patent: US 6426209-A 3 30-Jul-2002;				
	Location/Qualifiers				
	1..1721				
BASE COUNT	451 a	/organism="unknown"	413 c	410 g	447 t
ORIGIN					
Query Match	100.0%;	Score 1721;	DB 6;	Length 1721;	
Best Local Similarity	100.0%;	Pred. No. 0;			
Matches 1721; Conservative	0;	Mismatches	0;	Indels	0;
	Gaps	0;			
QY	1	CTAGAGCTTTGACACTCTCCGCTGCGCGGACACTGAGCGGGGAGACAGCCAGTGA	60		
Db	1	CTAGAGCTTTGACACTCTCCGCTGCGCGGACACTGAGCGGGGAGACAGCCAGTGA	60		
QY	61	AGATGCTCTGCTGCGCTCGAAGCTTGCGCTGCGCGCGCTGATGCTGCTCTGGGGC	120		
Db	61	AGATGCTCTGCTGCGCTCGAAGCTTGCGCTGCGCGCGCTGATGCTGCTCTGGGGC	120		
QY	121	CGCTGGGCTCCCTCTCTCCCTTGGCGCGCCCGCCGACCTGGCGGCAAGACAGGAGCTGGG	180		
Db	121	CGCTGGGCTCCCTCTCTCCCTTGGCGCGCCCGCCGACCTGGCGGCAAGACAGGAGCTGGG	180		
QY	181	ACCTGACCTTCTTACCCAGAGAGCGGCTGACCTGATGAGCCCTCGTTCTGTCCTGCA	240		
Db	181	ACCTGACCTTCTTACCCAGAGAGCGGCTGACCTGATGAGCCCTCGTTCTGTCCTGCA	240		

241 CCATTGACGCCAACCTGGCCACGACCCGCGTTCCTCATCTCTGGGTTCTCCAAAGC 300
 241 CCATTGACGCCAACCTGGCCACGACCCGCGTTCCTCATCTCTGGGTTCTCCAAAGC 300
 301 TTGCGTACCTGGCCAGAGGCTTGTCTCTGGTACCTGAGGTTGGTGGCACCAAGACAG 360
 301 TTGCGTACCTGGCCAGAGGCTTGTCTCTGGTACCTGAGGTTGGTGGCACCAAGACAG 360
 361 ACTTCCTAATTTTGGATCCCAAGAGGATCAACCTTTGAGAGGAGGATTAAGTGGCAAT 420
 361 ACTTCCTAATTTTGGATCCCAAGAGGATCAACCTTTGAGAGGAGGATTAAGTGGCAAT 420
 421 CTCAAGTCAACCCAGGATATTTGGCAATATGATCCATCCCTCTGATGTGAGAGGAGAGT 480
 421 CTCAAGTCAACCCAGGATATTTGGCAATATGATCCATCCCTCTGATGTGAGAGGAGAGT 480
 481 TACGGTTGGAAATGGCCCTACACGAGGCAATGCTCTCCGAGAACACTACACGAGAAAGT 540
 481 TACGGTTGGAAATGGCCCTACACGAGGCAATGCTCTCCGAGAACACTACACGAGAAAGT 540
 541 TCAGAGACGAGCACTACTCAAGAGCTGTGATGATGTGATACCTTTTGCAACTGCT 600
 541 TCAGAGACGAGCACTACTCAAGAGCTGTGATGATGTGATACCTTTTGCAACTGCT 600
 601 CAGGACTGAGCTTGAATCTTTGGCCCTTAATGCGTTTAAGAACACAGATTTGGAGTGA 660
 601 CAGGACTGAGCTTGAATCTTTGGCCCTTAATGCGTTTAAGAACACAGATTTGGAGTGA 660
 661 ACAGTTCTAATGCTCAAGTTGCTCTGAGACTACTGCTTTCCAGGGGATTAACATTTCTT 720
 661 ACAGTTCTAATGCTCAAGTTGCTCTGAGACTACTGCTTTCCAGGGGATTAACATTTCTT 720
 721 GGGAACTGAGGCAATGAACTTAACATTTCTTAAGAGGCTGATATTTTCAATCATATGGT 780
 721 GGGAACTGAGGCAATGAACTTAACATTTCTTAAGAGGCTGATATTTTCAATCATATGGT 780
 781 CGCAGTTAGGAGAAATTAATTTCAATTCATTAATCTTAAAGAGTCCACCTTCAAAA 840
 781 CGCAGTTAGGAGAAATTAATTTCAATTCATTAATCTTAAAGAGTCCACCTTCAAAA 840
 841 ATGCAAACTCTATGCTCTGATGTTGGTGTGACCTCGAAGAAAGACGGCTAAGATGCTGA 900
 841 ATGCAAACTCTATGCTCTGATGTTGGTGTGACCTCGAAGAAAGACGGCTAAGATGCTGA 900
 901 AGAGCTTCTGAAAGGCTGGTGGAGAGATGATGATGATGATGATGATGATGATGATGAT 960
 901 AGAGCTTCTGAAAGGCTGGTGGAGAGATGATGATGATGATGATGATGATGATGATGAT 960
 961 TGAATGAGCGAGCTGCTACCAAGGAAATTTCTAAACCTGATGATGATGATGATGATGAT 1020
 961 TGAATGAGCGAGCTGCTACCAAGGAAATTTCTAAACCTGATGATGATGATGATGATGAT 1020
 1021 TTTTCACTGTGCAAAAAGTTTTCAGGTGTTGAGAGCAACGAGCTGGCAAGAGTCT 1080
 1021 TTTTCACTGTGCAAAAAGTTTTCAGGTGTTGAGAGCAACGAGCTGGCAAGAGTCT 1080
 1081 GGTGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCTTGTCTATCCGACACTTTTG 1140
 1081 GGTGAGAGAAACAAGCTCTGATATGAGAGGCGAGCGCTTGTCTATCCGACACTTTTG 1140
 1141 CAGCTGGCTTATGAGCTGATTAATTTGGGCTGTGACCCGGAATGGAGATGAGAGTGG 1200
 1141 CAGCTGGCTTATGAGCTGATTAATTTGGGCTGTGACCCGGAATGGAGATGAGAGTGG 1200
 1201 TGATGAGGCAAGTATCTTTGAGAGCAAGAACTACCATTTAGTATGAGTAAAGTTGATC 1260
 1201 TGATGAGGCAAGTATCTTTGAGAGCAAGAACTACCATTTAGTATGAGTAAAGTTGATC 1260
 1261 CTTTACCTGATATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAACAGGTGTTAA 1320
 1261 CTTTACCTGATATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGCAACAGGTGTTAA 1320
 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGAGGCTTGAATATCTTCAATGCAACAAACA 1380

1321 TGGCAAGGCTCAAGTTCAAGAGAGAGAGGCTTGGATGATGATGATGATGATGATGATGAT 1380
 1381 CTGCAATCCCAAGGATTAAGAGAGAGGATTTAACTGATGATGATGATGATGATGATGATGAT 1440
 1381 CTGCAATCCCAAGGATTAAGAGAGAGGATTTAACTGATGATGATGATGATGATGATGATGAT 1440
 1441 TCACCAAGTACTTGGCTGATCCCTATCTTTTCTTAACAGAGAGTGGATTAATACCTTTC 1500
 1441 TCACCAAGTACTTGGCTGATCCCTATCTTTTCTTAACAGAGAGTGGATTAATACCTTTC 1500
 1501 TAAAGCTTTGGAGCTCATGATGATTTACTTTCCAAATCTGTCCAACTCATATGCTTAATC 1560
 1501 TAAAGCTTTGGAGCTCATGATGATTTACTTTCCAAATCTGTCCAACTCATATGCTTAATC 1560
 1561 TAAAGATGATGATGATTAACCTTTGCCACCTTTTAATGAGAAACCTTCCGGCCAGGAA 1620
 1561 TAAAGATGATGATGATTAACCTTTGCCACCTTTTAATGAGAAACCTTCCGGCCAGGAA 1620
 1621 GTTCACTGGGCTGGCAGCTTCTCATATGATTTTGTGATTAAGAAATGCCAAAGTTG 1680
 1621 GTTCACTGGGCTGGCAGCTTCTCATATGATTTTGTGATTAAGAAATGCCAAAGTTG 1680
 1681 CTGCTTGATCTGAAATTAATATATGATGATGATGATGATGATGATGATGATGATGATGAT 1721
 1681 CTGCTTGATCTGAAATTAATATATGATGATGATGATGATGATGATGATGATGATGATGAT 1721
 RESULT 9
 AR243203 1721 bp DNA linear PAT 20-DEC-2002
 LOCUS AR243203 Sequence 1 from patent US 6475763.
 DEFINITION AR243203
 ACCESSION AR243203
 VERSION AR243203.1 GI:27290318
 KEYWORDS
 SOURCE
 ORGANISM
 Unknown.
 Unclassified.
 1 (bases 1 to 1721)
 AUTHORS
 Ayal-Hershtovitz, M., Moskowitz, H., Miron, D., Gilboa, A., Mimon, M.,
 Ben-Artzi, H., Jacoby-Zeevi, O., Pecker, I., Peleg, Y. and Shlom, Y.
 Genetically modified cells and methods for expressing recombinant
 heparanase and methods of purifying same
 JOURNAL
 Patent: US 6475763-A 1 05-NOV-2002;
 FEATURES
 source
 1.1721
 location/Qualifiers
 BASE COUNT 451 a 413 c 410 g 447 t
 ORIGIN
 Query Match 100.0%; Score 1721; DB 6; Length 1721;
 Best Local Similarity 100.0%; Pred. No. 0;
 Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1 CTAGAGCTTTGAGCTCTCCGCTGCGGCACTGGCGGGGAGACAGCCAGTGAAGCCCA 60
 1 CTAGAGCTTTGAGCTCTCCGCTGCGGCACTGGCGGGGAGACAGCCAGTGAAGCCCA 60
 61 AGATGCTGTGGGCTGGAAGCTGGCGTGGCGCGCGCTGATGCTGCTCTGGGGC 120
 61 AGATGCTGTGGGCTGGAAGCTGGCGTGGCGCGCGCGCTGATGCTGCTCTGGGGC 120
 121 CGCTGGGCTCCCTCTCCCTGGCGGCTGGCCGACCTGGCGAACAAGACAGCTGCTGG 180
 121 CGCTGGGCTCCCTCTCCCTGGCGGCTGGCCGACCTGGCGAACAAGACAGCTGCTGG 180
 181 ACCTGAGCTTCTTCAACCCAGAGAGCGCTGACCTGATGAGCCCTGTTCTGTCGCTCA 240
 181 ACCTGAGCTTCTTCAACCCAGAGAGCGCTGACCTGATGAGCCCTGTTCTGTCGCTCA 240
 241 CCATTGACGCCAACCTGGCCACGACCCGCGTTCCTCATCTCTGGGTTCTCCAAAGC 300
 241 CCATTGACGCCAACCTGGCCACGACCCGCGTTCCTCATCTCTGGGTTCTCCAAAGC 300


```

Db 301 TTGCACTTGGCCAGAGGCTTCTCTCGCTACCTGAGGTTTGTGGCAACAGACAG 360
Qy 361 ACTTCTTAATTTTGGATCCCAAGAGATCAACCTTTGAAGAGAAATTACTGGCAAT 420
Db 361 ACTTCTTAATTTTGGATCCCAAGAGATCAACCTTTGAAGAGAAATTACTGGCAAT 420
Qy 421 CTCAAGTCAACAGAGATTTTGGCAATATGATCCATCTCTGATGTGGAGGAAGT 480
Db 421 CTCAAGTCAACAGAGATTTTGGCAATATGATCCATCTCTGATGTGGAGGAAGT 480
Qy 481 TACGGTGGATGGCCCTACAGAGGCAATTGCTACCGAGAACACTACAGAAAAGT 540
Db 481 TACGGTGGATGGCCCTACAGAGGCAATTGCTACCGAGAACACTACAGAAAAGT 540
Qy 541 TCAGAAACAGCACTACTCAAGAAAGCTGTAGATGCTATACACTTTTGGCAACTGCT 600
Db 541 TCAGAAACAGCACTACTCAAGAAAGCTGTAGATGCTATACACTTTTGGCAACTGCT 600
Qy 601 CAGGACTGGAATTGATCTTTGGCTTAAATGGCTTATTAAGAAACAGCAATTTGCACTGGA 660
Db 601 CAGGACTGGAATTGATCTTTGGCTTAAATGGCTTATTAAGAAACAGCAATTTGCACTGGA 660
Qy 661 ACAGTCTTAATGCTCAAGTTCCTCGGACTACGCTCTTCCAGAGGGTATTAACATTTCTT 720
Db 661 ACAGTCTTAATGCTCAAGTTCCTCGGACTACGCTCTTCCAGAGGGTATTAACATTTCTT 720
Qy 721 GGGAACTAGGCAATGAACCTTAACAGTTTCTTAAAGAGGCTGATATTTTCACTCAATGGGT 780
Db 721 GGGAACTAGGCAATGAACCTTAACAGTTTCTTAAAGAGGCTGATATTTTCACTCAATGGGT 780
Qy 781 CGCAGTTAGGAGAAATTATATTCATTTGATTAACCTTAAAGAAAGTCCACTTCAAAA 840
Db 781 CGCAGTTAGGAGAAATTATATTCATTTGATTAACCTTAAAGAAAGTCCACTTCAAAA 840
Qy 841 ATGCAAACTCTATAGTCTCTGATGTGGTCAAGCTTCAAGAAAGAGGCTTAAGATGCTGA 900
Db 841 ATGCAAACTCTATAGTCTCTGATGTGGTCAAGCTTCAAGAAAGAGGCTTAAGATGCTGA 900
Qy 901 AGAGCTCTGTAAGAGGCTGTGGAGAAAGTATGATTTAGTTACATGAGATCACTACTAT 960
Db 901 AGAGCTCTGTAAGAGGCTGTGGAGAAAGTATGATTTAGTTACATGAGATCACTACTAT 960
Qy 961 TGAATGACGAGCTGCTACACAGGAAAGATTTTCTTAACCTGATGATTTGAACATTTTGA 1020
Db 961 TGAATGACGAGCTGCTACACAGGAAAGATTTTCTTAACCTGATGATTTGAACATTTTGA 1020
Qy 1021 TTTTCACTGTGCAAAAAGTTTCCAGGTGTGGAGAGCAACAGGCTTGGCAAGAGTCT 1080
Db 1021 TTTTCACTGTGCAAAAAGTTTCCAGGTGTGGAGAGCAACAGGCTTGGCAAGAGTCT 1080
Qy 1081 GGTTAGGAGAAACAAAGCTCTGATATGAGAGGCGGCGCTTGTATCCGACACCTTGG 1140
Db 1081 GGTTAGGAGAAACAAAGCTCTGATATGAGAGGCGGCGCTTGTATCCGACACCTTGG 1140
Qy 1141 CAGCTGCTTATATGCTGATTAATTTGGGCTTCAAGCCGAATGGGAAATAGAAGTGG 1200
Db 1141 CAGCTGCTTATATGCTGATTAATTTGGGCTTCAAGCCGAATGGGAAATAGAAGTGG 1200
Qy 1201 TGATGAGGCAAGATTTCTTTGGAGAGAAACCTACATTTAGTGTATGAATAAACTTCGATC 1260
Db 1201 TGATGAGGCAAGATTTCTTTGGAGAGAAACCTACATTTAGTGTATGAATAAACTTCGATC 1260
Qy 1261 CTTTACCTGATTTATTTGGCTATCTCTTCTTCAAAAATTTGGTGGGCAACAAAGGTGTA 1320
Db 1261 CTTTACCTGATTTATTTGGCTATCTCTTCTTCAAAAATTTGGTGGGCAACAAAGGTGTA 1320
Qy 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGGCTTCAAGATATCTTCAATTTGCAAAAACA 1380
Db 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGGCTTCAAGATATCTTCAATTTGCAAAAACA 1380
Qy 1381 CTGACAAATCCAAAGGATTAAGATTTAATCTGTATGCAATTAACCTTCATTAACG 1440
Db 1381 CTGACAAATCCAAAGGATTAAGATTTAATCTGTATGCAATTAACCTTCATTAACG 1440

```

```

Qy 1441 TCACCAAGTACTTGGGTTAACCTTATCTTTTCTTAACAGCAAGTGTATTAATCTTC 1500
Db 1441 TCACCAAGTACTTGGGTTAACCTTATCTTTTCTTAACAGCAAGTGTATTAATCTTC 1500
Qy 1501 TAAAGCTTTGGGACCTCATGATGATTTACTTTTCAAAATGTCGCAACTCAATGCTTAATC 1560
Db 1501 TAAAGCTTTGGGACCTCATGATGATTTACTTTTCAAAATGTCGCAACTCAATGCTTAATC 1560
Qy 1561 TAAAGATGATGATGATCAAACTTGGCACTTTTAATGAGAAAACCTTCCGGCAGGAA 1620
Db 1561 TAAAGATGATGATGATCAAACTTGGCACTTTTAATGAGAAAACCTTCCGGCAGGAA 1620
Qy 1621 GTTCACTGGGCTTCCAGCTTCTCATATAGTTTCTTATGATTAAGAAATCCAAAGTTG 1680
Db 1621 GTTCACTGGGCTTCCAGCTTCTCATATAGTTTCTTATGATTAAGAAATCCAAAGTTG 1680
Qy 1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
Db 1681 CTGCTTGATCTGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721

RESULT 11
AR287435 1721 bp DNA linear PAT 10-APR-2003
LOCUS AR287435
DEFINITION Sequence 1 from patent US 6531129.
ACCESSION AR287435
VERSION AR287435.1 GI:29725129
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1721)
AUTHORS Pecker, I.; Vlodavsky, I.; Friedman, Y. and Perets, T.
TITLE Heparinase specific molecular probes and their use in research and
JOURNAL medical applications
FEATURES
source location/Qualifiers
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CTAGAGCTTTTGAAGCTTCCGCTGCGGCGAGCTGCGGGGAGAGCAAGCTGAGGCCA 60
Db 1 CTAGAGCTTTTGAAGCTTCCGCTGCGGCGAGCTGCGGGGAGAGCAAGCTGAGGCCA 60
Qy 61 AGATGCTGCTGCTGCTGCAAGGCTGCGTGCCTGCGCGCGCTGATGCTGCTCGGGGC 120
Db 61 AGATGCTGCTGCTGCTGCAAGGCTGCGTGCCTGCGCGCGCTGATGCTGCTCGGGGC 120
Qy 121 CGTGGGCTCCCTGCTCCCTGCGGCGCTGCGCGCACTGCGCAAGCAAGAGAGAGAGCTGG 180
Db 121 CGTGGGCTCCCTGCTCCCTGCGGCGCTGCGCGCACTGCGCAAGAGAGAGAGAGCTGG 180
Qy 181 ACTGGAATCTTTTGAACCCAGAGGCGCTGCACTGTGAGGCGCTGTTCTGTCGTCGA 240
Db 181 ACTGGAATCTTTTGAACCCAGAGGCGCTGCACTGTGAGGCGCTGTTCTGTCGTCGA 240
Qy 241 CCATTGAGCCCACTGCGCAAGGACCGCGGCTTCTATCTCTGAGGTTCTTCAAGC 300
Db 241 CCATTGAGCCCACTGCGCAAGGACCGCGGCTTCTATCTCTGAGGTTCTTCAAGC 300
Qy 301 TTGCACTTGGCCAGAGGCTTGTCTCTGCTGATCTGAGGTTTGTGGCAAGAGAGAG 360
Db 301 TTGCACTTGGCCAGAGGCTTGTCTCTGCTGATCTGAGGTTTGTGGCAAGAGAGAG 360
Qy 361 ACTTCTTAATTTTGGATCCCAAGAGATCAACCTTTGAAGAGAAATTACTGGCAAT 420

```

```

Db 361 ACTTCCTAATTTTCGATCCCAAGAAAGATCAACCTTTGAGAGAAATTACTGCGCAAT 420
Qy 421 CTCAGTCAACCAAGATATTGCAATATGATCCATCCCTGATGTGAGAGAAAGT 480
Db 421 CTCAGTCAACCAAGATATTGCAATATGATCCATCCCTGATGTGAGAGAAAGT 480
Qy 481 TACGGTTGGAATGGCCCTACAGAGCAATTGCTACTCCGAGAAACCTACAGAAAAGT 540
Db 481 TACGGTTGGAATGGCCCTACAGAGCAATTGCTACTCCGAGAAACCTACAGAAAAGT 540
Qy 541 TCAGAAACAGCACTTACTCAAGAGCTGTATGATGTGCTATACATTTTGCAAACTGCT 600
Db 541 TCAGAAACAGCACTTACTCAAGAGCTGTATGATGTGCTATACATTTTGCAAACTGCT 600
Qy 601 CAGGACTGGACTGTATCTTGGCTTAATGGCTTATTAAGACAGAGATTGCGAGTGA 660
Db 601 CAGGACTGGACTGTATCTTGGCTTAATGGCTTATTAAGACAGAGATTGCGAGTGA 660
Qy 661 ACAGTTCTAATGCTCAGTTGCTCTGSACTACTGCTCTTCAAGGGGTATTAACATTTCT 720
Db 661 ACAGTTCTAATGCTCAGTTGCTCTGSACTACTGCTCTTCAAGGGGTATTAACATTTCT 720
Qy 721 GGGAACTAGGCAATGAACTTAACAGTTCTTAAAGAGCTGATATTTTCAATGAGGT 780
Db 721 GGGAACTAGGCAATGAACTTAACAGTTCTTAAAGAGCTGATATTTTCAATGAGGT 780
Qy 781 CGCAGTTGAGGAAATATATATTAATGATGATTAAGTCTTAAAGTCCACTTCAAAA 840
Db 781 CGCAGTTGAGGAAATATATATTAATGATGATTAAGTCTTAAAGTCCACTTCAAAA 840
Qy 841 ATGCAAACTCTATGCTCTGATGTGCTGACCTCGAAGAAAGACGCGTAAAGATGCTGA 900
Db 841 ATGCAAACTCTATGCTCTGATGTGCTGACCTCGAAGAAAGACGCGTAAAGATGCTGA 900
Qy 901 AGAGCTCTCTGAGGCTGCTGAGAAAGTATGATTAACATGATGATCACTACTAT 960
Db 901 AGAGCTCTCTGAGGCTGCTGAGAAAGTATGATTAACATGATGATCACTACTAT 960
Qy 961 TGAATGAGCGGACTGCTACAGGAAAGTCTTAAACCTGATGATTTGCAATTTTGA 1020
Db 961 TGAATGAGCGGACTGCTACAGGAAAGTCTTAAACCTGATGATTTGCAATTTTGA 1020
Qy 1021 TTTCACTGTGCAAAAAGTTTCCAGGTGCTGAGAGCAACGAGCTGGCAAGAGTCT 1080
Db 1021 TTTCACTGTGCAAAAAGTTTCCAGGTGCTGAGAGCAACGAGCTGGCAAGAGTCT 1080
Qy 1081 GGTAGGAGAAACAAGCTCTGATATGAGAGCGGAGCGCTTGTATCCGACACTTTG 1140
Db 1081 GGTAGGAGAAACAAGCTCTGATATGAGAGCGGAGCGCTTGTATCCGACACTTTG 1140
Qy 1141 CAGCTGCTTTATGTGCTGAGTAAATGGGCTGCTCAGCCCGAATGGGAATGAAAGTGG 1200
Db 1141 CAGCTGCTTTATGTGCTGAGTAAATGGGCTGCTCAGCCCGAATGGGAATGAAAGTGG 1200
Qy 1201 TGATGAGCAAGTATCTTTGAGAGCAAGAACTACATTTAGTATGATGAAACTTCGATC 1260
Db 1201 TGATGAGCAAGTATCTTTGAGAGCAAGAACTACATTTAGTATGATGAAACTTCGATC 1260
Qy 1261 CTTTACTGATATTTGGCTATCTCTTGTCAAGAAATGGTGGCAACCAAGTGTGA 1320
Db 1261 CTTTACTGATATTTGGCTATCTCTTGTCAAGAAATGGTGGCAACCAAGTGTGA 1320
Qy 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGTCTGAGTATACCTTCAATGGCAAAACA 1380
Db 1321 TGGCAAGGCTGCAAGGTTCAAGAGAGAGTCTGAGTATACCTTCAATGGCAAAACA 1380
Qy 1381 CTGCAATCTCAAGTATTAAGAGAGATTTAACTCTGATGCAATTAACCTCCATAAG 1440
Db 1381 CTGCAATCTCAAGTATTAAGAGAGATTTAACTCTGATGCAATTAACCTCCATAAG 1440
Qy 1441 TCACCAAGTACTTGGGTTACCTTATCTTTTCTTCAACAGCAAGTGTAAATATCTTC 1500
Db 1441 TCACCAAGTACTTGGGTTACCTTATCTTTTCTTCAACAGCAAGTGTAAATATCTTC 1500

```

```

Qy 1501 TAAAGCTTTGGGACCTCATGAGATTAATCTTCCAAATCTGTCCAACTCAATGCTAATC 1560
Db 1501 TAAAGCTTTGGGACCTCATGAGATTAATCTTCCAAATCTGTCCAACTCAATGCTAATC 1560
Qy 1561 TAAAGATGATGATGATCAAACTTTGCCACCTTTATGAGAAAACCTCTCCGCGCAGAA 1620
Db 1561 TAAAGATGATGATGATCAAACTTTGCCACCTTTATGAGAAAACCTCTCCGCGCAGAA 1620
Qy 1621 GTTCACTGGGCTTGGCAGCTTTCATATATTTTTTTTGTGATTAAGAAATGCCAAAGTGG 1680
Db 1621 GTTCACTGGGCTTGGCAGCTTTCATATATTTTTTTTGTGATTAAGAAATGCCAAAGTGG 1680
Qy 1681 CTGCTTGATCTGAAAATTAATATATCTAGTCTGACACTG 1721
Db 1681 CTGCTTGATCTGAAAATTAATATATCTAGTCTGACACTG 1721

RESULT 12
AR287436 1721 bp DNA linear PAT 10-APR-2003
LOCUS AR287436
DEFINITION Sequence 3 from patent US 6531129.
ACCESSION AR287436
VERSION AR287436.1 GI:29725130
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 1721)
AUTHORS Pecker,I., Vlodavsky,I., Friedman,Y. and Perets,T.
TITLE Heparanase specific molecular probes and their use in research and
JOURNAL Patent: US 6531129-A 3 11-MAR-2003;
FEATURES
source location/Qualifiers
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN

Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CTAGAGCTTTGCACTCTCCGCTGCGGCGGACAGTGGGCGGAGAGAGCAGGTGAGCCCA 60
Db 1 CTAGAGCTTTGCACTCTCCGCTGCGGCGGACAGTGGGCGGAGAGAGCAGGTGAGCCCA 60
Qy 61 AGATGCTGCTGCGTCTGAGAGCTGCGGCTGCGGCGGCTGATCTGCTGCTGGGGC 120
Db 61 AGATGCTGCTGCGTCTGAGAGCTGCGGCTGCGGCGGCTGATCTGCTGCTGGGGC 120
Qy 121 CGCTGGGTCCTCTCTCCCTTGGCGCGCTGCGCCCGACCTGCGCAACAGAGAGCTGCG 180
Db 121 CGCTGGGTCCTCTCTCCCTTGGCGCGCTGCGCCCGACCTGCGCAACAGAGAGCTGCG 180
Qy 181 ACCTGGAATCTTCAACCCAGAGAGCGGCTGCACTGATGAGGCGCTGCTTCTGTCGCTCA 240
Db 181 ACCTGGAATCTTCAACCCAGAGAGCGGCTGCACTGATGAGGCGCTGCTTCTGTCGCTCA 240
Qy 241 CCATTGAGCGCAACCTGGCGACAGAGCCCGCGGTTCTCTATCTCTGCGGTTCTGCAAGC 300
Db 241 CCATTGAGCGCAACCTGGCGACAGAGCCCGCGGTTCTCTATCTCTGCGGTTCTGCAAGC 300
Qy 301 TTGCTACTTGGCCAGAGAGCTTGTCTCTGCTGATCTGAGGTTTGTGTGCAACAGACAG 360
Db 301 TTGCTACTTGGCCAGAGAGCTTGTCTCTGCTGATCTGAGGTTTGTGTGCAACAGACAG 360
Qy 361 ACTTCCTAATTTTGGATCCCAAGAGAAATCACTTTGAAGAGAGAACTTACTGGCAAT 420
Db 361 ACTTCCTAATTTTGGATCCCAAGAGAAATCACTTTGAAGAGAGAACTTACTGGCAAT 420
Qy 421 CTCAAGTCAACAGAGATTTTGAATATGATGATCATCTCTGATGTGAGAGAGAGT 480

```

```

Db      421 CTCAGTCACCGAGATATTTGCAAAATATGATCCATCCCTCTGATGTGGAGGAAGT 480
Qy      481 TACGGTGGAAATGGCCCTACACGAGCAATTTGCTACTCCGAGAGACTACAGAAAAAGT 540
Db      481 TACGGTGGAAATGGCCCTACACGAGCAATTTGCTACTCCGAGAGACTACAGAAAAAGT 540
Qy      541 TCAGAGACGACCTACTCAGAGAGCTCTGATAGTGTGCTATACCTTTTGGCAACTGCT 600
Db      541 TCAGAGACGACCTACTCAGAGAGCTCTGATAGTGTGCTATACCTTTTGGCAACTGCT 600
Qy      601 CAGAGCTGAGCTGATCTTTGGCCCTTAATGCTTATTAAGAACAGCAATTTGCACTGGA 660
Db      601 CAGAGCTGAGCTGATCTTTGGCCCTTAATGCTTATTAAGAACAGCAATTTGCACTGGA 660
Qy      661 ACAGTTCTAATGCTAGTTGCTCTGAGTACTGCTCTCAAGGGGATTAACATTTCTT 720
Db      661 ACAGTTCTAATGCTAGTTGCTCTGAGTACTGCTCTCAAGGGGATTAACATTTCTT 720
Qy      721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTTCATCAATGGT 780
Db      721 GGGAACTAGGCAATGAACTTAACAGTTTCTTAAGAGGCTGATATTTTTCATCAATGGT 780
Qy      781 CGCAGTTGAGAGAAATTAATTAATTAATGATTAATTAATTAATTAATTAATTAATTA 840
Db      781 CGCAGTTGAGAGAAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 840
Qy      841 ATGCAAACTCTATGCTCTGATGTTGCTGAGCTCTGAGAGAGAGAGAGAGAGAGAGAG 900
Db      841 ATGCAAACTCTATGCTCTGATGTTGCTGAGCTCTGAGAGAGAGAGAGAGAGAGAGAG 900
Qy      901 AGAGCTTCTGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
Db      901 AGAGCTTCTGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 960
Qy      961 TGAATGAGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020
Db      961 TGAATGAGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1020
Qy      1021 TTTCACTGCTGCAAAAGTTTCCAGGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAG 1080
Db      1021 TTTCACTGCTGCAAAAGTTTCCAGGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAG 1080
Qy      1081 GGTGAGAGAGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
Db      1081 GGTGAGAGAGAGAGAGCTGCTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1140
Qy      1141 CAGCTGGCTTTATGCTGAGATTAATTTGGGCTGCTGAGAGAGAGAGAGAGAGAGAG 1200
Db      1141 CAGCTGGCTTTATGCTGAGATTAATTTGGGCTGCTGAGAGAGAGAGAGAGAGAGAG 1200
Qy      1201 TGATGAGAGAGATTTCTTTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1260
Db      1201 TGATGAGAGAGATTTCTTTGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1260
Qy      1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGACAGAGAG 1320
Db      1261 CTTTACCTGATTAATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGACAGAGAG 1320
Qy      1321 TGGCAAGCTGCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Db      1321 TGGCAAGCTGCAAGGTTCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 1380
Qy      1381 CTGACAAATTCAGAGATTAAGAGAGAGATTAATCTGCTGATTAATCTGCTGATTA 1440
Db      1381 CTGACAAATTCAGAGATTAAGAGAGAGATTAATCTGCTGATTAATCTGCTGATTA 1440
Qy      1441 TCACCAAGACTTGGGCTTACCTTATCTTTTCTTAACAAGCAAGTGAATTAATCTTTC 1500
Db      1441 TCACCAAGACTTGGGCTTACCTTATCTTTTCTTAACAAGCAAGTGAATTAATCTTTC 1500
Qy      1501 TAAAGACTTTGGGAGCTCAATGATTAATTTCCAAATCTGTCCAACTCAATGGTCTAATCT 1560
Db      1501 TAAAGACTTTGGGAGCTCAATGATTAATTTCCAAATCTGTCCAACTCAATGGTCTAATCT 1560

```

```

Qy      1561 TAAAGATGTGATGATCAAACTTGGCAGCTTTAATGAAAAACCTTCCGGCAGAGA 1620
Db      1561 TAAAGATGTGATGATCAAACTTGGCAGCTTTAATGAAAAACCTTCCGGCAGAGA 1620
Qy      1621 GTTCACTGGGCTTGGCAGCTTTCATATTAATTTTGTGATTAAGAAATGCAAAAGTTG 1680
Db      1621 GTTCACTGGGCTTGGCAGCTTTCATATTAATTTTGTGATTAAGAAATGCAAAAGTTG 1680
Qy      1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1721
Db      1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1721

RESULT 13
BD074427
LOCUS      BD074427          1721 bp      DNA      linear      PAT 27-AUG-2002
DEFINITION Polynucleotide encoding polypeptide having heparanase activity and
            expression of the polypeptide in induced cell.
ACCESSION  BD074427
VERSION    BD074427.1 GI:22620030
KEYWORDS   JP 2001514855-A/8.
SOURCE     unidentified
ORGANISM   unidentified.
REFERENCE  1 (bases 1 to 1721)
            Pecker,I., Vlodavsky,I. and Elena,F.
            Polynucleotide encoding polypeptide having heparanase activity and
            expression of the polypeptide in induced cell
            Patent: JP 2001514855-A 8 18-SEP-2001;
            INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES
            & DEVELOPMENT LTD
COMMENT     OS Nucleic acid
            PN JP 2001514855-A/8
            PD 18-SEP-2001
            PF 31-AUG-1998 JP 2000508806
            PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US 09/109386 PI
            IRIS PECKER, ISRAEL VLODAVSKY, PEINSTEIN ELENA
            PC C12N5/09,A61K38/00,A61P9/10,A61P17/00,A61P29/00,A61P35/00, PC
            A61P37/00,
            PC A61P43/00,C12N5/10,C12N9/24,C12O1/68,G01N33/15,G01N33/50// PC
            A61K39/395,
            PC A61K39/395,C12N15/00,A61K37/02,C12N5/00
            CC Polynucleotide encoding polypeptide having
            heparanase activity
            CC and
            CC expression of the polypeptide in induced cell FH Key
            Location/Qualifiers
            FT source 1..1721
            FEATURES
            source Location/Qualifiers
            1..1721
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"
BASE COUNT 451 a 413 c 410 g 447 t
ORIGIN
Query Match 100.0%; Score 1721; DB 6; Length 1721;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 1721; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


BASE COUNT	451 a	413 c	410 g	447 t
ORIGIN				

Query Match	100.0%;	Score 1721;	DB 6;	Length 1721;
Best Local Similarity	100.0%;	Pred. No. 0;		
Matches 1721; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

OY	1	TTAGAGCTTTGGA	CTC	CGCTGC	CGG	CAG	CTGG	CGGGGG	GAG	CAG	CGATG	AGCC	60
Db	1	CTAAGGCTTTGGA	CTCTC	CGCTGC	CGG	CAG	CTGG	CGGGGG	GAG	CAG	CGATG	AGCC	60
OY	61	AGATGCTGCTGCG	CTCCGAA	AGCTGG	CGTGC	CGCCCG	CGCTGA	TGCTGTG	CTCTCG	GGGC	120		
Db	61	AGATGCTGCTGCG	CTCGA	AGCTGG	CGTGC	CGCCCG	CGCTGA	TGCTGTG	CTCTCG	GGGC	120		
OY	121	CGCTGGGTCCTCT	CCCCCTGG	CGCCCTGC	CGCCGAC	CTTGC	GCA	CA	CAGAC	CTGTGG	180		
Db	121	CGCTGGGTCCTCT	CCCCCTGG	CGCCCTGC	CGCCGAC	CTTGC	GCA	CA	CAGAC	CTGTGG	180		
OY	181	ACCTGGACTTCTT	CA	CCGAG	AGCCGCTGC	AC	CTGTGA	AGCCCTTC	GTTCCTG	CTCA	240		
Db	181	ACCTGGACTTCTT	CA	CCGAG	AGCCGCTGC	AC	CTGTGA	AGCCCTTC	GTTCCTG	CTCA	240		
OY	241	CCATTGACGCCAA	CCCTGG	CA	CGAC	CCGCGTTC	CTAT	CCCTCG	GGTTC	CCAAAGC	300		
Db	241	CCATTGACGCCAA	CCCTGG	CA	CGAC	CCGCGTTC	CTAT	CCCTCG	GGTTC	CCAAAGC	300		
OY	301	TTTCGTACCTTG	GC	CA	GAGGCTTGTCT	CTGC	CTA	CCCTGA	GTTTGTG	GC	360		
Db	301	TTTCGTACCTTG	GC	CA	GAGGCTTGTCT	CTGC	CTA	CCCTGA	GTTTGTG	GC	360		
OY	361	ACTTCTTAATTTT	GCA	TATCC	CA	AGAA	AGAA	TA	CA	CTTTGA	AGAGAA	420	
Db	361	ACTTCTTAATTTT	GCA	TATCC	CA	AGAA	AGAA	TA	CA	CTTTGA	AGAGAA	420	
OY	421	CTCAAGTCAAC	CA	GAGATAT	TTTG	CA	ATA	TGAT	TCCAT	CCCTCT	GATGTG	480	
Db	421	CTCAAGTCAAC	CA	GAGATAT	TTTG	CA	ATA	TGAT	TCCAT	CCCTCT	GATGTG	480	
OY	481	TACGGTTGAA	ATG	GCCCTTA	CCAG	GAG	CA	ATTG	CTA	CTCCG	AA	540	
Db	481	TACGGTTGAA	ATG	GCCCTTA	CCAG	GAG	CA	ATTG	CTA	CTCCG	AA	540	
OY	541	TCAGAAGACGA	CCCTA	CTCA	AGAA	AGCTCTG	TA	AGTGT	CTA	TAC	CTTTG	600	
Db	541	TCAGAAGACGA	CCCTA	CTCA	AGAA	AGCTCTG	TA	AGTGT	CTA	TAC	CTTTG	600	
OY	601	CAGACTGGA	CTTGATCT	TTTG	GCCTTA	ATATG	CTTATTA	AGAA	CAC	CAGATTTG	CA	660	
Db	601	CAGACTGGA	CTTGATCT	TTTG	GCCTTA	ATATG	CTTATTA	AGAA	CAC	CAGATTTG	CA	660	
OY	661	ACA	GTTCTA	TGCTCA	GTTGCTCT	CTG	CA	CTGCTCTT	CCAA	GGGGTAA	CA	720	
Db	661	ACA	GTTCTA	TGCTCA	GTTGCTCT	CTG	CA	CTGCTCTT	CCAA	GGGGTAA	CA	720	
OY	721	GGGAACTGAG	CAATGA	CTTA	CAGTTTC	CTTA	AGAA	GGCTGA	TATTTT	CA	CA	780	
Db	721	GGGAACTGAG	CAATGA	CTTA	CAGTTTC	CTTA	AGAA	GGCTGA	TATTTT	CA	CA	780	
OY	781	CGCAGTTAG	AGAA	GATTATAT	TTCA	ATTG	CA	TAA	CTTCTA	AGAA	AGTCA	840	
Db	781	CGCAGTTAG	AGAA	GATTATAT	TTCA	ATTG	CA	TAA	CTTCTA	AGAA	AGTCA	840	
OY	841	ATGCAAACTC	TATG	TGCTG	TATG	TGTC	AG	CCCTG	AA	AGAA	AGCGCTA	900	
Db	841	ATGCAAACTC	TATG	TGCTG	TATG	TGTC	AG	CCCTG	AA	AGAA	AGCGCTA	900	
OY	901	AGAGCTTCTGA	AGGCTGG	TGAG	AGATG	ATG	ATTC	AGTTA	CA	TG	GCATCT	960	
Db	901	AGAGCTTCTGA	AGGCTGG	TGAG	AGATG	ATG	ATTC	AGTTA	CA	TG	GCATCT	960	
OY	961	TGAATGAC	GCACTG	CTAC	CA	GGAA	GATTTT	CTAA	CCCTG	ATG	TATG	CA	1020
Db	961	TGAATGAC	GCACTG	CTAC	CA	GGAA	GATTTT	CTAA	CCCTG	ATG	TATG	CA	1020

Db	961	TGAATGACGGACGTCTACCCAGGGAAATTTTCTAAACCCCTGATGATATGGACATTTT	1020
Qy	1021	TTTTCATCTGTGCAAAAAGTTTTCCAGGTGGTTGAGACACACAGGCCCTGGCAAGAAGCTC	1080
Db	1021	TTTTCATCTGTGCAAAAAGTTTTCCAGGTGGTTGAGACACACAGGCCCTGGCAAGAAGCTC	1080
Qy	1081	GGTTAGGAGAAACAGAGCTCTGCATATGAGAGCGGAGGCCCTTCTATCCGACACCTT	1140
Db	1081	GGTTAGGAGAAACAGAGCTCTGCATATGAGAGCGGAGGCCCTTCTATCCGACACCTT	1140
Qy	1141	CAGCTGGCTTTATGTGGCTGGATTAATTTGGGCTGTCAAGCCCGAATGGGAATGAAAGTGG	1200
Db	1141	CAGCTGGCTTTATGTGGCTGGATTAATTTGGGCTGTCAAGCCCGAATGGGAATGAAAGTGG	1200
Qy	1201	TGATGAGGCAAGTATTTCTTTGGAGCAGGAACTTCAATTATGTGATGAAACCTTCGATC	1260
Db	1201	TGATGAGGCAAGTATTTCTTTGGAGCAGGAACTTCAATTATGTGATGAAACCTTCGATC	1260
Qy	1261	CTTACACCGATTAATTTGGCTATCTCTTCGTTCAAGAATGTGGGGACCAAGGTGTAA	1320
Db	1261	CTTACACCGATTAATTTGGCTATCTCTTCGTTCAAGAATGTGGGGACCAAGGTGTAA	1320
Qy	1321	TGGCAAGCGTGCAGAGTTCAAGAGAAAGAAAGAGTTCGAGTATACCTTCATTGCAAAACA	1380
Db	1321	TGGCAAGCGTGCAGAGTTCAAGAGAAAGAAAGTTCGAGTATACCTTCATTGCAAAACA	1380
Qy	1381	CTGACAAATCCAAAGGTATTAAGAGAGAGATTTAACTCTGTATGCCATAAACCTCCATAACG	1440
Db	1381	CTGACAAATCCAAAGGTATTAAGAGAGAGATTTAACTCTGTATGCCATAAACCTCCATAACG	1440
Qy	1441	TCACCAAGTACTTGGCGGTAAACCCATCTCTTTCTAACAGCAAGTGGATTAATACCTTC	1500
Db	1441	TCACCAAGTACTTGGCGGTAAACCCATCTCTTTCTAACAGCAAGTGGATTAATACCTTC	1500
Qy	1501	TAAAGACCTTTGGAGCTCATAGATTTACTCTTCCAAATCTGTCAACTCAATGCTTAATC	1560
Db	1501	TAAAGACCTTTGGAGCTCATAGATTTACTCTTCCAAATCTGTCAACTCAATGCTTAATC	1560
Qy	1561	TAAAGATGTTGATGATCAACCTTGCCACCTTTAATGAAAAACCTTCCGGCCAGGAA	1620
Db	1561	TAAAGATGTTGATGATCAACCTTGCCACCTTTAATGAAAAACCTTCCGGCCAGGAA	1620
Qy	1621	GTTCACTGGGCTTGCCAGCTTCTCATATAGTTTTTTTGATTAAGAAATCCAAAGTTG	1680
Db	1621	GTTCACTGGGCTTGCCAGCTTCTCATATAGTTTTTTTGATTAAGAAATCCAAAGTTG	1680
Qy	1681	CTGCTTGATCTGAAATTAATAATPACTAGTCCTGACACTG	1721
Db	1681	CTGCTTGATCTGAAATTAATAATPACTAGTCCTGACACTG	1721
RESULT 15			
BD074430			
LOCUS	BD074430	1899 bp	DNA linear PAT 27-AUG-2002
DEFINITION	polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell.		
ACCESSION	BD074430		
VERSION	BD074430.1	GI:22620033	
KEYWORDS	JP 2001514855-A/11.		
SOURCE	unidentified		
ORGANISM	unclassified.		
REFERENCE	1 (bases 1 to 1899)		
AUTHORS	Pecker,I., Vlodavsky,I. and Elena,F.		
TITLE	Polynucleotide encoding polypeptide having heparanase activity and expression of the polypeptide in induced cell		
JOURNAL	Patent: JP 2001514855-A 11 18-SEP-2001;		
	INSIGHT STRATEGY & MARKETING LTD, HADASIT MEDICAL RESEARCH SERVICES		
	& DEVELOPMENT LTD		
COMMENT	OS Nucleic acid		
	PN JP 2001514855-A/11		
	PD 18-SEP-2001		
	PF 31-AUG-1998 JP 2000508806		

```

PR 02-SEP-1997 US 08/922170, 02-JUL-1998 US 09/109386 PI
IRIS PICKER, ISRAEL VLODAVSKY, FEINSTEIN ELENA
PC C12N5/09, A61K38/00, A61P9/10, A61P17/00, A61P29/00, A61P35/00, PC
A61P37/00
PC A61P3/00, C12N5/10, C12N9/24, C12Q1/68, G01N33/15, G01N33/50// PC
A61K39/395,
PC A61K39/395, C12N15/00, A61K37/02, C12N5/00
CC Polynucleotide encoding polypeptide having
heparanase activity
and
CC expression of the polypeptide in induced cell FH Key
Location/Qualifiers
FT source 1. 1899
/organism='Nucleic acid'.
FEATURES
location/Qualifiers
1. 1899
/organism='unidentified'
/mol_type='genomic DNA'
/db_xref='taxon:32644'
BASE COUNT 495 a 433 c 510 g 461 t
ORIGIN
Query Match 99.9%; Score 1719.4; DB 6; Length 1899;
Best Local Similarity: 99.9%; Pred. No. 0;
Matches 1720; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1 CTAGAGCTTTGACCTCCGCTGCGGAGCTGGCGGGGGAGAGCGAGGTGAGCCCA 60
DB 179 CTAGAGCTCTGACCTCCGCTGCGGAGCTGGCGGGGGAGAGCGAGGTGAGCCCA 238
QY 61 AGATCTGCTGCGCTGGAAGCTGCGCTGCGCGCGCGCTGATGTGCTGCTCTGAGGAC 120
DB 239 AGATCTGCTGCGCTGGAAGCTGCGCTGCGCGCGCGCTGATGTGCTGCTCTGAGGAC 298
QY 121 CGCTGGTCCCTCTCCCTGCGCGCGCTGCGCGCGCTGATGTGCTGCTCTGAGGAC 180
DB 299 CGCTGGTCCCTCTCCCTGCGCGCGCTGCGCGCGCTGATGTGCTGCTCTGAGGAC 358
QY 181 ACCTGGACTCTTCAACCAAGAGCGGCTGCACTGATGAGCCCTGTTCCCTGCTGCA 240
DB 359 ACCTGGACTCTTCAACCAAGAGCGGCTGCACTGATGAGCCCTGTTCCCTGCTGCA 418
QY 241 CCATTGAGCGCAACCTGGCGCAAGAGCCGCGGTTCTCTATCTCTGAGTTCTCCAAAGC 300
DB 419 CCATTGAGCGCAACCTGGCGCAAGAGCCGCGGTTCTCTATCTCTGAGTTCTCCAAAGC 478
QY 301 TTCTGATCTGGCGCAAGAGCTTGTCTCTGCTGATCTGATGTTGGTGGCACCAAGACG 360
DB 479 TTCTGATCTGGCGCAAGAGCTTGTCTCTGCTGATCTGATGTTGGTGGCACCAAGACG 538
QY 361 ACTTCTTAATTTTTCATCCCAAGAGGATCAACCTTTGAAGAGAGATTACTGGCAAT 420
DB 539 ACTTCTTAATTTTTCATCCCAAGAGGATCAACCTTTGAAGAGAGATTACTGGCAAT 598
QY 421 CTCAAGTCAACCAAGAGATTTTGAATATGATTCATCTCTGATGTGAGAGAGAGT 480
DB 599 CTCAAGTCAACCAAGAGATTTTGAATATGATTCATCTCTGATGTGAGAGAGAGT 658
QY 481 TAGCGTTGATGCGCTTCAACAGAGCAATTGCTACTCCGAGAGCACTACCAAGAAAAGT 540
DB 659 TAGCGTTGATGCGCTTCAACAGAGCAATTGCTACTCCGAGAGCACTACCAAGAAAAGT 718
QY 541 TCAAAAGAGCACTTCAACAGAGCAATTGCTACTCCGAGAGCACTACCAAGAAAAGT 600
DB 719 TCAAAAGAGCACTTCAACAGAGCAATTGCTACTCCGAGAGCACTACCAAGAAAAGT 778
QY 601 CAGAGCTGAGCTTGAATCTTTGGCTTAATGCTATTAAGAGACAGATTGGAGTGA 660
DB 779 CAGAGCTGAGCTTGAATCTTTGGCTTAATGCTATTAAGAGACAGATTGGAGTGA 838
QY 661 ACAAGTTTAATGCTGAGTTGCTCTGAGACTAGTCTTCAAGGGGATTAACATTTCTT 720
DB 839 ACAAGTTTAATGCTGAGTTGCTCTGAGACTAGTCTTCAAGGGGATTAACATTTCTT 898

```

```

QY 721 GGAAGCTAGAGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT 780
DB 899 GGAAGCTAGAGCAATGAACCTTAACAGTTTCTTAAGAGGCTGATATTTTCATCATGGGT 958
QY 781 CGCAGTTAGAGAGATTAATTTCAATTTGATCAATACTTCAAGAAAGTCCACTTCAAA 840
DB 959 CGCAGTTAGAGAGATTAATTTCAATTTGATCAATACTTCAAGAAAGTCCACTTCAAA 1018
QY 841 ATGCAAACTCTAATGCTGATGTTGGTCAAGCTCCGAGAAAGCGGCTAAGATGCTGA 900
DB 1019 ATGCAAACTCTAATGCTGATGTTGGTCAAGCTCCGAGAAAGCGGCTAAGATGCTGA 1078
QY 901 AGAGCTTCTGAGAGGCTGAGAGAGATGATTTGATTTGATTTGATTTGATTTGATTTG 960
DB 1079 AGAGCTTCTGAGAGGCTGAGAGAGATGATTTGATTTGATTTGATTTGATTTGATTTG 1138
QY 961 TGAATGAGCGGACTGCTACCAAGGAGATTTTCTTAAACCTGATGATTTGACATTTTGA 1020
DB 1139 TGAATGAGCGGACTGCTACCAAGGAGATTTTCTTAAACCTGATGATTTGACATTTTGA 1198
QY 1021 TTTGATCTGAGCAAAAGTTTTCAGAGGTTGAGAGACCAAGGCTGAGCAAGGCTCT 1080
DB 1199 TTTGATCTGAGCAAAAGTTTTCAGAGGTTGAGAGACCAAGGCTGAGCAAGGCTCT 1258
QY 1081 GGTAGAGAGAAACAAGCTCTGATGAGAGCGGAGCGCTTGTCTATCCGACACTTTTG 1140
DB 1259 GGTAGAGAGAAACAAGCTCTGATGAGAGCGGAGCGCTTGTCTATCCGACACTTTTG 1318
QY 1141 CAGCTGCTTATGCTGCTGATTAATTTGGGCTGTCACCCGAGTGGAGATTAAGTGG 1200
DB 1319 CAGCTGCTTATGCTGCTGATTAATTTGGGCTGTCACCCGAGTGGAGATTAAGTGG 1378
QY 1201 TGATGAGCAAGTATTTCTTTGAGACAGAGAACTTCAATTTGATGATTAAGTGAATC 1260
DB 1379 TGATGAGCAAGTATTTCTTTGAGACAGAGAACTTCAATTTGATGATTAAGTGAATC 1438
QY 1261 CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGACCAAGTGTAA 1320
DB 1439 CTTTACCTGATTTATTTGGCTATCTCTTCTGTTCAAGAAATTTGGTGGACCAAGTGTAA 1498
QY 1321 TGGCAAGGTCGAAGTTTCAAGAGAGAGAGCTTCAAGATTTCAATTTGATTTGCAAAACA 1380
DB 1499 TGGCAAGGTCGAAGTTTCAAGAGAGAGAGCTTCAAGATTTCAATTTGATTTGCAAAACA 1558
QY 1381 CTGCAATCCCAAGTATTAAGAGAGATTTAATCTGATGATGATTAAGTGAATTAAGT 1440
DB 1559 CTGCAATCCCAAGTATTAAGAGAGATTTAATCTGATGATGATTAAGTGAATTAAGT 1618
QY 1441 TCACCAAGTATTTGCGTTACCTATCTTTTCTTCAAGAGAGAGTGAATTAAGTGAAT 1500
DB 1619 TCACCAAGTATTTGCGTTACCTATCTTTTCTTCAAGAGAGAGTGAATTAAGTGAAT 1678
QY 1501 TAAAGCTTTGGAGCTTCATGATTAATTTTCAAAATCTGTCGAATGATGATTAAGTGA 1560
DB 1679 TAAAGCTTTGGAGCTTCATGATTAATTTTCAAAATCTGTCGAATGATGATTAAGTGA 1738
QY 1561 TAAAGTGTGTGATTAAGTGAATTTTCACTTTTCAAGAGAGAGTGAATTAAGTGAAT 1620
DB 1739 TAAAGTGTGTGATTAAGTGAATTTTCACTTTTCAAGAGAGAGTGAATTAAGTGAAT 1798
QY 1621 GTTCACTGGGCTGCGAGCTTTCTCATTAATTTTGTGATTAAGAGAGTGAATTAAGTGA 1680
DB 1799 GTTCACTGGGCTGCGAGCTTTCTCATTAATTTTGTGATTAAGAGAGTGAATTAAGTGA 1858
QY 1681 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1721
DB 1859 CTGCTTGATCTGAATAATTAATTAATTAATTAATTAATTAATTAATTAATTAATTAAT 1899

```

Search completed: February 16, 2004, 11:42:58
Job time : 822.88 secs